ID,Gene,gene-onnection,Status,Variant and risk allele,P-value,P-value annotation,RAF,OR,Beta,CI,Mapped gene,Reported trait,Trait(s),Study accession,Location,Grouping
844,ARHGAP24,ARHGAP24,N/a,rs744597-<b>?</b>,2 x 10-6,,'-,'-,'-,'-,ARHGAP24,Peanut allergy,peanut allergy measurement,GCST006039,4:85415875,Allergy
2078,C11orf71,C11orf71,N/a,rs4938096-<b>T</b>,1 x 10-6,(African),0.21,1.3,'-,[1.17‐1.44],"NNMT, C11orf71",Asthma,asthma,GCST005212,11:114365008,Allergy
2080,C11orf71,C11orf71,N/a,rs11214966-<b>?</b>,6 x 10-7,,NR,'-,'-,'-,"C11orf71, NNMT",Asthma,asthma,GCST001182,11:114360533,Allergy
2071,NONOP2,NONOP2,N/a,rs67766926-<b>?</b>,7 x 10-9,(Shared),NR,'-,'-,'-,"NONOP2, REL",Inflammatory skin disease,"atopic eczema, psoriasis",GCST002740,2:60936446,Allergy
1641,S100A11,S100A11,N/a,rs115288876-<b>?</b>,2 x 10-28,,NR,'-,'-,'-,"NBPF18P, S100A11",Eczema,Eczema,GCST007075,1:152027641,Allergy
2072,S100A11,S100A11,N/a,rs78914480-<b>A</b>,8 x 10-11,,0.014657419,2.400272,'-,[1.843869165-3.124573471],S100A11,Atopic dermatitis,atopic eczema,GCST90013680,1:152033551,Allergy
2076,S100A11,S100A11,N/a,rs115045402-<b>A</b>,2 x 10-20,,NR,1.249,'-,[1.2-1.3],"SPTLC1P4, S100A11",Asthma,asthma,GCST007798,1:152057072,Allergy
2158,S100A11,S100A11,N/a,rs115288876-<b>?</b>,2 x 10-8,,NR,1.15,'-,[1.09-1.21],"NBPF18P, S100A11","Allergic disease (asthma, hay fever or eczema)","allergy, asthma",GCST007563,1:152027641,Allergy
2160,S100A11,S100A11,N/a,rs115045402-<b>A</b>,2 x 10-47,,0.028,'-,0.202 unit decrease,[0.17-0.23],"SPTLC1P4, S100A11","Allergic disease (asthma, hay fever and/or eczema) (age of onset)","allergy, age at onset",GCST010985,1:152057072,Allergy
2161,S100A11,S100A11,N/a,rs115045402-<b>A</b>,2 x 10-15,,0.028,'-,0.123 unit decrease,[0.094-0.152],"SPTLC1P4, S100A11","Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)",allergy,GCST010984,1:152057072,Allergy
2068,TGM3,TGM3,N/a,rs1012621-<b>?</b>,5 x 10-6,(Shared),NR,'-,'-,'-,TGM3,Inflammatory skin disease,"atopic eczema, psoriasis",GCST002740,20:2325666,Allergy
1655,ALG1L13P,ALG1L13P,N/a,rs2945247-<b>?</b>,5 x 10-11,,NR,'-,0.0163992 unit increase,[0.012-0.021],"ALG1L13P, FAM86B3P",Processed meat consumption,diet measurement,GCST010132,8:8238482,Anthropometric
1832,AP1S1,AP1S1,N/a,rs1048303-<b>T</b>,1 x 10-10,,0.5817,'-,0.011 unit decrease,[0.0077-0.0143],AP1S1,Body mass index,body mass index,GCST009004,7:101160859,Anthropometric
1833,AP1S1,AP1S1,N/a,rs2074683-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,AP1S1,Body mass index,body mass index,GCST007039,7:101160333,Anthropometric
1834,AP1S1,AP1S1,N/a,rs2074683-<b>?</b>,4 x 10-9,,NR,'-,'-,'-,AP1S1,Body mass index,body mass index,GCST009871,7:101160333,Anthropometric
1895,AP1S1,AP1S1,N/a,rs2074686-<b>G</b>,3 x 10-9,,0.410365,'-,0.00827977 unit increase,[0.0055-0.011],AP1S1,Adult body size,body height,GCST010988,7:101157354,Anthropometric
216,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Anthropometric
224,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Anthropometric
226,APOB,APOB,N/a,rs562338-<b>?</b>,3 x 10-25,,NR,'-,'-,'-,"APOB, TDRD15",Age-related disease endophenotypes,"total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement",GCST004046,2:21065449,Anthropometric
1443,ARHGAP24,ARHGAP24,N/a,rs17010957-<b>T</b>,2 x 10-32,,0.852799,'-,0.0310197 unit decrease,[0.026-0.036],ARHGAP24,Heel bone mineral density,heel bone mineral density,GCST006979,4:85798012,Anthropometric
1444,ARHGAP24,ARHGAP24,N/a,rs72976751-<b>?</b>,3 x 10-28,,NR,'-,0.0313374 unit decrease,[0.025-0.037],ARHGAP24,Heel bone mineral density,heel bone mineral density,GCST006433,4:85804806,Anthropometric
1445,ARHGAP24,ARHGAP24,N/a,rs17010957-<b>?</b>,1 x 10-29,,NR,'-,0.0316563 unit decrease,[0.026-0.037],ARHGAP24,Heel bone mineral density,heel bone mineral density,GCST006433,4:85798012,Anthropometric
1446,ARHGAP24,ARHGAP24,N/a,rs72976751-<b>A</b>,1 x 10-11,,0.860876,'-,0.0342643 unit decrease,[0.025-0.044],ARHGAP24,Heel bone mineral density,heel bone mineral density,GCST006288,4:85804806,Anthropometric
1447,ARHGAP24,ARHGAP24,N/a,rs72976751-<b>A</b>,5 x 10-11,(women),0.860578,'-,0.0427462 unit decrease,[0.03-0.056],ARHGAP24,Heel bone mineral density,heel bone mineral density,GCST006288,4:85804806,Anthropometric
1448,ARHGAP24,ARHGAP24,N/a,rs79980676-<b>?</b>,9 x 10-34,,NR,'-,'-,'-,ARHGAP24,Heel bone mineral density,heel bone mineral density,GCST007066,4:85825103,Anthropometric
1890,ARHGAP24,ARHGAP24,N/a,rs552283803-<b>C</b>,4 x 10-8,,0.0016,'-,0.05250504 m decrease,[0.034-0.071],ARHGAP24,Height,body height,GCST004212,4:85575677,Anthropometric
1891,ARHGAP24,ARHGAP24,N/a,rs17010957-<b>?</b>,1 x 10-20,,NR,'-,'-,'-,ARHGAP24,Height,body height,GCST007841,4:85798012,Anthropometric
1892,ARHGAP24,ARHGAP24,N/a,rs346508-<b>?</b>,6 x 10-12,,NR,'-,'-,'-,ARHGAP24,Height,body height,GCST007841,4:85942013,Anthropometric
746,CHL1,CHL1,N/a,rs6769747-<b>?</b>,1 x 10-7,(CHL1),NR,'-,0.16 unit increase,[0.1-0.22],CHL1,Protein levels in obesity,"protein measurement, obesity",GCST010196,3:203266,Anthropometric
1825,CHL1,CHL1,N/a,rs9841287-<b>A</b>,7 x 10-9,,0.8272,'-,0.003253 unit decrease,[0.0022-0.0043],"CHL1-AS2, LINC01986",Fasting blood insulin (BMI interaction),"body mass index, fasting blood insulin measurement",GCST001526,3:67310,Anthropometric
1826,CHL1,CHL1-AS2,N/a,rs9841287-<b>A</b>,7 x 10-9,,0.8272,'-,0.003253 unit decrease,[0.0022-0.0043],"CHL1-AS2, LINC01986",Fasting blood insulin (BMI interaction),"body mass index, fasting blood insulin measurement",GCST001526,3:67310,Anthropometric
2087,COQ10B,COQ10B,N/a,rs61327788-<b>G</b>,1 x 10-8,,0.500638,'-,0.0395407 unit increase,[0.026-0.053],COQ10B,Appendicular lean mass,appendicular lean mass,GCST009577,2:197473498,Anthropometric
7,DNM3,DNM3,N/a,rs17277127-<b>?</b>,8 x 10-9,,NR,'-,'-,'-,DNM3,Waist-hip ratio,waist-hip ratio,GCST007067,1:172167994,Anthropometric
8,DNM3,DNM3,N/a,rs12138803-<b>T</b>,7 x 10-25,,0.2001,'-,0.0198 unit increase,[0.016-0.024],"DNM3, PIGC",Waist-hip ratio,waist-hip ratio,GCST008996,1:172379683,Anthropometric
9,DNM3,DNM3,N/a,rs714515-<b>G</b>,5 x 10-8,,0.44,'-,'-,'-,"PIGC, DNM3",Waist-hip ratio,waist-hip ratio,GCST008734,1:172383850,Anthropometric
10,DNM3,DNM3,N/a,rs12138803-<b>T</b>,7 x 10-25,,0.2001,'-,0.0198 unit increase,[0.016-0.024],"DNM3, PIGC",Waist-hip ratio,waist-hip ratio,GCST008997,1:172379683,Anthropometric
11,DNM3,DNM3,N/a,rs10752944-<b>?</b>,6 x 10-46,,NR,'-,'-,'-,"PIGC, DNM3",Waist-hip ratio,waist-hip ratio,GCST007067,1:172394384,Anthropometric
12,DNM3,DNM3,N/a,rs1011731-<b>A</b>,7 x 10-8,"(EA, women)",0.5729,'-,0.0235 unit decrease,[0.015-0.032],"DNM3, PIGC",Waist-hip ratio,waist-hip ratio,GCST004064,1:172377408,Anthropometric
13,DNM3,DNM3,N/a,rs1011731-<b>A</b>,1 x 10-8,(EA),0.5729,'-,0.0191 unit decrease,[0.013-0.026],"DNM3, PIGC",Waist-hip ratio,waist-hip ratio,GCST004064,1:172377408,Anthropometric
14,DNM3,DNM3,N/a,rs1011731-<b>G</b>,1 x 10-17,,0.43,'-,0.03 unit increase,[NR],"DNM3, PIGC",Waist-hip ratio,waist-hip ratio,GCST000829,1:172377408,Anthropometric
458,DNM3,DNM3,N/a,rs714515-<b>A</b>,1 x 10-11,(women),0.5576,'-,0.0314 unit decrease,[0.022-0.04],"PIGC, DNM3",Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),"smoking behavior, BMI-adjusted waist-hip ratio",GCST004505,1:172383850,Anthropometric
459,DNM3,DNM3,N/a,rs714515-<b>A</b>,9 x 10-15,,0.5576,'-,0.0273 unit decrease,[0.02-0.034],"PIGC, DNM3",Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),"smoking behavior, BMI-adjusted waist-hip ratio",GCST004505,1:172383850,Anthropometric
460,DNM3,DNM3,N/a,rs714515-<b>A</b>,9 x 10-6,,0.5576,'-,'-,'-,"PIGC, DNM3",Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),"smoking behavior, BMI-adjusted waist-hip ratio",GCST004507,1:172383850,Anthropometric
461,DNM3,DNM3,N/a,rs714515-<b>A</b>,7 x 10-6,(women),0.5576,'-,'-,'-,"PIGC, DNM3",Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),"smoking behavior, BMI-adjusted waist-hip ratio",GCST004507,1:172383850,Anthropometric
1455,DNM3,DNM3,N/a,rs12041600-<b>G</b>,1 x 10-6,(men),0.520395,'-,0.0239793 unit increase,[0.014-0.034],DNM3,Heel bone mineral density,heel bone mineral density,GCST006288,1:172261089,Anthropometric
1456,DNM3,DNM3,N/a,rs672740-<b>T</b>,8 x 10-14,,0.519265,'-,0.0151798 unit decrease,[0.011-0.019],DNM3,Heel bone mineral density,heel bone mineral density,GCST006979,1:172167979,Anthropometric
1457,DNM3,DNM3,N/a,rs56682471-<b>A</b>,3 x 10-16,,0.783675,'-,0.0201441 unit decrease,[0.015-0.025],DNM3,Heel bone mineral density,heel bone mineral density,GCST006979,1:172267127,Anthropometric
1458,DNM3,DNM3,N/a,rs12041600-<b>?</b>,2 x 10-43,,NR,'-,0.0275149 unit increase,[0.023-0.032],DNM3,Heel bone mineral density,heel bone mineral density,GCST006433,1:172261089,Anthropometric
1459,DNM3,DNM3,N/a,rs10458358-<b>?</b>,6 x 10-37,,NR,'-,0.030854 unit decrease,[0.026-0.036],DNM3,Heel bone mineral density,heel bone mineral density,GCST006433,1:172244264,Anthropometric
1460,DNM3,DNM3,N/a,rs2586392-<b>?</b>,4 x 10-32,,NR,'-,0.027327 unit decrease,[0.023-0.032],DNM3,Heel bone mineral density,heel bone mineral density,GCST006433,1:172285053,Anthropometric
1461,DNM3,DNM3,N/a,rs145764789-<b>?</b>,6 x 10-35,,NR,'-,0.0301717 unit decrease,[0.025-0.035],DNM3,Heel bone mineral density,heel bone mineral density,GCST006433,1:172311313,Anthropometric
1462,DNM3,DNM3,N/a,rs17277932-<b>?</b>,5 x 10-15,,NR,'-,0.0229655 unit increase,[0.017-0.029],DNM3,Heel bone mineral density,heel bone mineral density,GCST006433,1:172353994,Anthropometric
1463,DNM3,DNM3,N/a,rs12041600-<b>G</b>,5 x 10-11,(women),0.52086,'-,0.02917 unit increase,[0.02-0.038],DNM3,Heel bone mineral density,heel bone mineral density,GCST006288,1:172261089,Anthropometric
1464,DNM3,DNM3,N/a,rs12041600-<b>G</b>,1 x 10-15,,0.520643,'-,0.0254858 unit increase,[0.019-0.032],DNM3,Heel bone mineral density,heel bone mineral density,GCST006288,1:172261089,Anthropometric
1465,DNM3,DNM3,N/a,rs12737669-<b>?</b>,2 x 10-43,,NR,'-,'-,'-,DNM3,Heel bone mineral density,heel bone mineral density,GCST007066,1:172263037,Anthropometric
1537,DNM3,DNM3,N/a,rs479336-<b>T</b>,9 x 10-15,,0.74,'-,0.04 unit decrease,[NR],DNM3,Femoral neck bone mineral density,femoral neck bone mineral density,GCST007691,1:172230433,Anthropometric
1822,DNM3,DNM3,N/a,rs633995-<b>A</b>,2 x 10-9,,0.4251,'-,0.0351 unit increase,'-,DNM3,Total body bone mineral density,bone density,GCST005348,1:172217589,Anthropometric
1823,DNM3,DNM3,N/a,rs6694387-<b>T</b>,2 x 10-8,,0.4476,'-,0.0329 unit decrease,'-,DNM3,Total body bone mineral density,bone density,GCST005348,1:172323065,Anthropometric
1898,DNM3,DNM3,N/a,rs609702-<b>?</b>,1 x 10-17,,NR,'-,0.025947371 unit increase,[0.02-0.032],DNM3,Height,body height,GCST008839,1:172231515,Anthropometric
1899,DNM3,DNM3,N/a,rs12075079-<b>?</b>,3 x 10-7,,NR,'-,0.04112592 unit increase,[0.025-0.057],DNM3,Height,body height,GCST008053,1:172250855,Anthropometric
1900,DNM3,DNM3,N/a,rs12410416-<b>?</b>,7 x 10-8,,NR,'-,0.04195971 unit increase,[0.027-0.057],DNM3,Height,body height,GCST008053,1:172224680,Anthropometric
1901,DNM3,DNM3,N/a,rs186897198-<b>?</b>,7 x 10-12,,NR,'-,'-,'-,DNM3,Height,body height,GCST007841,1:172089746,Anthropometric
1902,DNM3,DNM3,N/a,rs2289635-<b>?</b>,4 x 10-124,,NR,'-,'-,'-,DNM3,Height,body height,GCST007841,1:172239480,Anthropometric
1903,DNM3,DNM3,N/a,rs17369123-<b>?</b>,8 x 10-36,,NR,'-,'-,'-,"PIGC, DNM3",Height,body height,GCST007841,1:172386701,Anthropometric
1904,DNM3,DNM3,N/a,rs12409899-<b>C</b>,1 x 10-7,,0.7842,'-,0.0444 unit decrease,[0.028-0.061],DNM3,Height,body height,GCST008163,1:172257871,Anthropometric
1905,DNM3,DNM3,N/a,rs2421992-<b>?</b>,5 x 10-8,(Conditioned on rs17346452),NR,'-,'-,[NR],DNM3,Height,body height,GCST000817,1:172272111,Anthropometric
1906,DNM3,DNM3,N/a,rs6694089-<b>A</b>,4 x 10-33,,0.279,'-,0.039 unit increase,[0.033-0.045],DNM3,Height,body height,GCST002647,1:172114741,Anthropometric
1907,DNM3,DNM3,N/a,rs17346452-<b>T</b>,1 x 10-23,,0.73,'-,0.04 unit decrease,[NR],DNM3,Height,body height,GCST000817,1:172084147,Anthropometric
1908,DNM3,DNM3,N/a,rs12410416-<b>T</b>,2 x 10-10,,0.69,'-,0.028 unit decrease,[0.016-0.04],DNM3,Height,body height,GCST002702,1:172224680,Anthropometric
1909,DNM3,DNM3,N/a,rs678962-<b>G</b>,3 x 10-8,,0.22,'-,5.4 % s.d. increase,[3.44-7.36],DNM3,Height,body height,GCST000175,1:172220749,Anthropometric
1910,DNM3,DNM3,N/a,rs12075079-<b>G</b>,7 x 10-12,,0.21,1.2,'-,[NR],DNM3,Height,body height,GCST001956,1:172250855,Anthropometric
1911,DNM3,DNM3,N/a,rs34952786-<b>T</b>,2 x 10-7,,0.3411,'-,0.0383 unit increase,[0.024-0.053],"DNM3, DNM3OS",Height,body height,GCST008163,1:172144188,Anthropometric
1912,DNM3,DNM3OS,N/a,rs34952786-<b>T</b>,2 x 10-7,,0.3411,'-,0.0383 unit increase,[0.024-0.053],"DNM3, DNM3OS",Height,body height,GCST008163,1:172144188,Anthropometric
1922,DNM3,DNM3,N/a,rs714515-<b>A</b>,6 x 10-14,,0.573760827,'-,'-,'-,"PIGC, DNM3",Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test),"BMI-adjusted waist-hip ratio, sex interaction measurement, age at assessment",GCST005962,1:172383850,Anthropometric
1923,DNM3,DNM3,N/a,rs1894633-<b>G</b>,6 x 10-14,(women),0.3392,'-,0.0387 unit increase,[0.029-0.049],DNM3,Waist-to-hip ratio adjusted for body mass index,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004576,1:172361919,Anthropometric
1924,DNM3,DNM3,N/a,rs1894633-<b>G</b>,4 x 10-12,(women),0.3382,'-,0.0427 unit increase,[0.031-0.055],DNM3,Waist-to-hip ratio adjusted for BMI in active individuals,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004578,1:172361919,Anthropometric
1925,DNM3,DNM3,N/a,rs2001129-<b>T</b>,3 x 10-14,"(EA, women)",0.4363,'-,0.0387 unit increase,[0.029-0.049],DNM3,Waist-to-hip ratio adjusted for body mass index,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004576,1:172364108,Anthropometric
1926,DNM3,DNM3,N/a,rs2001129-<b>?</b>,6 x 10-16,(EA),0.4363,'-,'-,'-,DNM3,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004567,1:172364108,Anthropometric
1927,DNM3,DNM3,N/a,rs2001129-<b>?</b>,3 x 10-13,"(EA, women)",0.4363,'-,'-,'-,DNM3,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004567,1:172364108,Anthropometric
1928,DNM3,DNM3,N/a,rs2001129-<b>T</b>,5 x 10-16,(EA),0.4363,'-,0.032 unit increase,[0.024-0.04],DNM3,Waist-to-hip ratio adjusted for body mass index,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004576,1:172364108,Anthropometric
1929,DNM3,DNM3,N/a,rs1894633-<b>G</b>,4 x 10-12,(women),0.3382,'-,0.0427 unit increase,[0.031-0.055],DNM3,Waist-to-hip ratio adjusted for BMI in active individuals,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004578,1:172361919,Anthropometric
1930,DNM3,DNM3,N/a,rs1894633-<b>G</b>,5 x 10-13,,0.3392,'-,0.0346 unit increase,[0.025-0.044],DNM3,Waist-to-hip ratio adjusted for BMI in active individuals,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004578,1:172361919,Anthropometric
1931,DNM3,DNM3,N/a,rs2001129-<b>T</b>,3 x 10-12,"(EA, women)",0.436,'-,0.0402 unit increase,[0.029-0.052],DNM3,Waist-to-hip ratio adjusted for BMI in active individuals,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004578,1:172364108,Anthropometric
1932,DNM3,DNM3,N/a,rs2001129-<b>T</b>,8 x 10-14,(EA),0.4363,'-,0.0339 unit increase,[0.025-0.043],DNM3,Waist-to-hip ratio adjusted for BMI in active individuals,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004578,1:172364108,Anthropometric
1933,DNM3,DNM3,N/a,rs1894633-<b>?</b>,5 x 10-13,(women),0.3392,'-,'-,'-,DNM3,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004567,1:172361919,Anthropometric
1934,DNM3,DNM3,N/a,rs1894633-<b>?</b>,1 x 10-14,,0.3392,'-,'-,'-,DNM3,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004567,1:172361919,Anthropometric
1935,DNM3,DNM3,N/a,rs1894633-<b>G</b>,5 x 10-16,,0.3392,'-,0.032 unit increase,[0.024-0.04],DNM3,Waist-to-hip ratio adjusted for body mass index,"BMI-adjusted waist-hip ratio, physical activity measurement",GCST004576,1:172361919,Anthropometric
1937,DNM3,DNM3,N/a,rs633995-<b>?</b>,2 x 10-10,,NR,'-,'-,'-,DNM3,Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST009858,1:172217589,Anthropometric
1938,DNM3,DNM3,N/a,rs714515-<b>A</b>,3 x 10-16,,0.573760827,'-,0.02717696 units decrease,'-,"PIGC, DNM3",Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST005956,1:172383850,Anthropometric
1939,DNM3,DNM3,N/a,rs12138803-<b>T</b>,1 x 10-38,,0.2018,'-,0.0254 unit increase,[0.022-0.029],"DNM3, PIGC",Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST008994,1:172379683,Anthropometric
1940,DNM3,DNM3,N/a,rs12138803-<b>?</b>,2 x 10-32,,NR,'-,'-,'-,"DNM3, PIGC",Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST009858,1:172379683,Anthropometric
1941,DNM3,DNM3,N/a,rs76166162-<b>?</b>,3 x 10-14,,NR,'-,'-,'-,"PIGC, DNM3",Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST009858,1:172411786,Anthropometric
1942,DNM3,DNM3,N/a,rs714515-<b>G</b>,1 x 10-56,,0.44,'-,0.028 unit increase,[0.024-0.032],"PIGC, DNM3",Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST008733,1:172383850,Anthropometric
1943,DNM3,DNM3,N/a,rs714515-<b>G</b>,2 x 10-10,"(EA, women)",0.4271,'-,0.0289 unit increase,[0.02-0.038],"PIGC, DNM3",Waist-to-hip ratio adjusted for body mass index,BMI-adjusted waist-hip ratio,GCST002782,1:172383850,Anthropometric
1944,DNM3,DNM3,N/a,rs714515-<b>G</b>,4 x 10-15,(EA),0.4285,'-,0.027 unit increase,[0.02-0.034],"PIGC, DNM3",Waist-to-hip ratio adjusted for body mass index,BMI-adjusted waist-hip ratio,GCST002782,1:172383850,Anthropometric
1945,DNM3,DNM3,N/a,rs714515-<b>G</b>,9 x 10-7,"(EA, men)",0.43,'-,0.0247 unit increase,[0.015-0.035],"PIGC, DNM3",Waist-to-hip ratio adjusted for body mass index,BMI-adjusted waist-hip ratio,GCST002782,1:172383850,Anthropometric
1946,DNM3,DNM3,N/a,rs714515-<b>G</b>,3 x 10-7,(men),0.4334,'-,0.025 unit increase,[0.015-0.035],"PIGC, DNM3",Waist-to-hip ratio adjusted for body mass index,BMI-adjusted waist-hip ratio,GCST002782,1:172383850,Anthropometric
1947,DNM3,DNM3,N/a,rs714515-<b>G</b>,9 x 10-11,(women),0.4352,'-,0.029 unit increase,[0.02-0.038],"PIGC, DNM3",Waist-to-hip ratio adjusted for body mass index,BMI-adjusted waist-hip ratio,GCST002782,1:172383850,Anthropometric
1948,DNM3,DNM3,N/a,rs714515-<b>G</b>,1 x 10-15,,0.4369,'-,0.0272 unit increase,[0.021-0.034],"PIGC, DNM3",Waist-to-hip ratio adjusted for body mass index,BMI-adjusted waist-hip ratio,GCST002782,1:172383850,Anthropometric
1950,DNM3,DNM3,N/a,rs1894633-<b>G</b>,2 x 10-10,"(EA, women)",0.3388,'-,0.0332 cm increase,[0.023-0.043],DNM3,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,1:172361919,Anthropometric
1951,DNM3,DNM3,N/a,rs1894633-<b>?</b>,3 x 10-11,,0.3521,'-,'-,'-,DNM3,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,1:172361919,Anthropometric
1952,DNM3,DNM3,N/a,rs1894633-<b>G</b>,6 x 10-11,(EA),0.3388,'-,0.0261 cm increase,[0.018-0.034],DNM3,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,1:172361919,Anthropometric
1953,DNM3,DNM3,N/a,rs1894633-<b>?</b>,2 x 10-10,(EA),0.3388,'-,'-,'-,DNM3,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,1:172361919,Anthropometric
1954,DNM3,DNM3,N/a,rs1894633-<b>G</b>,2 x 10-8,"(EA,women)",0.3378,'-,0.0327 cm increase,[0.021-0.044],DNM3,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,1:172361919,Anthropometric
1955,DNM3,DNM3,N/a,rs1894633-<b>G</b>,2 x 10-9,(EA),0.3388,'-,0.0274 cm increase,[0.018-0.036],DNM3,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,1:172361919,Anthropometric
1956,DNM3,DNM3,N/a,rs1894633-<b>G</b>,5 x 10-10,,0.3521,'-,0.0271 cm increase,[0.018-0.036],DNM3,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,1:172361919,Anthropometric
1957,DNM3,DNM3,N/a,rs1894633-<b>G</b>,1 x 10-11,,0.3521,'-,0.0255 cm increase,[0.018-0.033],DNM3,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,1:172361919,Anthropometric
1958,DNM3,DNM3,N/a,rs1894633-<b>?</b>,6 x 10-10,"(EA, women)",0.3388,'-,'-,'-,DNM3,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,1:172361919,Anthropometric
1962,DNM3,DNM3,N/a,rs9425573-<b>?</b>,2 x 10-18,,NR,'-,'-,'-,DNM3,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,1:172361297,Anthropometric
1963,DNM3,DNM3,N/a,rs12063247-<b>?</b>,1 x 10-17,,NR,'-,'-,'-,DNM3,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,1:172229080,Anthropometric
1964,DNM3,DNM3,N/a,rs2422073-<b>?</b>,3 x 10-8,,NR,'-,'-,'-,DNM3,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,1:172261640,Anthropometric
1965,DNM3,DNM3,N/a,rs16844417-<b>?</b>,5 x 10-10,,NR,'-,'-,'-,"DNM3, PIGC",Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,1:172408605,Anthropometric
1970,DNM3,DNM3,N/a,rs17346473-<b>A</b>,2 x 10-10,"(EA, women)",0.7233,'-,0.0322 unit decrease,[0.022-0.042],DNM3,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,1:172113953,Anthropometric
1971,DNM3,DNM3,N/a,rs17346473-<b>A</b>,4 x 10-6,"(EA,men)",0.7233,'-,0.0264 unit decrease,[0.015-0.038],DNM3,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,1:172113953,Anthropometric
1972,DNM3,DNM3,N/a,rs17346473-<b>A</b>,3 x 10-14,(EA),0.7233,'-,0.03 unit decrease,[0.022-0.038],DNM3,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,1:172113953,Anthropometric
16,DPP7,DPP7,N/a,rs192111487-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,DPP7,Waist-hip ratio,waist-hip ratio,GCST007067,9:137113669,Anthropometric
1949,DPP7,DPP7,N/a,rs192111487-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,DPP7,Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST009858,9:137113669,Anthropometric
15,FAM180B,FAM180B,N/a,rs12287076-<b>C</b>,4 x 10-21,,0.625,'-,0.0192 unit increase,[0.015-0.023],"NDUFS3, FAM180B",Waist-hip ratio,waist-hip ratio,GCST008996,11:47585313,Anthropometric
1916,FAM180B,FAM180B,N/a,rs11605348-<b>A</b>,2 x 10-8,,0.349,'-,0.0402 unit decrease,[0.026-0.054],"NDUFS3, FAM180B",Height,body height,GCST008163,11:47584931,Anthropometric
1918,FGF12,FGF12,N/a,rs558068948-<b>?</b>,2 x 10-7,,NR,'-,5.249 unit decrease,NR,FGF12,Height,body height,GCST011692,3:192552536,Anthropometric
1973,FGF12,FGF12,N/a,rs4571187-<b>A</b>,6 x 10-6,,0.315,'-,0.0458 unit decrease,[0.026-0.066],FGF12,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST008156,3:192335485,Anthropometric
1893,H2AC6,H2AC6,N/a,rs16891359-<b>T</b>,4 x 10-6,,0.9405,'-,0.0734 unit increase,[0.042-0.105],"H2AC6, H1-4",Height,body height,GCST008163,6:26148772,Anthropometric
1894,H2AC6,H2AC6,N/a,rs75499503-<b>C</b>,8 x 10-12,,0.77991,'-,0.0114761 unit increase,[0.0082-0.0148],"H1-4, H2AC6",Adult body size,body height,GCST010988,6:26144989,Anthropometric
17,IL20RB,IL20RB,N/a,rs835649-<b>?</b>,5 x 10-9,,NR,'-,'-,'-,IL20RB,Waist-hip ratio,waist-hip ratio,GCST007067,3:136953048,Anthropometric
1920,IL20RB,IL20RB,N/a,rs34687891-<b>A</b>,3 x 10-6,,0.0775,'-,0.0613 unit decrease,[0.036-0.087],IL20RB,Height,body height,GCST008163,3:137077379,Anthropometric
1967,IL20RB,IL20RB,N/a,rs835633-<b>?</b>,4 x 10-12,,NR,'-,'-,'-,IL20RB,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,3:136957654,Anthropometric
1968,IL20RB,IL20RB,N/a,rs9843104-<b>?</b>,5 x 10-8,,NR,'-,'-,'-,IL20RB,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,3:137096333,Anthropometric
1820,KHSRPP1,KHSRPP1,N/a,rs7035284-<b>G</b>,1 x 10-8,(males),0.279,'-,0.277 Z score increase,[0.18-0.37],"H3P30, KHSRPP1",Pediatric bone mineral content (radius),bone mineral content measurement,GCST002952,9:21678974,Anthropometric
1821,KHSRPP1,KHSRPP1,N/a,rs11999970-<b>C</b>,5 x 10-7,(Males),0.195,'-,0.318959 unit increase,[0.2-0.44],"KHSRPP1, H3P30",Pediatric bone mineral content (radius),bone mineral content measurement,GCST004175,9:21677314,Anthropometric
1454,LINC00578,LINC00578,N/a,rs13077994-<b>?</b>,8 x 10-8,,NR,'-,'-,'-,LINC00578,Heel bone mineral density,heel bone mineral density,GCST007066,3:177587917,Anthropometric
1897,LINC00578,LINC00578,N/a,rs7634107-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,LINC00578,Height,body height,GCST007841,3:177717331,Anthropometric
1829,LINC02574,LINC02574,N/a,rs2076463-<b>G</b>,2 x 10-8,(Japanese),0.264,'-,0.023 unit decrease,[0.015-0.031],"LINC02574, FGR",Body mass index,body mass index,GCST004904,1:27644581,Anthropometric
1830,MGST1,MGST1,N/a,rs11056875-<b>?</b>,7 x 10-10,,NR,'-,'-,'-,"SLC15A5, MGST1",Body mass index,body mass index,GCST007039,12:16317984,Anthropometric
1831,MGST1,MGST1,N/a,rs11056875-<b>?</b>,2 x 10-10,,NR,'-,'-,'-,"SLC15A5, MGST1",Body mass index,body mass index,GCST009871,12:16317984,Anthropometric
1576,MYO1B,MYO1B,N/a,rs1823913-<b>A</b>,9 x 10-6,(Diet carbohydrate ),0.38,'-,0.03 g/d increase,[NR],MYO1B,Obesity-related traits,energy intake,GCST001762,2:191253321,Anthropometric
1507,NANOS3,NANOS3,N/a,rs12162265-<b>A</b>,5 x 10-8,,0.2384,'-,0.002 unit decrease,[0.0014-0.0026],"NANOS3, MIR23AHG",Hand grip strength,grip strength measurement,GCST005830,19:13844347,Anthropometric
6,NDST1,NDST1,N/a,rs17726577-<b>?</b>,4 x 10-9,,NR,'-,'-,'-,NDST1,Waist-hip ratio,waist-hip ratio,GCST007067,5:150504862,Anthropometric
1936,NDST1,NDST1,N/a,rs113681861-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,NDST1,Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST009858,5:150505607,Anthropometric
1467,PHF2,PHF2,N/a,rs10992867-<b>G</b>,3 x 10-10,(women),0.745392,'-,0.0322475 unit decrease,[0.022-0.043],PHF2,Heel bone mineral density,heel bone mineral density,GCST006288,9:93698731,Anthropometric
1468,PHF2,PHF2,N/a,rs10992867-<b>G</b>,3 x 10-17,,0.745283,'-,0.0311923 unit decrease,[0.024-0.039],PHF2,Heel bone mineral density,heel bone mineral density,GCST006288,9:93698731,Anthropometric
1469,PHF2,PHF2,N/a,rs4743930-<b>?</b>,1 x 10-40,,NR,'-,'-,'-,PHF2,Heel bone mineral density,heel bone mineral density,GCST007066,9:93683312,Anthropometric
1470,PHF2,PHF2,N/a,rs10992867-<b>?</b>,2 x 10-35,,NR,'-,0.0284212 unit decrease,[0.024-0.033],PHF2,Heel bone mineral density,heel bone mineral density,GCST006433,9:93698731,Anthropometric
1471,PHF2,PHF2,N/a,rs12683791-<b>?</b>,3 x 10-36,,NR,'-,0.0280191 unit decrease,[0.023-0.033],PHF2,Heel bone mineral density,heel bone mineral density,GCST006433,9:93700812,Anthropometric
1472,PHF2,PHF2,N/a,rs10992867-<b>G</b>,4 x 10-8,(men),0.745158,'-,0.0311791 unit decrease,[0.02-0.043],PHF2,Heel bone mineral density,heel bone mineral density,GCST006288,9:93698731,Anthropometric
1473,PHF2,PHF2,N/a,rs4743930-<b>C</b>,5 x 10-31,,0.747683,'-,0.0253988 unit decrease,[0.021-0.03],PHF2,Heel bone mineral density,heel bone mineral density,GCST006979,9:93683312,Anthropometric
1876,PHF2,PHF2,N/a,rs2398861-<b>?</b>,1 x 10-14,,NR,'-,'-,'-,PHF2,Body mass index,body mass index,GCST007039,9:93668465,Anthropometric
1877,PHF2,PHF2,N/a,rs9695734-<b>C</b>,1 x 10-6,,0.84,'-,0.052 unit increase,[0.03-0.074],PHF2,Childhood body mass index,body mass index,GCST90002409,9:93645701,Anthropometric
1878,PHF2,PHF2,N/a,rs10116955-<b>?</b>,1 x 10-10,,NR,'-,'-,'-,PHF2,Body mass index,body mass index,GCST009871,9:93595110,Anthropometric
1879,PHF2,PHF2,N/a,rs10761247-<b>A</b>,5 x 10-11,,0.587,'-,0.0113 unit decrease,[0.008-0.0146],PHF2,Body mass index,body mass index,GCST009004,9:93641085,Anthropometric
1880,PHF2,PHF2,N/a,rs59597511-<b>?</b>,9 x 10-9,,NR,'-,'-,'-,PHF2,Body mass index,body mass index,GCST009871,9:93633936,Anthropometric
1917,PHF2,PHF2,N/a,rs10821196-<b>G</b>,5 x 10-13,,0.317602,'-,0.0107393 unit increase,[0.0078-0.0136],PHF2,Adult body size,body height,GCST010988,9:93671114,Anthropometric
1835,PPM1K,PPM1K,N/a,rs1129043-<b>?</b>,1 x 10-8,,NR,'-,'-,'-,PPM1K,Body mass index,body mass index,GCST009871,4:88261979,Anthropometric
1323,PSMG4,PSMG4,N/a,rs4317455-<b>C</b>,1 x 10-7,,NR,'-,0.4538 unit decrease,[NR],PSMG4,Bone mineral density (femoral neck) in inflammatory bowel disease,"inflammatory bowel disease, femoral neck bone mineral density",GCST005784,6:3263257,Anthropometric
1324,PSMG4,PSMG4,N/a,rs4317455-<b>C</b>,1 x 10-7,,NR,'-,0.4538 unit decrease,[NR],PSMG4,Bone mineral density (femoral neck) in inflammatory bowel disease,"inflammatory bowel disease, femoral neck bone mineral density",GCST005784,6:3263257,Anthropometric
1449,RN7SL252P,RN7SL252P,N/a,rs17598132-<b>C</b>,7 x 10-6,(men),0.868116,'-,0.0306063 unit increase,[0.016-0.045],"DLX6-AS1, RN7SL252P",Heel bone mineral density,heel bone mineral density,GCST006288,7:96950027,Anthropometric
1450,RN7SL252P,RN7SL252P,N/a,rs17598132-<b>C</b>,2 x 10-9,,0.868057,'-,0.028236 unit increase,[0.019-0.038],"DLX6-AS1, RN7SL252P",Heel bone mineral density,heel bone mineral density,GCST006288,7:96950027,Anthropometric
1451,RN7SL252P,RN7SL252P,N/a,rs17598306-<b>?</b>,5 x 10-23,,NR,'-,0.029887 unit increase,[0.024-0.036],"DLX6-AS1, RN7SL252P",Heel bone mineral density,heel bone mineral density,GCST006433,7:96952499,Anthropometric
1452,RN7SL252P,RN7SL252P,N/a,rs17598132-<b>?</b>,7 x 10-23,,NR,'-,0.0297962 unit increase,[0.024-0.036],"DLX6-AS1, RN7SL252P",Heel bone mineral density,heel bone mineral density,GCST006433,7:96950027,Anthropometric
1966,RPS3AP5,RPS3AP5,N/a,rs150795097-<b>T</b>,4 x 10-6,,0.002,'-,0.471 unit increase,[0.27-0.67],RPS3AP5,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST008161,10:84569594,Anthropometric
462,SLC22A4,SLC22A4,N/a,rs272869-<b>A</b>,2 x 10-8,,0.4005,'-,'-,'-,"MIR3936HG, SLC22A4",Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),"smoking behavior, BMI-adjusted waist circumference",GCST004501,5:132342304,Anthropometric
463,SLC22A4,SLC22A4,N/a,rs272869-<b>A</b>,2 x 10-8,,0.4005,'-,0.0194 unit decrease,[0.013-0.026],"MIR3936HG, SLC22A4",Waist circumference adjusted for BMI (adjusted for smoking behaviour),"smoking behavior, BMI-adjusted waist circumference",GCST004500,5:132342304,Anthropometric
1959,SLC22A4,SLC22A4,N/a,rs272869-<b>A</b>,2 x 10-7,"(EA, men)",0.4038,'-,0.025 unit decrease,[0.016-0.034],"MIR3936HG, SLC22A4",Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST004063,5:132342304,Anthropometric
1960,SLC22A4,SLC22A4,N/a,rs272869-<b>A</b>,7 x 10-10,(EA),0.4038,'-,0.0212 unit decrease,[0.015-0.028],"MIR3936HG, SLC22A4",Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST004063,5:132342304,Anthropometric
1961,SLC22A4,SLC22A4,N/a,rs272869-<b>A</b>,2 x 10-7,,0.4005,'-,0.0205 unit decrease,[0.013-0.028],"MIR3936HG, SLC22A4",Waist circumference adjusted for BMI in non-smokers,BMI-adjusted waist circumference,GCST004504,5:132342304,Anthropometric
1896,SMURF2,SMURF2,N/a,rs80215473-<b>?</b>,8 x 10-10,,NR,'-,'-,'-,SMURF2,Height,body height,GCST007841,17:64593460,Anthropometric
1969,SPTBN4,SPTBN4,N/a,rs7260380-<b>?</b>,1 x 10-8,,NR,'-,'-,'-,SPTBN4,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,19:40480396,Anthropometric
1466,THAP3,THAP3,N/a,rs3830771-<b>?</b>,9 x 10-21,,NR,'-,0.0194123 unit increase,[0.015-0.024],THAP3,Heel bone mineral density,heel bone mineral density,GCST006433,1:6633582,Anthropometric
1915,THAP3,THAP3,N/a,rs2076363-<b>C</b>,3 x 10-8,,0.663112,'-,0.00803062 unit decrease,[0.0052-0.0109],"PHF13, THAP3",Adult body size,body height,GCST010988,1:6624846,Anthropometric
1824,TMEM45B,TMEM45B,N/a,rs10894147-<b>A</b>,7 x 10-6,(Weight z-score change ),0.104,'-,0.03 SD/y increase,[NR],TMEM45B,Obesity-related traits,body weight,GCST001762,11:129828961,Anthropometric
450,TNNI3K,TNNI3K,N/a,rs12566985-<b>A</b>,3 x 10-7,(women),0.5312,'-,0.0219 kg/m2 decrease,[0.013-0.03],"TNNI3K, FPGT-TNNI3K",BMI (adjusted for smoking behaviour),"smoking behavior, body mass index",GCST004495,1:74536509,Anthropometric
451,TNNI3K,TNNI3K,N/a,rs12566985-<b>A</b>,2 x 10-8,,0.5312,'-,0.0184 kg/m2 decrease,[0.012-0.025],"TNNI3K, FPGT-TNNI3K",BMI (adjusted for smoking behaviour),"smoking behavior, body mass index",GCST004495,1:74536509,Anthropometric
452,TNNI3K,TNNI3K,N/a,rs12566985-<b>A</b>,7 x 10-9,,0.5312,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index (joint analysis main effects and smoking interaction),"smoking behavior, body mass index",GCST004497,1:74536509,Anthropometric
453,TNNI3K,TNNI3K,N/a,rs12566985-<b>A</b>,8 x 10-7,(women),0.5312,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index (joint analysis main effects and smoking interaction),"smoking behavior, body mass index",GCST004497,1:74536509,Anthropometric
454,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>A</b>,3 x 10-7,(women),0.5312,'-,0.0219 kg/m2 decrease,[0.013-0.03],"TNNI3K, FPGT-TNNI3K",BMI (adjusted for smoking behaviour),"smoking behavior, body mass index",GCST004495,1:74536509,Anthropometric
455,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>A</b>,2 x 10-8,,0.5312,'-,0.0184 kg/m2 decrease,[0.012-0.025],"TNNI3K, FPGT-TNNI3K",BMI (adjusted for smoking behaviour),"smoking behavior, body mass index",GCST004495,1:74536509,Anthropometric
456,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>A</b>,7 x 10-9,,0.5312,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index (joint analysis main effects and smoking interaction),"smoking behavior, body mass index",GCST004497,1:74536509,Anthropometric
457,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>A</b>,8 x 10-7,(women),0.5312,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index (joint analysis main effects and smoking interaction),"smoking behavior, body mass index",GCST004497,1:74536509,Anthropometric
493,TNNI3K,TNNI3K,N/a,rs1514174-<b>C</b>,1 x 10-15,,0.43,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Body mass index x sex x age interaction (4df test),"sex interaction measurement, body mass index, age at assessment",GCST005950,1:74527379,Anthropometric
494,TNNI3K,FPGT-TNNI3K,N/a,rs1514174-<b>C</b>,1 x 10-15,,0.43,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Body mass index x sex x age interaction (4df test),"sex interaction measurement, body mass index, age at assessment",GCST005950,1:74527379,Anthropometric
717,TNNI3K,TNNI3K,N/a,rs1514174-<b>C</b>,6 x 10-6,"(Pubertal growth, females)",0.47,'-,0.08 unit decrease,[0.045-0.115],"FPGT-TNNI3K, TNNI3K",Pubertal anthropometrics,"puberty, height growth measurement",GCST001876,1:74527379,Anthropometric
718,TNNI3K,FPGT-TNNI3K,N/a,rs1514174-<b>C</b>,6 x 10-6,"(Pubertal growth, females)",0.47,'-,0.08 unit decrease,[0.045-0.115],"FPGT-TNNI3K, TNNI3K",Pubertal anthropometrics,"puberty, height growth measurement",GCST001876,1:74527379,Anthropometric
810,TNNI3K,TNNI3K,N/a,rs7526762-<b>?</b>,3 x 10-10,,NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index (joint analysis main effects and physical activity interaction),"physical activity measurement, body mass index",GCST004558,1:74527634,Anthropometric
811,TNNI3K,TNNI3K,N/a,rs7526762-<b>?</b>,4 x 10-9,(EA),NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index (joint analysis main effects and physical activity interaction),"physical activity measurement, body mass index",GCST004558,1:74527634,Anthropometric
812,TNNI3K,TNNI3K,N/a,rs7551507-<b>?</b>,2 x 10-8,"(EA, women)",NR,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Body mass index (joint analysis main effects and physical activity interaction),"physical activity measurement, body mass index",GCST004558,1:74529541,Anthropometric
813,TNNI3K,TNNI3K,N/a,rs7551507-<b>C</b>,1 x 10-9,(EA),0.443,'-,0.0228 kg/m2 increase,[0.016-0.03],"FPGT-TNNI3K, TNNI3K",Body mass index,"physical activity measurement, body mass index",GCST004557,1:74529541,Anthropometric
814,TNNI3K,TNNI3K,N/a,rs7551507-<b>C</b>,5 x 10-9,"(EA, women)",0.443,'-,0.0281 kg/m2 increase,[0.019-0.038],"FPGT-TNNI3K, TNNI3K",Body mass index,"physical activity measurement, body mass index",GCST004557,1:74529541,Anthropometric
815,TNNI3K,TNNI3K,N/a,rs7551507-<b>C</b>,9 x 10-9,"(EA,women)",0.4416,'-,0.0305 kg/m2 increase,[0.02-0.041],"FPGT-TNNI3K, TNNI3K",Body mass index in physically active individuals,"physical activity measurement, body mass index",GCST004559,1:74529541,Anthropometric
816,TNNI3K,TNNI3K,N/a,rs7551507-<b>C</b>,4 x 10-8,(EA),0.443,'-,0.0229 kg/m2 increase,[0.015-0.031],"FPGT-TNNI3K, TNNI3K",Body mass index in physically active individuals,"physical activity measurement, body mass index",GCST004559,1:74529541,Anthropometric
817,TNNI3K,TNNI3K,N/a,rs7526762-<b>A</b>,6 x 10-8,,0.4599,'-,0.0218 kg/m2 increase,[0.014-0.03],"TNNI3K, FPGT-TNNI3K",Body mass index in physically active individuals,"physical activity measurement, body mass index",GCST004559,1:74527634,Anthropometric
818,TNNI3K,TNNI3K,N/a,rs3843262-<b>?</b>,2 x 10-8,(women),NR,'-,'-,'-,"TNNI3K, ERICH3",Body mass index (joint analysis main effects and physical activity interaction),"physical activity measurement, body mass index",GCST004558,1:74547370,Anthropometric
819,TNNI3K,TNNI3K,N/a,rs7526762-<b>A</b>,4 x 10-10,,0.4599,'-,0.0222 kg/m2 increase,[0.015-0.029],"TNNI3K, FPGT-TNNI3K",Body mass index,"physical activity measurement, body mass index",GCST004557,1:74527634,Anthropometric
820,TNNI3K,TNNI3K,N/a,rs3843262-<b>A</b>,6 x 10-9,(women),0.4276,'-,0.027 kg/m2 increase,[0.018-0.036],"TNNI3K, ERICH3",Body mass index,"physical activity measurement, body mass index",GCST004557,1:74547370,Anthropometric
821,TNNI3K,TNNI3K,N/a,rs3843262-<b>A</b>,2 x 10-8,(women),0.4341,'-,0.0285 kg/m2 increase,[0.019-0.038],"TNNI3K, ERICH3",Body mass index in physically active individuals,"physical activity measurement, body mass index",GCST004559,1:74547370,Anthropometric
822,TNNI3K,FPGT-TNNI3K,N/a,rs7526762-<b>?</b>,3 x 10-10,,NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index (joint analysis main effects and physical activity interaction),"physical activity measurement, body mass index",GCST004558,1:74527634,Anthropometric
823,TNNI3K,FPGT-TNNI3K,N/a,rs7526762-<b>?</b>,4 x 10-9,(EA),NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index (joint analysis main effects and physical activity interaction),"physical activity measurement, body mass index",GCST004558,1:74527634,Anthropometric
824,TNNI3K,FPGT-TNNI3K,N/a,rs7551507-<b>?</b>,2 x 10-8,"(EA, women)",NR,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Body mass index (joint analysis main effects and physical activity interaction),"physical activity measurement, body mass index",GCST004558,1:74529541,Anthropometric
825,TNNI3K,FPGT-TNNI3K,N/a,rs7551507-<b>C</b>,1 x 10-9,(EA),0.443,'-,0.0228 kg/m2 increase,[0.016-0.03],"FPGT-TNNI3K, TNNI3K",Body mass index,"physical activity measurement, body mass index",GCST004557,1:74529541,Anthropometric
826,TNNI3K,FPGT-TNNI3K,N/a,rs7551507-<b>C</b>,5 x 10-9,"(EA, women)",0.443,'-,0.0281 kg/m2 increase,[0.019-0.038],"FPGT-TNNI3K, TNNI3K",Body mass index,"physical activity measurement, body mass index",GCST004557,1:74529541,Anthropometric
827,TNNI3K,FPGT-TNNI3K,N/a,rs7551507-<b>C</b>,9 x 10-9,"(EA,women)",0.4416,'-,0.0305 kg/m2 increase,[0.02-0.041],"FPGT-TNNI3K, TNNI3K",Body mass index in physically active individuals,"physical activity measurement, body mass index",GCST004559,1:74529541,Anthropometric
828,TNNI3K,FPGT-TNNI3K,N/a,rs7551507-<b>C</b>,4 x 10-8,(EA),0.443,'-,0.0229 kg/m2 increase,[0.015-0.031],"FPGT-TNNI3K, TNNI3K",Body mass index in physically active individuals,"physical activity measurement, body mass index",GCST004559,1:74529541,Anthropometric
829,TNNI3K,FPGT-TNNI3K,N/a,rs7526762-<b>A</b>,6 x 10-8,,0.4599,'-,0.0218 kg/m2 increase,[0.014-0.03],"TNNI3K, FPGT-TNNI3K",Body mass index in physically active individuals,"physical activity measurement, body mass index",GCST004559,1:74527634,Anthropometric
830,TNNI3K,FPGT-TNNI3K,N/a,rs7526762-<b>A</b>,4 x 10-10,,0.4599,'-,0.0222 kg/m2 increase,[0.015-0.029],"TNNI3K, FPGT-TNNI3K",Body mass index,"physical activity measurement, body mass index",GCST004557,1:74527634,Anthropometric
869,TNNI3K,TNNI3K,N/a,rs10493544-<b>T</b>,2 x 10-11,(EA),NR,'-,0.1321 unit increase,[0.093-0.171],"FPGT-TNNI3K, TNNI3K",Childhood obesity,obesity,GCST009382,1:74518151,Anthropometric
870,TNNI3K,TNNI3K,N/a,rs1514177-<b>C</b>,5 x 10-9,(Obesity class I),0.43,1.06,'-,[NR],"TNNI3K, FPGT-TNNI3K",Obesity,obesity,GCST001953,1:74525718,Anthropometric
871,TNNI3K,TNNI3K,N/a,rs1514174-<b>C</b>,1 x 10-8,(Overweight),0.44,1.04,'-,[NR],"FPGT-TNNI3K, TNNI3K",Obesity,obesity,GCST001953,1:74527379,Anthropometric
872,TNNI3K,FPGT-TNNI3K,N/a,rs10493544-<b>T</b>,2 x 10-11,(EA),NR,'-,0.1321 unit increase,[0.093-0.171],"FPGT-TNNI3K, TNNI3K",Childhood obesity,obesity,GCST009382,1:74518151,Anthropometric
873,TNNI3K,FPGT-TNNI3K,N/a,rs1514177-<b>C</b>,5 x 10-9,(Obesity class I),0.43,1.06,'-,[NR],"TNNI3K, FPGT-TNNI3K",Obesity,obesity,GCST001953,1:74525718,Anthropometric
874,TNNI3K,FPGT-TNNI3K,N/a,rs1514174-<b>C</b>,1 x 10-8,(Overweight),0.44,1.04,'-,[NR],"FPGT-TNNI3K, TNNI3K",Obesity,obesity,GCST001953,1:74527379,Anthropometric
1355,TNNI3K,TNNI3K,N/a,rs6604866-<b>C</b>,3 x 10-7,"(EA,women)",0.5564,'-,0.0239 unit decrease,[0.015-0.033],"FPGT-TNNI3K, TNNI3K",Hip circumference,hip circumference,GCST004066,1:74526862,Anthropometric
1356,TNNI3K,TNNI3K,N/a,rs6604866-<b>C</b>,4 x 10-10,(EA),0.5564,'-,0.0222 unit decrease,[0.015-0.029],"FPGT-TNNI3K, TNNI3K",Hip circumference,hip circumference,GCST004066,1:74526862,Anthropometric
1357,TNNI3K,FPGT-TNNI3K,N/a,rs6604866-<b>C</b>,3 x 10-7,"(EA,women)",0.5564,'-,0.0239 unit decrease,[0.015-0.033],"FPGT-TNNI3K, TNNI3K",Hip circumference,hip circumference,GCST004066,1:74526862,Anthropometric
1358,TNNI3K,FPGT-TNNI3K,N/a,rs6604866-<b>C</b>,4 x 10-10,(EA),0.5564,'-,0.0222 unit decrease,[0.015-0.029],"FPGT-TNNI3K, TNNI3K",Hip circumference,hip circumference,GCST004066,1:74526862,Anthropometric
1541,TNNI3K,TNNI3K,N/a,rs12041852-<b>?</b>,1 x 10-13,,NR,'-,9.774 z score decrease,NR,"FPGT-TNNI3K, TNNI3K",Childhood body fatness,fat body mass,GCST011370,1:74537816,Anthropometric
1542,TNNI3K,FPGT-TNNI3K,N/a,rs12041852-<b>?</b>,1 x 10-13,,NR,'-,9.774 z score decrease,NR,"FPGT-TNNI3K, TNNI3K",Childhood body fatness,fat body mass,GCST011370,1:74537816,Anthropometric
1734,TNNI3K,TNNI3K,N/a,rs12042908-<b>A</b>,3 x 10-84,,0.437703,'-,0.0274603 unit increase,[0.025-0.03],"TNNI3K, FPGT-TNNI3K",Body size at age 10,"comparative body size at age 10, self-reported",GCST010989,1:74532078,Anthropometric
1735,TNNI3K,FPGT-TNNI3K,N/a,rs12042908-<b>A</b>,3 x 10-84,,0.437703,'-,0.0274603 unit increase,[0.025-0.03],"TNNI3K, FPGT-TNNI3K",Body size at age 10,"comparative body size at age 10, self-reported",GCST010989,1:74532078,Anthropometric
1827,TNNI3K,TNNI3K,N/a,rs1514174-<b>C</b>,3 x 10-6,,0.43,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Body mass index x age interaction,"body mass index, age at assessment",GCST005954,1:74527379,Anthropometric
1828,TNNI3K,FPGT-TNNI3K,N/a,rs1514174-<b>C</b>,3 x 10-6,,0.43,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Body mass index x age interaction,"body mass index, age at assessment",GCST005954,1:74527379,Anthropometric
1836,TNNI3K,TNNI3K,N/a,rs1514174-<b>C</b>,4 x 10-13,,0.43,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Body mass index,body mass index,GCST005951,1:74527379,Anthropometric
1837,TNNI3K,TNNI3K,N/a,rs7553348-<b>A</b>,4 x 10-17,,0.55755072,'-,0.022879148 unit decrease,'-,"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST005951,1:74539383,Anthropometric
1838,TNNI3K,TNNI3K,N/a,rs1514174-<b>C</b>,3 x 10-15,,0.43,'-,0.039 unit increase,'-,"FPGT-TNNI3K, TNNI3K",Body mass index (age <50),body mass index,GCST005953,1:74527379,Anthropometric
1839,TNNI3K,TNNI3K,N/a,rs12566985-<b>A</b>,6 x 10-19,,0.53,'-,0.025 unit decrease,[0.019-0.031],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST004904,1:74536509,Anthropometric
1840,TNNI3K,TNNI3K,N/a,rs953567-<b>A</b>,2 x 10-28,,0.5903,'-,0.0184 unit decrease,[0.015-0.022],"FPGT-TNNI3K, LRRC53, TNNI3K",Body mass index,body mass index,GCST009003,1:74511741,Anthropometric
1841,TNNI3K,TNNI3K,N/a,rs12566985-<b>G</b>,2 x 10-15,,0.455,'-,0.024 kg/m2 increase,[0.018-0.03],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST002783,1:74536509,Anthropometric
1842,TNNI3K,TNNI3K,N/a,rs12566985-<b>G</b>,3 x 10-15,(EA),0.446,'-,0.024 kg/m2 increase,[0.018-0.03],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST002783,1:74536509,Anthropometric
1843,TNNI3K,TNNI3K,N/a,rs12566985-<b>G</b>,1 x 10-11,"(EA, women)",0.444,'-,0.027 kg/m2 increase,[0.019-0.035],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST002783,1:74536509,Anthropometric
1844,TNNI3K,TNNI3K,N/a,rs12566985-<b>G</b>,1 x 10-7,"(EA, men)",0.448,'-,0.022 kg/m2 increase,[0.014-0.03],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST002783,1:74536509,Anthropometric
1845,TNNI3K,TNNI3K,N/a,rs12042908-<b>A</b>,1 x 10-17,,NR,'-,0.022 unit increase,[NR],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST006368,1:74532078,Anthropometric
1846,TNNI3K,TNNI3K,N/a,rs12042908-<b>A</b>,3 x 10-14,,0.46,'-,0.059 unit increase,[0.043-0.075],"TNNI3K, FPGT-TNNI3K",Childhood body mass index,body mass index,GCST90002409,1:74532078,Anthropometric
1847,TNNI3K,TNNI3K,N/a,rs146823532-<b>A</b>,4 x 10-7,,0.87,'-,0.14 unit increase,[0.085-0.195],"TNNI3K, FPGT-TNNI3K",Childhood body mass index,body mass index,GCST90002409,1:74513442,Anthropometric
1848,TNNI3K,TNNI3K,N/a,rs953567-<b>?</b>,1 x 10-18,,NR,'-,'-,'-,"FPGT-TNNI3K, LRRC53, TNNI3K",Body mass index,body mass index,GCST009871,1:74511741,Anthropometric
1849,TNNI3K,TNNI3K,N/a,rs1514177-<b>C</b>,8 x 10-30,,0.4255,'-,0.0184 unit increase,[0.015-0.022],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST009004,1:74525718,Anthropometric
1850,TNNI3K,TNNI3K,N/a,rs7553158-<b>?</b>,2 x 10-19,,NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST007039,1:74539554,Anthropometric
1851,TNNI3K,TNNI3K,N/a,rs1514177-<b>C</b>,8 x 10-30,,0.4255,'-,0.0184 unit increase,[0.015-0.022],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST009001,1:74525718,Anthropometric
1852,TNNI3K,TNNI3K,N/a,rs12041852-<b>G</b>,2 x 10-10,,0.46,'-,0.046 unit increase,[0.032-0.06],"FPGT-TNNI3K, TNNI3K",Childhood body mass index,body mass index,GCST003177,1:74537816,Anthropometric
1853,TNNI3K,TNNI3K,N/a,rs12566985-<b>G</b>,2 x 10-10,,NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Childhood body mass index,body mass index,GCST003177,1:74536509,Anthropometric
1854,TNNI3K,TNNI3K,N/a,rs1514175-<b>A</b>,3 x 10-11,,0.43,'-,0.06 unit increase,[0.042-0.078],"FPGT-TNNI3K, TNNI3K",Body mass index,body mass index,GCST002021,1:74525960,Anthropometric
1855,TNNI3K,TNNI3K,N/a,rs1514175-<b>A</b>,8 x 10-14,,0.43,'-,0.07 kg/m2 increase,[0.03-0.11],"FPGT-TNNI3K, TNNI3K",Body mass index,body mass index,GCST000830,1:74525960,Anthropometric
1856,TNNI3K,FPGT-TNNI3K,N/a,rs1514174-<b>C</b>,4 x 10-13,,0.43,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Body mass index,body mass index,GCST005951,1:74527379,Anthropometric
1857,TNNI3K,FPGT-TNNI3K,N/a,rs7553348-<b>A</b>,4 x 10-17,,0.55755072,'-,0.022879148 unit decrease,'-,"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST005951,1:74539383,Anthropometric
1858,TNNI3K,FPGT-TNNI3K,N/a,rs1514174-<b>C</b>,3 x 10-15,,0.43,'-,0.039 unit increase,'-,"FPGT-TNNI3K, TNNI3K",Body mass index (age <50),body mass index,GCST005953,1:74527379,Anthropometric
1859,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>A</b>,6 x 10-19,,0.53,'-,0.025 unit decrease,[0.019-0.031],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST004904,1:74536509,Anthropometric
1860,TNNI3K,FPGT-TNNI3K,N/a,rs953567-<b>A</b>,2 x 10-28,,0.5903,'-,0.0184 unit decrease,[0.015-0.022],"FPGT-TNNI3K, LRRC53, TNNI3K",Body mass index,body mass index,GCST009003,1:74511741,Anthropometric
1861,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>G</b>,2 x 10-15,,0.455,'-,0.024 kg/m2 increase,[0.018-0.03],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST002783,1:74536509,Anthropometric
1862,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>G</b>,3 x 10-15,(EA),0.446,'-,0.024 kg/m2 increase,[0.018-0.03],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST002783,1:74536509,Anthropometric
1863,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>G</b>,1 x 10-11,"(EA, women)",0.444,'-,0.027 kg/m2 increase,[0.019-0.035],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST002783,1:74536509,Anthropometric
1864,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>G</b>,1 x 10-7,"(EA, men)",0.448,'-,0.022 kg/m2 increase,[0.014-0.03],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST002783,1:74536509,Anthropometric
1865,TNNI3K,FPGT-TNNI3K,N/a,rs12042908-<b>A</b>,1 x 10-17,,NR,'-,0.022 unit increase,[NR],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST006368,1:74532078,Anthropometric
1866,TNNI3K,FPGT-TNNI3K,N/a,rs12042908-<b>A</b>,3 x 10-14,,0.46,'-,0.059 unit increase,[0.043-0.075],"TNNI3K, FPGT-TNNI3K",Childhood body mass index,body mass index,GCST90002409,1:74532078,Anthropometric
1867,TNNI3K,FPGT-TNNI3K,N/a,rs146823532-<b>A</b>,4 x 10-7,,0.87,'-,0.14 unit increase,[0.085-0.195],"TNNI3K, FPGT-TNNI3K",Childhood body mass index,body mass index,GCST90002409,1:74513442,Anthropometric
1868,TNNI3K,FPGT-TNNI3K,N/a,rs953567-<b>?</b>,1 x 10-18,,NR,'-,'-,'-,"FPGT-TNNI3K, LRRC53, TNNI3K",Body mass index,body mass index,GCST009871,1:74511741,Anthropometric
1869,TNNI3K,FPGT-TNNI3K,N/a,rs1514177-<b>C</b>,8 x 10-30,,0.4255,'-,0.0184 unit increase,[0.015-0.022],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST009004,1:74525718,Anthropometric
1870,TNNI3K,FPGT-TNNI3K,N/a,rs7553158-<b>?</b>,2 x 10-19,,NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST007039,1:74539554,Anthropometric
1871,TNNI3K,FPGT-TNNI3K,N/a,rs1514177-<b>C</b>,8 x 10-30,,0.4255,'-,0.0184 unit increase,[0.015-0.022],"TNNI3K, FPGT-TNNI3K",Body mass index,body mass index,GCST009001,1:74525718,Anthropometric
1872,TNNI3K,FPGT-TNNI3K,N/a,rs12041852-<b>G</b>,2 x 10-10,,0.46,'-,0.046 unit increase,[0.032-0.06],"FPGT-TNNI3K, TNNI3K",Childhood body mass index,body mass index,GCST003177,1:74537816,Anthropometric
1873,TNNI3K,FPGT-TNNI3K,N/a,rs12566985-<b>G</b>,2 x 10-10,,NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Childhood body mass index,body mass index,GCST003177,1:74536509,Anthropometric
1874,TNNI3K,FPGT-TNNI3K,N/a,rs1514175-<b>A</b>,3 x 10-11,,0.43,'-,0.06 unit increase,[0.042-0.078],"FPGT-TNNI3K, TNNI3K",Body mass index,body mass index,GCST002021,1:74525960,Anthropometric
1875,TNNI3K,FPGT-TNNI3K,N/a,rs1514175-<b>A</b>,8 x 10-14,,0.43,'-,0.07 kg/m2 increase,[0.03-0.11],"FPGT-TNNI3K, TNNI3K",Body mass index,body mass index,GCST000830,1:74525960,Anthropometric
1913,TNNI3K,TNNI3K,N/a,rs7553158-<b>G</b>,2 x 10-14,,0.437549,'-,0.0105556 unit increase,[0.0079-0.0133],"TNNI3K, FPGT-TNNI3K",Adult body size,body height,GCST010988,1:74539554,Anthropometric
1914,TNNI3K,FPGT-TNNI3K,N/a,rs7553158-<b>G</b>,2 x 10-14,,0.437549,'-,0.0105556 unit increase,[0.0079-0.0133],"TNNI3K, FPGT-TNNI3K",Adult body size,body height,GCST010988,1:74539554,Anthropometric
2086,UROS,UROS,N/a,rs10901430-<b>G</b>,5 x 10-8,,0.791657,'-,0.0436941 unit increase,[0.027-0.06],"MMP21, UROS",Appendicular lean mass,appendicular lean mass,GCST009577,10:125780518,Anthropometric
1508,VIRMA,VIRMA,N/a,rs12680855-<b>A</b>,2 x 10-8,,0.6826,'-,0.002 unit decrease,[0.0014-0.0026],"LINC02894, VIRMA",Hand grip strength,grip strength measurement,GCST005830,8:94570427,Anthropometric
1881,VIRMA,VIRMA,N/a,rs4366055-<b>C</b>,2 x 10-9,(Japanese),0.49,'-,0.02 unit decrease,[0.014-0.026],VIRMA,Body mass index,body mass index,GCST004904,8:94495100,Anthropometric
1882,VIRMA,VIRMA,N/a,rs12680842-<b>G</b>,2 x 10-11,,0.39,'-,0.016 unit decrease,[0.012-0.02],"VIRMA, LINC02894",Body mass index,body mass index,GCST004904,8:94570378,Anthropometric
1883,VIRMA,VIRMA,N/a,rs12680842-<b>A</b>,3 x 10-16,,0.6839,'-,0.0142 unit increase,[0.011-0.018],"VIRMA, LINC02894",Body mass index,body mass index,GCST009004,8:94570378,Anthropometric
1884,VIRMA,VIRMA,N/a,rs12680842-<b>?</b>,3 x 10-11,,NR,'-,'-,'-,"VIRMA, LINC02894",Body mass index,body mass index,GCST007039,8:94570378,Anthropometric
1885,VIRMA,VIRMA,N/a,rs12680842-<b>A</b>,3 x 10-6,,0.666,'-,0.015 kg/m2 increase,[0.0085-0.0211],"VIRMA, LINC02894",Body mass index,body mass index,GCST002783,8:94570378,Anthropometric
1886,VIRMA,VIRMA,N/a,rs12678226-<b>?</b>,2 x 10-11,,NR,'-,'-,'-,"VIRMA, LINC02894",Body mass index,body mass index,GCST009871,8:94611879,Anthropometric
1887,VIRMA,VIRMA,N/a,rs75072578-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,"VIRMA, LINC02894",Body mass index,body mass index,GCST009871,8:94617521,Anthropometric
1888,VIRMA,VIRMA,N/a,rs10104041-<b>A</b>,1 x 10-11,,0.2873,'-,0.0143 unit decrease,[0.01-0.018],"VIRMA, LINC02894",Body mass index,body mass index,GCST009001,8:94559374,Anthropometric
1919,VIRMA,VIRMA,N/a,rs2114210-<b>G</b>,1 x 10-11,,0.664094,'-,0.00986173 unit decrease,[0.007-0.0127],"LINC02894, VIRMA",Adult body size,body height,GCST010988,8:94582934,Anthropometric
1474,WDR86,WDR86,N/a,rs28665356-<b>?</b>,5 x 10-10,,NR,'-,'-,'-,"CRYGN, WDR86-AS1",Heel bone mineral density,heel bone mineral density,GCST007066,7:151423712,Anthropometric
1475,WDR86,WDR86,N/a,rs28665356-<b>?</b>,1 x 10-12,,NR,'-,0.0157725 unit increase,[0.011-0.02],"CRYGN, WDR86-AS1",Heel bone mineral density,heel bone mineral density,GCST006433,7:151423712,Anthropometric
1476,WDR86,WDR86,N/a,rs7781279-<b>T</b>,6 x 10-15,,0.755674,'-,0.0165614 unit increase,[0.012-0.021],"WDR86-AS1, CRYGN",Heel bone mineral density,heel bone mineral density,GCST006979,7:151420596,Anthropometric
1477,WDR86,WDR86-AS1,N/a,rs28665356-<b>?</b>,5 x 10-10,,NR,'-,'-,'-,"CRYGN, WDR86-AS1",Heel bone mineral density,heel bone mineral density,GCST007066,7:151423712,Anthropometric
1478,WDR86,WDR86-AS1,N/a,rs28665356-<b>?</b>,1 x 10-12,,NR,'-,0.0157725 unit increase,[0.011-0.02],"CRYGN, WDR86-AS1",Heel bone mineral density,heel bone mineral density,GCST006433,7:151423712,Anthropometric
1479,WDR86,WDR86-AS1,N/a,rs7781279-<b>T</b>,6 x 10-15,,0.755674,'-,0.0165614 unit increase,[0.012-0.021],"WDR86-AS1, CRYGN",Heel bone mineral density,heel bone mineral density,GCST006979,7:151420596,Anthropometric
2025,CCDC201,CCDC201,N/a,rs10265133-<b>G</b>,2 x 10-9,,0.857555,'-,0.027396 unit increase,[0.018-0.036],"RNU6-326P, CCDC201",Offspring birth weight,"birth weight, parental genotype effect measurement",GCST008363,7:45856005,Birth
412,GUCY1A1,GUCY1A1,N/a,rs1965937-<b>?</b>,9 x 10-6,,NR,4.347826,'-,'-,GUCY1A1,Spontaneous preterm birth without premature rupture of membranes,spontaneous preterm birth,GCST008181,4:155592141,Birth
853,PPM1K,PPM1K,N/a,rs893971-<b>T</b>,7 x 10-6,(maternal warmth),0.6,'-,1.15 unit decrease,[NR],PPM1K,Conduct disorder (maternal expressed emotions interaction),"parental emotion expression measurmement, conduct disorder",GCST000245,4:88282518,Birth
670,ALG1L13P,ALG1L13P,N/a,rs2948294-<b>G</b>,6 x 10-26,,0.4329,'-,0.03831231 unit increase,[0.031-0.045],"FAM86B3P, ALG1L13P",Red cell distribution width,red blood cell distribution width,GCST004621,8:8237439,Blood
2037,ALG1L13P,ALG1L13P,N/a,rs2955587-<b>G</b>,2 x 10-13,,0.48198,'-,'-,'-,"ALG1L13P, FAM86B3P",Basophil count,basophil count,GCST90002296,8:8240557,Blood
1997,AP3M2,AP3M2,N/a,rs77346091-<b>T</b>,1 x 10-12,"(PLAT, 2212_69_1)",0.973125,'-,0.54916763 unit increase,[0.4-0.7],AP3M2,Blood protein levels,blood protein measurement,GCST006585,8:42162640,Blood
211,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Blood
219,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Blood
229,APOB,APOB,N/a,rs562338-<b>?</b>,3 x 10-25,,NR,'-,'-,'-,"APOB, TDRD15",Age-related disease endophenotypes,"total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement",GCST004046,2:21065449,Blood
688,APOB,APOB,N/a,rs1042034-<b>C</b>,2 x 10-24,,0.207313,'-,0.023703 SD unit increase,[0.019-0.028],APOB,Red cell distribution width,red blood cell distribution width,GCST90002369,2:21002409,Blood
689,APOB,APOB,N/a,rs1042034-<b>C</b>,4 x 10-23,,0.213292,'-,'-,'-,APOB,Red cell distribution width,red blood cell distribution width,GCST90002372,2:21002409,Blood
690,APOB,APOB,N/a,rs1042034-<b>T</b>,6 x 10-20,,0.793363,'-,0.025019975 unit decrease,[0.02-0.03],APOB,Red cell distribution width,red blood cell distribution width,GCST90002404,2:21002409,Blood
691,APOB,APOB,N/a,rs1042034-<b>?</b>,2 x 10-18,,NR,'-,'-,'-,APOB,Red cell distribution width,red blood cell distribution width,GCST007074,2:21002409,Blood
777,APOB,APOB,N/a,rs11680233-<b>C</b>,9 x 10-11,,0.715436,'-,0.016191924 unit decrease,[0.011-0.021],APOB,Plateletcrit,platelet crit,GCST90002400,2:21017159,Blood
785,APOB,APOB,N/a,rs11680233-<b>C</b>,2 x 10-10,,0.619281,'-,'-,'-,APOB,Platelet count,platelet count,GCST90002361,2:21017159,Blood
786,APOB,APOB,N/a,rs11680233-<b>C</b>,1 x 10-11,,0.715009,'-,0.013763 SD unit decrease,[0.0098-0.0177],APOB,Platelet count,platelet count,GCST90002357,2:21017159,Blood
787,APOB,APOB,N/a,rs11126598-<b>G</b>,1 x 10-12,,0.712041,'-,0.017617486 unit decrease,[0.013-0.022],APOB,Platelet count,platelet count,GCST90002402,2:21017492,Blood
1423,APOB,APOB,N/a,rs563290-<b>A</b>,3 x 10-11,,0.845276,'-,'-,'-,"TDRD15, APOB",Hemoglobin concentration,hemoglobin measurement,GCST90002314,2:21065354,Blood
1424,APOB,APOB,N/a,rs563290-<b>A</b>,2 x 10-12,,0.817876,'-,0.016813 SD unit decrease,[0.012-0.021],"TDRD15, APOB",Hemoglobin concentration,hemoglobin measurement,GCST90002310,2:21065354,Blood
1425,APOB,APOB,N/a,rs515135-<b>C</b>,3 x 10-10,,0.819926,'-,0.018069103 unit decrease,[0.012-0.024],"APOB, TDRD15",Hemoglobin,hemoglobin measurement,GCST90002384,2:21063185,Blood
1433,APOB,APOB,N/a,rs668948-<b>A</b>,6 x 10-10,,0.846176,'-,'-,'-,"APOB, TDRD15",Hematocrit,hematocrit,GCST90002308,2:21068657,Blood
1434,APOB,APOB,N/a,rs515135-<b>C</b>,1 x 10-9,,0.819944,'-,0.017346524 unit decrease,[0.012-0.023],"APOB, TDRD15",Hematocrit,hematocrit,GCST90002383,2:21063185,Blood
1435,APOB,APOB,N/a,rs563290-<b>A</b>,5 x 10-11,,0.81772,'-,0.015715 SD unit decrease,[0.011-0.02],"TDRD15, APOB",Hematocrit,hematocrit,GCST90002304,2:21065354,Blood
1989,APOB,APOB,N/a,rs679899-<b>G</b>,6 x 10-24,"(APOB, 2797_56_2)",0.503125,'-,0.24644051 unit decrease,[0.2-0.29],APOB,Blood protein levels,blood protein measurement,GCST006585,2:21028042,Blood
1990,APOB,APOB,N/a,rs679899-<b>G</b>,1 x 10-21,"(SLC5A8, 13691_10_3)",0.503125,'-,0.23186418 unit decrease,[0.18-0.28],APOB,Blood protein levels,blood protein measurement,GCST006585,2:21028042,Blood
1991,APOB,APOB,N/a,rs4665710-<b>C</b>,2 x 10-20,"(Sodium-coupled monocarboxylate transporter 1, SLC5A8.13691.10.3)",0.794,'-,0.28 unit decrease,[0.22-0.34],APOB,Blood protein levels,blood protein measurement,GCST005806,2:20998163,Blood
1992,APOB,APOB,N/a,rs679899-<b>G</b>,6 x 10-13,"(LRP1B, 7640_29_3)",0.503125,'-,0.1736701 unit decrease,[0.13-0.22],APOB,Blood protein levels,blood protein measurement,GCST006585,2:21028042,Blood
1993,APOB,APOB,N/a,rs679899-<b>G</b>,1 x 10-14,"(KCNMB3, 8905_20_3)",0.503125,'-,0.18513301 unit decrease,[0.14-0.23],APOB,Blood protein levels,blood protein measurement,GCST006585,2:21028042,Blood
2088,APOB,APOB,N/a,rs520354-<b>G</b>,7 x 10-13,"(EA, Apolipoprotein B)",0.4733936,'-,0.3033 unit increase,[0.22-0.38],APOB,Blood protein levels,apolipoprotein B measurement,GCST004365,2:21036740,Blood
625,CD8B2,CD8B2,N/a,rs143354638-<b>?</b>,7 x 10-7,,NR,10,'-,[4.02-24.88],CD8B2,Sulfasalazine-induced agranulocytosis,"response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,2:106508384,Blood
1982,CHL1,CHL1,N/a,rs13077895-<b>A</b>,8 x 10-14,"(CHL1, 3601_54_3)",0.64328125,'-,0.190407 unit increase,[0.14-0.24],"CHL1-AS2, LINC01986",Blood protein levels,blood protein measurement,GCST006585,3:51395,Blood
1983,CHL1,CHL1,N/a,rs13077895-<b>A</b>,7 x 10-13,"(CHL1, 8958_51_3)",0.64328125,'-,0.18331695 unit increase,[0.13-0.23],"CHL1-AS2, LINC01986",Blood protein levels,blood protein measurement,GCST006585,3:51395,Blood
1984,CHL1,CHL1,N/a,rs1015456-<b>C</b>,3 x 10-16,"(Neural cell adhesion molecule L1-like protein, CHL1.3601.54.3)",0.392,'-,0.21 unit decrease,[0.15-0.27],"CHL1-AS2, LINC01986",Blood protein levels,blood protein measurement,GCST005806,3:66093,Blood
1985,CHL1,CHL1-AS2,N/a,rs13077895-<b>A</b>,8 x 10-14,"(CHL1, 3601_54_3)",0.64328125,'-,0.190407 unit increase,[0.14-0.24],"CHL1-AS2, LINC01986",Blood protein levels,blood protein measurement,GCST006585,3:51395,Blood
1986,CHL1,CHL1-AS2,N/a,rs13077895-<b>A</b>,7 x 10-13,"(CHL1, 8958_51_3)",0.64328125,'-,0.18331695 unit increase,[0.13-0.23],"CHL1-AS2, LINC01986",Blood protein levels,blood protein measurement,GCST006585,3:51395,Blood
1987,CHL1,CHL1-AS2,N/a,rs1015456-<b>C</b>,3 x 10-16,"(Neural cell adhesion molecule L1-like protein, CHL1.3601.54.3)",0.392,'-,0.21 unit decrease,[0.15-0.27],"CHL1-AS2, LINC01986",Blood protein levels,blood protein measurement,GCST005806,3:66093,Blood
2214,CHRNA1,CHRNA1,N/a,"rs2600685-<b>T</b>, rs2600683-<b>C</b>, rs935863-<b>A</b>",1 x 10-6,,0.527,'-,'-,'-,CHRNA1; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,2:174762320,Blood
2216,CHRNA1,CHRNA1,N/a,"rs2359319-<b>C</b>, rs935866-<b>G</b>, rs6732758-<b>A</b>, rs6732427-<b>T</b>, rs7561169-<b>G</b>, rs935867-<b>T</b>, rs10497429-<b>C</b>, rs2123117-<b>C</b>, rs6728978-<b>C</b>",5 x 10-6,,0.533,'-,'-,'-,H3P6 - CHRNA1; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,2:174733568,Blood
2224,DCAF6,DCAF6,N/a,"rs11558511-<b>T</b>, rs6672997-<b>G</b>, rs10489202-<b>G</b>, rs17485889-<b>G</b>, rs12059592-<b>G</b>, rs275147-<b>A</b>, rs12097632-<b>A</b>, rs275137-<b>C</b>, rs275154-<b>A</b>, rs10918809-<b>G</b>, rs11578006-<b>C</b>, rs399273-<b>C</b>, rs17557162-<b>T</b>, rs202273-<b>T</b>, rs1060041-<b>C</b>, rs413168-<b>G</b>, rs10918822-<b>T</b>, rs41322644-<b>A</b>, rs12404574-<b>A</b>",1 x 10-11,,0.204,'-,'-,'-,DCAF6; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:168044612,Blood
2226,DCAF6,DCAF6,N/a,"rs11558511-<b>T</b>, rs6672997-<b>G</b>, rs10489202-<b>G</b>, rs17485889-<b>G</b>, rs12059592-<b>G</b>, rs275147-<b>A</b>, rs12097632-<b>C</b>, rs275137-<b>C</b>, rs275154-<b>A</b>, rs10918809-<b>G</b>, rs11578006-<b>C</b>, rs399273-<b>C</b>, rs17557162-<b>T</b>, rs202273-<b>T</b>, rs1060041-<b>C</b>, rs413168-<b>G</b>, rs10918822-<b>T</b>, rs41322644-<b>A</b>, rs12404574-<b>A</b>",4 x 10-7,,0.187,'-,'-,'-,DCAF6; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:168044612,Blood
700,DNM3,DNM3,N/a,rs112744418-<b>A</b>,1 x 10-20,,0.312497,'-,0.018426 SD unit decrease,[0.015-0.022],DNM3,Red blood cell count,red blood cell density measurement,GCST90002363,1:172194568,Blood
701,DNM3,DNM3,N/a,rs7535241-<b>A</b>,5 x 10-18,,0.249309,'-,'-,'-,DNM3,Red blood cell count,red blood cell density measurement,GCST90002367,1:172205456,Blood
789,DNM3,DNM3,N/a,rs56125409-<b>G</b>,2 x 10-19,,0.1233,'-,0.05061637 unit decrease,[0.04-0.062],DNM3,Platelet count,platelet count,GCST004603,1:171960311,Blood
790,DNM3,DNM3,N/a,rs6425521-<b>A</b>,2 x 10-46,,0.8012,'-,0.06523987 unit decrease,[0.056-0.074],DNM3,Platelet count,platelet count,GCST004603,1:171973643,Blood
791,DNM3,DNM3,N/a,rs2038479-<b>A</b>,3 x 10-166,,0.804552,'-,0.063269 SD unit decrease,[0.059-0.068],DNM3,Platelet count,platelet count,GCST90002357,1:171970150,Blood
792,DNM3,DNM3,N/a,rs6425522-<b>T</b>,1 x 10-33,,0.202812,'-,0.056143 SD units increase,[0.047-0.065],DNM3,Platelet count,platelet count,GCST90002358,1:171976942,Blood
793,DNM3,DNM3,N/a,rs2038479-<b>A</b>,2 x 10-196,,0.803165,'-,'-,'-,DNM3,Platelet count,platelet count,GCST90002361,1:171970150,Blood
794,DNM3,DNM3,N/a,rs56125409-<b>G</b>,1 x 10-24,,0.120715,'-,0.03619553 unit decrease,[0.029-0.043],DNM3,Platelet count,platelet count,GCST90002402,1:171960311,Blood
795,DNM3,DNM3,N/a,rs2038479-<b>A</b>,3 x 10-81,,0.802601,'-,0.055071093 unit decrease,[0.049-0.061],DNM3,Platelet count,platelet count,GCST90002402,1:171970150,Blood
796,DNM3,DNM3,N/a,rs11497367-<b>A</b>,5 x 10-17,,0.042089,'-,0.047138393 unit decrease,[0.036-0.058],DNM3,Platelet count,platelet count,GCST90002402,1:172027484,Blood
797,DNM3,DNM3,N/a,rs2208368-<b>?</b>,4 x 10-8,(conditional on round 2),NR,'-,0.026077408 unit decrease,[0.017-0.035],DNM3,Platelet count,platelet count,GCST005991,1:171923265,Blood
798,DNM3,DNM3,N/a,rs6662263-<b>?</b>,3 x 10-16,,NR,'-,0.04289 unit decrease,[0.033-0.053],DNM3,Platelet count,platelet count,GCST005991,1:171975102,Blood
799,DNM3,DNM3,N/a,rs10914144-<b>T</b>,2 x 10-12,,NR,'-,3.417 10^9/l increase,[2.46-4.37],DNM3,Platelet count,platelet count,GCST001337,1:171980610,Blood
802,DNM3,DNM3,N/a,rs1998174-<b>A</b>,4 x 10-9,,0.6401,'-,0.02197815 unit increase,[0.015-0.029],DNM3,Platelet distribution width,platelet component distribution width,GCST004616,1:171939384,Blood
803,DNM3,DNM3,N/a,rs78346539-<b>G</b>,4 x 10-68,,0.0161,'-,0.2515199 unit decrease,[0.22-0.28],DNM3,Platelet distribution width,platelet component distribution width,GCST004616,1:171966088,Blood
804,DNM3,DNM3,N/a,rs2038480-<b>T</b>,4 x 10-265,,0.8024,'-,0.1570992 unit increase,[0.15-0.17],DNM3,Platelet distribution width,platelet component distribution width,GCST004616,1:171970501,Blood
805,DNM3,DNM3,N/a,rs6681480-<b>G</b>,5 x 10-225,,0.630777,'-,0.103377216 unit decrease,[0.097-0.11],DNM3,Platelet distribution width,platelet component distribution width,GCST90002401,1:171925452,Blood
806,DNM3,DNM3,N/a,rs78346539-<b>G</b>,5 x 10-44,,0.016767,'-,0.12637499 unit decrease,[0.11-0.14],DNM3,Platelet distribution width,platelet component distribution width,GCST90002401,1:171966088,Blood
807,DNM3,DNM3,N/a,rs6425522-<b>C</b>,1 x 10-695,,0.801156,'-,0.22388959 unit increase,[0.22-0.23],DNM3,Platelet distribution width,platelet component distribution width,GCST90002401,1:171976942,Blood
808,DNM3,DNM3,N/a,rs2421986-<b>T</b>,1 x 10-19,,0.17029,'-,0.029460466 unit increase,[0.023-0.036],DNM3,Platelet distribution width,platelet component distribution width,GCST90002401,1:172131456,Blood
809,DNM3,DNM3,N/a,rs7528296-<b>C</b>,1 x 10-15,,0.386846,'-,0.018554658 unit decrease,[0.014-0.023],"PIGC, DNM3",Platelet distribution width,platelet component distribution width,GCST90002401,1:172412243,Blood
993,DNM3,DNM3,N/a,rs6681480-<b>G</b>,4 x 10-12,,0.63,'-,0.02597416 unit increase,[0.019-0.033],DNM3,Mean platelet volume,mean platelet volume,GCST004599,1:171925452,Blood
994,DNM3,DNM3,N/a,rs78346539-<b>G</b>,7 x 10-45,,0.0161,'-,0.2039364 unit decrease,[0.18-0.23],DNM3,Mean platelet volume,mean platelet volume,GCST004599,1:171966088,Blood
995,DNM3,DNM3,N/a,rs2038480-<b>T</b>,1 x 10-181,,0.8024,'-,0.1305419 unit increase,[0.12-0.14],DNM3,Mean platelet volume,mean platelet volume,GCST004599,1:171970501,Blood
996,DNM3,DNM3,N/a,rs2038479-<b>C</b>,1 x 10-10,,0.199169,'-,0.115422 SD units decrease,[0.08-0.15],DNM3,Mean platelet volume,mean platelet volume,GCST90002345,1:171970150,Blood
997,DNM3,DNM3,N/a,rs2038480-<b>A</b>,5 x 10-630,,0.197865,'-,'-,'-,DNM3,Mean platelet volume,mean platelet volume,GCST90002349,1:171970501,Blood
998,DNM3,DNM3,N/a,rs10914144-<b>C</b>,1 x 10-24,,NR,'-,0.014 ln(fl) increase,[0.012-0.016],DNM3,Mean platelet volume,mean platelet volume,GCST001335,1:171980610,Blood
999,DNM3,DNM3,N/a,rs10914144-<b>T</b>,2 x 10-8,,NR,'-,0.11 unit increase,[NR],DNM3,Mean platelet volume,mean platelet volume,GCST002184,1:171980610,Blood
1000,DNM3,DNM3,N/a,rs10914144-<b>C</b>,2 x 10-14,,NR,'-,0.01 fl increase,[0.009-0.017],DNM3,Mean platelet volume,mean platelet volume,GCST000497,1:171980610,Blood
1001,DNM3,DNM3,N/a,rs2038480-<b>A</b>,3 x 10-624,,0.196928,'-,0.128314 SD unit decrease,[0.12-0.13],DNM3,Mean platelet volume,mean platelet volume,GCST90002346,1:171970501,Blood
1002,DNM3,DNM3,N/a,rs10798758-<b>A</b>,1 x 10-121,,0.630567,'-,0.06975688 unit decrease,[0.064-0.076],DNM3,Mean platelet volume,mean platelet volume,GCST90002395,1:171923641,Blood
1003,DNM3,DNM3,N/a,rs78795075-<b>C</b>,1 x 10-21,,0.017378,'-,0.08431484 unit decrease,[0.067-0.102],DNM3,Mean platelet volume,mean platelet volume,GCST90002395,1:172086359,Blood
1004,DNM3,DNM3,N/a,rs2038479-<b>A</b>,3 x 10-477,,0.802609,'-,0.17365976 unit increase,[0.17-0.18],DNM3,Mean platelet volume,mean platelet volume,GCST90002395,1:171970150,Blood
1427,DNM3,DNM3,N/a,rs554019-<b>T</b>,4 x 10-9,,0.4168,'-,0.02124103 unit decrease,[0.014-0.028],DNM3,Hemoglobin concentration,hemoglobin measurement,GCST004615,1:172171408,Blood
1428,DNM3,DNM3,N/a,rs7535241-<b>A</b>,4 x 10-22,,0.251112,'-,'-,'-,DNM3,Hemoglobin concentration,hemoglobin measurement,GCST90002314,1:172205456,Blood
1429,DNM3,DNM3,N/a,rs112744418-<b>A</b>,1 x 10-24,,0.31275,'-,0.020346 SD unit decrease,[0.016-0.024],DNM3,Hemoglobin concentration,hemoglobin measurement,GCST90002310,1:172194568,Blood
1430,DNM3,DNM3,N/a,rs2209098-<b>C</b>,4 x 10-19,,0.311085,'-,0.021332135 unit decrease,[0.017-0.026],DNM3,Hemoglobin,hemoglobin measurement,GCST90002384,1:172198086,Blood
1431,DNM3,DNM3,N/a,rs554019-<b>T</b>,7 x 10-19,,'-,'-,0.02 unit decrease,[NR],DNM3,Hemoglobin levels,hemoglobin measurement,GCST010083,1:172171408,Blood
1440,DNM3,DNM3,N/a,rs7535241-<b>A</b>,1 x 10-22,,0.253128,'-,'-,'-,DNM3,Hematocrit,hematocrit,GCST90002308,1:172205456,Blood
1441,DNM3,DNM3,N/a,rs2209098-<b>C</b>,2 x 10-19,,0.311118,'-,0.021511815 unit decrease,[0.017-0.026],DNM3,Hematocrit,hematocrit,GCST90002383,1:172198086,Blood
1442,DNM3,DNM3,N/a,rs112744418-<b>A</b>,9 x 10-26,,0.312704,'-,0.020818 SD unit decrease,[0.017-0.025],DNM3,Hematocrit,hematocrit,GCST90002304,1:172194568,Blood
1563,DNM3,DNM3,N/a,rs17277127-<b>T</b>,2 x 10-14,,0.311809,'-,0.018332152 unit decrease,[0.014-0.023],DNM3,Red blood cell count,erythrocyte count,GCST90002403,1:172167994,Blood
1564,DNM3,DNM3,N/a,rs2209098-<b>?</b>,2 x 10-19,,NR,'-,'-,'-,DNM3,Red blood cell count,erythrocyte count,GCST007069,1:172198086,Blood
1565,DNM3,DNM3,N/a,rs7534393-<b>?</b>,2 x 10-14,,NR,'-,'-,'-,DNM3,Red blood cell count,erythrocyte count,GCST007069,1:172348891,Blood
1566,DNM3,DNM3,N/a,rs7517737-<b>A</b>,2 x 10-9,,0.566625,'-,0.013339029 unit decrease,[0.009-0.0177],"DNM3, PIGC",Red blood cell count,erythrocyte count,GCST90002403,1:172372835,Blood
1653,DNM3,DNM3,N/a,rs113989831-<b>G</b>,7 x 10-6,(African American),0.08,'-,0.31 unit increase,0.18-0.45,"EEF1AKNMT, DNM3",Diffusing capacity of carbon monoxide,diffusing capacity of the lung for carbon monoxide,GCST007637,1:171814725,Blood
1998,DPP7,DPP7,N/a,rs10747049-<b>C</b>,2 x 10-39,"(Dipeptidyl peptidase 2, DPP7.8346.9.3)",0.75,'-,0.36 unit increase,[0.3-0.42],DPP7,Blood protein levels,blood protein measurement,GCST005806,9:137114298,Blood
1421,DTD1,DTD1,N/a,rs6136437-<b>C</b>,1 x 10-10,,0.111507,'-,0.018859 SD unit increase,[0.013-0.025],DTD1,Hemoglobin concentration,hemoglobin measurement,GCST90002310,20:18615780,Blood
692,EIF3L,EIF3L,N/a,rs184901441-<b>A</b>,1 x 10-12,,0.000482,'-,0.424205 SD unit increase,[0.31-0.54],EIF3L,Red cell distribution width,red blood cell distribution width,GCST90002369,22:37881160,Blood
509,FCGR2A,FCGR2A,N/a,rs146883516-<b>C</b>,8 x 10-11,,NR,'-,0.1609 unit decrease,[0.11-0.21],FCGR2A,Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,1:161518033,Blood
510,FCGR2A,FCGR2A,N/a,rs6678315-<b>C</b>,2 x 10-9,,NR,'-,0.0193 unit increase,[0.013-0.026],"RNU6-481P, FCGR2A",Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,1:161418623,Blood
511,FCGR2A,FCGR2A,N/a,rs71639066-<b>T</b>,2 x 10-9,,NR,'-,0.0404 unit increase,[0.027-0.054],"FCGR2A, RNU6-481P",Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,1:161483076,Blood
512,FCGR2A,FCGR2A,N/a,rs115944227-<b>G</b>,2 x 10-9,,NR,'-,0.0341 unit increase,[0.023-0.045],"FCGR2A, RNU6-481P",Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,1:161494146,Blood
513,FCGR2A,FCGR2A,N/a,rs61446694-<b>A</b>,1 x 10-11,,NR,'-,0.0347 unit increase,[0.025-0.045],"FCGR2A, RNU6-481P",Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,1:161480363,Blood
514,FCGR2A,FCGR2A,N/a,rs79106728-<b>A</b>,3 x 10-13,,NR,'-,0.0373 unit increase,[0.027-0.047],"RNU6-481P, FCGR2A",Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,1:161440015,Blood
1225,FCGR2A,FCGR2A,N/a,rs7551957-<b>C</b>,2 x 10-111,(Low affinity immunoglobulin gamma Fc region receptor II-a/b),0.4259073,'-,0.8857 unit increase,[0.82-0.95],"FCGR2A, RNU6-481P",Blood protein levels,low affinity immunoglobulin gamma Fc region receptor II-a/b measurement,GCST004365,1:161500252,Blood
1419,FCGR2A,FCGR2A,N/a,rs9427398-<b>G</b>,7 x 10-21,,'-,'-,0.031 unit increase,[NR],FCGR2A,Hemoglobin levels,hemoglobin measurement,GCST010083,1:161506415,Blood
1432,FCGR2A,FCGR2A,N/a,rs17400517-<b>T</b>,3 x 10-9,,0.1144,'-,0.03329163 unit increase,[0.022-0.044],FCGR2A,Hematocrit,hematocrit,GCST004604,1:161515469,Blood
1562,FCGR2A,FCGR2A,N/a,rs9427403-<b>?</b>,8 x 10-17,,NR,'-,'-,'-,"FCGR2A, HSPA6",Red blood cell count,erythrocyte count,GCST007069,1:161524532,Blood
1976,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,4 x 10-12,,NR,'-,0.03668 unit increase,[0.026-0.047],FCGR2A,Serum total protein level,blood protein measurement,GCST005989,1:161509955,Blood
1977,FCGR2A,FCGR2A,N/a,rs1801274-<b>G</b>,1 x 10-2102,"(Low affinity immunoglobulin gamma Fc region receptor II-a, FCGR2A.3309.2.2)",0.533,'-,1.24 unit increase,[1.22-1.26],FCGR2A,Blood protein levels,blood protein measurement,GCST005806,1:161509955,Blood
1978,FCGR2A,FCGR2A,N/a,rs4657041-<b>C</b>,8 x 10-426,"(Low affinity immunoglobulin gamma Fc region receptor II-b, FCGR2B.3310.62.1)",0.532,'-,0.87 unit increase,[0.83-0.91],FCGR2A,Blood protein levels,blood protein measurement,GCST005806,1:161509069,Blood
1979,FCGR2A,FCGR2A,N/a,rs7535475-<b>C</b>,6 x 10-514,"(FCGR2A, 3309_2_2)",0.37703125,'-,1.0405178 unit decrease,[1.01-1.08],"FCGR2A, RNU6-481P",Blood protein levels,blood protein measurement,GCST006585,1:161493797,Blood
1980,FCGR2A,FCGR2A,N/a,rs79106728-<b>A</b>,5 x 10-11,,NR,'-,0.0336 unit increase,[0.024-0.044],"RNU6-481P, FCGR2A",Serum total protein level,blood protein measurement,GCST90019522,1:161440015,Blood
1981,FCGR2A,FCGR2A,N/a,rs61446694-<b>A</b>,5 x 10-11,,NR,'-,0.0336 unit increase,[0.024-0.044],"FCGR2A, RNU6-481P",Serum total protein level,blood protein measurement,GCST90019522,1:161480363,Blood
2035,FCGR2A,FCGR2A,N/a,rs1801274-<b>G</b>,2 x 10-18,,0.531328,'-,0.019701969 unit increase,[0.015-0.024],FCGR2A,Basophil percentage of white cells,basophil percentage of leukocytes,GCST90002380,1:161509955,Blood
2038,FCGR2A,FCGR2A,N/a,rs1801274-<b>G</b>,3 x 10-14,,0.531311,'-,0.017115898 unit increase,[0.013-0.022],FCGR2A,Basophil count,basophil count,GCST90002379,1:161509955,Blood
2234,FGF12,FGF12,N/a,"rs1875731-<b>T</b>, rs1875732-<b>G</b>, rs1827546-<b>A</b>, rs2654693-<b>C</b>, rs1875730-<b>G</b>, rs2708309-<b>C</b>, rs2654689-<b>G</b>, rs2134634-<b>G</b>, rs1827545-<b>A</b>, rs2174178-<b>G</b>",3 x 10-14,,0,'-,'-,'-,FGF12; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:192595268,Blood
2236,FGF12,FGF12,N/a,"rs1875731-<b>T</b>, rs1875732-<b>G</b>, rs1827546-<b>A</b>, rs2654693-<b>C</b>, rs1875730-<b>A</b>, rs2708309-<b>C</b>, rs2654689-<b>G</b>, rs2134634-<b>G</b>, rs1827545-<b>A</b>, rs2174178-<b>G</b>",6 x 10-7,,0.16,'-,'-,'-,FGF12; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:192595268,Blood
925,GUCY1A1,GUCY1A1,N/a,rs10517621-<b>T</b>,3 x 10-10,,0.244402,'-,'-,'-,"GUCY1B1, GUCY1A1",White blood cell count,myeloid white cell count,GCST90002378,4:155756440,Blood
954,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,4 x 10-9,,0.234634,'-,0.015340015 unit decrease,[0.01-0.02],GUCY1A1,Monocyte count,monocyte count,GCST90002393,4:155724361,Blood
1082,GUCY1A1,GUCY1A1,N/a,rs13143871-<b>C</b>,1 x 10-10,,0.261747,'-,0.014007 SD unit decrease,[0.0098-0.0182],GUCY1A1,Lymphocyte counts,lymphocyte count,GCST90002316,4:155698052,Blood
1083,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,4 x 10-9,,0.234634,'-,0.015340015 unit decrease,[0.01-0.02],GUCY1A1,Lymphocyte counts,lymphocyte count,GCST90002388,4:155724361,Blood
1254,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>?</b>,5 x 10-9,,NR,'-,'-,'-,GUCY1A1,White blood cell count,leukocyte count,GCST007070,4:155724361,Blood
687,H2AC6,H2AC6,N/a,rs198805-<b>G</b>,4 x 10-425,,0.153208,'-,'-,'-,H2AC6,Red cell distribution width,red blood cell distribution width,GCST90002372,6:26134444,Blood
948,H2AC6,H2AC6,N/a,rs4645-<b>T</b>,1 x 10-9,,0.215579,'-,0.016967934 unit increase,[0.012-0.022],H2AC6,Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST90002394,6:26124406,Blood
932,IL20RB,IL20RB,N/a,rs835636-<b>C</b>,4 x 10-16,,0.489868,'-,0.015098 SD unit increase,[0.011-0.019],IL20RB,White blood cell count,myeloid white cell count,GCST90002374,3:136955658,Blood
1261,IL20RB,IL20RB,N/a,rs835649-<b>A</b>,4 x 10-9,,0.449796,'-,0.013114219 unit increase,[0.0087-0.0175],IL20RB,White blood cell count,leukocyte count,GCST90002407,3:136953048,Blood
504,KC6,KC6,N/a,rs9958032-<b>?</b>,3 x 10-6,,NR,'-,1.467 unit increase,[0.85-2.08],KC6,Blood trace element (Zn levels),serum zinc measurement,GCST002040,18:41648346,Blood
1426,LINC00578,LINC00578,N/a,rs11915331-<b>G</b>,6 x 10-11,,0.60257,'-,0.01236 SD unit decrease,[0.0087-0.0161],"LINC00501, LINC00578",Hemoglobin concentration,hemoglobin measurement,GCST90002310,3:177360846,Blood
1437,LINC00578,LINC00578,N/a,rs9861140-<b>T</b>,6 x 10-10,,0.44637,'-,'-,'-,"LINC00578, LINC00501",Hematocrit,hematocrit,GCST90002308,3:177367935,Blood
1438,LINC00578,LINC00578,N/a,rs9861140-<b>T</b>,4 x 10-12,,0.4553,'-,0.013081 SD unit decrease,[0.0094-0.0168],"LINC00578, LINC00501",Hematocrit,hematocrit,GCST90002304,3:177367935,Blood
1439,LINC00578,LINC00578,N/a,rs9861140-<b>T</b>,3 x 10-9,,0.453552,'-,0.013249877 unit decrease,[0.0089-0.0176],"LINC00578, LINC00501",Hematocrit,hematocrit,GCST90002383,3:177367935,Blood
1484,LINC00578,LINC00578,N/a,rs2047564-<b>T</b>,2 x 10-9,,NR,'-,0.0217 unit decrease,[0.015-0.029],"LINC00501, LINC00578",Glycated hemoglobin levels,HbA1c measurement,GCST90019509,3:177420964,Blood
2222,LINC00578,LINC00578,N/a,"rs6443497-<b>A</b>, rs3922740-<b>A</b>, rs6785573-<b>C</b>, rs16828637-<b>G</b>, rs9829938-<b>T</b>, rs7430456-<b>A</b>, rs4857739-<b>T</b>, rs4857741-<b>A</b>, rs16828642-<b>G</b>, rs6443502-<b>T</b>, rs13071694-<b>G</b>, rs17636221-<b>G</b>, rs9875579-<b>C</b>",4 x 10-8,,0,'-,'-,'-,LINC00578; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:177756272,Blood
2228,LINC02414,LINC02414,N/a,"rs11247024-<b>C</b>, rs7294672-<b>T</b>",6 x 10-9,,0.185,'-,'-,'-,N/A - LINC02414; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,12:131618173,Blood
1534,LINC02502,LINC02502,N/a,rs1845344-<b>T</b>,7 x 10-6,,0.27,'-,0.97 unit increase,[0.56-1.38],"LINC02502, MAD2L1",F-cell distribution in sickle cell anaemia,"fetal hemoglobin measurement, Sickle cell anemia",GCST000982,4:120041230,Blood
2210,MGST1,MGST1,N/a,"rs9332908-<b>A</b>, rs3844373-<b>G</b>, rs7312090-<b>A</b>, rs2287152-<b>T</b>, rs4149203-<b>G</b>",9 x 10-25,,0.001,'-,'-,'-,MGST1; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,12:16356132,Blood
2212,MGST1,MGST1,N/a,"rs9332908-<b>A</b>, rs3844373-<b>G</b>, rs7312090-<b>A</b>, rs2287152-<b>T</b>, rs4149203-<b>A</b>",5 x 10-16,,0.321,'-,'-,'-,MGST1; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,12:16356132,Blood
893,NDST1,NDST1,N/a,rs12519827-<b>A</b>,2 x 10-9,,0.084517,'-,0.023865528 unit increase,[0.016-0.032],NDST1,Neutrophil count,neutrophil count,GCST90002398,5:150488763,Blood
1255,NDST1,NDST1,N/a,rs3846706-<b>?</b>,1 x 10-8,,NR,'-,'-,'-,NDST1,White blood cell count,leukocyte count,GCST007070,5:150496169,Blood
1994,NDST1,NDST1,N/a,rs35413298-<b>G</b>,2 x 10-6,"(NDST1, 6927_7_3)",0.6834375,'-,0.123065755 unit increase,[0.072-0.174],"SYNPO, NDST1",Blood protein levels,blood protein measurement,GCST006585,5:150559860,Blood
415,OR51B5,OR51B5,N/a,rs372091-<b>G</b>,8 x 10-12,,NR,'-,0.2217 unit increase,[0.16-0.29],"HBE1, OR51B5, HBG2",Urinary sodium excretion,sodium measurement,GCST90019519,11:5496926,Blood
492,OR51B5,OR51B5,N/a,rs7948471-<b>A</b>,3 x 10-10,,0.21,'-,0.26 unit decrease,[0.18-0.34],"OR51B5, HBG2, OR51I2, HBE1",Sickle cell anemia (haemolysis),Sickle cell anemia,GCST001862,11:5450516,Blood
979,OR51B5,OR51B5,N/a,rs770182365-<b>G</b>,3 x 10-9,,0.000205,'-,0.65014344 unit decrease,[0.44-0.86],"OR51B5, HBE1, HBG2",Mean reticulocyte volume,mean reticulocyte volume,GCST90002396,11:5408539,Blood
1016,OR51B5,OR51B5,N/a,rs770182365-<b>G</b>,2 x 10-13,,0.000205,'-,0.8002152 unit decrease,[0.59-1.01],"OR51B5, HBE1, HBG2",Mean spheric corpuscular volume,mean corpuscular volume,GCST90002397,11:5408539,Blood
1422,OR51B5,OR51B5,N/a,rs557129696-<b>G</b>,5 x 10-11,(Pomak),0.004,'-,2.027 unit decrease,[1.42-2.63],"HBE1, HBG2, OR51B5",Hemoglobin,hemoglobin measurement,GCST004536,11:5307453,Blood
1536,OR51B5,OR51B5,N/a,rs5006884-<b>A</b>,3 x 10-8,(African),0.25,'-,0.16 unit increase,[NR],"OR51B6, OR51B5, HBE1, HBG2",Fetal hemoglobin levels,fetal hemoglobin measurement,GCST000545,11:5352021,Blood
988,PCDHGA2,PCDHGA2,N/a,rs72790070-<b>G</b>,4 x 10-31,,0.968206,'-,0.063642 SD unit decrease,[0.053-0.074],"PCDHGB3, PCDHGA5, PCDHGC3, PCDHGA7, PCDHGA4, PCDHGA1, PCDHGA3, PCDHGC4, PCDHGA10, PCDHGC5, PCDHGA8, PCDHGB5, PCDHGA9, PCDHGB7, PCDHGB6, PCDHGA11, PCDHGB4, PCDHGA2, PCDHGA6, PCDHGB2, PCDHGA12, PCDHGB1",Mean platelet volume,mean platelet volume,GCST90002346,5:141500114,Blood
989,PCDHGA2,PCDHGA2,N/a,rs72790070-<b>A</b>,5 x 10-22,,0.031776,'-,0.06204156 unit increase,[0.049-0.075],"PCDHGB3, PCDHGA5, PCDHGC3, PCDHGA7, PCDHGA4, PCDHGA1, PCDHGA3, PCDHGC4, PCDHGA10, PCDHGC5, PCDHGA8, PCDHGB5, PCDHGA9, PCDHGB7, PCDHGB6, PCDHGA11, PCDHGB4, PCDHGA2, PCDHGA6, PCDHGB2, PCDHGA12, PCDHGB1",Mean platelet volume,mean platelet volume,GCST90002395,5:141500114,Blood
1046,PDGFD,PDGFD,N/a,rs60621493-<b>?</b>,3 x 10-9,(MMP-12),NR,'-,0.586531 unit decrease,[0.39-0.78],PDGFD,Blood protein levels,matrix metalloproteinase 12 measurement,GCST009696,11:103909394,Blood
1995,PDGFD,PDGFD,N/a,rs10895596-<b>G</b>,3 x 10-129,"(PDGFD, 9341_1_3)",0.69953125,'-,0.62404776 unit increase,[0.58-0.67],PDGFD,Blood protein levels,blood protein measurement,GCST006585,11:104161315,Blood
1996,PDGFD,PDGFD,N/a,rs7950273-<b>G</b>,1 x 10-24,"(Platelet-derived growth factor D, PDGFD.9341.1.3)",0.288,'-,0.27 unit decrease,[0.21-0.33],PDGFD,Blood protein levels,blood protein measurement,GCST005806,11:104160870,Blood
2218,PDGFD,PDGFD,N/a,"rs11226159-<b>G</b>, rs11226158-<b>C</b>",3 x 10-15,,0.313,'-,'-,'-,PDGFD; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,11:104107812,Blood
2220,PDGFD,PDGFD,N/a,"rs11226159-<b>T</b>, rs11226158-<b>C</b>",1 x 10-11,,0.544,'-,'-,'-,PDGFD; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,11:104107812,Blood
2230,PHF2,PHF2,N/a,"rs7855940-<b>G</b>, rs2487010-<b>C</b>, rs10761280-<b>A</b>, rs11792101-<b>A</b>, rs7874836-<b>C</b>, rs10821216-<b>T</b>, rs9409699-<b>T</b>, rs7859190-<b>C</b>, rs10739959-<b>A</b>, rs2491000-<b>G</b>, rs2487020-<b>T</b>, rs4744280-<b>A</b>, rs2398873-<b>C</b>, rs10114823-<b>C</b>, rs10821219-<b>C</b>, rs2490998-<b>G</b>, rs10116474-<b>T</b>, rs2253589-<b>C</b>, rs7854820-<b>T</b>, rs2265800-<b>T</b>, rs2243742-<b>G</b>",1 x 10-10,,0.166,'-,'-,'-,PHF2 - MIR4291; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,9:93773684,Blood
2232,PHF2,PHF2,N/a,"rs7855940-<b>G</b>, rs2487010-<b>C</b>, rs10761280-<b>A</b>, rs11792101-<b>A</b>, rs7874836-<b>C</b>, rs10821216-<b>T</b>, rs9409699-<b>T</b>, rs7859190-<b>C</b>, rs10739959-<b>A</b>, rs2491000-<b>G</b>, rs2487020-<b>C</b>, rs4744280-<b>A</b>, rs2398873-<b>C</b>, rs10114823-<b>C</b>, rs10821219-<b>C</b>, rs2490998-<b>G</b>, rs10116474-<b>T</b>, rs2253589-<b>C</b>, rs7854820-<b>T</b>, rs2265800-<b>T</b>, rs2243742-<b>G</b>",1 x 10-9,,0,'-,'-,'-,PHF2 - MIR4291; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,9:93773684,Blood
961,PMAIP1,PMAIP1,N/a,rs9916942-<b>C</b>,2 x 10-12,,0.170168,'-,0.01767 SD unit decrease,[0.013-0.023],PMAIP1,Monocyte count,monocyte count,GCST90002340,18:59895221,Blood
962,PMAIP1,PMAIP1,N/a,rs8087293-<b>A</b>,1 x 10-11,,0.154618,'-,'-,'-,PMAIP1,Monocyte count,monocyte count,GCST90002344,18:59896576,Blood
1765,PMAIP1,PMAIP1,N/a,rs4368253-<b>C</b>,8 x 10-7,,0.677,1.18,'-,[1.11-1.26],"NFE2L3P1, PMAIP1",Chronic lymphocytic leukemia,chronic lymphocytic leukemia,GCST003468,18:59955055,Blood
1767,PMAIP1,PMAIP1,N/a,rs4368253-<b>C</b>,3 x 10-8,,0.69,1.19,'-,[1.12-1.27],"NFE2L3P1, PMAIP1",Chronic lymphocytic leukemia,chronic lymphocytic leukemia,GCST002073,18:59955055,Blood
677,PRC1,PRC1,N/a,rs547122663-<b>G</b>,6 x 10-14,,0.003744,'-,0.14160238 unit increase,[0.1-0.18],PRC1,Red cell distribution width,red blood cell distribution width,GCST90002404,15:90966318,Blood
678,PRC1,PRC1,N/a,rs28584391-<b>G</b>,7 x 10-405,,0.143766,'-,'-,'-,"PRC1-AS1, PRC1",Red cell distribution width,red blood cell distribution width,GCST90002372,15:90980533,Blood
679,PRC1,PRC1,N/a,rs2290202-<b>T</b>,1 x 10-183,,0.129287,'-,0.116811916 unit increase,[0.11-0.12],"PRC1-AS1, PRC1",Red cell distribution width,red blood cell distribution width,GCST90002404,15:90969037,Blood
680,PRC1,PRC1,N/a,rs79383275-<b>T</b>,1 x 10-14,,0.017697,'-,0.06712465 unit decrease,[0.05-0.084],"PRC1, PRC1-AS1",Red cell distribution width,red blood cell distribution width,GCST90002404,15:90966628,Blood
681,PRC1,PRC1,N/a,rs8028409-<b>T</b>,1 x 10-110,,NR,'-,0.129599 unit increase,[0.12-0.14],"RCCD1, PRC1",Red cell distribution width,red blood cell distribution width,GCST006804,15:90963192,Blood
682,PRC1,PRC1,N/a,rs8028409-<b>T</b>,9 x 10-123,,0.1301,'-,0.1244932 unit increase,[0.11-0.13],"RCCD1, PRC1",Red cell distribution width,red blood cell distribution width,GCST004621,15:90963192,Blood
683,PRC1,PRC1,N/a,rs77554484-<b>C</b>,6 x 10-432,,0.871853,'-,0.1314 SD unit decrease,[0.13-0.14],"RCCD1, PRC1",Red cell distribution width,red blood cell distribution width,GCST90002369,15:90965985,Blood
684,PRC1,PRC1-AS1,N/a,rs28584391-<b>G</b>,7 x 10-405,,0.143766,'-,'-,'-,"PRC1-AS1, PRC1",Red cell distribution width,red blood cell distribution width,GCST90002372,15:90980533,Blood
685,PRC1,PRC1-AS1,N/a,rs2290202-<b>T</b>,1 x 10-183,,0.129287,'-,0.116811916 unit increase,[0.11-0.12],"PRC1-AS1, PRC1",Red cell distribution width,red blood cell distribution width,GCST90002404,15:90969037,Blood
686,PRC1,PRC1-AS1,N/a,rs79383275-<b>T</b>,1 x 10-14,,0.017697,'-,0.06712465 unit decrease,[0.05-0.084],"PRC1, PRC1-AS1",Red cell distribution width,red blood cell distribution width,GCST90002404,15:90966628,Blood
781,PRC1,PRC1,N/a,rs8037137-<b>C</b>,8 x 10-11,,0.1299,'-,0.03544713 unit decrease,[0.025-0.046],"RCCD1, PRC1",Platelet count,platelet count,GCST004603,15:90963407,Blood
782,PRC1,PRC1,N/a,rs8037137-<b>C</b>,6 x 10-18,,0.129742,'-,0.02914947 unit decrease,[0.023-0.036],"RCCD1, PRC1",Platelet count,platelet count,GCST90002402,15:90963407,Blood
783,PRC1,PRC1,N/a,rs8037137-<b>C</b>,3 x 10-30,,0.20698,'-,'-,'-,"RCCD1, PRC1",Platelet count,platelet count,GCST90002361,15:90963407,Blood
784,PRC1,PRC1,N/a,rs8037137-<b>C</b>,1 x 10-26,,0.131239,'-,0.029523 SD unit decrease,[0.024-0.035],"RCCD1, PRC1",Platelet count,platelet count,GCST90002357,15:90963407,Blood
980,PRC1,PRC1,N/a,rs12595025-<b>T</b>,1 x 10-19,,0.1292,'-,0.04882719 unit increase,[0.038-0.059],"PRC1, PRC1-AS1",Mean platelet volume,mean platelet volume,GCST004599,15:90976901,Blood
981,PRC1,PRC1,N/a,rs2290202-<b>G</b>,1 x 10-54,,0.867315,'-,'-,'-,"PRC1-AS1, PRC1",Mean platelet volume,mean platelet volume,GCST90002349,15:90969037,Blood
982,PRC1,PRC1,N/a,rs2290202-<b>G</b>,2 x 10-54,,0.870613,'-,0.044777 SD unit decrease,[0.039-0.05],"PRC1-AS1, PRC1",Mean platelet volume,mean platelet volume,GCST90002346,15:90969037,Blood
983,PRC1,PRC1,N/a,rs2290202-<b>T</b>,6 x 10-35,,0.128824,'-,0.04160258 unit increase,[0.035-0.048],"PRC1-AS1, PRC1",Mean platelet volume,mean platelet volume,GCST90002395,15:90969037,Blood
984,PRC1,PRC1-AS1,N/a,rs12595025-<b>T</b>,1 x 10-19,,0.1292,'-,0.04882719 unit increase,[0.038-0.059],"PRC1, PRC1-AS1",Mean platelet volume,mean platelet volume,GCST004599,15:90976901,Blood
985,PRC1,PRC1-AS1,N/a,rs2290202-<b>G</b>,1 x 10-54,,0.867315,'-,'-,'-,"PRC1-AS1, PRC1",Mean platelet volume,mean platelet volume,GCST90002349,15:90969037,Blood
986,PRC1,PRC1-AS1,N/a,rs2290202-<b>G</b>,2 x 10-54,,0.870613,'-,0.044777 SD unit decrease,[0.039-0.05],"PRC1-AS1, PRC1",Mean platelet volume,mean platelet volume,GCST90002346,15:90969037,Blood
987,PRC1,PRC1-AS1,N/a,rs2290202-<b>T</b>,6 x 10-35,,0.128824,'-,0.04160258 unit increase,[0.035-0.048],"PRC1-AS1, PRC1",Mean platelet volume,mean platelet volume,GCST90002395,15:90969037,Blood
992,PSMG4,PSMG4,N/a,rs4479984-<b>T</b>,9 x 10-11,,0.861712,'-,0.02115308 unit decrease,[0.015-0.028],"PSMG4, SLC22A23",Mean platelet volume,mean platelet volume,GCST90002395,6:3280971,Blood
617,RBM25,RBM25,N/a,rs139155492-<b>CTGTCCTGGGTGCA</b>,4 x 10-10,,0.093866,'-,0.02435803 unit increase,[0.017-0.032],"PSEN1, RBM25",Reticulocyte fraction of red cells,reticulocyte measurement,GCST90002406,14:73133639,Blood
780,RCN2,RCN2,N/a,rs62027291-<b>A</b>,6 x 10-9,,0.1628,'-,0.02916964 unit decrease,[0.019-0.039],"RCN2, RN7SL278P",Plateletcrit,platelet crit,GCST004607,15:76973710,Blood
1420,RN7SL252P,RN7SL252P,N/a,rs754689812-<b>G</b>,3 x 10-10,,'-,'-,0.168 unit increase,[NR],"DLX6-AS1, RN7SL252P",Hemoglobin levels,hemoglobin measurement,GCST010083,7:96944129,Blood
696,RN7SL824P,RN7SL824P,N/a,rs76337287-<b>T</b>,4 x 10-14,,0.197922,'-,0.018529 SD unit increase,[0.014-0.023],"RN7SL824P, GFI1",Red cell distribution width,red blood cell distribution width,GCST90002369,1:92457909,Blood
697,RN7SL824P,RN7SL824P,N/a,rs186001783-<b>T</b>,1 x 10-11,,0.187342,'-,'-,'-,"GFI1, RN7SL824P",Red cell distribution width,red blood cell distribution width,GCST90002372,1:92457910,Blood
698,RN7SL824P,RN7SL824P,N/a,rs76337287-<b>T</b>,2 x 10-10,,0.197564,'-,0.017844677 unit increase,[0.012-0.023],"RN7SL824P, GFI1",Red cell distribution width,red blood cell distribution width,GCST90002404,1:92457909,Blood
800,RN7SL824P,RN7SL824P,N/a,rs79900185-<b>C</b>,2 x 10-12,,0.0303881,'-,'-,'-,"GFI1, RN7SL824P",Platelet count,platelet count,GCST90002361,1:92439055,Blood
951,RN7SL824P,RN7SL824P,N/a,rs115427247-<b>T</b>,1 x 10-35,,0.0302,'-,0.1303333 unit decrease,[0.11-0.15],"GFI1, RN7SL824P",Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST004609,1:92412850,Blood
952,RN7SL824P,RN7SL824P,N/a,rs141819830-<b>A</b>,3 x 10-69,,0.029431,'-,0.11655016 unit decrease,[0.1-0.13],"RN7SL824P, GFI1",Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST90002394,1:92460150,Blood
953,RN7SL824P,RN7SL824P,N/a,rs150649461-<b>C</b>,3 x 10-340,,0.014752,'-,0.3836553 unit increase,[0.36-0.4],"RN7SL824P, GFI1",Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST90002394,1:92460097,Blood
960,RN7SL824P,RN7SL824P,N/a,rs150649461-<b>C</b>,5 x 10-587,,0.0144998,'-,'-,'-,"RN7SL824P, GFI1",Monocyte count,monocyte count,GCST90002344,1:92460097,Blood
1081,RN7SL824P,RN7SL824P,N/a,rs150649461-<b>C</b>,5 x 10-37,,0.014751,'-,0.11969867 unit decrease,[0.1-0.14],"RN7SL824P, GFI1",Lymphocyte percentage of white cells,lymphocyte percentage of leukocytes,GCST90002389,1:92460097,Blood
1259,RN7SL824P,RN7SL824P,N/a,rs150649461-<b>C</b>,2 x 10-14,,0.014754,'-,0.07178956 unit increase,[0.053-0.09],"RN7SL824P, GFI1",White blood cell count,leukocyte count,GCST90002407,1:92460097,Blood
1260,RN7SL824P,RN7SL824P,N/a,rs150649461-<b>?</b>,1 x 10-12,,NR,'-,'-,'-,"RN7SL824P, GFI1",White blood cell count,leukocyte count,GCST007070,1:92460097,Blood
2000,ROR1,ROR1,N/a,rs12135035-<b>C</b>,3 x 10-14,"(ROR1, 8474_6_3)",0.6703125,'-,0.18854144 unit increase,[0.14-0.24],ROR1,Blood protein levels,blood protein measurement,GCST006585,1:64181069,Blood
2001,ROR1,ROR1,N/a,rs6671162-<b>A</b>,3 x 10-15,"(ROR1, 2590_69_4)",0.6765625,'-,0.19881703 unit increase,[0.15-0.25],"ROR1, ROR1-AS1",Blood protein levels,blood protein measurement,GCST006585,1:64159463,Blood
2002,ROR1,ROR1,N/a,rs1408416-<b>T</b>,2 x 10-40,"(Tyrosine-protein kinase transmembrane receptor ROR1, ROR1.2590.69.4)",0.162,'-,0.44 unit decrease,[0.38-0.5],"ROR1-AS1, ROR1",Blood protein levels,blood protein measurement,GCST005806,1:64148812,Blood
2003,ROR1,ROR1,N/a,rs12080955-<b>C</b>,2 x 10-7,"(ROR1, 13400_13_3)",0.67203125,'-,0.13338667 unit increase,[0.083-0.184],"ROR1, UBE2U",Blood protein levels,blood protein measurement,GCST006585,1:64184945,Blood
2004,ROR1,ROR1-AS1,N/a,rs6671162-<b>A</b>,3 x 10-15,"(ROR1, 2590_69_4)",0.6765625,'-,0.19881703 unit increase,[0.15-0.25],"ROR1, ROR1-AS1",Blood protein levels,blood protein measurement,GCST006585,1:64159463,Blood
2005,ROR1,ROR1-AS1,N/a,rs1408416-<b>T</b>,2 x 10-40,"(Tyrosine-protein kinase transmembrane receptor ROR1, ROR1.2590.69.4)",0.162,'-,0.44 unit decrease,[0.38-0.5],"ROR1-AS1, ROR1",Blood protein levels,blood protein measurement,GCST005806,1:64148812,Blood
2242,ROR1,ROR1,N/a,"rs1324359-<b>G</b>, rs6588083-<b>C</b>",1 x 10-8,,0.175,'-,'-,'-,ROR1; ROR1-AS1; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:64150746,Blood
2244,ROR1,ROR1,N/a,"rs649195-<b>G</b>, rs631029-<b>G</b>, rs675893-<b>G</b>, rs679386-<b>A</b>, rs636119-<b>C</b>, rs11208300-<b>G</b>, rs11208305-<b>C</b>, rs1390116-<b>G</b>, rs582428-<b>A</b>, rs10889450-<b>T</b>, rs619334-<b>G</b>, rs11581982-<b>C</b>",6 x 10-12,,0.032,'-,'-,'-,ROR1; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:63852664,Blood
2246,ROR1,ROR1,N/a,"rs649195-<b>G</b>, rs631029-<b>G</b>, rs675893-<b>G</b>, rs679386-<b>A</b>, rs636119-<b>C</b>, rs11208300-<b>G</b>, rs11208305-<b>C</b>, rs1390116-<b>G</b>, rs582428-<b>A</b>, rs10889450-<b>T</b>, rs619334-<b>G</b>, rs11581982-<b>T</b>",3 x 10-11,,0.223,'-,'-,'-,ROR1; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:63852664,Blood
2248,ROR1,ROR1-AS1,N/a,"rs1324359-<b>G</b>, rs6588083-<b>C</b>",1 x 10-8,,0.175,'-,'-,'-,ROR1; ROR1-AS1; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:64150746,Blood
618,SLC22A4,SLC22A4,N/a,rs538021413-<b>T</b>,3 x 10-10,,0.6334,'-,0.02369591 unit increase,[0.016-0.031],"SLC22A4, MIR3936HG",Immature fraction of reticulocytes,reticulocyte count,GCST004628,5:132328824,Blood
693,SLC22A4,SLC22A4,N/a,rs12777-<b>?</b>,4 x 10-9,,NR,'-,'-,'-,"MIR3936HG, SLC22A4",Red cell distribution width,red blood cell distribution width,GCST007074,5:132335969,Blood
788,SLC22A4,SLC22A4,N/a,rs200800380-<b>C</b>,7 x 10-9,,0.539435,'-,0.015068927 unit decrease,[0.01-0.0202],"MIR3936HG, SLC22A4",Platelet count,platelet count,GCST90002402,5:132328838,Blood
888,SLC22A4,SLC22A4,N/a,rs10075801-<b>G</b>,4 x 10-22,,0.4855,'-,0.03509937 unit decrease,[0.028-0.042],"MIR3936HG, SLC22A4",Sum neutrophil eosinophil counts,"neutrophil count, eosinophil count",GCST004613,5:132341949,Blood
890,SLC22A4,SLC22A4,N/a,rs10075801-<b>G</b>,2 x 10-16,,0.4855,'-,0.02985189 unit decrease,[0.023-0.037],"MIR3936HG, SLC22A4",Sum basophil neutrophil counts,"neutrophil count, basophil count",GCST004620,5:132341949,Blood
894,SLC22A4,SLC22A4,N/a,rs10075801-<b>G</b>,8 x 10-16,,0.4855,'-,0.02915474 unit decrease,[0.022-0.036],"MIR3936HG, SLC22A4",Neutrophil count,neutrophil count,GCST004629,5:132341949,Blood
927,SLC22A4,SLC22A4,N/a,rs10075801-<b>G</b>,5 x 10-25,,0.4855,'-,0.0376138 unit decrease,[0.03-0.045],"MIR3936HG, SLC22A4",Myeloid white cell count,myeloid white cell count,GCST004626,5:132341949,Blood
928,SLC22A4,SLC22A4,N/a,rs11242109-<b>T</b>,5 x 10-72,,0.477227,'-,0.033069 SD unit decrease,[0.029-0.037],"SLC22A4, MIR3936HG",White blood cell count,myeloid white cell count,GCST90002374,5:132341354,Blood
955,SLC22A4,SLC22A4,N/a,rs34301845-<b>C</b>,4 x 10-15,,0.5353,'-,0.02859679 unit decrease,[0.021-0.036],"MIR3936HG, SLC22A4",Monocyte count,monocyte count,GCST004625,5:132329474,Blood
956,SLC22A4,SLC22A4,N/a,rs11242109-<b>T</b>,5 x 10-33,,0.478171,'-,0.022463 SD unit decrease,[0.019-0.026],"SLC22A4, MIR3936HG",Monocyte count,monocyte count,GCST90002340,5:132341354,Blood
957,SLC22A4,SLC22A4,N/a,rs538021413-<b>T</b>,2 x 10-10,,0.627443,'-,0.015776893 unit decrease,[0.011-0.021],"SLC22A4, MIR3936HG",Monocyte count,monocyte count,GCST90002393,5:132328824,Blood
991,SLC22A4,SLC22A4,N/a,rs11950562-<b>C</b>,3 x 10-33,,0.4766,'-,0.04343237 unit increase,[0.036-0.051],"MIR3936HG, SLC22A4",Mean platelet volume,mean platelet volume,GCST004599,5:132316836,Blood
1084,SLC22A4,SLC22A4,N/a,rs538021413-<b>T</b>,2 x 10-10,,0.627443,'-,0.015776893 unit decrease,[0.011-0.021],"SLC22A4, MIR3936HG",Lymphocyte counts,lymphocyte count,GCST90002388,5:132328824,Blood
1256,SLC22A4,SLC22A4,N/a,rs10075801-<b>G</b>,7 x 10-26,,0.4856,'-,0.03816809 unit decrease,[0.031-0.045],"MIR3936HG, SLC22A4",White blood cell count,leukocyte count,GCST004610,5:132341949,Blood
1510,SLC22A4,SLC22A4,N/a,rs10075801-<b>G</b>,8 x 10-23,,0.4855,'-,0.03571686 unit decrease,[0.029-0.043],"MIR3936HG, SLC22A4",Granulocyte count,granulocyte count,GCST004614,5:132341949,Blood
2039,SLC22A4,SLC22A4,N/a,rs72795121-<b>A</b>,1 x 10-9,,0.39296,'-,'-,'-,SLC22A4,Basophil count,basophil count,GCST90002296,5:132302631,Blood
2250,SPTBN4,SPTBN4,N/a,"rs843777-<b>G</b>, rs4332846-<b>A</b>, rs1165840-<b>C</b>",6 x 10-25,,0.15,'-,'-,'-,SPTBN4; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:40550886,Blood
2252,SPTBN4,SPTBN4,N/a,"rs843777-<b>A</b>, rs4332846-<b>A</b>, rs1165840-<b>C</b>",7 x 10-23,,0.449,'-,'-,'-,SPTBN4; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:40550886,Blood
694,SSBP4,SSBP4,N/a,rs9749546-<b>C</b>,1 x 10-11,,0.291237,'-,0.016840778 unit increase,[0.012-0.022],"LRRC25, SSBP4",Red cell distribution width,red blood cell distribution width,GCST90002404,19:18407406,Blood
695,SSBP4,SSBP4,N/a,rs10424080-<b>?</b>,3 x 10-19,,NR,'-,'-,'-,"LRRC25, SSBP4",Red cell distribution width,red blood cell distribution width,GCST007074,19:18407968,Blood
885,SSBP4,SSBP4,N/a,rs11668719-<b>C</b>,2 x 10-14,,0.4676,'-,0.02722951 unit increase,[0.02-0.034],"LRRC25, SSBP4",Neutrophil percentage of white cells,neutrophil percentage of leukocytes,GCST004633,19:18404931,Blood
886,SSBP4,SSBP4,N/a,rs1985157-<b>C</b>,9 x 10-43,,0.410708,'-,0.030757667 unit increase,[0.026-0.035],"SSBP4, LRRC25",Neutrophil percentage of white cells,neutrophil percentage of leukocytes,GCST90002399,19:18402784,Blood
889,SSBP4,SSBP4,N/a,rs575404063-<b>C</b>,1 x 10-12,,0.4871,'-,0.02584471 unit increase,[0.019-0.033],"LRRC25, SSBP4",Sum neutrophil eosinophil counts,"neutrophil count, eosinophil count",GCST004613,19:18405498,Blood
891,SSBP4,SSBP4,N/a,rs575404063-<b>C</b>,3 x 10-13,,0.4872,'-,0.02659022 unit increase,[0.019-0.034],"LRRC25, SSBP4",Sum basophil neutrophil counts,"neutrophil count, basophil count",GCST004620,19:18405498,Blood
895,SSBP4,SSBP4,N/a,rs575404063-<b>C</b>,2 x 10-13,,0.4872,'-,0.02677423 unit increase,[0.02-0.034],"LRRC25, SSBP4",Neutrophil count,neutrophil count,GCST004629,19:18405498,Blood
896,SSBP4,SSBP4,N/a,rs1985157-<b>C</b>,5 x 10-31,,0.410687,'-,0.02602827 unit increase,[0.022-0.03],"SSBP4, LRRC25",Neutrophil count,neutrophil count,GCST90002398,19:18402784,Blood
897,SSBP4,SSBP4,N/a,rs1985157-<b>C</b>,2 x 10-35,,0.391786,'-,'-,'-,"SSBP4, LRRC25",Neutrophil count,neutrophil count,GCST90002355,19:18402784,Blood
898,SSBP4,SSBP4,N/a,rs1985157-<b>C</b>,1 x 10-38,,0.410403,'-,0.026496 SD unit increase,[0.023-0.03],"SSBP4, LRRC25",Neutrophil count,neutrophil count,GCST90002351,19:18402784,Blood
929,SSBP4,SSBP4,N/a,rs575404063-<b>C</b>,7 x 10-10,,0.487,'-,0.02256855 unit increase,[0.015-0.03],"LRRC25, SSBP4",Myeloid white cell count,myeloid white cell count,GCST004626,19:18405498,Blood
930,SSBP4,SSBP4,N/a,rs1985157-<b>C</b>,3 x 10-16,,0.377911,'-,'-,'-,"SSBP4, LRRC25",White blood cell count,myeloid white cell count,GCST90002378,19:18402784,Blood
931,SSBP4,SSBP4,N/a,rs1985157-<b>C</b>,2 x 10-18,,0.409933,'-,0.017255 SD unit increase,[0.013-0.021],"SSBP4, LRRC25",White blood cell count,myeloid white cell count,GCST90002374,19:18402784,Blood
949,SSBP4,SSBP4,N/a,rs5827412-<b>T</b>,1 x 10-27,,0.4122,'-,0.03952068 unit decrease,[0.032-0.047],"LRRC25, SSBP4",Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST004609,19:18402008,Blood
950,SSBP4,SSBP4,N/a,rs5827412-<b>T</b>,3 x 10-76,,0.410404,'-,0.042196006 unit decrease,[0.038-0.047],"LRRC25, SSBP4",Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST90002394,19:18402008,Blood
959,SSBP4,SSBP4,N/a,rs28375303-<b>G</b>,2 x 10-10,,0.3295,'-,0.02409441 unit decrease,[0.017-0.032],SSBP4,Monocyte count,monocyte count,GCST004625,19:18419351,Blood
1027,SSBP4,SSBP4,N/a,rs142780001-<b>C</b>,6 x 10-18,,0.338511,'-,0.0142766 unit decrease,[0.0097-0.0189],"LRRC25, SSBP4",Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST90002391,19:18409188,Blood
1257,SSBP4,SSBP4,N/a,rs1560117-<b>T</b>,1 x 10-12,,0.471563,'-,0.015697714 unit increase,[0.011-0.02],"LRRC25, SSBP4",White blood cell count,leukocyte count,GCST90002407,19:18402122,Blood
1258,SSBP4,SSBP4,N/a,rs1985157-<b>?</b>,4 x 10-11,,NR,'-,'-,'-,"SSBP4, LRRC25",White blood cell count,leukocyte count,GCST007070,19:18402784,Blood
1509,SSBP4,SSBP4,N/a,rs1985157-<b>C</b>,7 x 10-30,,0.4123,'-,0.04115012 unit increase,[0.034-0.048],"SSBP4, LRRC25",Granulocyte percentage of myeloid white cells,granulocyte percentage of myeloid white cells,GCST004608,19:18402784,Blood
1511,SSBP4,SSBP4,N/a,rs575404063-<b>C</b>,1 x 10-12,,0.4871,'-,0.02594769 unit increase,[0.019-0.033],"LRRC25, SSBP4",Granulocyte count,granulocyte count,GCST004614,19:18405498,Blood
2040,SSBP4,SSBP4,N/a,rs7257932-<b>A</b>,9 x 10-11,,0.330106,'-,0.015309215 unit increase,[0.011-0.02],"SSBP4, LRRC25",Basophil count,basophil count,GCST90002379,19:18416447,Blood
2041,SSBP4,SSBP4,N/a,rs7257932-<b>A</b>,3 x 10-13,,0.329141,'-,'-,'-,"SSBP4, LRRC25",Basophil count,basophil count,GCST90002296,19:18416447,Blood
201,TF,TF,N/a,rs6762719-<b>A</b>,4 x 10-25,,NR,'-,0.149 unit increase,[0.12-0.18],TF,Iron status biomarkers (transferrin saturation),transferrin saturation measurement,GCST004572,3:133761973,Blood
202,TF,TF,N/a,rs6762719-<b>A</b>,4 x 10-25,,NR,'-,0.149 unit increase,NR,TF,Iron status biomarkers (transferrin saturation),transferrin saturation measurement,GCST004572,3:133761973,Blood
203,TF,TF,N/a,rs4854760-<b>G</b>,1 x 10-82,,0.313,'-,0.096 SD decrease,[0.11-0.086],TF,Iron status biomarkers (transferrin saturation),transferrin saturation measurement,GCST011366,3:133779897,Blood
204,TF,TF,N/a,rs3811647-<b>A</b>,3 x 10-47,(transferrin),0.29,'-,15.34 mg/dl increase,[13.26-17.42],TF,Iron status biomarkers,transferrin measurement,GCST000935,3:133765185,Blood
206,TF,TF,N/a,rs6762719-<b>A</b>,1 x 10-323,,NR,'-,0.676 unit decrease,'-,TF,Iron status biomarkers (total iron binding capacity),total iron binding capacity,GCST004571,3:133761973,Blood
207,TF,TF,N/a,rs8177248-<b>C</b>,4 x 10-322,,NR,'-,0.649 unit decrease,[0.62-0.68],TF,Iron status biomarkers (total iron binding capacity),total iron binding capacity,GCST004571,3:133760782,Blood
208,TF,TF,N/a,rs4854760-<b>G</b>,1 x 10-300,,0.313,'-,0.34 SD increase,[0.33-0.36],TF,Iron status biomarkers (total iron binding capacity),total iron binding capacity,GCST011368,3:133779897,Blood
508,TF,TF,N/a,rs1799852-<b>T</b>,3 x 10-9,,NR,'-,0.0252 unit decrease,[0.017-0.033],TF,Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,3:133756878,Blood
539,TF,TF,N/a,rs2692666-<b>G</b>,3 x 10-6,,NR,'-,0.306 unit increase,'-,TF,Iron status biomarkers (iron levels),serum iron measurement,GCST004570,3:133759510,Blood
540,TF,TF,N/a,rs4854760-<b>G</b>,6 x 10-33,,0.313,'-,0.053 SD increase,[0.044-0.062],TF,Iron status biomarkers (iron levels),serum iron measurement,GCST011367,3:133779897,Blood
542,TF,TF,N/a,rs3811647-<b>?</b>,2 x 10-16,(Tf),NR,'-,0.338 ng/ml increase,[0.26-0.42],TF,Hepcidin levels,serum hepcidin measurement,GCST001174,3:133765185,Blood
671,TF,TF,N/a,rs1799852-<b>C</b>,1 x 10-15,,0.903151,'-,'-,'-,TF,Red cell distribution width,red blood cell distribution width,GCST90002372,3:133756878,Blood
672,TF,TF,N/a,rs1799852-<b>T</b>,6 x 10-16,,0.094272,'-,0.030574786 unit decrease,[0.023-0.038],TF,Red cell distribution width,red blood cell distribution width,GCST90002404,3:133756878,Blood
673,TF,TF,N/a,rs150854910-<b>T</b>,5 x 10-11,,0.001241,'-,0.20589449 unit decrease,[0.14-0.27],TF,Red cell distribution width,red blood cell distribution width,GCST90002404,3:133757925,Blood
674,TF,TF,N/a,rs1799852-<b>?</b>,2 x 10-15,,NR,'-,'-,'-,TF,Red cell distribution width,red blood cell distribution width,GCST007074,3:133756878,Blood
675,TF,TF,N/a,rs8177318-<b>A</b>,6 x 10-12,,0.0013,'-,0.3511039 unit increase,[0.25-0.45],"INHCAP, TF",Red cell distribution width,red blood cell distribution width,GCST004621,3:133748533,Blood
676,TF,TF,N/a,rs8177318-<b>A</b>,3 x 10-18,,0.000784,'-,0.38752565 unit increase,[0.3-0.47],"INHCAP, TF",Red cell distribution width,red blood cell distribution width,GCST90002404,3:133748533,Blood
699,TF,TF,N/a,rs8177248-<b>T</b>,2 x 10-20,,0.36095,'-,'-,'-,TF,Red blood cell count,red blood cell density measurement,GCST90002367,3:133760782,Blood
1005,TF,TF,N/a,rs150854910-<b>T</b>,3 x 10-13,,0.0015,'-,0.356681 unit increase,[0.26-0.45],TF,Mean corpuscular volume,mean corpuscular volume,GCST004602,3:133757925,Blood
1006,TF,TF,N/a,rs34252038-<b>T</b>,7 x 10-12,,0.341,'-,0.02545329 unit decrease,[0.018-0.033],TF,Mean corpuscular volume,mean corpuscular volume,GCST004602,3:133771777,Blood
1007,TF,TF,N/a,rs150854910-<b>C</b>,9 x 10-49,,0.998713,'-,0.383347 SD unit decrease,[0.33-0.43],TF,Mean corpuscular volume,mean corpuscular volume,GCST90002334,3:133757925,Blood
1008,TF,TF,N/a,rs150854910-<b>C</b>,1 x 10-47,,0.998712,'-,'-,'-,TF,Mean corpuscular volume,mean corpuscular volume,GCST90002338,3:133757925,Blood
1009,TF,TF,N/a,rs8177240-<b>T</b>,4 x 10-13,,0.532675,'-,0.029673 SD units increase,[0.022-0.038],TF,Mean corpuscular volume,mean corpuscular volume,GCST90002335,3:133758857,Blood
1010,TF,TF,N/a,rs150854910-<b>T</b>,7 x 10-43,,0.001237,'-,0.42594 unit increase,[0.37-0.48],TF,Mean corpuscular volume,mean corpuscular volume,GCST90002392,3:133757925,Blood
1011,TF,TF,N/a,rs4854760-<b>G</b>,4 x 10-13,,0.340755,'-,0.0232442 unit decrease,[0.019-0.027],TF,Mean corpuscular volume,mean corpuscular volume,GCST90002392,3:133779897,Blood
1012,TF,TF,N/a,rs6794370-<b>C</b>,9 x 10-12,,0.806262,'-,0.0282002 unit decrease,[0.023-0.033],TF,Mean corpuscular volume,mean corpuscular volume,GCST90002392,3:133771490,Blood
1013,TF,TF,N/a,rs150854910-<b>T</b>,2 x 10-13,,0.001242,'-,0.23253189 unit increase,[0.17-0.29],TF,Mean spheric corpuscular volume,mean corpuscular volume,GCST90002397,3:133757925,Blood
1014,TF,TF,N/a,rs8177318-<b>A</b>,2 x 10-12,,0.0013,'-,0.3581947 unit decrease,[0.26-0.46],"INHCAP, TF",Mean corpuscular volume,mean corpuscular volume,GCST004602,3:133748533,Blood
1015,TF,TF,N/a,rs8177318-<b>A</b>,7 x 10-22,,0.000784,'-,0.402291 unit decrease,[0.32-0.48],"INHCAP, TF",Mean corpuscular volume,mean corpuscular volume,GCST90002392,3:133748533,Blood
1017,TF,TF,N/a,rs8177297-<b>?</b>,3 x 10-8,,NR,'-,0.02406 unit decrease,[0.016-0.033],TF,Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST005992,3:133772601,Blood
1018,TF,TF,N/a,rs72382362-<b>T</b>,6 x 10-9,,0.5116,'-,0.02032941 unit decrease,[0.013-0.027],TF,Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST004605,3:133773486,Blood
1019,TF,TF,N/a,rs8177260-<b>T</b>,2 x 10-17,,0.53319,'-,0.034897 SD units increase,[0.027-0.043],TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,GCST90002323,3:133761614,Blood
1020,TF,TF,N/a,rs150854910-<b>C</b>,3 x 10-58,,0.998736,'-,0.442349 SD unit decrease,[0.39-0.5],TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,GCST90002322,3:133757925,Blood
1021,TF,TF,N/a,rs1358023-<b>C</b>,1 x 10-17,,0.339799,'-,0.018065 SD unit decrease,[0.014-0.022],TF,Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST90002328,3:133765549,Blood
1022,TF,TF,N/a,rs1358023-<b>C</b>,4 x 10-25,,0.363173,'-,'-,'-,TF,Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST90002332,3:133765549,Blood
1023,TF,TF,N/a,rs8177297-<b>C</b>,4 x 10-12,,0.602264,'-,0.028345 SD units increase,[0.02-0.036],TF,Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST90002329,3:133772601,Blood
1024,TF,TF,N/a,rs150854910-<b>T</b>,8 x 10-9,,0.001235,'-,0.180883 unit increase,[0.12-0.24],TF,Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST90002391,3:133757925,Blood
1025,TF,TF,N/a,rs8177318-<b>A</b>,2 x 10-10,,0.0013,'-,0.3197374 unit decrease,[0.22-0.42],"INHCAP, TF",Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST004605,3:133748533,Blood
1026,TF,TF,N/a,rs8177318-<b>A</b>,4 x 10-12,,0.000782,'-,0.290727 unit decrease,[0.2-0.38],"INHCAP, TF",Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST90002391,3:133748533,Blood
1030,TF,TF,N/a,rs150854910-<b>T</b>,3 x 10-13,,0.0015,'-,0.3582461 unit increase,[0.26-0.45],TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST004630,3:133757925,Blood
1031,TF,TF,N/a,rs1358023-<b>C</b>,7 x 10-17,,0.3403,'-,0.03109293 unit decrease,[0.024-0.038],TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST004630,3:133765549,Blood
1032,TF,TF,N/a,rs150854910-<b>T</b>,2 x 10-47,,0.001237,'-,0.45218804 unit increase,[0.39-0.51],TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST90002390,3:133757925,Blood
1033,TF,TF,N/a,rs4854760-<b>G</b>,1 x 10-17,,0.34071,'-,0.021326935 unit decrease,[0.016-0.026],TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST90002390,3:133779897,Blood
1034,TF,TF,N/a,rs6794370-<b>C</b>,3 x 10-12,,0.806282,'-,0.021012042 unit decrease,[0.015-0.027],TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST90002390,3:133771490,Blood
1035,TF,TF,N/a,rs6762719-<b>?</b>,3 x 10-32,,NR,'-,'-,'-,TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST007068,3:133761973,Blood
1036,TF,TF,N/a,rs8177318-<b>A</b>,2 x 10-18,,0.0013,'-,0.4480368 unit decrease,[0.35-0.55],"INHCAP, TF",Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST004630,3:133748533,Blood
1037,TF,TF,N/a,rs8177318-<b>A</b>,5 x 10-31,,0.000784,'-,0.5124362 unit decrease,[0.43-0.6],"INHCAP, TF",Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST90002390,3:133748533,Blood
1038,TF,TF,N/a,rs9843728-<b>?</b>,3 x 10-16,,NR,'-,0.03541 unit decrease,[0.027-0.044],TF,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST005993,3:133782563,Blood
1274,TF,TF,N/a,rs8177240-<b>T</b>,7 x 10-38,,0.669,'-,0.1 unit increase,[0.084-0.116],TF,Iron status biomarkers (transferrin saturation),"iron biomarker measurement, transferrin saturation measurement",GCST002680,3:133758857,Blood
1275,TF,TF,N/a,rs1799852-<b>T</b>,7 x 10-9,,0.098,'-,0.11 unit increase,[0.073-0.147],TF,Iron status biomarkers (transferrin saturation),"iron biomarker measurement, transferrin saturation measurement",GCST002680,3:133756878,Blood
1276,TF,TF,N/a,rs8177240-<b>T</b>,8 x 10-610,,0.669,'-,0.38 unit decrease,[0.37-0.39],TF,Iron status biomarkers (transferrin levels),"iron biomarker measurement, transferrin measurement",GCST002678,3:133758857,Blood
1277,TF,TF,N/a,rs3811647-<b>A</b>,5 x 10-10,(Total iron-binding capacity),NR,'-,21.49 ug/dL increase,[NR],TF,Iron status biomarkers,"iron biomarker measurement, total iron binding capacity",GCST001021,3:133765185,Blood
1278,TF,TF,N/a,rs8177240-<b>T</b>,7 x 10-20,,0.669,'-,0.066 unit decrease,[0.052-0.080],TF,Iron status biomarkers (iron levels),"iron biomarker measurement, serum iron measurement",GCST002679,3:133758857,Blood
1279,TF,TF,N/a,rs3811647-<b>?</b>,3 x 10-15,(serum transferrin),NR,'-,0.46 s.d. decrease,[0.34-0.58],TF,Iron status biomarkers,iron biomarker measurement,GCST000301,3:133765185,Blood
1280,TF,TF,N/a,rs1799852-<b>?</b>,5 x 10-6,(serum transferrin),0.09,'-,0.43 s.d. decrease,[0.25-0.61],TF,Iron status biomarkers,iron biomarker measurement,GCST000301,3:133756878,Blood
1281,TF,TF,N/a,rs3811647-<b>A</b>,8 x 10-6,(Unsaturated iron-binding capacity),NR,'-,21.62 ug/dL increase,[NR],TF,Iron status biomarkers,iron biomarker measurement,GCST001021,3:133765185,Blood
1282,TF,TF,N/a,rs1830084-<b>A</b>,1 x 10-9,(serum transferrin),0.36,'-,0.43 s.d. increase,[NR],"SRPRB, TF",Iron status biomarkers,iron biomarker measurement,GCST000302,3:133789620,Blood
1416,TF,TF,N/a,rs3811647-<b>?</b>,2 x 10-20,(Trasferrin),NR,'-,0.4 unit decrease,[0.32-0.48],TF,Hereditary hemochromatosis-related traits (HFE mutation homozygotes),"hereditary hemochromatosis type 1, transferrin measurement",GCST002660,3:133765185,Blood
1417,TF,TF,N/a,rs3811647-<b>?</b>,9 x 10-11,(Serum Iron levels),NR,'-,0.28 unit decrease,[0.20-0.36],TF,Hereditary hemochromatosis-related traits (HFE mutation homozygotes),"hereditary hemochromatosis type 1, serum iron measurement",GCST002660,3:133765185,Blood
1558,TF,TF,N/a,rs150854910-<b>T</b>,1 x 10-11,,0.001235,'-,0.21286973 unit decrease,[0.15-0.27],TF,Red blood cell count,erythrocyte count,GCST90002403,3:133757925,Blood
1559,TF,TF,N/a,rs4854761-<b>A</b>,3 x 10-15,,0.340419,'-,0.01836411 unit increase,[0.014-0.023],TF,Red blood cell count,erythrocyte count,GCST90002403,3:133779945,Blood
1560,TF,TF,N/a,rs8177247-<b>?</b>,1 x 10-16,,NR,'-,'-,'-,TF,Red blood cell count,erythrocyte count,GCST007069,3:133760655,Blood
1561,TF,TF,N/a,rs8177318-<b>A</b>,4 x 10-10,,0.000781,'-,0.27812424 unit increase,[0.19-0.37],"INHCAP, TF",Red blood cell count,erythrocyte count,GCST90002403,3:133748533,Blood
1974,TF,TF,N/a,rs4854760-<b>A</b>,2 x 10-25,"(NAALAD2, 7986_98_3)",0.7353125,'-,0.29006043 unit decrease,[0.24-0.34],TF,Blood protein levels,blood protein measurement,GCST006585,3:133779897,Blood
1975,TF,TF,N/a,rs4854760-<b>A</b>,6 x 10-16,"(TF, 4162_54_2)",0.7353125,'-,0.22745943 unit decrease,[0.17-0.28],TF,Blood protein levels,blood protein measurement,GCST006585,3:133779897,Blood
2206,TF,TF,N/a,"rs8177248-<b>C</b>, rs8177277-<b>T</b>, rs1115219-<b>T</b>, rs2715632-<b>T</b>, rs1358022-<b>G</b>, rs7638018-<b>A</b>, rs2718796-<b>C</b>, rs8177253-<b>C</b>, rs1525892-<b>G</b>, rs8177262-<b>G</b>, rs1049296-<b>C</b>, rs2715627-<b>C</b>, rs8177272-<b>G</b>, rs2715631-<b>G</b>",3 x 10-16,,0,'-,'-,'-,TF; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:133760782,Blood
2208,TF,TF,N/a,"rs8177248-<b>C</b>, rs8177277-<b>T</b>, rs1115219-<b>C</b>, rs2715632-<b>T</b>, rs1358022-<b>G</b>, rs7638018-<b>A</b>, rs2718796-<b>C</b>, rs8177253-<b>C</b>, rs1525892-<b>G</b>, rs8177262-<b>G</b>, rs1049296-<b>C</b>, rs2715627-<b>C</b>, rs8177272-<b>G</b>, rs2715631-<b>G</b>",4 x 10-12,,0.236,'-,'-,'-,TF; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:133760782,Blood
779,TGM3,TGM3,N/a,rs560600212-<b>T</b>,2 x 10-11,,0.000598,'-,0.47624338 unit decrease,[0.34-0.61],"STK35, TGM3",Plateletcrit,platelet crit,GCST90002400,20:2207190,Blood
515,TNIP1,TNIP1,N/a,rs4958435-<b>T</b>,8 x 10-14,,NR,'-,0.0187 unit increase,[0.014-0.024],TNIP1,Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,5:151058723,Blood
887,TNIP1,TNIP1,N/a,rs3792783-<b>G</b>,2 x 10-11,,0.155,'-,0.03317528 unit increase,[0.023-0.043],TNIP1,Neutrophil percentage of granulocytes,neutrophil percentage of granulocytes,GCST004623,5:151076171,Blood
958,TNIP1,TNIP1,N/a,rs8177833-<b>G</b>,3 x 10-13,,0.055143,'-,0.03541474 unit decrease,[0.026-0.045],TNIP1,Monocyte count,monocyte count,GCST90002393,5:151087130,Blood
1080,TNIP1,TNIP1,N/a,rs79901336-<b>T</b>,1 x 10-9,,0.054582,'-,0.030893918 unit decrease,[0.021-0.041],"TNIP1, ANXA6",Lymphocyte percentage of white cells,lymphocyte percentage of leukocytes,GCST90002389,5:151097114,Blood
1085,TNIP1,TNIP1,N/a,rs8177833-<b>G</b>,3 x 10-13,,0.055143,'-,0.03541474 unit decrease,[0.026-0.045],TNIP1,Lymphocyte counts,lymphocyte count,GCST90002388,5:151087130,Blood
1568,TNIP1,TNIP1,N/a,rs960709-<b>G</b>,6 x 10-17,,0.239112,'-,0.021755753 unit decrease,[0.017-0.027],TNIP1,Eosinophil percentage of white cells,eosinophil percentage of leukocytes,GCST90002382,5:151081488,Blood
1569,TNIP1,TNIP1,N/a,rs960709-<b>G</b>,7 x 10-14,,0.2382,'-,0.03160719 unit decrease,[0.023-0.04],TNIP1,Eosinophil percentage of white cells,eosinophil percentage of leukocytes,GCST004600,5:151081488,Blood
1570,TNIP1,TNIP1,N/a,rs960709-<b>G</b>,1 x 10-11,,0.2382,'-,0.02882201 unit decrease,[0.021-0.037],TNIP1,Eosinophil percentage of granulocytes,eosinophil percentage of granulocytes,GCST004617,5:151081488,Blood
1571,TNIP1,TNIP1,N/a,rs960709-<b>G</b>,4 x 10-23,,0.239769,'-,0.023189 SD unit decrease,[0.019-0.028],TNIP1,Eosinophil counts,eosinophil count,GCST90002298,5:151081488,Blood
1572,TNIP1,TNIP1,N/a,rs960709-<b>G</b>,5 x 10-19,,0.239117,'-,0.023164537 unit decrease,[0.018-0.028],TNIP1,Eosinophil counts,eosinophil count,GCST90002381,5:151081488,Blood
1573,TNIP1,TNIP1,N/a,rs960709-<b>G</b>,7 x 10-16,,0.2382,'-,0.03412575 unit decrease,[0.026-0.042],TNIP1,Eosinophil counts,eosinophil count,GCST004606,5:151081488,Blood
1574,TNIP1,TNIP1,N/a,rs960709-<b>?</b>,1 x 10-15,,NR,'-,'-,'-,TNIP1,Eosinophil counts,eosinophil count,GCST007065,5:151081488,Blood
1575,TNIP1,TNIP1,N/a,rs960709-<b>G</b>,1 x 10-22,,0.322002,'-,'-,'-,TNIP1,Eosinophil counts,eosinophil count,GCST90002302,5:151081488,Blood
2036,TNIP1,TNIP1,N/a,rs960709-<b>G</b>,2 x 10-14,,0.2382,'-,0.03247268 unit decrease,[0.024-0.041],TNIP1,Sum eosinophil basophil counts,"basophil count, eosinophil count",GCST004624,5:151081488,Blood
627,TUBB4BP4,TUBB4BP4,N/a,rs149020156-<b>?</b>,6 x 10-7,,NR,7.41,'-,[3.38-16.25],"LINC02756, TUBB4BP4",Sulfasalazine-induced agranulocytosis,"response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,11:91940355,Blood
1567,TUBB4BP4,TUBB4BP4,N/a,rs17571502-<b>C</b>,8 x 10-6,,0.3548,'-,0.08258 unit increase,[NR],"LINC02756, TUBB4BP4",Erythrocyte cadmium concentration,erythrocyte cadmium measurement,GCST003449,11:91903993,Blood
1988,UROS,UROS,N/a,rs2027515-<b>C</b>,4 x 10-27,"(UROS, 11248_43_3)",0.78546875,'-,0.32375023 unit decrease,[0.27-0.38],UROS,Blood protein levels,blood protein measurement,GCST006585,10:125807263,Blood
516,VIRMA,VIRMA,N/a,rs1023767-<b>A</b>,2 x 10-12,,NR,'-,0.0206 unit increase,[0.015-0.026],VIRMA,Non-albumin protein levels,serum non-albumin protein measurement,GCST90019515,8:94518741,Blood
1999,VIRMA,VIRMA,N/a,rs10111287-<b>T</b>,2 x 10-11,,NR,'-,0.0185 unit increase,[0.013-0.024],"VIRMA, LINC02894",Serum total protein level,blood protein measurement,GCST90019522,8:94566198,Blood
1028,YWHAZP2,YWHAZP2,N/a,rs2119151-<b>T</b>,5 x 10-12,,0.581286,'-,0.014155 SD unit increase,[0.01-0.018],"GYPC, YWHAZP2",Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST90002328,2:126651295,Blood
1029,YWHAZP2,YWHAZP2,N/a,rs13395010-<b>G</b>,4 x 10-11,,0.595947,'-,'-,'-,"YWHAZP2, GYPC",Mean corpuscular hemoglobin concentration,mean corpuscular hemoglobin concentration,GCST90002332,2:126653637,Blood
2238,YWHAZP2,YWHAZP2,N/a,"rs12995563-<b>A</b>, rs7598155-<b>T</b>, rs7598599-<b>G</b>, rs4577234-<b>T</b>, rs7562097-<b>C</b>, rs7606197-<b>G</b>",1 x 10-10,,0.002,'-,'-,'-,N/A - YWHAZP2; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,2:126515885,Blood
2240,YWHAZP2,YWHAZP2,N/a,"rs12995563-<b>G</b>, rs7598155-<b>T</b>, rs7598599-<b>G</b>, rs4577234-<b>T</b>, rs7562097-<b>C</b>, rs7606197-<b>G</b>",2 x 10-9,,0.173,'-,'-,'-,N/A - YWHAZP2; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,2:126515885,Blood
215,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Cancer
223,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Cancer
855,APOB,APOB,N/a,rs183117027-<b>A</b>,4 x 10-8,,0.006,2.34,'-,[1.72–3.16],APOB,Pancreatic cancer,pancreatic carcinoma,GCST009895,2:21004340,Cancer
1073,APOB,APOB,N/a,rs76588427-<b>A</b>,3 x 10-6,,0.017,2.05,'-,[1.52-2.76],"APOB, LINC02850",Marginal zone lymphoma,marginal zone B-cell lymphoma,GCST002742,2:20935927,Cancer
1557,APOB,APOB,N/a,rs11901649-<b>?</b>,1 x 10-7,,NR,'-,0.084 unit increase,[0.053-0.115],APOB,Barrett's esophagus  or Esophageal adenocarcinoma,"esophageal adenocarcinoma, Barrett's esophagus",GCST008831,2:21027351,Cancer
917,ARHGAP24,ARHGAP24,N/a,rs4693128-<b>T</b>,1 x 10-7,,0.17587,1.09834,'-,[1.06-1.13],ARHGAP24,Neuroblastoma or malignant cutaneous melanoma,"neuroblastoma, cutaneous melanoma",GCST010152,4:85809561,Cancer
1797,ARHGAP24,ARHGAP24,N/a,rs71599425-<b>A</b>,6 x 10-6,(EA),0.0382,'-,0.0797 unit decrease,[0.045-0.114],ARHGAP24,Breast cancer,breast carcinoma,GCST004988,4:85740190,Cancer
638,CHRNA1,CHRNA1,N/a,rs77530448-<b>G</b>,7 x 10-8,,0.09,'-,0.36 unit increase,[0.23-0.49],"CHRNA1, H3P6",Response to radiotherapy in prostate cancer (overall toxicity),"response to radiation, prostate carcinoma",GCST003583,2:174729547,Cancer
2215,CHRNA1,CHRNA1,N/a,"rs2600685-<b>T</b>, rs2600683-<b>C</b>, rs935863-<b>A</b>",1 x 10-6,,0.527,'-,'-,'-,CHRNA1; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,2:174762320,Cancer
2217,CHRNA1,CHRNA1,N/a,"rs2359319-<b>C</b>, rs935866-<b>G</b>, rs6732758-<b>A</b>, rs6732427-<b>T</b>, rs7561169-<b>G</b>, rs935867-<b>T</b>, rs10497429-<b>C</b>, rs2123117-<b>C</b>, rs6728978-<b>C</b>",5 x 10-6,,0.533,'-,'-,'-,H3P6 - CHRNA1; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,2:174733568,Cancer
2225,DCAF6,DCAF6,N/a,"rs11558511-<b>T</b>, rs6672997-<b>G</b>, rs10489202-<b>G</b>, rs17485889-<b>G</b>, rs12059592-<b>G</b>, rs275147-<b>A</b>, rs12097632-<b>A</b>, rs275137-<b>C</b>, rs275154-<b>A</b>, rs10918809-<b>G</b>, rs11578006-<b>C</b>, rs399273-<b>C</b>, rs17557162-<b>T</b>, rs202273-<b>T</b>, rs1060041-<b>C</b>, rs413168-<b>G</b>, rs10918822-<b>T</b>, rs41322644-<b>A</b>, rs12404574-<b>A</b>",1 x 10-11,,0.204,'-,'-,'-,DCAF6; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:168044612,Cancer
2227,DCAF6,DCAF6,N/a,"rs11558511-<b>T</b>, rs6672997-<b>G</b>, rs10489202-<b>G</b>, rs17485889-<b>G</b>, rs12059592-<b>G</b>, rs275147-<b>A</b>, rs12097632-<b>C</b>, rs275137-<b>C</b>, rs275154-<b>A</b>, rs10918809-<b>G</b>, rs11578006-<b>C</b>, rs399273-<b>C</b>, rs17557162-<b>T</b>, rs202273-<b>T</b>, rs1060041-<b>C</b>, rs413168-<b>G</b>, rs10918822-<b>T</b>, rs41322644-<b>A</b>, rs12404574-<b>A</b>",4 x 10-7,,0.187,'-,'-,'-,DCAF6; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:168044612,Cancer
865,DNM3,DNM3,N/a,rs484686-<b>?</b>,8 x 10-6,,'-,1.3,'-,[1.16-1.46],DNM3,Ovarian cancer,ovarian carcinoma,GCST009830,1:172183062,Cancer
867,DNM3,DNM3,N/a,rs12117623-<b>C</b>,1 x 10-6,,0.5306,1.312336,'-,[1.18-1.46],DNM3,Ovarian cancer,ovarian carcinoma,GCST007239,1:172072640,Cancer
1811,DNM3,DNM3,N/a,rs1894633-<b>G</b>,2 x 10-6,(EA),0.3337,'-,0.0312 unit decrease,[0.018-0.044],DNM3,Breast cancer,breast carcinoma,GCST004988,1:172361919,Cancer
1784,FGF12,FGF12,N/a,rs975121-<b>?</b>,7 x 10-6,,NR,2.17,'-,[1.55-3.03],FGF12,Ileal carcinoids,carcinoid tumor,GCST000908,3:192179429,Cancer
2235,FGF12,FGF12,N/a,"rs1875731-<b>T</b>, rs1875732-<b>G</b>, rs1827546-<b>A</b>, rs2654693-<b>C</b>, rs1875730-<b>G</b>, rs2708309-<b>C</b>, rs2654689-<b>G</b>, rs2134634-<b>G</b>, rs1827545-<b>A</b>, rs2174178-<b>G</b>",3 x 10-14,,0,'-,'-,'-,FGF12; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:192595268,Cancer
2237,FGF12,FGF12,N/a,"rs1875731-<b>T</b>, rs1875732-<b>G</b>, rs1827546-<b>A</b>, rs2654693-<b>C</b>, rs1875730-<b>A</b>, rs2708309-<b>C</b>, rs2654689-<b>G</b>, rs2134634-<b>G</b>, rs1827545-<b>A</b>, rs2174178-<b>G</b>",6 x 10-7,,0.16,'-,'-,'-,FGF12; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:192595268,Cancer
406,H2AC6,H2AC6,N/a,rs36109883-<b>A</b>,6 x 10-12,,0.068507564,1.2887794,'-,[1.198871275-1.385430147],H2AC6,Squamous cell lung carcinoma,squamous cell lung carcinoma,GCST004750,6:26132842,Cancer
420,H2AC6,H2AC6,N/a,rs36109883-<b>A</b>,2 x 10-7,,0.067018189,1.1676731,'-,[1.102051078-1.237202699],H2AC6,Lung cancer in ever smokers,"smoking status measurement, lung carcinoma",GCST004749,6:26132842,Cancer
408,KDM4A-AS1,KDM4A-AS1,N/a,rs113688544-<b>C</b>,4 x 10-6,,0.747240408,1.1049403,'-,[1.06-1.15],"KDM4A, KDM4A-AS1",Squamous cell lung carcinoma,squamous cell lung carcinoma,GCST004750,1:43686240,Cancer
404,KHSRPP1,KHSRPP1,N/a,rs12686364-<b>G</b>,6 x 10-9,,0.004,8.49,'-,[4.12-17.49],"KHSRPP1, H3P30",Familial squamous cell lung carcinoma,"squamous cell lung carcinoma, family history of lung cancer",GCST006088,9:21670088,Cancer
978,KHSRPP1,KHSRPP1,N/a,rs141111252-<b>A</b>,7 x 10-8,,NR,1.3846581,'-,NR,"RN7SL151P, KHSRPP1",Melanoma,melanoma,GCST90011809,9:21698290,Cancer
636,LINC00578,LINC00578,N/a,rs6791846-<b>?</b>,5 x 10-7,,0.45,1.47,'-,[1.26-1.71],"LINC00578, LINC00501",Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event),"response to radiation, prostate carcinoma, Abnormality of the urinary system",GCST008382,3:177401529,Cancer
2223,LINC00578,LINC00578,N/a,"rs6443497-<b>A</b>, rs3922740-<b>A</b>, rs6785573-<b>C</b>, rs16828637-<b>G</b>, rs9829938-<b>T</b>, rs7430456-<b>A</b>, rs4857739-<b>T</b>, rs4857741-<b>A</b>, rs16828642-<b>G</b>, rs6443502-<b>T</b>, rs13071694-<b>G</b>, rs17636221-<b>G</b>, rs9875579-<b>C</b>",4 x 10-8,,0,'-,'-,'-,LINC00578; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:177756272,Cancer
2229,LINC02414,LINC02414,N/a,"rs11247024-<b>C</b>, rs7294672-<b>T</b>",6 x 10-9,,0.185,'-,'-,'-,N/A - LINC02414; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,12:131618173,Cancer
967,MGST1,MGST1,N/a,rs7300446-<b>?</b>,1 x 10-6,,'-,1.56,'-,[1.30-1.87],MGST1,Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics,"metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,12:16521286,Cancer
1551,MGST1,MGST1,N/a,rs35827298-<b>A</b>,4 x 10-8,,NR,'-,'-,'-,MGST1,Barrett's esophagus or esophageal adenocarcinoma x sex interaction (2df test),"esophageal adenocarcinoma, Barrett's esophagus, sex interaction measurement",GCST011462,12:16414631,Cancer
1553,MGST1,MGST1,N/a,rs35827298-<b>A</b>,1 x 10-8,(male),NR,0.87,'-,[0.82-0.91],MGST1,Barrett's esophagus  or Esophageal adenocarcinoma,"esophageal adenocarcinoma, Barrett's esophagus",GCST011461,12:16414631,Cancer
1555,MGST1,MGST1,N/a,rs35827298-<b>A</b>,5 x 10-9,,NR,0.87,'-,[0.83-0.91],MGST1,Barrett's esophagus  or Esophageal adenocarcinoma,"esophageal adenocarcinoma, Barrett's esophagus",GCST011461,12:16414631,Cancer
2211,MGST1,MGST1,N/a,"rs9332908-<b>A</b>, rs3844373-<b>G</b>, rs7312090-<b>A</b>, rs2287152-<b>T</b>, rs4149203-<b>G</b>",9 x 10-25,,0.001,'-,'-,'-,MGST1; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,12:16356132,Cancer
2213,MGST1,MGST1,N/a,"rs9332908-<b>A</b>, rs3844373-<b>G</b>, rs7312090-<b>A</b>, rs2287152-<b>T</b>, rs4149203-<b>A</b>",5 x 10-16,,0.321,'-,'-,'-,MGST1; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,12:16356132,Cancer
1803,NANOS3,NANOS3,N/a,rs2594714-<b>G</b>,1 x 10-8,(EA),0.77,1.0309278,'-,[1.01-1.05],"MIR23AHG, NANOS3",Breast cancer,breast carcinoma,GCST004988,19:13843757,Cancer
1680,OR51B5,OR51B5,N/a,rs10838094-<b>A</b>,1 x 10-9,,0.4106,0.2393,'-,[-0.26109-0.73969],"HBG2, OR51B5, OR51Q1, HBE1",Cutaneous mastocytosis (adult),cutaneous mastocytosis,GCST011380,11:5422663,Cancer
1682,OR51B5,OR51B5,N/a,rs10838094-<b>A</b>,2 x 10-25,,0.4106,0.1646,'-,[-0.22152-0.55072],"HBG2, OR51B5, OR51Q1, HBE1",Cutaneous mastocytosis,cutaneous mastocytosis,GCST011381,11:5422663,Cancer
1684,OR51B5,OR51B5,N/a,rs10838094-<b>A</b>,9 x 10-18,,0.4106,0.1089,'-,[-0.50517-0.72297],"HBG2, OR51B5, OR51Q1, HBE1",Cutaneous mastocytosis (childhood),cutaneous mastocytosis,GCST011379,11:5422663,Cancer
2219,PDGFD,PDGFD,N/a,"rs11226159-<b>G</b>, rs11226158-<b>C</b>",3 x 10-15,,0.313,'-,'-,'-,PDGFD; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,11:104107812,Cancer
2221,PDGFD,PDGFD,N/a,"rs11226159-<b>T</b>, rs11226158-<b>C</b>",1 x 10-11,,0.544,'-,'-,'-,PDGFD; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,11:104107812,Cancer
2231,PHF2,PHF2,N/a,"rs7855940-<b>G</b>, rs2487010-<b>C</b>, rs10761280-<b>A</b>, rs11792101-<b>A</b>, rs7874836-<b>C</b>, rs10821216-<b>T</b>, rs9409699-<b>T</b>, rs7859190-<b>C</b>, rs10739959-<b>A</b>, rs2491000-<b>G</b>, rs2487020-<b>T</b>, rs4744280-<b>A</b>, rs2398873-<b>C</b>, rs10114823-<b>C</b>, rs10821219-<b>C</b>, rs2490998-<b>G</b>, rs10116474-<b>T</b>, rs2253589-<b>C</b>, rs7854820-<b>T</b>, rs2265800-<b>T</b>, rs2243742-<b>G</b>",1 x 10-10,,0.166,'-,'-,'-,PHF2 - MIR4291; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,9:93773684,Cancer
2233,PHF2,PHF2,N/a,"rs7855940-<b>G</b>, rs2487010-<b>C</b>, rs10761280-<b>A</b>, rs11792101-<b>A</b>, rs7874836-<b>C</b>, rs10821216-<b>T</b>, rs9409699-<b>T</b>, rs7859190-<b>C</b>, rs10739959-<b>A</b>, rs2491000-<b>G</b>, rs2487020-<b>C</b>, rs4744280-<b>A</b>, rs2398873-<b>C</b>, rs10114823-<b>C</b>, rs10821219-<b>C</b>, rs2490998-<b>G</b>, rs10116474-<b>T</b>, rs2253589-<b>C</b>, rs7854820-<b>T</b>, rs2265800-<b>T</b>, rs2243742-<b>G</b>",1 x 10-9,,0,'-,'-,'-,PHF2 - MIR4291; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,9:93773684,Cancer
1764,PMAIP1,PMAIP1,N/a,rs4368253-<b>C</b>,8 x 10-7,,0.677,1.18,'-,[1.11-1.26],"NFE2L3P1, PMAIP1",Chronic lymphocytic leukemia,chronic lymphocytic leukemia,GCST003468,18:59955055,Cancer
1766,PMAIP1,PMAIP1,N/a,rs4368253-<b>C</b>,3 x 10-8,,0.69,1.19,'-,[1.12-1.27],"NFE2L3P1, PMAIP1",Chronic lymphocytic leukemia,chronic lymphocytic leukemia,GCST002073,18:59955055,Cancer
53,PPM1K,PPM1K,N/a,rs74962708-<b>T</b>,3 x 10-12,,NR,'-,0.074 unit increase,[0.053-0.095],"PPM1K, PPM1K-DT",Urate levels,urate measurement,GCST90019524,4:88284508,Cancer
56,PPM1K,PPM1K,N/a,rs28793136-<b>C</b>,6 x 10-55,,NR,'-,0.0707 unit increase,[0.062-0.08],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88295616,Cancer
59,PPM1K,PPM1K,N/a,rs4693211-<b>C</b>,1 x 10-82,,NR,'-,0.0941 unit increase,[0.084-0.104],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88327909,Cancer
62,PPM1K,PPM1K-DT,N/a,rs28793136-<b>C</b>,6 x 10-55,,NR,'-,0.0707 unit increase,[0.062-0.08],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88295616,Cancer
65,PPM1K,PPM1K-DT,N/a,rs4693211-<b>C</b>,1 x 10-82,,NR,'-,0.0941 unit increase,[0.084-0.104],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88327909,Cancer
68,PPM1K,PPM1K-DT,N/a,rs74962708-<b>T</b>,3 x 10-12,,NR,'-,0.074 unit increase,[0.053-0.095],"PPM1K, PPM1K-DT",Urate levels,urate measurement,GCST90019524,4:88284508,Cancer
642,PPM1K,PPM1K,N/a,rs72661666-<b>C</b>,7 x 10-6,,0.988771,12.519281,'-,NR,PPM1K,Stent thrombosis in response to clopidogrel treatment,"response to clopidogrel, cardiovascular event measurement",GCST010484,4:88275046,Cancer
1799,PPM1K,PPM1K,N/a,rs10022462-<b>T</b>,2 x 10-9,(EA),0.44,1.04,'-,[1.02-1.06],PPM1K-DT,Breast cancer,breast carcinoma,GCST004988,4:88322666,Cancer
1801,PPM1K,PPM1K-DT,N/a,rs10022462-<b>T</b>,2 x 10-9,(EA),0.44,1.04,'-,[1.02-1.06],PPM1K-DT,Breast cancer,breast carcinoma,GCST004988,4:88322666,Cancer
859,PRC1,PRC1,N/a,rs8037137-<b>C</b>,1 x 10-7,,0.133619,1.1235955,'-,[1.08-1.18],"RCCD1, PRC1",Serous invasive ovarian cancer,ovarian serous carcinoma,GCST004478,15:90963407,Cancer
861,PRC1,PRC1,N/a,rs8037137-<b>C</b>,7 x 10-8,,0.133619,1.1363636,'-,[1.09-1.19],"RCCD1, PRC1",High-grade serous ovarian cancer,ovarian serous carcinoma,GCST004480,15:90963407,Cancer
863,PRC1,PRC1,N/a,rs8037137-<b>C</b>,5 x 10-7,,0.134,1.098901,'-,[1.06-1.15],"RCCD1, PRC1",Invasive epithelial ovarian cancer,ovarian carcinoma,GCST004415,15:90963407,Cancer
1787,PRC1,PRC1,N/a,rs2290203-<b>G</b>,8 x 10-10,,0.79,1.0638298,'-,[1.04-1.09],"PRC1, PRC1-AS1",Breast cancer,breast carcinoma,GCST004988,15:90968837,Cancer
1789,PRC1,PRC1,N/a,rs77554484-<b>A</b>,1 x 10-15,(EA),0.1319,'-,0.0741 unit decrease,[0.056-0.092],"RCCD1, PRC1",Breast cancer,breast carcinoma,GCST004988,15:90965985,Cancer
1791,PRC1,PRC1,N/a,rs2290203-<b>G</b>,4 x 10-8,(East Asian),0.504,1.08,'-,[1.05-1.11],"PRC1, PRC1-AS1",Breast cancer,breast carcinoma,GCST002537,15:90968837,Cancer
1793,PRC1,PRC1-AS1,N/a,rs2290203-<b>G</b>,8 x 10-10,,0.79,1.0638298,'-,[1.04-1.09],"PRC1, PRC1-AS1",Breast cancer,breast carcinoma,GCST004988,15:90968837,Cancer
1795,PRC1,PRC1-AS1,N/a,rs2290203-<b>G</b>,4 x 10-8,(East Asian),0.504,1.08,'-,[1.05-1.11],"PRC1, PRC1-AS1",Breast cancer,breast carcinoma,GCST002537,15:90968837,Cancer
1651,PSMG4,PSMG4,N/a,rs4959799-<b>?</b>,5 x 10-6,(disease-free survival),'-,3.5,'-,[2.05-5.99],"SLC22A23, PSMG4",Survival in rectal cancer,"disease free survival, rectum cancer",GCST002821,6:3294794,Cancer
1754,PSMG4,PSMG4,N/a,rs9385905-<b>?</b>,2 x 10-6,,'-,'-,'-,'-,"MCHR2, PSMG4",Clostridium difficile infection in multiple myeloma,"clostridium difficile infection, multiple myeloma",GCST005686,6:99843632,Cancer
71,RCN2,RCN2,N/a,rs932046-<b>T</b>,5 x 10-11,,NR,'-,0.056 unit increase,[0.039-0.073],"RN7SL278P, RCN2",Urate levels,urate measurement,GCST90019524,15:76955213,Cancer
505,RCN2,RCN2,N/a,rs932046-<b>T</b>,7 x 10-12,,NR,'-,0.0584 unit increase,[0.042-0.075],"RN7SL278P, RCN2",Urea levels,serum urea measurement,GCST90019525,15:76955213,Cancer
639,RN7SL252P,RN7SL252P,N/a,rs17598306-<b>?</b>,9 x 10-6,,0.08,'-,'-,'-,"DLX6-AS1, RN7SL252P",Radiation response,response to radiation,GCST000823,7:96952499,Cancer
422,RNU5E-5P,RNU5E-5P,N/a,rs7979031-<b>C</b>,7 x 10-6,,0.455423445,1.205228,'-,[1.110720693-1.307776555],"RNA5SP367, RNU5E-5P",Lung cancer in never smokers,"smoking status measurement, lung carcinoma",GCST004747,12:101467714,Cancer
857,ROR1,ROR1,N/a,rs1747924-<b>A</b>,7 x 10-6,,0.767,1.1111112,'-,[1.06-1.16],ROR1,Pancreatic cancer,pancreatic carcinoma,GCST002991,1:64073289,Cancer
2243,ROR1,ROR1,N/a,"rs1324359-<b>G</b>, rs6588083-<b>C</b>",1 x 10-8,,0.175,'-,'-,'-,ROR1; ROR1-AS1; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:64150746,Cancer
2245,ROR1,ROR1,N/a,"rs649195-<b>G</b>, rs631029-<b>G</b>, rs675893-<b>G</b>, rs679386-<b>A</b>, rs636119-<b>C</b>, rs11208300-<b>G</b>, rs11208305-<b>C</b>, rs1390116-<b>G</b>, rs582428-<b>A</b>, rs10889450-<b>T</b>, rs619334-<b>G</b>, rs11581982-<b>C</b>",6 x 10-12,,0.032,'-,'-,'-,ROR1; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:63852664,Cancer
2247,ROR1,ROR1,N/a,"rs649195-<b>G</b>, rs631029-<b>G</b>, rs675893-<b>G</b>, rs679386-<b>A</b>, rs636119-<b>C</b>, rs11208300-<b>G</b>, rs11208305-<b>C</b>, rs1390116-<b>G</b>, rs582428-<b>A</b>, rs10889450-<b>T</b>, rs619334-<b>G</b>, rs11581982-<b>T</b>",3 x 10-11,,0.223,'-,'-,'-,ROR1; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:63852664,Cancer
2249,ROR1,ROR1-AS1,N/a,"rs1324359-<b>G</b>, rs6588083-<b>C</b>",1 x 10-8,,0.175,'-,'-,'-,ROR1; ROR1-AS1; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,1:64150746,Cancer
1805,SLC22A4,SLC22A4,N/a,rs6860806-<b>G</b>,8 x 10-8,(EA),0.5391,'-,0.0335 unit increase,[0.021-0.046],SLC22A4,Breast cancer,breast carcinoma,GCST004988,5:132304843,Cancer
1807,SLC22A4,SLC22A4,N/a,rs6860806-<b>?</b>,3 x 10-8,,NR,'-,'-,'-,SLC22A4,Breast cancer,breast carcinoma,GCST010098,5:132304843,Cancer
2251,SPTBN4,SPTBN4,N/a,"rs843777-<b>G</b>, rs4332846-<b>A</b>, rs1165840-<b>C</b>",6 x 10-25,,0.15,'-,'-,'-,SPTBN4; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:40550886,Cancer
2253,SPTBN4,SPTBN4,N/a,"rs843777-<b>A</b>, rs4332846-<b>A</b>, rs1165840-<b>C</b>",7 x 10-23,,0.449,'-,'-,'-,SPTBN4; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:40550886,Cancer
1809,SSBP4,SSBP4,N/a,rs7258465-<b>C</b>,3 x 10-28,(EA),0.3436,'-,0.0725 unit decrease,[0.06-0.085],SSBP4,Breast cancer,breast carcinoma,GCST004988,19:18422832,Cancer
2207,TF,TF,N/a,"rs8177248-<b>C</b>, rs8177277-<b>T</b>, rs1115219-<b>T</b>, rs2715632-<b>T</b>, rs1358022-<b>G</b>, rs7638018-<b>A</b>, rs2718796-<b>C</b>, rs8177253-<b>C</b>, rs1525892-<b>G</b>, rs8177262-<b>G</b>, rs1049296-<b>C</b>, rs2715627-<b>C</b>, rs8177272-<b>G</b>, rs2715631-<b>G</b>",3 x 10-16,,0,'-,'-,'-,TF; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:133760782,Cancer
2209,TF,TF,N/a,"rs8177248-<b>C</b>, rs8177277-<b>T</b>, rs1115219-<b>C</b>, rs2715632-<b>T</b>, rs1358022-<b>G</b>, rs7638018-<b>A</b>, rs2718796-<b>C</b>, rs8177253-<b>C</b>, rs1525892-<b>G</b>, rs8177262-<b>G</b>, rs1049296-<b>C</b>, rs2715627-<b>C</b>, rs8177272-<b>G</b>, rs2715631-<b>G</b>",4 x 10-12,,0.236,'-,'-,'-,TF; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,3:133760782,Cancer
878,TGM3,TGM3,N/a,rs6082600-<b>T</b>,1 x 10-18,,NR,1.25,'-,[1.19-1.32],TGM3,Non-melanoma skin cancer,non-melanoma skin carcinoma,GCST005896,20:2281891,Cancer
1267,TGM3,TGM3,N/a,rs214831-<b>G</b>,1 x 10-12,,0.608868,1.06,'-,[1.05-1.08],TGM3,Keratinocyte cancer (MTAG),keratinocyte carcinoma,GCST008870,20:2340717,Cancer
1269,TGM3,TGM3,N/a,rs214803-<b>C</b>,6 x 10-66,,0.179072,1.2,'-,[1.17-1.22],TGM3,Keratinocyte cancer (MTAG),keratinocyte carcinoma,GCST008870,20:2309687,Cancer
1271,TGM3,TGM3,N/a,rs6137442-<b>T</b>,7 x 10-18,,0.361945,1.08,'-,[1.06-1.10],"STK35, TGM3",Keratinocyte cancer (MTAG),keratinocyte carcinoma,GCST008870,20:2249690,Cancer
2043,TGM3,TGM3,N/a,rs214803-<b>C</b>,3 x 10-81,,0.1836,1.2195122,'-,[1.19-1.25],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST008871,20:2309687,Cancer
2045,TGM3,TGM3,N/a,rs214785-<b>C</b>,8 x 10-33,,0.18,1.19,'-,[NR],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST003726,20:2302811,Cancer
2047,TGM3,TGM3,N/a,rs214803-<b>C</b>,1 x 10-59,,0.179593,'-,0.21616812 unit increase,[0.19-0.24],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST90013410,20:2309687,Cancer
2049,TGM3,TGM3,N/a,rs214830-<b>G</b>,1 x 10-11,,0.371612,'-,0.077058256 unit decrease,[0.055-0.099],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST90013410,20:2340459,Cancer
2051,TGM3,TGM3,N/a,rs6113392-<b>A</b>,5 x 10-20,,0.439823,'-,0.1027148 unit decrease,[0.081-0.125],"STK35, TGM3",Basal cell carcinoma,basal cell carcinoma,GCST90013410,20:2254824,Cancer
2053,TGM3,TGM3,N/a,rs214782-<b>G</b>,6 x 10-17,,0.17,1.29,'-,[1.22-1.37],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST002331,20:2301324,Cancer
2055,TGM3,TGM3,N/a,rs214782-<b>G</b>,2 x 10-13,,0.171,1.28,'-,[NR],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST002842,20:2301324,Cancer
2057,TGM3,TGM3,N/a,rs59586681-<b>T</b>,3 x 10-9,,0.61,1.16,'-,[1.11-1.22],"TGM3, STK35",Basal cell carcinoma,basal cell carcinoma,GCST002331,20:2239664,Cancer
1676,TUBB4BP4,TUBB4BP4,N/a,rs12225068-<b>A</b>,6 x 10-10,,0.917154,'-,'-,'-,"LINC02756, TUBB4BP4",Cutaneous melanoma or hair colour,"cutaneous melanoma, hair color",GCST010302,11:91883525,Cancer
2239,YWHAZP2,YWHAZP2,N/a,"rs12995563-<b>A</b>, rs7598155-<b>T</b>, rs7598599-<b>G</b>, rs4577234-<b>T</b>, rs7562097-<b>C</b>, rs7606197-<b>G</b>",1 x 10-10,,0.002,'-,'-,'-,N/A - YWHAZP2; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,2:126515885,Cancer
2241,YWHAZP2,YWHAZP2,N/a,"rs12995563-<b>G</b>, rs7598155-<b>T</b>, rs7598599-<b>G</b>, rs4577234-<b>T</b>, rs7562097-<b>C</b>, rs7606197-<b>G</b>",2 x 10-9,,0.173,'-,'-,'-,N/A - YWHAZP2; No mapped genes; No mapped genes; No mapped genes; No mapped genes; No mapped genes,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,2:126515885,Cancer
1783,ADH1A,ADH1A,N/a,rs2201728-<b>G</b>,5 x 10-6,(Dichotomous variable),NR,3.13,'-,[1.92-5],"ADH1A, ADH6",Cardiac Troponin-T levels,cardiac troponin T measurement,GCST001776,4:99242716,Cardiovascular
125,APOB,APOB,N/a,rs581411-<b>A</b>,2 x 10-6,,NR,'-,0.012 unit increase,NR,"TDRD15, APOB",Triglyceride levels in current drinkers,"triglyceride measurement, alcohol drinking",GCST008087,2:21066560,Cardiovascular
126,APOB,APOB,N/a,rs581411-<b>A</b>,6 x 10-6,,NR,'-,'-,'-,"TDRD15, APOB",Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),"triglyceride measurement, alcohol consumption measurement",GCST008074,2:21066560,Cardiovascular
129,APOB,APOB,N/a,rs4564803-<b>G</b>,4 x 10-59,(EA),0.761,'-,0.078 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:20982630,Cardiovascular
130,APOB,APOB,N/a,rs4564803-<b>G</b>,1 x 10-7,(Hispanic),0.742,'-,0.082 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:20982630,Cardiovascular
131,APOB,APOB,N/a,rs4564803-<b>G</b>,8 x 10-64,,NR,'-,0.073 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:20982630,Cardiovascular
132,APOB,APOB,N/a,rs13392272-<b>C</b>,3 x 10-33,(EA),0.526,'-,0.049 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:20994618,Cardiovascular
133,APOB,APOB,N/a,rs13392272-<b>C</b>,2 x 10-40,,NR,'-,0.051 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:20994618,Cardiovascular
134,APOB,APOB,N/a,rs4665710-<b>A</b>,9 x 10-67,(EA),0.215,'-,0.087 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:20998163,Cardiovascular
135,APOB,APOB,N/a,rs4665710-<b>A</b>,2 x 10-7,(Hispanic),0.247,'-,0.082 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:20998163,Cardiovascular
136,APOB,APOB,N/a,rs4665710-<b>A</b>,1 x 10-70,,NR,'-,0.08 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:20998163,Cardiovascular
137,APOB,APOB,N/a,rs1042034-<b>C</b>,3 x 10-67,(EA),0.215,'-,0.087 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21002409,Cardiovascular
138,APOB,APOB,N/a,rs1042034-<b>C</b>,7 x 10-7,(Hispanic),0.244,'-,0.079 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21002409,Cardiovascular
139,APOB,APOB,N/a,rs1042034-<b>C</b>,1 x 10-72,,NR,'-,0.081 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21002409,Cardiovascular
140,APOB,APOB,N/a,rs2678379-<b>A</b>,1 x 10-66,(EA),0.215,'-,0.087 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21003688,Cardiovascular
141,APOB,APOB,N/a,rs676210-<b>G</b>,6 x 10-197,,0.794704,'-,0.0734811 unit increase,[0.069-0.078],APOB,Triglyceride levels,triglyceride measurement,GCST010244,2:21008652,Cardiovascular
142,APOB,APOB,N/a,rs4665710-<b>C</b>,1 x 10-31,,0.76,'-,0.082 s.d. increase,[0.068-0.096],APOB,Triglycerides,triglyceride measurement,GCST002897,2:20998163,Cardiovascular
143,APOB,APOB,N/a,rs1041968-<b>?</b>,1 x 10-7,,NR,'-,0.02369624 unit increase,[0.015-0.032],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:21009932,Cardiovascular
144,APOB,APOB,N/a,rs1042034-<b>?</b>,4 x 10-8,,NR,'-,0.02705578 unit increase,[0.017-0.037],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:21002409,Cardiovascular
145,APOB,APOB,N/a,rs6544366-<b>T</b>,2 x 10-67,,0.2243,'-,0.0549 mg dl-1 decrease,[0.049-0.061],APOB,Triglycerides,triglyceride measurement,GCST006613,2:20981153,Cardiovascular
146,APOB,APOB,N/a,rs1042031-<b>T</b>,1 x 10-16,,NR,'-,0.0257 unit increase,[0.02-0.032],APOB,Triglyceride levels,triglyceride measurement,GCST90019523,2:21002881,Cardiovascular
147,APOB,APOB,N/a,rs533617-<b>C</b>,2 x 10-67,,NR,'-,0.1065 unit decrease,[0.095-0.118],APOB,Triglyceride levels,triglyceride measurement,GCST90019523,2:21011100,Cardiovascular
148,APOB,APOB,N/a,rs72788528-<b>C</b>,4 x 10-11,,NR,'-,0.0344 unit increase,[0.024-0.045],"APOB, LINC02850",Triglyceride levels,triglyceride measurement,GCST90019523,2:20916057,Cardiovascular
149,APOB,APOB,N/a,rs74629722-<b>C</b>,1 x 10-13,,NR,'-,0.0273 unit increase,[0.02-0.035],"APOB, LINC02850",Triglyceride levels,triglyceride measurement,GCST90019523,2:20927284,Cardiovascular
150,APOB,APOB,N/a,rs2678379-<b>A</b>,3 x 10-7,(Hispanic),0.247,'-,0.081 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21003688,Cardiovascular
151,APOB,APOB,N/a,rs2678379-<b>A</b>,2 x 10-71,,NR,'-,0.08 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21003688,Cardiovascular
152,APOB,APOB,N/a,rs676210-<b>G</b>,8 x 10-67,(EA),0.785,'-,0.087 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21008652,Cardiovascular
153,APOB,APOB,N/a,rs676210-<b>G</b>,5 x 10-7,(Hispanic),0.757,'-,0.08 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21008652,Cardiovascular
154,APOB,APOB,N/a,rs676210-<b>G</b>,7 x 10-72,,NR,'-,0.081 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21008652,Cardiovascular
155,APOB,APOB,N/a,rs1041968-<b>G</b>,1 x 10-35,(EA),0.511,'-,0.051 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21009932,Cardiovascular
156,APOB,APOB,N/a,rs1041968-<b>G</b>,4 x 10-41,,NR,'-,0.052 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21009932,Cardiovascular
157,APOB,APOB,N/a,rs533617-<b>T</b>,2 x 10-25,(EA),0.96,'-,0.109 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21011100,Cardiovascular
158,APOB,APOB,N/a,rs533617-<b>T</b>,1 x 10-26,,NR,'-,0.108 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21011100,Cardiovascular
159,APOB,APOB,N/a,rs673548-<b>G</b>,4 x 10-66,(EA),0.785,'-,0.086 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21014672,Cardiovascular
160,APOB,APOB,N/a,rs673548-<b>G</b>,8 x 10-7,(Hispanic),0.754,'-,0.078 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21014672,Cardiovascular
161,APOB,APOB,N/a,rs673548-<b>G</b>,1 x 10-69,,NR,'-,0.079 unit increase,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21014672,Cardiovascular
162,APOB,APOB,N/a,rs1367117-<b>G</b>,3 x 10-14,(EA),0.688,'-,0.034 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21041028,Cardiovascular
163,APOB,APOB,N/a,rs1367117-<b>G</b>,1 x 10-16,,NR,'-,0.034 unit decrease,'-,APOB,Triglycerides,triglyceride measurement,GCST007142,2:21041028,Cardiovascular
164,APOB,APOB,N/a,rs673548-<b>A</b>,2 x 10-6,,0.221,'-,0.053 unit decrease,[0.031-0.075],APOB,Triglycerides,triglyceride measurement,GCST008985,2:21014672,Cardiovascular
165,APOB,APOB,N/a,rs12992267-<b>?</b>,1 x 10-11,,NR,'-,0.05102 unit increase,[0.036-0.066],APOB,Triglyceride levels,triglyceride measurement,GCST006003,2:20992773,Cardiovascular
166,APOB,APOB,N/a,rs676210-<b>?</b>,1 x 10-117,,NR,'-,0.0745 unit decrease,[0.069-0.08],APOB,Triglyceride levels,triglyceride measurement,GCST010173,2:21008652,Cardiovascular
167,APOB,APOB,N/a,rs1042034-<b>T</b>,1 x 10-22,(EA),0.7862,'-,0.0319 unit increase,[0.025-0.038],APOB,Triglyceride levels,triglyceride measurement,GCST008702,2:21002409,Cardiovascular
168,APOB,APOB,N/a,rs7557067-<b>?</b>,1 x 10-8,,NR,'-,0.02773443 unit decrease,[0.018-0.037],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:20985339,Cardiovascular
169,APOB,APOB,N/a,rs4665710-<b>?</b>,7 x 10-7,,NR,'-,0.02314104 unit increase,[0.014-0.032],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:20998163,Cardiovascular
170,APOB,APOB,N/a,rs6544366-<b>?</b>,2 x 10-8,,NR,'-,0.0275576 unit decrease,[0.018-0.037],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:20981153,Cardiovascular
171,APOB,APOB,N/a,rs673548-<b>?</b>,4 x 10-7,,NR,'-,0.02367532 unit decrease,[0.015-0.033],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:21014672,Cardiovascular
172,APOB,APOB,N/a,rs6754295-<b>?</b>,3 x 10-8,,NR,'-,0.02489028 unit decrease,[0.016-0.034],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:20983311,Cardiovascular
173,APOB,APOB,N/a,rs676210-<b>?</b>,2 x 10-8,,NR,'-,0.02768427 unit decrease,[0.018-0.037],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:21008652,Cardiovascular
174,APOB,APOB,N/a,rs693-<b>?</b>,1 x 10-7,,NR,'-,0.02378812 unit increase,[0.015-0.033],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:21009323,Cardiovascular
175,APOB,APOB,N/a,rs11902417-<b>?</b>,5 x 10-8,,NR,'-,0.02562767 unit decrease,[0.016-0.035],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:20976028,Cardiovascular
176,APOB,APOB,N/a,rs13392272-<b>?</b>,3 x 10-6,,NR,'-,0.02097973 unit increase,[0.012-0.03],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:20994618,Cardiovascular
177,APOB,APOB,N/a,rs1367117-<b>?</b>,7 x 10-8,,NR,'-,0.0269989 unit increase,[0.017-0.037],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:21041028,Cardiovascular
178,APOB,APOB,N/a,rs2678379-<b>?</b>,5 x 10-7,,NR,'-,0.02340742 unit increase,[0.014-0.033],APOB,Triglyceride levels,triglyceride measurement,GCST008046,2:21003688,Cardiovascular
179,APOB,APOB,N/a,rs6754295-<b>C</b>,3 x 10-8,,0.25,'-,0.08 s.d. decrease,[NR],APOB,Triglycerides,triglyceride measurement,GCST000289,2:20983311,Cardiovascular
181,APOB,APOB,N/a,rs6544366-<b>T</b>,2 x 10-7,,0.22,'-,0.04 unit decrease,[0.03-0.05],APOB,Triglycerides,triglyceride measurement,GCST000809,2:20981153,Cardiovascular
182,APOB,APOB,N/a,rs693-<b>A</b>,2 x 10-7,,0.48,'-,0.08 unit increase,[0.04-0.12],APOB,Triglycerides,triglyceride measurement,GCST000138,2:21009323,Cardiovascular
183,APOB,APOB,N/a,rs1042034-<b>C</b>,1 x 10-45,,0.22,'-,5.99 mg/dL decrease,[5.11-6.87],APOB,Triglycerides,triglyceride measurement,GCST000758,2:21002409,Cardiovascular
184,APOB,APOB,N/a,rs7557067-<b>G</b>,9 x 10-12,,0.22,'-,0.08 s.d. decrease,[0.04-0.12],APOB,Triglycerides,triglyceride measurement,GCST000286,2:20985339,Cardiovascular
185,APOB,APOB,N/a,rs673548-<b>A</b>,1 x 10-173,,NR,'-,0.082 unit decrease,[0.076-0.088],APOB,Triglyceride levels,triglyceride measurement,GCST90019523,2:21014672,Cardiovascular
186,APOB,APOB,N/a,rs11676704-<b>G</b>,6 x 10-28,,NR,'-,0.0344 unit decrease,[0.028-0.04],APOB,Triglyceride levels,triglyceride measurement,GCST90019523,2:21021486,Cardiovascular
187,APOB,APOB,N/a,rs934198-<b>G</b>,3 x 10-9,(EA),0.677,'-,0.026 unit decrease,'-,"TDRD15, APOB",Triglycerides,triglyceride measurement,GCST007142,2:21055901,Cardiovascular
188,APOB,APOB,N/a,rs934198-<b>G</b>,6 x 10-11,,NR,'-,0.027 unit decrease,'-,"TDRD15, APOB",Triglycerides,triglyceride measurement,GCST007142,2:21055901,Cardiovascular
189,APOB,APOB,N/a,rs515135-<b>T</b>,9 x 10-6,,NR,'-,0.021 unit decrease,'-,"APOB, TDRD15",Triglycerides,triglyceride measurement,GCST007142,2:21063185,Cardiovascular
190,APOB,APOB,N/a,rs563290-<b>G</b>,2 x 10-7,,NR,'-,0.025 unit decrease,'-,"TDRD15, APOB",Triglycerides,triglyceride measurement,GCST007142,2:21065354,Cardiovascular
191,APOB,APOB,N/a,rs562338-<b>A</b>,4 x 10-6,,NR,'-,0.022 unit decrease,'-,"APOB, TDRD15",Triglycerides,triglyceride measurement,GCST007142,2:21065449,Cardiovascular
192,APOB,APOB,N/a,rs668948-<b>G</b>,4 x 10-7,,NR,'-,0.025 unit decrease,'-,"APOB, TDRD15",Triglycerides,triglyceride measurement,GCST007142,2:21068657,Cardiovascular
193,APOB,APOB,N/a,rs541041-<b>G</b>,6 x 10-7,,NR,'-,0.024 unit decrease,'-,"TDRD15, APOB",Triglycerides,triglyceride measurement,GCST007142,2:21072103,Cardiovascular
194,APOB,APOB,N/a,rs568938-<b>C</b>,3 x 10-6,,NR,'-,0.022 unit decrease,'-,"TDRD15, APOB",Triglycerides,triglyceride measurement,GCST007142,2:21080744,Cardiovascular
195,APOB,APOB,N/a,rs397870692-<b>?</b>,5 x 10-19,,'-,'-,0.0662 unit decrease,[0.052-0.081],"LINC02850, APOB",Triglyceride levels,triglyceride measurement,GCST011345,2:20949129,Cardiovascular
212,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Cardiovascular
220,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Cardiovascular
228,APOB,APOB,N/a,rs562338-<b>?</b>,3 x 10-25,,NR,'-,'-,'-,"APOB, TDRD15",Age-related disease endophenotypes,"total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement",GCST004046,2:21065449,Cardiovascular
474,APOB,APOB,N/a,rs4296389-<b>?</b>,7 x 10-25,,NR,'-,0.02271 unit decrease,[0.018-0.027],"LINC02850, APOB",Triglyceride levels x long total sleep time interaction (2df test),"sleep duration, triglyceride measurement",GCST009364,2:20943234,Cardiovascular
476,APOB,APOB,N/a,rs4296389-<b>?</b>,3 x 10-29,,NR,'-,0.02383 unit decrease,[0.019-0.028],"LINC02850, APOB",Triglyceride levels x short total sleep time interaction (2df test),"sleep duration, triglyceride measurement",GCST009363,2:20943234,Cardiovascular
1207,APOB,APOB,N/a,rs10199768-<b>T</b>,8 x 10-15,(LDL),0.47,'-,0.11 mmol/l increase,[0.083-0.137],APOB,Cardiovascular disease risk factors,low density lipoprotein cholesterol measurement,GCST001247,2:21021128,Cardiovascular
1710,APOB,APOB,N/a,rs13306206-<b>?</b>,5 x 10-35,,NR,'-,0.324647 unit increase,[0.27-0.38],APOB,Coronary artery disease,coronary artery disease,GCST010867,2:21019859,Cardiovascular
1711,APOB,APOB,N/a,rs515135-<b>T</b>,6 x 10-17,,0.1837,'-,0.0555 unit decrease,[0.043-0.068],"APOB, TDRD15",Coronary artery disease,coronary artery disease,GCST005195,2:21063185,Cardiovascular
1712,APOB,APOB,N/a,rs512535-<b>?</b>,1 x 10-6,,NR,'-,0.060281 unit decrease,[0.036-0.085],"APOB, TDRD15",Coronary artery disease,coronary artery disease,GCST010867,2:21044910,Cardiovascular
1713,APOB,APOB,N/a,rs11124924-<b>G</b>,4 x 10-9,,0.92,1.09,'-,[1.04-1.14],APOB,Coronary artery disease,coronary artery disease,GCST010479,2:20983403,Cardiovascular
1714,APOB,APOB,N/a,rs585967-<b>C</b>,3 x 10-8,,0.844,1.07,'-,[1.04-1.09],"TDRD15, APOB","Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",coronary artery disease,GCST004787,2:21047682,Cardiovascular
1715,APOB,APOB,N/a,rs668948-<b>A</b>,2 x 10-17,,0.815,'-,0.063 unit increase,[0.048-0.078],"APOB, TDRD15",Coronary artery disease,coronary artery disease,GCST005196,2:21068657,Cardiovascular
1736,APOB,APOB,N/a,rs515135-<b>T</b>,8 x 10-8,,0.18,'-,0.0487 unit decrease,[0.047-0.05],"APOB, TDRD15",Carotid intima media thickness,common carotid intimal medial thickness,GCST007436,2:21063185,Cardiovascular
1782,APOB,APOB,N/a,rs1367117-<b>?</b>,2 x 10-17,,NR,'-,'-,'-,APOB,Cardiovascular disease,cardiovascular disease,GCST007072,2:21041028,Cardiovascular
334,ARHGAP24,ARHGAP24,N/a,rs2014912-<b>C</b>,7 x 10-10,"(EA, initial)",0.853,'-,0.63 unit decrease,[0.43-0.83],ARHGAP24,Systolic blood pressure,systolic blood pressure,GCST004776,4:85794517,Cardiovascular
335,ARHGAP24,ARHGAP24,N/a,rs17010957-<b>T</b>,3 x 10-8,(East Asian),0.7712,'-,0.4189 unit decrease,[0.27-0.57],ARHGAP24,Systolic blood pressure,systolic blood pressure,GCST007703,4:85798012,Cardiovascular
336,ARHGAP24,ARHGAP24,N/a,rs2014912-<b>T</b>,4 x 10-7,,'-,'-,0.269 unit increase,'-,ARHGAP24,Systolic blood pressure,systolic blood pressure,GCST007099,4:85794517,Cardiovascular
337,ARHGAP24,ARHGAP24,N/a,rs17010961-<b>?</b>,2 x 10-23,,NR,'-,'-,'-,ARHGAP24,Systolic blood pressure,systolic blood pressure,GCST007087,4:85801950,Cardiovascular
338,ARHGAP24,ARHGAP24,N/a,rs12506184-<b>T</b>,4 x 10-13,,0.8789,'-,0.381 mmHg decrease,[0.28-0.48],ARHGAP24,Systolic blood pressure,systolic blood pressure,GCST007267,4:85818748,Cardiovascular
339,ARHGAP24,ARHGAP24,N/a,rs17010957-<b>T</b>,2 x 10-9,,0.857,'-,0.498 mm Hg decrease,[0.34-0.66],ARHGAP24,Systolic blood pressure,systolic blood pressure,GCST006259,4:85798012,Cardiovascular
340,ARHGAP24,ARHGAP24,N/a,rs2014912-<b>T</b>,5 x 10-17,,0.1645974,'-,0.61964464 mmHg increase,[0.48-0.76],ARHGAP24,Systolic blood pressure,systolic blood pressure,GCST003272,4:85794517,Cardiovascular
418,ARHGAP24,ARHGAP24,N/a,rs17010957-<b>?</b>,2 x 10-17,,NR,'-,'-,'-,ARHGAP24,Systolic blood pressure (cigarette smoking interaction),"smoking status measurement, systolic blood pressure",GCST006188,4:85798012,Cardiovascular
706,ARHGAP24,ARHGAP24,N/a,rs117824133-<b>A</b>,2 x 10-6,,0.01,'-,14.82 ms decrease,[8.76-20.88],ARHGAP24,QT interval,QT interval,GCST005171,4:85768423,Cardiovascular
709,ARHGAP24,ARHGAP24,N/a,rs2014912-<b>C</b>,4 x 10-10,"(EA, initial)",0.853,'-,0.418 unit decrease,[0.29-0.55],ARHGAP24,Pulse pressure,pulse pressure measurement,GCST004775,4:85794517,Cardiovascular
710,ARHGAP24,ARHGAP24,N/a,rs17011002-<b>G</b>,5 x 10-12,,0.8606,'-,0.2485 mmHg decrease,[0.18-0.32],ARHGAP24,Pulse pressure,pulse pressure measurement,GCST007269,4:85810232,Cardiovascular
711,ARHGAP24,ARHGAP24,N/a,rs2014912-<b>T</b>,6 x 10-8,,'-,'-,0.191 unit increase,'-,ARHGAP24,Pulse pressure,pulse pressure measurement,GCST007096,4:85794517,Cardiovascular
760,ARHGAP24,ARHGAP24,N/a,rs13137008-<b>T</b>,1 x 10-14,,0.697,'-,1.764 unit increase,[1.32-2.21],ARHGAP24,PR segment duration,PR segment,GCST002456,4:85753046,Cardiovascular
762,ARHGAP24,ARHGAP24,N/a,rs13105921-<b>A</b>,6 x 10-11,(Hispanic),0.41,'-,1.76 ms increase,[1.23-2.29],ARHGAP24,PR interval,PR interval,GCST005080,4:85778573,Cardiovascular
763,ARHGAP24,ARHGAP24,N/a,rs2624021-<b>T</b>,1 x 10-6,(AA),0.2367,'-,2.4314 ms increase,[1.45-3.41],ARHGAP24,PR interval,PR interval,GCST010321,4:85736267,Cardiovascular
764,ARHGAP24,ARHGAP24,N/a,rs13105921-<b>A</b>,5 x 10-12,(Hispanic/Latino),0.3987,'-,2.0123 ms increase,[1.44-2.58],ARHGAP24,PR interval,PR interval,GCST010321,4:85778573,Cardiovascular
765,ARHGAP24,ARHGAP24,N/a,rs2624021-<b>T</b>,2 x 10-178,,0.6791,'-,1.9786 ms increase,[1.84-2.11],ARHGAP24,PR interval,PR interval,GCST010321,4:85736267,Cardiovascular
766,ARHGAP24,ARHGAP24,N/a,rs11732231-<b>?</b>,7 x 10-13,,NR,'-,1.767805 unit increase,[1.29-2.25],ARHGAP24,PR interval,PR interval,GCST008042,4:85762407,Cardiovascular
767,ARHGAP24,ARHGAP24,N/a,rs13137008-<b>?</b>,5 x 10-15,,NR,'-,1.877909 unit increase,[1.41-2.35],ARHGAP24,PR interval,PR interval,GCST008042,4:85753046,Cardiovascular
768,ARHGAP24,ARHGAP24,N/a,rs7660702-<b>?</b>,3 x 10-10,,NR,'-,1.46842 unit decrease,[1.01-1.93],ARHGAP24,PR interval,PR interval,GCST008042,4:85730311,Cardiovascular
769,ARHGAP24,ARHGAP24,N/a,rs7692808-<b>?</b>,6 x 10-14,,NR,'-,1.814801 unit increase,[1.34-2.29],ARHGAP24,PR interval,PR interval,GCST008042,4:85719996,Cardiovascular
770,ARHGAP24,ARHGAP24,N/a,rs343849-<b>A</b>,3 x 10-61,,0.3,'-,2.1 ms decrease,[1.85-2.35],ARHGAP24,PR interval,PR interval,GCST007045,4:85741902,Cardiovascular
771,ARHGAP24,ARHGAP24,N/a,rs13111293-<b>T</b>,6 x 10-21,,0.703,'-,1.881 unit increase,[1.49-2.27],ARHGAP24,PR interval,PR interval,GCST007226,4:85761815,Cardiovascular
772,ARHGAP24,ARHGAP24,N/a,rs7692808-<b>A</b>,6 x 10-20,,0.31,'-,2.01 ms decrease,[1.58-2.44],ARHGAP24,PR interval,PR interval,GCST000562,4:85719996,Cardiovascular
773,ARHGAP24,ARHGAP24,N/a,rs7660702-<b>T</b>,3 x 10-17,(PR interval),0.74,'-,8.46 % s.d. increase,[6.50-10.42],ARHGAP24,Electrocardiographic traits,PR interval,GCST000561,4:85730311,Cardiovascular
774,ARHGAP24,ARHGAP24,N/a,rs11732231-<b>C</b>,3 x 10-9,,0.23,'-,2.28 unit increase,[1.52-3.04],ARHGAP24,PR interval,PR interval,GCST001735,4:85762407,Cardiovascular
1578,ARHGAP24,ARHGAP24,N/a,rs7692808-<b>?</b>,1 x 10-11,,NR,'-,'-,'-,ARHGAP24,Electrocardiographic traits (multivariate),electrocardiography,GCST011010,4:85719996,Cardiovascular
1579,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,3 x 10-50,(-96 ms),0.321763,'-,0.0907208 unit increase,[0.079-0.103],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1580,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,2 x 10-49,(-94 ms),0.321763,'-,0.0894543 unit increase,[0.077-0.102],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1581,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,3 x 10-45,(-92 ms),0.321763,'-,0.0853523 unit increase,[0.073-0.097],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1582,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,5 x 10-40,(-90 ms),0.321763,'-,0.0804937 unit increase,[0.068-0.093],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1583,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,7 x 10-36,(-88 ms),0.321763,'-,0.0761197 unit increase,[0.064-0.088],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1584,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,2 x 10-31,(-86 ms),0.321763,'-,0.0709943 unit increase,[0.059-0.083],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1585,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,2 x 10-28,(-84 ms),0.321763,'-,0.0679398 unit increase,[0.056-0.08],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1586,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,6 x 10-26,(-82 ms),0.321763,'-,0.0650779 unit increase,[0.053-0.077],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1587,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,9 x 10-21,(-80 ms),0.321763,'-,0.0579752 unit increase,[0.046-0.07],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1588,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,2 x 10-15,(-78 ms),0.321763,'-,0.0487146 unit increase,[0.037-0.061],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1589,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,7 x 10-13,(-76 ms),0.321763,'-,0.0440473 unit increase,[0.032-0.056],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1590,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,1 x 10-10,(-74 ms),0.321763,'-,0.0400224 unit increase,[0.028-0.052],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1591,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,6 x 10-56,(-108 ms),0.321763,'-,0.0955415 unit increase,[0.084-0.108],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1592,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,1 x 10-11,(-208 ms),0.321763,'-,0.0421184 unit decrease,[0.03-0.054],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1593,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,7 x 10-12,(-206 ms),0.321763,'-,0.0424599 unit decrease,[0.03-0.055],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1594,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,1 x 10-11,(-204 ms),0.321763,'-,0.0419803 unit decrease,[0.03-0.054],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1595,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,3 x 10-12,(-202 ms),0.321763,'-,0.0432726 unit decrease,[0.031-0.055],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1596,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,2 x 10-13,(-200 ms),0.321763,'-,0.0453661 unit decrease,[0.033-0.057],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1597,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,1 x 10-19,(-190 ms),0.321763,'-,0.0550745 unit decrease,[0.043-0.067],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1598,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,5 x 10-51,(-112 ms),0.321763,'-,0.0908493 unit increase,[0.079-0.103],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1599,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,8 x 10-55,(-110 ms),0.321763,'-,0.0938002 unit increase,[0.082-0.106],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1600,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,1 x 10-55,(-106 ms),0.321763,'-,0.0953429 unit increase,[0.083-0.107],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1601,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,5 x 10-55,(-104 ms),0.321763,'-,0.0938928 unit increase,[0.082-0.106],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1602,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,8 x 10-54,(-100 ms),0.321763,'-,0.0938956 unit increase,[0.082-0.106],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
1603,ARHGAP24,ARHGAP24,N/a,rs199745043-<b>AG</b>,1 x 10-51,(-98 ms),0.321763,'-,0.0919426 unit increase,[0.08-0.104],ARHGAP24,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:85760064,Cardiovascular
2118,ARHGAP24,ARHGAP24,N/a,rs17010961-<b>A</b>,1 x 10-6,,0.141,1.2,'-,[1.13-1.27],ARHGAP24,Calcific aortic valve stenosis,"aortic stenosis, aortic valve calcification",GCST009870,4:85801950,Cardiovascular
401,CHL1,CHL1,N/a,rs6764363-<b>?</b>,6 x 10-6,(Recessive),0.36,1.19,'-,[1.10-1.28],CHL1,Sudden cardiac arrest,sudden cardiac arrest,GCST001099,3:270666,Cardiovascular
705,CHL1,CHL1,N/a,rs11917787-<b>?</b>,9 x 10-6,,NR,'-,'-,'-,CHL1,QT interval in Tripanosoma cruzi seropositivity,"QT interval, Trypanosoma cruzi seropositivity",GCST002278,3:212236,Cardiovascular
1660,CHL1,CHL1,N/a,rs767055246-<b>T</b>,6 x 10-7,,0.7846,'-,1.3136 mmHg decrease,[0.8-1.83],CHL1,Diastolic blood pressure (long-term average),diastolic blood pressure,GCST011905,3:239595,Cardiovascular
1661,CHL1,CHL1,N/a,rs767055246-<b>T</b>,6 x 10-7,,0.7846,'-,1.3136 mmHg decrease,[0.8-1.83],CHL1,Diastolic blood pressure (long-term average),diastolic blood pressure,GCST011895,3:239595,Cardiovascular
43,DNM3,DNM3,N/a,rs12077769-<b>A</b>,4 x 10-6,,NR,'-,4.631 Z score increase,[NR],"PIGC, DNM3",Very long-chain saturated fatty acid levels (fatty acid 22:0),very long-chain saturated fatty acid measurement,GCST002688,1:172379811,Cardiovascular
196,DNM3,DNM3,N/a,rs7519429-<b>A</b>,2 x 10-9,(EA),0.625,'-,0.026 unit increase,'-,"PIGC, DNM3",Triglycerides,triglyceride measurement,GCST007142,1:172380106,Cardiovascular
197,DNM3,DNM3,N/a,rs7519429-<b>A</b>,1 x 10-10,,NR,'-,0.025 unit increase,'-,"PIGC, DNM3",Triglycerides,triglyceride measurement,GCST007142,1:172380106,Cardiovascular
198,DNM3,DNM3,N/a,rs10797996-<b>C</b>,5 x 10-12,,0.433192,'-,0.0138307 unit increase,[0.0099-0.0178],"DNM3, PIGC",Triglyceride levels,triglyceride measurement,GCST010244,1:172384171,Cardiovascular
199,DNM3,DNM3,N/a,rs1011731-<b>A</b>,8 x 10-9,,0.57,'-,0.018 unit decrease,'-,"DNM3, PIGC",Triglyceride levels,triglyceride measurement,GCST009149,1:172377408,Cardiovascular
349,DNM3,DNM3,N/a,rs10911356-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,DNM3,Systolic blood pressure,systolic blood pressure,GCST007087,1:172240607,Cardiovascular
350,DNM3,DNM3,N/a,rs12405515-<b>G</b>,1 x 10-6,,'-,'-,0.189 unit increase,'-,"DNM3, PIGC",Systolic blood pressure,systolic blood pressure,GCST007099,1:172388301,Cardiovascular
623,DNM3,DNM3,N/a,rs12132562-<b>?</b>,4 x 10-7,(AA),NR,'-,8.5 ms increase,[5.17-11.83],"PIGC, DNM3",QT interval (sulfonylurea treatment interaction),"response to sulfonylurea, QT interval",GCST004031,1:172384331,Cardiovascular
1668,DNM3,DNM3,N/a,rs12405515-<b>T</b>,1 x 10-9,,0.56,'-,0.165 unit decrease,[0.11-0.22],"DNM3, PIGC",Diastolic blood pressure,diastolic blood pressure,GCST004280,1:172388301,Cardiovascular
1669,DNM3,DNM3,N/a,rs12405515-<b>G</b>,1 x 10-12,,'-,'-,0.17 unit increase,'-,"DNM3, PIGC",Diastolic blood pressure,diastolic blood pressure,GCST007094,1:172388301,Cardiovascular
663,FGF12,FGF12,N/a,rs55636532-<b>C</b>,2 x 10-6,,0.019,3.495,'-,[2.077-5.883],FGF12,Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker,"response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,3:192194678,Cardiovascular
775,FGF12,FGF12,N/a,rs4687352-<b>A</b>,1 x 10-16,,0.41,'-,0.53 ms increase,[0.41-0.65],FGF12,PR interval,PR interval,GCST010321,3:192655972,Cardiovascular
776,FGF12,FGF12,N/a,rs4687352-<b>A</b>,5 x 10-15,,0.4012,'-,0.5269 ms increase,[0.39-0.66],FGF12,PR interval,PR interval,GCST010320,3:192655972,Cardiovascular
1342,FGF12,FGF12,N/a,rs142971575-<b>CTTAAT</b>,4 x 10-6,,0.074,1.05,'-,[1.08-20.22],FGF12,Idiopathic dilated cardiomyopathy,idiopathic dilated cardiomyopathy,GCST005588,3:192461558,Cardiovascular
351,FGF8,FGF8,N/a,rs3218248-<b>A</b>,4 x 10-8,,0.0208,'-,0.5752 mmHg increase,[0.37-0.78],"FGF8, FBXW4",Systolic blood pressure,systolic blood pressure,GCST007267,10:101768487,Cardiovascular
1727,GIMAP1-GIMAP5,GIMAP1-GIMAP5,N/a,rs61751050-<b>?</b>,4 x 10-6,,NR,'-,0.292 unit decrease,[0.12-0.46],"GIMAP1-GIMAP5, GIMAP5",Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,"coronary artery calcification, type II diabetes mellitus",GCST005173,7:150742952,Cardiovascular
1733,GSKIP,GSKIP,N/a,rs35946663-<b>?</b>,5 x 10-6,,NR,1.272462,'-,[1.147109-1.411514],GSKIP,Conotruncal heart defects (inherited effects),Conotruncal heart malformations,GCST004720,14:96363661,Cardiovascular
328,GUCY1A1,GUCY1A1,N/a,rs11725969-<b>T</b>,6 x 10-19,"(Asian, EA, Hispanic)",0.25,'-,'-,'-,GUCY1A1,Systolic blood pressure x alcohol consumption interaction (2df test),"systolic blood pressure, alcohol drinking",GCST006434,4:155705436,Cardiovascular
329,GUCY1A1,GUCY1A1,N/a,rs11731886-<b>A</b>,1 x 10-15,"(Asian, EA)",0.76,'-,'-,'-,"GUCY1A1, GUCY1B1",Systolic blood pressure x alcohol consumption interaction (2df test),"systolic blood pressure, alcohol drinking",GCST006434,4:155738667,Cardiovascular
330,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,9 x 10-15,(EA),0.23,'-,'-,'-,GUCY1A1,Systolic blood pressure x alcohol consumption interaction (2df test),"systolic blood pressure, alcohol drinking",GCST006434,4:155724361,Cardiovascular
341,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,5 x 10-6,"(EA, initial)",0.236,'-,0.386 unit decrease,[0.22-0.55],GUCY1A1,Systolic blood pressure,systolic blood pressure,GCST004776,4:155724361,Cardiovascular
342,GUCY1A1,GUCY1A1,N/a,rs3796592-<b>C</b>,2 x 10-12,,0.7958,'-,0.2949 mmHg increase,[0.21-0.38],GUCY1A1,Systolic blood pressure,systolic blood pressure,GCST007267,4:155710193,Cardiovascular
343,GUCY1A1,GUCY1A1,N/a,rs56329057-<b>?</b>,3 x 10-23,,NR,'-,'-,'-,GUCY1A1,Systolic blood pressure,systolic blood pressure,GCST007087,4:155712292,Cardiovascular
344,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>C</b>,6 x 10-13,,'-,'-,0.319 unit increase,'-,GUCY1A1,Systolic blood pressure,systolic blood pressure,GCST007099,4:155724361,Cardiovascular
345,GUCY1A1,GUCY1A1,N/a,rs13143871-<b>T</b>,5 x 10-8,,0.8,'-,0.96 unit increase,[0.61-1.31],GUCY1A1,Systolic blood pressure,systolic blood pressure,GCST002630,4:155698052,Cardiovascular
346,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>C</b>,1 x 10-6,,0.76,'-,0.321 mmHg increase,[NR],GUCY1A1,Systolic blood pressure,systolic blood pressure,GCST001227,4:155724361,Cardiovascular
419,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>?</b>,8 x 10-19,,NR,'-,'-,'-,GUCY1A1,Systolic blood pressure (cigarette smoking interaction),"smoking status measurement, systolic blood pressure",GCST006188,4:155724361,Cardiovascular
424,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>?</b>,1 x 10-24,,'-,'-,'-,'-,GUCY1A1,Diastolic blood pressure (cigarette smoking interaction),"smoking status measurement, diastolic blood pressure",GCST006187,4:155724361,Cardiovascular
921,GUCY1A1,GUCY1A1,N/a,rs72689147-<b>G</b>,7 x 10-13,,0.819431,1.07,'-,[1.05-1.09],GUCY1A1,Myocardial infarction,myocardial infarction,GCST011365,4:155718736,Cardiovascular
922,GUCY1A1,GUCY1A1,N/a,rs72689147-<b>G</b>,2 x 10-8,,0.82,1.08,'-,[1.05-1.1],GUCY1A1,Myocardial infarction,myocardial infarction,GCST003117,4:155718736,Cardiovascular
1041,GUCY1A1,GUCY1A1,N/a,rs11725969-<b>T</b>,7 x 10-12,"(Asian, EA, Hispanic)",0.25,'-,'-,'-,GUCY1A1,Mean arterial pressure x alcohol consumption interaction (2df test),"mean arterial pressure, alcohol drinking",GCST006167,4:155705436,Cardiovascular
1042,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,2 x 10-9,(EA),0.24,'-,'-,'-,GUCY1A1,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),"mean arterial pressure, alcohol consumption measurement",GCST006172,4:155724361,Cardiovascular
1043,GUCY1A1,GUCY1A1,N/a,rs11725969-<b>T</b>,1 x 10-8,"(AA, EA)",0.25,'-,'-,'-,GUCY1A1,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),"mean arterial pressure, alcohol consumption measurement",GCST006172,4:155705436,Cardiovascular
1044,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>C</b>,3 x 10-7,(Mean Arterial Pressure),0.74,'-,0.289 mmHg increase,[0.18-0.40],GUCY1A1,Blood pressure,mean arterial pressure,GCST001236,4:155724361,Cardiovascular
1345,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,6 x 10-6,(Japanese),0.2447,'-,0.0719 unit decrease,[0.041-0.103],GUCY1A1,Hypertension,hypertension,GCST007707,4:155724361,Cardiovascular
1346,GUCY1A1,GUCY1A1,N/a,rs13143871-<b>T</b>,1 x 10-6,,0.8,'-,'-,'-,GUCY1A1,Hypertension,hypertension,GCST002627,4:155698052,Cardiovascular
1347,GUCY1A1,GUCY1A1,N/a,rs6536088-<b>A</b>,2 x 10-9,(East Asian),0.5549,'-,0.0665 unit increase,[0.045-0.088],"GUCY1B1, GUCY1A1",Hypertension,hypertension,GCST007707,4:155745839,Cardiovascular
1656,GUCY1A1,GUCY1A1,N/a,rs11731886-<b>A</b>,2 x 10-18,(EA),0.76,'-,'-,'-,"GUCY1A1, GUCY1B1",Diastolic blood pressure x alcohol consumption interaction (2df test),"diastolic blood pressure, alcohol drinking",GCST006166,4:155738667,Cardiovascular
1657,GUCY1A1,GUCY1A1,N/a,rs11725969-<b>T</b>,2 x 10-22,"(AA, Asian, EA, Hispanic)",0.25,'-,'-,'-,GUCY1A1,Diastolic blood pressure x alcohol consumption interaction (2df test),"diastolic blood pressure, alcohol drinking",GCST006166,4:155705436,Cardiovascular
1658,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,3 x 10-9,(EA),0.24,'-,'-,'-,GUCY1A1,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),"diastolic blood pressure, alcohol consumption measurement",GCST006169,4:155724361,Cardiovascular
1659,GUCY1A1,GUCY1A1,N/a,rs11725969-<b>T</b>,2 x 10-8,"(AA, EA)",0.25,'-,'-,'-,GUCY1A1,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),"diastolic blood pressure, alcohol consumption measurement",GCST006169,4:155705436,Cardiovascular
1662,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,2 x 10-6,"(EA, initial)",0.236,'-,0.247 unit decrease,[0.15-0.35],GUCY1A1,Diastolic blood pressure,diastolic blood pressure,GCST004777,4:155724361,Cardiovascular
1663,GUCY1A1,GUCY1A1,N/a,rs7692387-<b>A</b>,2 x 10-8,,0.1992,'-,0.0226 unit decrease,'-,GUCY1A1,Diastolic blood pressure,diastolic blood pressure,GCST006020,4:155714157,Cardiovascular
1664,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>C</b>,3 x 10-19,,'-,'-,0.242 unit increase,'-,GUCY1A1,Diastolic blood pressure,diastolic blood pressure,GCST007094,4:155724361,Cardiovascular
1665,GUCY1A1,GUCY1A1,N/a,rs13143871-<b>T</b>,6 x 10-7,,0.8,'-,0.49 unit increase,[0.29-0.69],GUCY1A1,Diastolic blood pressure,diastolic blood pressure,GCST002631,4:155698052,Cardiovascular
1666,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>C</b>,2 x 10-10,,0.76,'-,0.26 mmHg increase,[NR],GUCY1A1,Diastolic blood pressure,diastolic blood pressure,GCST001228,4:155724361,Cardiovascular
1701,GUCY1A1,GUCY1A1,N/a,rs13131930-<b>T</b>,5 x 10-19,,0.257,'-,0.065 unit decrease,[0.051-0.079],GUCY1A1,Coronary artery disease,coronary artery disease,GCST005194,4:155693032,Cardiovascular
1702,GUCY1A1,GUCY1A1,N/a,rs7692387-<b>A</b>,4 x 10-22,,0.1904,'-,0.0687 unit decrease,[0.055-0.083],GUCY1A1,Coronary artery disease,coronary artery disease,GCST005196,4:155714157,Cardiovascular
1703,GUCY1A1,GUCY1A1,N/a,rs7692387-<b>A</b>,3 x 10-23,,0.1892,'-,0.0643 unit decrease,[0.052-0.077],GUCY1A1,Coronary artery disease,coronary artery disease,GCST005195,4:155714157,Cardiovascular
1704,GUCY1A1,GUCY1A1,N/a,rs3796587-<b>?</b>,5 x 10-27,,NR,'-,0.0656284 unit decrease,[0.054-0.078],GUCY1A1,Coronary artery disease,coronary artery disease,GCST010866,4:155716921,Cardiovascular
1705,GUCY1A1,GUCY1A1,N/a,rs13139571-<b>A</b>,3 x 10-10,,0.233,'-,'-,'-,GUCY1A1,Coronary artery disease,coronary artery disease,GCST008370,4:155724361,Cardiovascular
1706,GUCY1A1,GUCY1A1,N/a,rs2306556-<b>A</b>,1 x 10-9,,0.816,1.07,'-,[1.04-1.09],GUCY1A1,"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",coronary artery disease,GCST004787,4:155717421,Cardiovascular
1707,GUCY1A1,GUCY1A1,N/a,rs72689147-<b>G</b>,6 x 10-9,,0.816978,1.07,'-,[1.05- 1.10],GUCY1A1,Coronary artery disease,coronary artery disease,GCST003116,4:155718736,Cardiovascular
1708,GUCY1A1,GUCY1A1,N/a,rs34914832-<b>G</b>,3 x 10-11,,0.79,1.07,'-,[1.05-1.08],GUCY1A1,Coronary artery disease,coronary artery disease,GCST010479,4:155704926,Cardiovascular
1709,GUCY1A1,GUCY1A1,N/a,rs1842896-<b>T</b>,1 x 10-11,,0.76,1.14,'-,[1.10-1.19],GUCY1A1,Coronary heart disease,coronary artery disease,GCST001587,4:155590307,Cardiovascular
1781,GUCY1A1,GUCY1A1,N/a,rs11724647-<b>?</b>,2 x 10-20,,NR,'-,'-,'-,GUCY1A1,Cardiovascular disease,cardiovascular disease,GCST007072,4:155725188,Cardiovascular
2033,GUCY1A1,GUCY1A1,N/a,rs11731886-<b>C</b>,4 x 10-8,,0.236995,'-,0.0532221 unit decrease,[0.034-0.072],"GUCY1A1, GUCY1B1",Medication use (beta blocking agents),Beta blocking agent use measurement,GCST007927,4:155738667,Cardiovascular
127,H2AC6,H2AC6,N/a,rs806973-<b>A</b>,7 x 10-10,,0.611714,'-,0.0125629 unit increase,[0.0086-0.0166],"H2AC6, H1-4",Triglyceride levels,triglyceride measurement,GCST010244,6:26148098,Cardiovascular
712,H2AC6,H2AC6,N/a,rs36109883-<b>A</b>,4 x 10-20,,0.0774,'-,0.438 mmHg increase,[0.34-0.53],H2AC6,Pulse pressure,pulse pressure measurement,GCST007269,6:26132842,Cardiovascular
1040,H2AC6,H2AC6,N/a,rs198812-<b>C</b>,1 x 10-14,(EA),0.86,'-,'-,'-,H2AC6,Mean arterial pressure x alcohol consumption interaction (2df test),"mean arterial pressure, alcohol drinking",GCST006167,6:26128182,Cardiovascular
348,LINC02502,LINC02502,N/a,rs111346133-<b>?</b>,7 x 10-9,,NR,'-,'-,'-,"LINC02502, MAD2L1",Systolic blood pressure,systolic blood pressure,GCST007087,4:119996191,Cardiovascular
924,LINC02502,LINC02502,N/a,rs7678555-<b>C</b>,2 x 10-7,,0.280094,1.04,'-,[1.03-1.06],"LINC02502, MAD2L1",Myocardial infarction,myocardial infarction,GCST011365,4:119988346,Cardiovascular
1718,LINC02502,LINC02502,N/a,rs11723436-<b>A</b>,6 x 10-14,,0.6947,'-,0.0519 unit decrease,[0.038-0.065],"MAD2L1, LINC02502",Coronary artery disease,coronary artery disease,GCST005196,4:119980181,Cardiovascular
1719,LINC02502,LINC02502,N/a,rs7678555-<b>A</b>,3 x 10-15,,0.717,'-,0.056 unit decrease,[0.042-0.07],"LINC02502, MAD2L1",Coronary artery disease,coronary artery disease,GCST005194,4:119988346,Cardiovascular
1720,LINC02502,LINC02502,N/a,rs7678555-<b>A</b>,1 x 10-14,,0.7166,'-,0.0486 unit decrease,[0.036-0.061],"LINC02502, MAD2L1",Coronary artery disease,coronary artery disease,GCST005195,4:119988346,Cardiovascular
1721,LINC02502,LINC02502,N/a,rs13134800-<b>?</b>,1 x 10-14,,NR,'-,0.0413897 unit decrease,[0.031-0.052],"MAD2L1, LINC02502",Coronary artery disease,coronary artery disease,GCST010866,4:119979127,Cardiovascular
1722,LINC02502,LINC02502,N/a,rs7678555-<b>C</b>,3 x 10-8,,0.29,1.06,'-,[1.04-1.08],"LINC02502, MAD2L1",Coronary artery disease,coronary artery disease,GCST007990,4:119988346,Cardiovascular
1723,LINC02502,LINC02502,N/a,rs7678555-<b>C</b>,1 x 10-8,,0.279,1.052,'-,[1.034-1.070],"LINC02502, MAD2L1","Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",coronary artery disease,GCST004787,4:119988346,Cardiovascular
1724,LINC02502,LINC02502,N/a,rs1847331-<b>G</b>,2 x 10-8,,0.27,1.05,'-,[1.02-1.08],"LINC02502, MAD2L1",Coronary artery disease,coronary artery disease,GCST010479,4:120015426,Cardiovascular
347,LINC02574,LINC02574,N/a,rs2076460-<b>C</b>,4 x 10-9,(East Asian),0.3006,'-,0.4158 unit decrease,[0.28-0.55],"LINC02574, FGR",Systolic blood pressure,systolic blood pressure,GCST007703,1:27645547,Cardiovascular
713,LINC02574,LINC02574,N/a,rs2076460-<b>C</b>,2 x 10-6,(East Asian),0.3111,'-,0.2277 unit decrease,[0.13-0.32],"LINC02574, FGR",Pulse pressure,pulse pressure measurement,GCST007705,1:27645547,Cardiovascular
1045,LINC02574,LINC02574,N/a,rs2076460-<b>C</b>,8 x 10-8,(East Asian),0.3111,'-,0.2662 unit decrease,[0.17-0.36],"LINC02574, FGR",Mean arterial pressure,mean arterial pressure,GCST007706,1:27645547,Cardiovascular
128,MGST1,MGST1,N/a,rs10846378-<b>G</b>,2 x 10-9,,NR,'-,0.0144 unit decrease,[0.0097-0.0191],"LMO3, MGST1",Triglyceride levels,triglyceride measurement,GCST90019523,12:16590500,Cardiovascular
761,MGST1,MGST1,N/a,rs9332958-<b>?</b>,5 x 10-6,,NR,'-,'-,'-,MGST1,PR interval in Tripanosoma cruzi seropositivity,"PR interval, Trypanosoma cruzi seropositivity",GCST002279,12:16366329,Cardiovascular
333,MRPL40P1,MRPL40P1,N/a,rs4143175-<b>T</b>,5 x 10-10,,0.2409,'-,0.2187 mmHg increase,[0.15-0.29],"MRPL40P1, NTAN1P3",Systolic blood pressure,systolic blood pressure,GCST006628,12:67388617,Cardiovascular
1344,PHF2,PHF2,N/a,rs1806524-<b>T</b>,7 x 10-6,,0.3042,0.7685,'-,[0.685-0.8622],PHF2,Coronary artery disease in hypertension,"hypertension, coronary artery disease",GCST90014125,9:93622242,Cardiovascular
643,PPM1K,PPM1K,N/a,rs72661666-<b>C</b>,7 x 10-6,,0.988771,12.519281,'-,NR,PPM1K,Stent thrombosis in response to clopidogrel treatment,"response to clopidogrel, cardiovascular event measurement",GCST010484,4:88275046,Cardiovascular
708,PROM1,PROM1,N/a,rs4698433-<b>T</b>,6 x 10-6,,'-,'-,7.23 ms increase,[NR],"PROM1, FGFBP2",QT interval,QT interval,GCST001922,4:15963240,Cardiovascular
714,PROM1,PROM1,N/a,rs11730129-<b>T</b>,1 x 10-10,,0.2179,'-,0.1608 unit decrease,[0.11-0.21],PROM1,Pulse pressure,pulse pressure measurement,GCST006626,4:16031325,Cardiovascular
1604,PROM1,PROM1,N/a,rs2292804-<b>C</b>,2 x 10-9,(-16 ms),0.225608,'-,0.0390552 unit decrease,[0.026-0.052],PROM1,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:16035461,Cardiovascular
1605,PROM1,PROM1,N/a,rs2292804-<b>C</b>,3 x 10-8,(-20 ms),0.225608,'-,0.0375823 unit decrease,[0.024-0.051],PROM1,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:16035461,Cardiovascular
1606,PROM1,PROM1,N/a,rs2292804-<b>C</b>,3 x 10-9,(-18 ms),0.225608,'-,0.0397178 unit decrease,[0.027-0.053],PROM1,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:16035461,Cardiovascular
1607,PROM1,PROM1,N/a,rs2292804-<b>C</b>,2 x 10-8,(-14 ms),0.225608,'-,0.035972 unit decrease,[0.023-0.049],PROM1,Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,4:16035461,Cardiovascular
1343,PSMG4,PSMG4,N/a,rs9378357-<b>A</b>,1 x 10-6,(sICAM-1 ),0.185,'-,0.03 pg/mL increase,[NR],"PSMG4, SLC22A23",Obesity-related traits,ICAM-1 measurement,GCST001762,6:3294590,Cardiovascular
1608,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,7 x 10-13,(114 ms),0.933125,'-,0.0777514 unit increase,[0.056-0.099],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1609,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,7 x 10-11,(82 ms),0.933125,'-,0.0714798 unit increase,[0.05-0.093],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1610,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,7 x 10-10,(84 ms),0.933125,'-,0.0668287 unit increase,[0.045-0.089],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1611,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,6 x 10-10,(156 ms),0.933125,'-,0.0664209 unit increase,[0.045-0.088],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1612,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-10,(158 ms),0.933125,'-,0.0680886 unit increase,[0.046-0.09],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1613,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,2 x 10-9,(166 ms),0.933125,'-,0.063304 unit increase,[0.042-0.085],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1614,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-8,(170 ms),0.933125,'-,0.0606286 unit increase,[0.039-0.082],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1615,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-8,(172 ms),0.933125,'-,0.060749 unit increase,[0.039-0.082],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1616,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,5 x 10-9,(90 ms),0.933125,'-,0.0643704 unit increase,[0.043-0.086],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1617,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-8,(96 ms),0.933125,'-,0.063406 unit increase,[0.042-0.085],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1618,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,6 x 10-10,(98 ms),0.933125,'-,0.0671264 unit increase,[0.045-0.089],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1619,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,5 x 10-10,(106 ms),0.933125,'-,0.0675031 unit increase,[0.046-0.089],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1620,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-9,(108 ms),0.933125,'-,0.0660855 unit increase,[0.044-0.088],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1621,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,2 x 10-8,(110 ms),0.933125,'-,0.0612496 unit increase,[0.04-0.083],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1622,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,3 x 10-10,(112 ms),0.933125,'-,0.0687352 unit increase,[0.047-0.09],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1623,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,9 x 10-12,(116 ms),0.933125,'-,0.0727283 unit increase,[0.051-0.094],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1624,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-10,(118 ms),0.933125,'-,0.0690176 unit increase,[0.047-0.091],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1625,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,3 x 10-12,(120 ms),0.933125,'-,0.0749531 unit increase,[0.053-0.097],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1626,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,4 x 10-12,(122 ms),0.933125,'-,0.0758088 unit increase,[0.054-0.098],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1627,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-10,(124 ms),0.933125,'-,0.0677284 unit increase,[0.046-0.089],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1628,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,3 x 10-10,(126 ms),0.933125,'-,0.0662138 unit increase,[0.045-0.088],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1629,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,4 x 10-11,(128 ms),0.933125,'-,0.0698971 unit increase,[0.048-0.092],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1630,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,3 x 10-10,(130 ms),0.933125,'-,0.0660853 unit increase,[0.044-0.088],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1631,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-8,(132 ms),0.933125,'-,0.0603223 unit increase,[0.039-0.082],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1632,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,6 x 10-9,(134 ms),0.933125,'-,0.0625292 unit increase,[0.041-0.084],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1633,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,3 x 10-10,(136 ms),0.933125,'-,0.0690086 unit increase,[0.047-0.091],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1634,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,2 x 10-11,(138 ms),0.933125,'-,0.0705194 unit increase,[0.049-0.092],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1635,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,2 x 10-11,(140 ms),0.933125,'-,0.0699696 unit increase,[0.048-0.092],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1636,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-11,(142 ms),0.933125,'-,0.0718698 unit increase,[0.05-0.094],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1637,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,4 x 10-11,(148 ms),0.933125,'-,0.0690076 unit increase,[0.047-0.091],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1638,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,1 x 10-10,(150 ms),0.933125,'-,0.0678752 unit increase,[0.046-0.09],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1639,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,3 x 10-10,(152 ms),0.933125,'-,0.0668502 unit increase,[0.045-0.089],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
1640,PSMG4,PSMG4,N/a,rs61367953-<b>G</b>,4 x 10-9,(154 ms),0.933125,'-,0.0638317 unit increase,[0.042-0.085],"PSMG4, SLC22A23",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,6:3287747,Cardiovascular
715,RBM25,RBM25,N/a,rs11392696-<b>G</b>,5 x 10-13,,0.3152,'-,0.2049 mmHg decrease,[0.15-0.26],RBM25,Pulse pressure,pulse pressure measurement,GCST007269,14:73112414,Cardiovascular
44,ROR1,ROR1,N/a,rs11392719-<b>TA</b>,7 x 10-6,,'-,'-,0.0837 SD units increase,[0.047-0.12],ROR1,Vascular endothelial growth factor levels,vascular endothelial growth factor measurement,GCST004422,1:63792780,Cardiovascular
331,SLC16A1,SLC16A1,N/a,rs773430-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,SLC16A1-AS1,Systolic blood pressure,systolic blood pressure,GCST007087,1:112993425,Cardiovascular
332,SLC16A1,SLC16A1-AS1,N/a,rs773430-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,SLC16A1-AS1,Systolic blood pressure,systolic blood pressure,GCST007087,1:112993425,Cardiovascular
923,SLC22A4,SLC22A4,N/a,rs273909-<b>G</b>,9 x 10-6,,0.112207,1.05,'-,[1.03-1.08],"MIR3936HG, SLC22A4",Myocardial infarction,myocardial infarction,GCST011365,5:132331660,Cardiovascular
1716,SLC22A4,SLC22A4,N/a,rs273909-<b>A</b>,3 x 10-10,,0.8736,'-,0.0534 unit decrease,[0.037-0.07],"MIR3936HG, SLC22A4",Coronary artery disease,coronary artery disease,GCST005196,5:132331660,Cardiovascular
1717,SLC22A4,SLC22A4,N/a,rs273909-<b>A</b>,5 x 10-10,,0.8754,'-,0.0488 unit decrease,[0.034-0.064],"MIR3936HG, SLC22A4",Coronary artery disease,coronary artery disease,GCST005195,5:132331660,Cardiovascular
707,SMURF2,SMURF2,N/a,rs9900062-<b>A</b>,5 x 10-6,,0.71,'-,1.15 ms decrease,[0.66-1.64],"SMURF2, MICOS10P2",QT interval,QT interval,GCST005171,17:64743456,Cardiovascular
716,SPTBN4,SPTBN4,N/a,rs12982298-<b>T</b>,6 x 10-19,,0.3398,'-,0.1862 mmHg increase,[0.15-0.23],SPTBN4,Pulse pressure,pulse pressure measurement,GCST007269,19:40541454,Cardiovascular
1667,TGM3,TGM3,N/a,rs13040824-<b>?</b>,9 x 10-7,(Pre-puberty),NR,'-,0.902 unit decrease,[0.054-0.127],"STK35, TGM3",Diastolic blood pressure,diastolic blood pressure,GCST003671,20:2245223,Cardiovascular
1725,WDR86,WDR86,N/a,rs13232179-<b>A</b>,1 x 10-6,,0.11,1.67,'-,[1.36-2.06],"WDR86-AS1, CRYGN",Coronary heart disease,coronary artery disease,GCST000972,7:151423862,Cardiovascular
1726,WDR86,WDR86-AS1,N/a,rs13232179-<b>A</b>,1 x 10-6,,0.11,1.67,'-,[1.36-2.06],"WDR86-AS1, CRYGN",Coronary heart disease,coronary artery disease,GCST000972,7:151423862,Cardiovascular
1780,WDR86,WDR86,N/a,rs77300744-<b>A</b>,5 x 10-6,,NR,'-,0.44842723 unit increase,[0.26-0.64],"WDR86, NUB1",Carotid plaque burden,carotid plaque build,GCST004162,7:151377657,Cardiovascular
1361,ADH1A,ADH1A,N/a,rs13132430-<b>A</b>,1 x 10-8,,0.01,'-,0.17 s.d. increase,[0.11-0.23],"ADH1B, ADH1A",HDL cholesterol,high density lipoprotein cholesterol measurement,GCST002899,4:99302913,Cholesterol
210,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Cholesterol
218,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Cholesterol
230,APOB,APOB,N/a,rs562338-<b>?</b>,3 x 10-25,,NR,'-,'-,'-,"APOB, TDRD15",Age-related disease endophenotypes,"total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement",GCST004046,2:21065449,Cholesterol
234,APOB,APOB,N/a,rs57825321-<b>?</b>,8 x 10-32,,NR,'-,0.07307 unit decrease,[0.061-0.085],APOB,Total cholesterol levels,total cholesterol measurement,GCST006034,2:21024193,Cholesterol
235,APOB,APOB,N/a,rs2678379-<b>A</b>,3 x 10-17,(EA),0.215,'-,0.047 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21003688,Cholesterol
236,APOB,APOB,N/a,rs2678379-<b>A</b>,1 x 10-11,,NR,'-,0.034 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21003688,Cholesterol
237,APOB,APOB,N/a,rs676210-<b>G</b>,2 x 10-17,(EA),0.785,'-,0.047 unit increase,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21008652,Cholesterol
238,APOB,APOB,N/a,rs676210-<b>G</b>,9 x 10-12,,NR,'-,0.034 unit increase,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21008652,Cholesterol
239,APOB,APOB,N/a,rs1041968-<b>G</b>,3 x 10-94,(EA),0.511,'-,0.094 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21009932,Cholesterol
240,APOB,APOB,N/a,rs1041968-<b>G</b>,5 x 10-7,(Hispanic),0.675,'-,0.085 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21009932,Cholesterol
241,APOB,APOB,N/a,rs1041968-<b>G</b>,7 x 10-104,,NR,'-,0.094 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21009932,Cholesterol
242,APOB,APOB,N/a,rs533617-<b>T</b>,2 x 10-30,(EA),0.96,'-,0.133 unit increase,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21011100,Cholesterol
243,APOB,APOB,N/a,rs533617-<b>T</b>,4 x 10-32,,NR,'-,0.133 unit increase,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21011100,Cholesterol
244,APOB,APOB,N/a,rs673548-<b>G</b>,1 x 10-17,(EA),0.785,'-,0.048 unit increase,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21014672,Cholesterol
245,APOB,APOB,N/a,rs673548-<b>G</b>,1 x 10-11,,NR,'-,0.034 unit increase,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21014672,Cholesterol
246,APOB,APOB,N/a,rs1367117-<b>G</b>,5 x 10-109,(EA),0.688,'-,0.109 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21041028,Cholesterol
247,APOB,APOB,N/a,rs1367117-<b>G</b>,4 x 10-11,(Hispanic),0.723,'-,0.11 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21041028,Cholesterol
248,APOB,APOB,N/a,rs1367117-<b>G</b>,2 x 10-125,,NR,'-,0.109 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21041028,Cholesterol
249,APOB,APOB,N/a,rs4564803-<b>G</b>,1 x 10-25,(EA),0.761,'-,0.056 unit increase,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:20982630,Cholesterol
250,APOB,APOB,N/a,rs4564803-<b>G</b>,2 x 10-19,,NR,'-,0.043 unit increase,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:20982630,Cholesterol
251,APOB,APOB,N/a,rs13392272-<b>C</b>,3 x 10-78,(EA),0.526,'-,0.085 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:20994618,Cholesterol
252,APOB,APOB,N/a,rs13392272-<b>C</b>,1 x 10-6,(Hispanic),0.607,'-,0.074 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:20994618,Cholesterol
253,APOB,APOB,N/a,rs13392272-<b>C</b>,3 x 10-87,,NR,'-,0.084 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:20994618,Cholesterol
254,APOB,APOB,N/a,rs4665710-<b>A</b>,2 x 10-18,(EA),0.215,'-,0.049 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:20998163,Cholesterol
255,APOB,APOB,N/a,rs4665710-<b>A</b>,2 x 10-12,,NR,'-,0.035 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:20998163,Cholesterol
256,APOB,APOB,N/a,rs1042034-<b>C</b>,3 x 10-18,(EA),0.215,'-,0.048 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21002409,Cholesterol
257,APOB,APOB,N/a,rs1042034-<b>C</b>,2 x 10-12,,NR,'-,0.035 unit decrease,'-,APOB,Total cholesterol levels,total cholesterol measurement,GCST007143,2:21002409,Cholesterol
258,APOB,APOB,N/a,rs1041968-<b>A</b>,5 x 10-54,,0.48,'-,0.095 s.d. increase,[0.083-0.107],APOB,"Cholesterol, total",total cholesterol measurement,GCST002896,2:21009932,Cholesterol
259,APOB,APOB,N/a,rs1041968-<b>?</b>,5 x 10-13,,NR,'-,2.812376 unit increase,[2.05-3.57],APOB,Total cholesterol levels,total cholesterol measurement,GCST008045,2:21009932,Cholesterol
260,APOB,APOB,N/a,rs12713956-<b>?</b>,7 x 10-14,,NR,'-,3.480172 unit decrease,[2.57-4.39],APOB,Total cholesterol levels,total cholesterol measurement,GCST008045,2:21018633,Cholesterol
261,APOB,APOB,N/a,rs13392272-<b>?</b>,6 x 10-12,,NR,'-,2.694755 unit increase,[1.93-3.46],APOB,Total cholesterol levels,total cholesterol measurement,GCST008045,2:20994618,Cholesterol
262,APOB,APOB,N/a,rs1367117-<b>?</b>,4 x 10-22,,NR,'-,4.138443 unit increase,[3.3-4.98],APOB,Total cholesterol levels,total cholesterol measurement,GCST008045,2:21041028,Cholesterol
263,APOB,APOB,N/a,rs1367117-<b>?</b>,1 x 10-49,,'-,'-,0.074 unit decrease,[0.064-0.084],APOB,Total cholesterol levels,total cholesterol measurement,GCST011346,2:21041028,Cholesterol
264,APOB,APOB,N/a,rs693-<b>?</b>,4 x 10-13,,NR,'-,2.828003 unit increase,[2.07-3.59],APOB,Total cholesterol levels,total cholesterol measurement,GCST008045,2:21009323,Cholesterol
265,APOB,APOB,N/a,rs9282603-<b>G</b>,2 x 10-10,(AA),0.0038,'-,0.316 mg dl-1 increase,[0.22-0.41],APOB,Total cholesterol levels,total cholesterol measurement,GCST006614,2:21041014,Cholesterol
266,APOB,APOB,N/a,rs13306194-<b>A</b>,4 x 10-6,,0.124,'-,4.1917 unit decrease,[2.41-5.97],APOB,Total cholesterol levels,total cholesterol measurement,GCST007441,2:21029662,Cholesterol
267,APOB,APOB,N/a,rs1042031-<b>T</b>,2 x 10-65,,NR,'-,0.0529 unit decrease,[0.047-0.059],APOB,Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21002881,Cholesterol
268,APOB,APOB,N/a,rs673548-<b>A</b>,1 x 10-55,,NR,'-,0.0459 unit decrease,[0.04-0.052],APOB,Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21014672,Cholesterol
269,APOB,APOB,N/a,rs1801701-<b>T</b>,6 x 10-33,,NR,'-,0.048 unit increase,[0.04-0.056],APOB,Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21005955,Cholesterol
270,APOB,APOB,N/a,rs550619-<b>A</b>,7 x 10-123,,NR,'-,0.1018 unit increase,[0.093-0.11],APOB,Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21037729,Cholesterol
271,APOB,APOB,N/a,rs533617-<b>C</b>,1 x 10-102,,NR,'-,0.132 unit decrease,[0.12-0.14],APOB,Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21011100,Cholesterol
272,APOB,APOB,N/a,rs12691202-<b>T</b>,4 x 10-85,,NR,'-,0.1214 unit decrease,[0.11-0.13],APOB,Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21026844,Cholesterol
273,APOB,APOB,N/a,rs562338-<b>A</b>,2 x 10-127,,NR,'-,0.13 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21065449,Cholesterol
274,APOB,APOB,N/a,rs668948-<b>G</b>,1 x 10-118,(EA),0.19,'-,0.135 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21068657,Cholesterol
275,APOB,APOB,N/a,rs668948-<b>G</b>,4 x 10-14,(Hispanic),0.175,'-,0.148 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21068657,Cholesterol
276,APOB,APOB,N/a,rs668948-<b>G</b>,2 x 10-132,,NR,'-,0.133 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21068657,Cholesterol
277,APOB,APOB,N/a,rs541041-<b>G</b>,3 x 10-119,(EA),0.189,'-,0.135 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21072103,Cholesterol
278,APOB,APOB,N/a,rs541041-<b>G</b>,4 x 10-14,(Hispanic),0.174,'-,0.149 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21072103,Cholesterol
279,APOB,APOB,N/a,rs541041-<b>G</b>,3 x 10-133,,NR,'-,0.133 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21072103,Cholesterol
280,APOB,APOB,N/a,rs568938-<b>C</b>,2 x 10-99,(EA),0.205,'-,0.12 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21080744,Cholesterol
281,APOB,APOB,N/a,rs568938-<b>C</b>,5 x 10-12,(Hispanic),0.183,'-,0.133 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21080744,Cholesterol
282,APOB,APOB,N/a,rs568938-<b>C</b>,7 x 10-110,,NR,'-,0.118 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21080744,Cholesterol
283,APOB,APOB,N/a,rs934198-<b>G</b>,3 x 10-88,(EA),0.677,'-,0.097 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21055901,Cholesterol
284,APOB,APOB,N/a,rs934198-<b>G</b>,2 x 10-8,(Hispanic),0.716,'-,0.092 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21055901,Cholesterol
285,APOB,APOB,N/a,rs934198-<b>G</b>,3 x 10-101,,NR,'-,0.097 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21055901,Cholesterol
286,APOB,APOB,N/a,rs515135-<b>T</b>,2 x 10-115,(EA),0.192,'-,0.132 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21063185,Cholesterol
287,APOB,APOB,N/a,rs515135-<b>T</b>,5 x 10-10,(Hispanic),0.196,'-,0.117 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21063185,Cholesterol
288,APOB,APOB,N/a,rs515135-<b>T</b>,3 x 10-112,,NR,'-,0.119 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21063185,Cholesterol
289,APOB,APOB,N/a,rs563290-<b>G</b>,8 x 10-117,(EA),0.191,'-,0.133 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21065354,Cholesterol
290,APOB,APOB,N/a,rs563290-<b>G</b>,4 x 10-14,(Hispanic),0.178,'-,0.147 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21065354,Cholesterol
291,APOB,APOB,N/a,rs563290-<b>G</b>,3 x 10-130,,NR,'-,0.131 unit decrease,'-,"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21065354,Cholesterol
292,APOB,APOB,N/a,rs562338-<b>A</b>,5 x 10-115,(EA),0.192,'-,0.132 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21065449,Cholesterol
293,APOB,APOB,N/a,rs562338-<b>A</b>,1 x 10-13,(Hispanic),0.177,'-,0.145 unit decrease,'-,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST007143,2:21065449,Cholesterol
294,APOB,APOB,N/a,rs672889-<b>G</b>,4 x 10-16,,0.1356,'-,0.1294899 mg/dl increase,[0.098-0.161],"APOB, TDRD15","Cholesterol, total",total cholesterol measurement,GCST004209,2:21096144,Cholesterol
295,APOB,APOB,N/a,rs515135-<b>?</b>,7 x 10-12,,NR,'-,2.774797 unit increase,[1.98-3.57],"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST008045,2:21063185,Cholesterol
296,APOB,APOB,N/a,rs562338-<b>?</b>,3 x 10-23,,NR,'-,4.219739 unit increase,[3.39-5.05],"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST008045,2:21065449,Cholesterol
297,APOB,APOB,N/a,rs563290-<b>?</b>,4 x 10-24,,NR,'-,4.317919 unit increase,[3.48-5.15],"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST008045,2:21065354,Cholesterol
298,APOB,APOB,N/a,rs568938-<b>?</b>,1 x 10-25,,NR,'-,4.39789 unit increase,[3.57-5.22],"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST008045,2:21080744,Cholesterol
299,APOB,APOB,N/a,rs934198-<b>?</b>,3 x 10-19,,NR,'-,3.75396 unit increase,[2.93-4.57],"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST008045,2:21055901,Cholesterol
300,APOB,APOB,N/a,rs668948-<b>?</b>,1 x 10-24,,NR,'-,4.349579 unit increase,[3.52-5.18],"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST008045,2:21068657,Cholesterol
301,APOB,APOB,N/a,rs73920524-<b>?</b>,4 x 10-6,,NR,'-,5.870639 unit decrease,[3.37-8.37],"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST008045,2:21088668,Cholesterol
302,APOB,APOB,N/a,rs10692845-<b>?</b>,6 x 10-209,,0.3038,'-,0.0972 mg dl-1 decrease,[0.091-0.103],"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST006614,2:21070464,Cholesterol
303,APOB,APOB,N/a,rs72902579-<b>C</b>,4 x 10-63,,NR,'-,0.0966 unit decrease,[0.085-0.108],"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21053136,Cholesterol
304,APOB,APOB,N/a,rs74629722-<b>C</b>,3 x 10-73,,NR,'-,0.0663 unit increase,[0.059-0.074],"APOB, LINC02850",Total cholesterol levels,total cholesterol measurement,GCST90019501,2:20927284,Cholesterol
305,APOB,APOB,N/a,rs111548358-<b>C</b>,1 x 10-68,,NR,'-,0.0793 unit increase,[0.07-0.088],"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21114434,Cholesterol
306,APOB,APOB,N/a,rs7575840-<b>T</b>,3 x 10-23,,0.33,'-,3.19 unit increase,[2.56-3.82],"TDRD15, APOB",Total cholesterol levels,total cholesterol measurement,GCST90010363,2:21050618,Cholesterol
307,APOB,APOB,N/a,rs17041688-<b>?</b>,9 x 10-6,,NR,'-,0.092 unit decrease,[0.051-0.133],APOB,Total cholesterol levels,total cholesterol measurement,GCST008594,2:20976554,Cholesterol
308,APOB,APOB,N/a,rs13306194-<b>A</b>,6 x 10-12,,0.128,'-,0.13 unit decrease,[0.091-0.169],APOB,Total cholesterol levels,total cholesterol measurement,GCST009919,2:21029662,Cholesterol
309,APOB,APOB,N/a,rs10172650-<b>A</b>,5 x 10-15,"(Asian initial, BMI unadjusted)",0.13,'-,0.094 unit decrease,[0.07-0.118],APOB,Total cholesterol levels,total cholesterol measurement,GCST004235,2:20982585,Cholesterol
310,APOB,APOB,N/a,rs1367117-<b>A</b>,3 x 10-136,(Trans-ethnic initial),0.288,'-,0.0995 unit increase,[0.092-0.107],APOB,Total cholesterol levels,total cholesterol measurement,GCST004235,2:21041028,Cholesterol
311,APOB,APOB,N/a,rs10172650-<b>A</b>,3 x 10-13,(BMI unadjusted),0.13,'-,0.102 unit decrease,[0.075-0.129],APOB,Total cholesterol levels,total cholesterol measurement,GCST004231,2:20982585,Cholesterol
312,APOB,APOB,N/a,rs1367117-<b>A</b>,3 x 10-139,,0.32,'-,0.1 unit increase,[NR],APOB,"Cholesterol, total",total cholesterol measurement,GCST002221,2:21041028,Cholesterol
313,APOB,APOB,N/a,rs693-<b>G</b>,9 x 10-23,,0.52,'-,0.1 s.d. decrease,[NR],APOB,"Cholesterol, total",total cholesterol measurement,GCST000285,2:21009323,Cholesterol
314,APOB,APOB,N/a,rs1367117-<b>A</b>,4 x 10-96,,0.3,'-,4.16 mg/dL increase,[3.73-4.59],APOB,"Cholesterol, total",total cholesterol measurement,GCST000760,2:21041028,Cholesterol
315,APOB,APOB,N/a,rs12720842-<b>C</b>,1 x 10-39,,NR,'-,0.0841 unit increase,[0.072-0.097],APOB,Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21035055,Cholesterol
316,APOB,APOB,N/a,rs12713559-<b>A</b>,1 x 10-21,,NR,'-,0.3502 unit increase,[0.28-0.42],APOB,Total cholesterol levels,total cholesterol measurement,GCST90019501,2:21006196,Cholesterol
317,APOB,APOB,N/a,rs562338-<b>?</b>,8 x 10-16,,NR,'-,0.125 unit increase,[0.094-0.156],"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST008594,2:21065449,Cholesterol
318,APOB,APOB,N/a,rs312949-<b>C</b>,7 x 10-6,,0.28,'-,1.594 unit increase,[0.9-2.29],"TDRD15, APOB","Cholesterol, total",total cholesterol measurement,GCST003214,2:21111411,Cholesterol
319,APOB,APOB,N/a,rs562338-<b>?</b>,6 x 10-7,,NR,'-,5.006 unit decrease,NR,"APOB, TDRD15",Total cholesterol levels,total cholesterol measurement,GCST011691,2:21065449,Cholesterol
320,APOB,APOB,N/a,rs10175646-<b>C</b>,3 x 10-10,,NR,'-,0.0407 unit decrease,[0.028-0.053],"APOB, LINC02850",Total cholesterol levels,total cholesterol measurement,GCST90019501,2:20945905,Cholesterol
477,APOB,APOB,N/a,rs150856817-<b>?</b>,7 x 10-23,,NR,'-,2.742 unit decrease,[2.17-3.32],APOB,LDL cholesterol levels x long total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009366,2:21016994,Cholesterol
478,APOB,APOB,N/a,rs1367117-<b>?</b>,1 x 10-80,,NR,'-,3.414 unit increase,[3.03-3.79],APOB,LDL cholesterol levels x short total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009365,2:21041028,Cholesterol
479,APOB,APOB,N/a,rs3903032-<b>?</b>,2 x 10-20,,NR,'-,2.518 unit decrease,[1.88-3.16],"LINC02850, APOB",LDL cholesterol levels x long total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009366,2:20920090,Cholesterol
480,APOB,APOB,N/a,rs4296389-<b>?</b>,1 x 10-17,,NR,'-,1.483 unit decrease,[1.12-1.85],"LINC02850, APOB",LDL cholesterol levels x long total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009366,2:20943234,Cholesterol
481,APOB,APOB,N/a,rs934197-<b>?</b>,3 x 10-78,,NR,'-,3.395 unit increase,[3.01-3.78],"TDRD15, APOB",LDL cholesterol levels x long total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009366,2:21044589,Cholesterol
482,APOB,APOB,N/a,rs668948-<b>?</b>,5 x 10-90,,NR,'-,3.795 unit increase,[3.4-4.19],"APOB, TDRD15",LDL cholesterol levels x long total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009366,2:21068657,Cholesterol
483,APOB,APOB,N/a,rs139919599-<b>?</b>,2 x 10-21,,NR,'-,2.76 unit decrease,[2.14-3.38],"APOB, LINC02850",LDL cholesterol levels x short total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009365,2:20949664,Cholesterol
484,APOB,APOB,N/a,rs60403635-<b>?</b>,2 x 10-23,,NR,'-,3.847 unit increase,[3-4.7],"TDRD15, APOB",LDL cholesterol levels x short total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009365,2:21049906,Cholesterol
485,APOB,APOB,N/a,rs28562532-<b>?</b>,5 x 10-74,,NR,'-,4.48 unit decrease,[3.98-4.98],"TDRD15, APOB",LDL cholesterol levels x short total sleep time interaction (2df test),"sleep duration, low density lipoprotein cholesterol measurement",GCST009365,2:21086250,Cholesterol
486,APOB,APOB,N/a,rs676210-<b>?</b>,1 x 10-29,,NR,'-,0.01191 unit increase,[0.0096-0.0142],APOB,HDL cholesterol levels x short total sleep time interaction (2df test),"sleep duration, high density lipoprotein cholesterol measurement",GCST009367,2:21008652,Cholesterol
487,APOB,APOB,N/a,rs4296389-<b>?</b>,1 x 10-28,,NR,'-,0.01104 unit increase,[0.0089-0.0131],"LINC02850, APOB",HDL cholesterol levels x long total sleep time interaction (2df test),"sleep duration, high density lipoprotein cholesterol measurement",GCST009368,2:20943234,Cholesterol
629,APOB,APOB,N/a,rs1713222-<b>A</b>,5 x 10-8,,0.145,'-,0.013 unit decrease,[0.0091-0.0169],"TDRD15, APOB",Response to statins (LDL cholesterol change),"response to statin, LDL cholesterol change measurement",GCST010338,2:21048451,Cholesterol
631,APOB,APOB,N/a,rs541041-<b>G</b>,8 x 10-6,"(LDL, sum)",0.16,'-,'-,'-,"TDRD15, APOB",Response to statin therapy,response to statin,GCST000635,2:21072103,Cholesterol
879,APOB,APOB,N/a,rs7567217-<b>?</b>,1 x 10-6,,NR,'-,4.893 unit increase,NR,"APOB, TDRD15",NHDL cholesterol levels,non-high density lipoprotein cholesterol measurement,GCST011694,2:21080598,Cholesterol
1086,APOB,APOB,N/a,rs548145-<b>T</b>,6 x 10-156,,0.2416,'-,'-,'-,"TDRD15, APOB",LDL cholesterol x physical activity interaction (2df test),"low density lipoprotein cholesterol measurement, physical activity",GCST007284,2:21068440,Cholesterol
1087,APOB,APOB,N/a,rs676210-<b>?</b>,4 x 10-30,(Oxidized LDL),NR,'-,'-,'-,APOB,Lipid or lipoprotein levels,"low density lipoprotein cholesterol measurement, lipid or lipoprotein measurement",GCST009165,2:21008652,Cholesterol
1088,APOB,APOB,N/a,rs1801702-<b>?</b>,5 x 10-7,(African American),'-,'-,0.20006934 unit decrease,[0.12-0.28],APOB,LDL cholesterol levels in HIV infection,"low density lipoprotein cholesterol measurement, HIV infection",GCST011741,2:21002613,Cholesterol
1091,APOB,APOB,N/a,rs581411-<b>A</b>,5 x 10-213,(EA),NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008079,2:21066560,Cholesterol
1092,APOB,APOB,N/a,rs581411-<b>A</b>,2 x 10-249,,NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008079,2:21066560,Cholesterol
1093,APOB,APOB,N/a,rs581411-<b>A</b>,6 x 10-11,(AA),NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008079,2:21066560,Cholesterol
1094,APOB,APOB,N/a,rs581411-<b>A</b>,1 x 10-14,(Asian),NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008079,2:21066560,Cholesterol
1095,APOB,APOB,N/a,rs581411-<b>A</b>,3 x 10-23,(Hispanic),NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008079,2:21066560,Cholesterol
1096,APOB,APOB,N/a,rs581411-<b>A</b>,2 x 10-127,,NR,'-,4.566 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels in current drinkers,"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008086,2:21066560,Cholesterol
1097,APOB,APOB,N/a,rs581411-<b>A</b>,1 x 10-10,(AA),NR,'-,3.087 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels in current drinkers,"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008086,2:21066560,Cholesterol
1098,APOB,APOB,N/a,rs581411-<b>A</b>,9 x 10-10,(Asian),NR,'-,4.97 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels in current drinkers,"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008086,2:21066560,Cholesterol
1099,APOB,APOB,N/a,rs581411-<b>A</b>,2 x 10-18,(Hispanic),NR,'-,5.153 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels in current drinkers,"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008086,2:21066560,Cholesterol
1100,APOB,APOB,N/a,rs581411-<b>A</b>,2 x 10-101,(EA),NR,'-,4.773 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels in current drinkers,"low density lipoprotein cholesterol measurement, alcohol drinking",GCST008086,2:21066560,Cholesterol
1101,APOB,APOB,N/a,rs581411-<b>A</b>,2 x 10-193,(EA),NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol consumption measurement",GCST008078,2:21066560,Cholesterol
1102,APOB,APOB,N/a,rs581411-<b>A</b>,2 x 10-11,(AA),NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol consumption measurement",GCST008078,2:21066560,Cholesterol
1103,APOB,APOB,N/a,rs581411-<b>A</b>,4 x 10-13,(Asian),NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol consumption measurement",GCST008078,2:21066560,Cholesterol
1104,APOB,APOB,N/a,rs581411-<b>A</b>,2 x 10-22,(Hispanic),NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol consumption measurement",GCST008078,2:21066560,Cholesterol
1105,APOB,APOB,N/a,rs581411-<b>A</b>,5 x 10-226,,NR,'-,'-,'-,"TDRD15, APOB",LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),"low density lipoprotein cholesterol measurement, alcohol consumption measurement",GCST008078,2:21066560,Cholesterol
1110,APOB,APOB,N/a,rs1367117-<b>G</b>,7 x 10-125,(EA),0.688,'-,0.12 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21041028,Cholesterol
1111,APOB,APOB,N/a,rs1367117-<b>G</b>,5 x 10-14,(Hispanic),0.723,'-,0.126 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21041028,Cholesterol
1112,APOB,APOB,N/a,rs1367117-<b>G</b>,1 x 10-144,,NR,'-,0.12 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21041028,Cholesterol
1113,APOB,APOB,N/a,rs4564803-<b>G</b>,2 x 10-29,(EA),0.761,'-,0.062 unit increase,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:20982630,Cholesterol
1114,APOB,APOB,N/a,rs4564803-<b>G</b>,4 x 10-22,,NR,'-,0.047 unit increase,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:20982630,Cholesterol
1115,APOB,APOB,N/a,rs13392272-<b>C</b>,9 x 10-86,(EA),0.526,'-,0.092 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:20994618,Cholesterol
1116,APOB,APOB,N/a,rs13392272-<b>C</b>,5 x 10-8,(Hispanic),0.607,'-,0.084 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:20994618,Cholesterol
1117,APOB,APOB,N/a,rs13392272-<b>C</b>,3 x 10-95,,NR,'-,0.09 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:20994618,Cholesterol
1118,APOB,APOB,N/a,rs4665710-<b>A</b>,4 x 10-21,(EA),0.215,'-,0.054 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:20998163,Cholesterol
1119,APOB,APOB,N/a,rs4665710-<b>A</b>,3 x 10-14,,NR,'-,0.039 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:20998163,Cholesterol
1120,APOB,APOB,N/a,rs1042034-<b>C</b>,7 x 10-21,(EA),0.215,'-,0.054 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21002409,Cholesterol
1121,APOB,APOB,N/a,rs1042034-<b>C</b>,3 x 10-14,,NR,'-,0.039 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21002409,Cholesterol
1122,APOB,APOB,N/a,rs2678379-<b>A</b>,4 x 10-20,(EA),0.215,'-,0.052 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21003688,Cholesterol
1123,APOB,APOB,N/a,rs2678379-<b>A</b>,2 x 10-13,,NR,'-,0.037 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21003688,Cholesterol
1124,APOB,APOB,N/a,rs676210-<b>G</b>,6 x 10-20,(EA),0.785,'-,0.052 unit increase,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21008652,Cholesterol
1125,APOB,APOB,N/a,rs676210-<b>G</b>,2 x 10-13,,NR,'-,0.038 unit increase,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21008652,Cholesterol
1126,APOB,APOB,N/a,rs1041968-<b>G</b>,8 x 10-105,(EA),0.511,'-,0.102 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21009932,Cholesterol
1127,APOB,APOB,N/a,rs1041968-<b>G</b>,2 x 10-8,(Hispanic),0.675,'-,0.095 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21009932,Cholesterol
1128,APOB,APOB,N/a,rs1041968-<b>G</b>,7 x 10-116,,NR,'-,0.101 unit decrease,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21009932,Cholesterol
1129,APOB,APOB,N/a,rs533617-<b>T</b>,4 x 10-37,(EA),0.96,'-,0.151 unit increase,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21011100,Cholesterol
1130,APOB,APOB,N/a,rs533617-<b>T</b>,2 x 10-39,,NR,'-,0.151 unit increase,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21011100,Cholesterol
1131,APOB,APOB,N/a,rs673548-<b>G</b>,3 x 10-20,(EA),0.785,'-,0.053 unit increase,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21014672,Cholesterol
1132,APOB,APOB,N/a,rs673548-<b>G</b>,1 x 10-13,,NR,'-,0.037 unit increase,'-,APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21014672,Cholesterol
1133,APOB,APOB,N/a,rs13392272-<b>?</b>,1 x 10-306,,NR,'-,0.095 unit decrease,[0.09-0.1],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST010204,2:20994618,Cholesterol
1134,APOB,APOB,N/a,rs1367117-<b>?</b>,3 x 10-27,,NR,'-,4.134983 unit increase,[3.39-4.88],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21041028,Cholesterol
1135,APOB,APOB,N/a,rs1041968-<b>?</b>,2 x 10-17,,NR,'-,2.932701 unit increase,[2.26-3.61],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21009932,Cholesterol
1136,APOB,APOB,N/a,rs12713956-<b>?</b>,6 x 10-16,,NR,'-,3.362497 unit decrease,[2.55-4.18],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21018633,Cholesterol
1137,APOB,APOB,N/a,rs13392272-<b>?</b>,1 x 10-16,,NR,'-,2.879721 unit increase,[2.2-3.56],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:20994618,Cholesterol
1138,APOB,APOB,N/a,rs6752026-<b>?</b>,9 x 10-6,,NR,'-,3.473921 unit decrease,[1.94-5.01],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21038062,Cholesterol
1139,APOB,APOB,N/a,rs693-<b>?</b>,2 x 10-17,,NR,'-,2.939653 unit increase,[2.26-3.62],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21009323,Cholesterol
1140,APOB,APOB,N/a,rs72653060-<b>C</b>,9 x 10-11,(AA),0.0014,'-,0.519 mg dl-1 increase,[0.36-0.68],APOB,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST006612,2:21034825,Cholesterol
1141,APOB,APOB,N/a,rs5742904-<b>?</b>,6 x 10-34,(EA),0.0005,'-,71 mg/dl increase,'-,APOB,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST007848,2:21006288,Cholesterol
1142,APOB,APOB,N/a,rs11902417-<b>?</b>,4 x 10-9,,0.385383,'-,'-,'-,APOB,Oxidized LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST011428,2:20976028,Cholesterol
1143,APOB,APOB,N/a,rs1801701-<b>T</b>,2 x 10-42,,NR,'-,0.0548 unit increase,[0.047-0.063],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21005955,Cholesterol
1144,APOB,APOB,N/a,rs12720842-<b>C</b>,3 x 10-42,,NR,'-,0.087 unit increase,[0.074-0.1],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21035055,Cholesterol
1145,APOB,APOB,N/a,rs1042031-<b>T</b>,5 x 10-68,,NR,'-,0.054 unit decrease,[0.048-0.06],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21002881,Cholesterol
1146,APOB,APOB,N/a,rs1801699-<b>C</b>,2 x 10-11,,NR,'-,0.0583 unit increase,[0.041-0.075],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21011127,Cholesterol
1147,APOB,APOB,N/a,rs79106033-<b>T</b>,2 x 10-9,,NR,'-,0.0451 unit decrease,[0.03-0.06],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:20971271,Cholesterol
1148,APOB,APOB,N/a,rs12713559-<b>A</b>,1 x 10-26,,NR,'-,0.3912 unit increase,[0.32-0.46],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21006196,Cholesterol
1149,APOB,APOB,N/a,rs533617-<b>C</b>,1 x 10-155,,NR,'-,0.1631 unit decrease,[0.15-0.18],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21011100,Cholesterol
1150,APOB,APOB,N/a,rs550619-<b>A</b>,2 x 10-132,,NR,'-,0.1058 unit increase,[0.097-0.114],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21037729,Cholesterol
1151,APOB,APOB,N/a,rs673548-<b>A</b>,5 x 10-112,,NR,'-,0.0657 unit decrease,[0.06-0.071],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21014672,Cholesterol
1152,APOB,APOB,N/a,rs12691202-<b>T</b>,4 x 10-99,,NR,'-,0.1314 unit decrease,[0.12-0.14],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21026844,Cholesterol
1153,APOB,APOB,N/a,rs934198-<b>G</b>,3 x 10-100,(EA),0.677,'-,0.107 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21055901,Cholesterol
1154,APOB,APOB,N/a,rs934198-<b>G</b>,2 x 10-10,(Hispanic),0.716,'-,0.106 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21055901,Cholesterol
1155,APOB,APOB,N/a,rs934198-<b>G</b>,1 x 10-115,,NR,'-,0.106 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21055901,Cholesterol
1156,APOB,APOB,N/a,rs515135-<b>T</b>,1 x 10-125,(EA),0.192,'-,0.141 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21063185,Cholesterol
1157,APOB,APOB,N/a,rs515135-<b>T</b>,2 x 10-11,(Hispanic),0.196,'-,0.128 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21063185,Cholesterol
1158,APOB,APOB,N/a,rs515135-<b>T</b>,3 x 10-124,,NR,'-,0.128 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21063185,Cholesterol
1159,APOB,APOB,N/a,rs563290-<b>G</b>,1 x 10-127,(EA),0.191,'-,0.143 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21065354,Cholesterol
1160,APOB,APOB,N/a,rs563290-<b>G</b>,1 x 10-15,(Hispanic),0.178,'-,0.156 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21065354,Cholesterol
1161,APOB,APOB,N/a,rs563290-<b>G</b>,2 x 10-142,,NR,'-,0.141 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21065354,Cholesterol
1162,APOB,APOB,N/a,rs562338-<b>A</b>,7 x 10-126,(EA),0.192,'-,0.142 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21065449,Cholesterol
1163,APOB,APOB,N/a,rs562338-<b>A</b>,2 x 10-15,(Hispanic),0.177,'-,0.156 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21065449,Cholesterol
1164,APOB,APOB,N/a,rs562338-<b>A</b>,4 x 10-140,,NR,'-,0.139 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21065449,Cholesterol
1165,APOB,APOB,N/a,rs668948-<b>G</b>,1 x 10-129,(EA),0.19,'-,0.145 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21068657,Cholesterol
1166,APOB,APOB,N/a,rs668948-<b>G</b>,4 x 10-16,(Hispanic),0.175,'-,0.161 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21068657,Cholesterol
1167,APOB,APOB,N/a,rs668948-<b>G</b>,2 x 10-145,,NR,'-,0.142 unit decrease,'-,"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21068657,Cholesterol
1168,APOB,APOB,N/a,rs541041-<b>G</b>,9 x 10-131,(EA),0.189,'-,0.145 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21072103,Cholesterol
1169,APOB,APOB,N/a,rs541041-<b>G</b>,3 x 10-16,(Hispanic),0.174,'-,0.161 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21072103,Cholesterol
1170,APOB,APOB,N/a,rs541041-<b>G</b>,1 x 10-146,,NR,'-,0.143 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21072103,Cholesterol
1171,APOB,APOB,N/a,rs568938-<b>C</b>,3 x 10-109,(EA),0.205,'-,0.129 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21080744,Cholesterol
1172,APOB,APOB,N/a,rs568938-<b>C</b>,6 x 10-14,(Hispanic),0.183,'-,0.146 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21080744,Cholesterol
1173,APOB,APOB,N/a,rs568938-<b>C</b>,2 x 10-121,,NR,'-,0.126 unit decrease,'-,"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,2:21080744,Cholesterol
1174,APOB,APOB,N/a,rs581411-<b>A</b>,9 x 10-57,(EA),NR,'-,4.753 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST008077,2:21066560,Cholesterol
1175,APOB,APOB,N/a,rs581411-<b>A</b>,1 x 10-6,(AA),NR,'-,2.74 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST008077,2:21066560,Cholesterol
1176,APOB,APOB,N/a,rs581411-<b>A</b>,7 x 10-10,(Asian),NR,'-,5.049 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST008077,2:21066560,Cholesterol
1177,APOB,APOB,N/a,rs581411-<b>A</b>,5 x 10-14,(Hispanic),NR,'-,5.3 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST008077,2:21066560,Cholesterol
1178,APOB,APOB,N/a,rs581411-<b>A</b>,1 x 10-78,,NR,'-,4.453 unit increase,NR,"TDRD15, APOB",LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST008077,2:21066560,Cholesterol
1179,APOB,APOB,N/a,rs934197-<b>G</b>,9 x 10-312,,0.664558,'-,0.0831886 unit decrease,[0.079-0.088],"TDRD15, APOB",LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST010245,2:21044589,Cholesterol
1180,APOB,APOB,N/a,rs1713222-<b>A</b>,1 x 10-26,,0.145,'-,0.027 unit decrease,[0.021-0.033],"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST009757,2:21048451,Cholesterol
1181,APOB,APOB,N/a,rs515135-<b>C</b>,2 x 10-63,,0.83,'-,0.135 s.d. increase,[0.12-0.15],"APOB, TDRD15",LDL cholesterol,low density lipoprotein cholesterol measurement,GCST002898,2:21063185,Cholesterol
1182,APOB,APOB,N/a,rs515135-<b>?</b>,1 x 10-16,,NR,'-,3.018563 unit increase,[2.31-3.73],"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21063185,Cholesterol
1183,APOB,APOB,N/a,rs73920524-<b>?</b>,2 x 10-6,,NR,'-,5.5581 unit decrease,[3.25-7.86],"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21088668,Cholesterol
1184,APOB,APOB,N/a,rs934198-<b>?</b>,2 x 10-25,,NR,'-,3.89272 unit increase,[3.16-4.62],"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21055901,Cholesterol
1185,APOB,APOB,N/a,rs562338-<b>?</b>,2 x 10-31,,NR,'-,4.453379 unit increase,[3.71-5.2],"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21065449,Cholesterol
1186,APOB,APOB,N/a,rs563290-<b>?</b>,1 x 10-29,,NR,'-,4.33531 unit increase,[3.59-5.09],"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21065354,Cholesterol
1187,APOB,APOB,N/a,rs568938-<b>?</b>,2 x 10-31,,NR,'-,4.403345 unit increase,[3.66-5.14],"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21080744,Cholesterol
1188,APOB,APOB,N/a,rs668948-<b>?</b>,4 x 10-31,,NR,'-,4.42303 unit increase,[3.68-5.17],"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008037,2:21068657,Cholesterol
1189,APOB,APOB,N/a,rs577584-<b>A</b>,1 x 10-229,,0.6896,'-,0.1008 mg dl-1 increase,[0.095-0.107],"TDRD15, APOB",LDL cholesterol,low density lipoprotein cholesterol measurement,GCST006612,2:21076995,Cholesterol
1190,APOB,APOB,N/a,rs7575840-<b>T</b>,4 x 10-28,,0.33,'-,3.26 unit increase,[2.67-3.85],"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90010364,2:21050618,Cholesterol
1191,APOB,APOB,N/a,rs10175646-<b>C</b>,3 x 10-15,,NR,'-,0.0511 unit decrease,[0.038-0.064],"APOB, LINC02850",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:20945905,Cholesterol
1192,APOB,APOB,N/a,rs74629722-<b>C</b>,6 x 10-95,,NR,'-,0.0758 unit increase,[0.069-0.083],"APOB, LINC02850",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:20927284,Cholesterol
1193,APOB,APOB,N/a,rs111548358-<b>C</b>,1 x 10-84,,NR,'-,0.0885 unit increase,[0.08-0.097],"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21114434,Cholesterol
1194,APOB,APOB,N/a,rs72902579-<b>C</b>,2 x 10-77,,NR,'-,0.1073 unit decrease,[0.096-0.119],"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,2:21053136,Cholesterol
1195,APOB,APOB,N/a,rs57825321-<b>?</b>,4 x 10-30,,NR,'-,0.09537 unit decrease,[0.079-0.112],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST006004,2:21024193,Cholesterol
1196,APOB,APOB,N/a,rs1367117-<b>?</b>,2 x 10-10,,NR,'-,0.06198 unit increase,[0.043-0.081],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST006004,2:21041028,Cholesterol
1197,APOB,APOB,N/a,rs1367117-<b>A</b>,3 x 10-64,,0.2888,'-,3.0777 unit increase,[2.72-3.43],APOB,LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST008676,2:21041028,Cholesterol
1198,APOB,APOB,N/a,rs13392272-<b>T</b>,2 x 10-12,(Hispanic),0.387,'-,0.095 unit increase,[0.068-0.122],APOB,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST003303,2:20994618,Cholesterol
1199,APOB,APOB,N/a,rs10172650-<b>A</b>,1 x 10-12,(BMI unadjusted),0.13,'-,0.1 unit decrease,[0.073-0.127],APOB,LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST004236,2:20982585,Cholesterol
1200,APOB,APOB,N/a,rs1367117-<b>A</b>,2 x 10-179,(Trans-ethnic initial),0.288,'-,0.119 unit increase,[0.11-0.13],APOB,LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST004233,2:21041028,Cholesterol
1201,APOB,APOB,N/a,rs10172650-<b>A</b>,4 x 10-14,"(Asian initial, BMI unadjusted)",0.13,'-,0.092 unit decrease,[0.068-0.116],APOB,LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST004233,2:20982585,Cholesterol
1202,APOB,APOB,N/a,rs1367117-<b>?</b>,2 x 10-60,,'-,'-,0.09 unit decrease,[0.079-0.101],APOB,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST011347,2:21041028,Cholesterol
1203,APOB,APOB,N/a,rs1367117-<b>A</b>,1 x 10-182,,0.32,'-,0.119 unit increase,[NR],APOB,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST002222,2:21041028,Cholesterol
1204,APOB,APOB,N/a,rs693-<b>G</b>,4 x 10-17,,0.52,'-,0.1 s.d. decrease,[NR],APOB,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000282,2:21009323,Cholesterol
1205,APOB,APOB,N/a,rs693-<b>A</b>,3 x 10-11,,0.41,'-,0.12 mmol/l increase,[0.09-0.16],APOB,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000283,2:21009323,Cholesterol
1206,APOB,APOB,N/a,rs693-<b>A</b>,7 x 10-7,,0.49,'-,1 (% variance) increase,'-,APOB,LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST004920,2:21009323,Cholesterol
1208,APOB,APOB,N/a,rs693-<b>A</b>,1 x 10-21,,0.48,'-,0.12 unit increase,[0.10-0.14],APOB,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000134,2:21009323,Cholesterol
1209,APOB,APOB,N/a,rs1367117-<b>A</b>,4 x 10-114,,0.3,'-,4.05 mg/dL increase,[3.68-4.42],APOB,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000759,2:21041028,Cholesterol
1210,APOB,APOB,N/a,rs676210-<b>G</b>,3 x 10-47,,0.77,'-,10.5 U/L increase,'-,APOB,LDL (oxidized),low density lipoprotein cholesterol measurement,GCST001777,2:21008652,Cholesterol
1211,APOB,APOB,N/a,rs7575840-<b>?</b>,4 x 10-18,,NR,'-,0.129 unit increase,[0.1-0.158],"TDRD15, APOB",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008593,2:21050618,Cholesterol
1212,APOB,APOB,N/a,rs562338-<b>?</b>,3 x 10-19,,NR,'-,0.15 unit increase,[0.12-0.18],"APOB, TDRD15",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST008593,2:21065449,Cholesterol
1213,APOB,APOB,N/a,rs515135-<b>T</b>,1 x 10-56,(EA),0.1866,'-,3.7366 unit decrease,[3.27-4.2],"APOB, TDRD15",LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST008676,2:21063185,Cholesterol
1214,APOB,APOB,N/a,rs754523-<b>G</b>,6 x 10-6,,0.247,'-,4.65 z score increase,NR,"TDRD15, APOB",LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST011417,2:21088819,Cholesterol
1215,APOB,APOB,N/a,rs312949-<b>C</b>,3 x 10-6,,0.28,'-,1.415 unit increase,[0.82-2.01],"TDRD15, APOB",LDL cholesterol,low density lipoprotein cholesterol measurement,GCST003216,2:21111411,Cholesterol
1216,APOB,APOB,N/a,rs562338-<b>T</b>,1 x 10-9,,0.2,'-,0.04 mmol/L decrease,[0.02-0.06],"APOB, TDRD15",LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000151,2:21065449,Cholesterol
1217,APOB,APOB,N/a,rs515135-<b>A</b>,2 x 10-20,,0.19,'-,0.04 unit decrease,[0.03-0.05],"APOB, TDRD15",LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000807,2:21063185,Cholesterol
1218,APOB,APOB,N/a,rs562338-<b>G</b>,6 x 10-22,,0.82,'-,4.89 mg/dl increase,[NR],"APOB, TDRD15",LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000132,2:21065449,Cholesterol
1219,APOB,APOB,N/a,rs515135-<b>T</b>,5 x 10-29,,0.2,'-,0.16 s.d. decrease,[0.12-0.20],"APOB, TDRD15",LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000287,2:21063185,Cholesterol
1242,APOB,APOB,N/a,rs6413458-<b>T</b>,2 x 10-7,(mass),0.02,'-,0.0398 ng/ml decrease,[0.0088-0.0708],APOB,Lipoprotein-associated phospholipase A2 activity and mass,lipoprotein-associated phospholipase A(2) measurement,GCST001727,2:21008720,Cholesterol
1253,APOB,APOB,N/a,rs12713956-<b>G</b>,4 x 10-8,(AA),0.183,'-,4.86 unit decrease,[NR],APOB,LDL cholesterol,lipid measurement,GCST002042,2:21018633,Cholesterol
1265,APOB,APOB,N/a,rs13306194-<b>A</b>,1 x 10-12,,0.128,'-,0.13 unit decrease,[0.091-0.169],APOB,LDL cholesterol levels,LDL cholesterol change measurement,GCST009917,2:21029662,Cholesterol
1351,APOB,APOB,N/a,rs1367117-<b>A</b>,9 x 10-72,,0.337599,'-,0.10572609 unit increase,[0.094-0.117],APOB,Medication use (HMG CoA reductase inhibitors),HMG CoA reductase inhibitor use measurement,GCST007931,2:21041028,Cholesterol
1353,APOB,APOB,N/a,rs73228424-<b>A</b>,1 x 10-8,,0.0164566,'-,0.12550563 unit decrease,[0.082-0.169],"LINC02850, APOB",Medication use (HMG CoA reductase inhibitors),HMG CoA reductase inhibitor use measurement,GCST007931,2:20928534,Cholesterol
1362,APOB,APOB,N/a,rs676210-<b>G</b>,1 x 10-7,(Hispanic),0.757,'-,0.076 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21008652,Cholesterol
1363,APOB,APOB,N/a,rs676210-<b>G</b>,6 x 10-58,,NR,'-,0.066 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21008652,Cholesterol
1364,APOB,APOB,N/a,rs1041968-<b>G</b>,4 x 10-15,(EA),0.511,'-,0.03 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21009932,Cholesterol
1365,APOB,APOB,N/a,rs1041968-<b>G</b>,3 x 10-18,,NR,'-,0.031 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21009932,Cholesterol
1366,APOB,APOB,N/a,rs533617-<b>T</b>,9 x 10-20,(EA),0.96,'-,0.087 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21011100,Cholesterol
1367,APOB,APOB,N/a,rs533617-<b>T</b>,7 x 10-21,,NR,'-,0.087 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21011100,Cholesterol
1368,APOB,APOB,N/a,rs673548-<b>G</b>,8 x 10-51,(EA),0.785,'-,0.069 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21014672,Cholesterol
1369,APOB,APOB,N/a,rs673548-<b>G</b>,3 x 10-7,(Hispanic),0.754,'-,0.074 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21014672,Cholesterol
1370,APOB,APOB,N/a,rs673548-<b>G</b>,1 x 10-56,,NR,'-,0.065 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21014672,Cholesterol
1371,APOB,APOB,N/a,rs1367117-<b>G</b>,3 x 10-6,,NR,'-,0.018 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21041028,Cholesterol
1372,APOB,APOB,N/a,rs4564803-<b>G</b>,7 x 10-43,(EA),0.761,'-,0.06 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:20982630,Cholesterol
1373,APOB,APOB,N/a,rs4564803-<b>G</b>,4 x 10-8,(Hispanic),0.742,'-,0.078 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:20982630,Cholesterol
1374,APOB,APOB,N/a,rs4564803-<b>G</b>,1 x 10-47,,NR,'-,0.058 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:20982630,Cholesterol
1375,APOB,APOB,N/a,rs13392272-<b>C</b>,7 x 10-14,(EA),0.526,'-,0.028 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:20994618,Cholesterol
1376,APOB,APOB,N/a,rs13392272-<b>C</b>,2 x 10-17,,NR,'-,0.03 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:20994618,Cholesterol
1377,APOB,APOB,N/a,rs4665710-<b>A</b>,9 x 10-51,(EA),0.215,'-,0.069 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:20998163,Cholesterol
1378,APOB,APOB,N/a,rs4665710-<b>A</b>,5 x 10-7,(Hispanic),0.247,'-,0.072 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:20998163,Cholesterol
1379,APOB,APOB,N/a,rs4665710-<b>A</b>,7 x 10-56,,NR,'-,0.064 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:20998163,Cholesterol
1380,APOB,APOB,N/a,rs1042034-<b>C</b>,2 x 10-51,(EA),0.215,'-,0.069 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21002409,Cholesterol
1381,APOB,APOB,N/a,rs1042034-<b>C</b>,4 x 10-7,(Hispanic),0.244,'-,0.074 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21002409,Cholesterol
1382,APOB,APOB,N/a,rs1042034-<b>C</b>,5 x 10-58,,NR,'-,0.066 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21002409,Cholesterol
1383,APOB,APOB,N/a,rs2678379-<b>A</b>,2 x 10-52,(EA),0.215,'-,0.07 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21003688,Cholesterol
1384,APOB,APOB,N/a,rs2678379-<b>A</b>,3 x 10-7,(Hispanic),0.247,'-,0.074 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21003688,Cholesterol
1385,APOB,APOB,N/a,rs2678379-<b>A</b>,2 x 10-58,,NR,'-,0.066 unit increase,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21003688,Cholesterol
1386,APOB,APOB,N/a,rs676210-<b>G</b>,1 x 10-50,(EA),0.785,'-,0.069 unit decrease,'-,APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,2:21008652,Cholesterol
1387,APOB,APOB,N/a,rs2678379-<b>A</b>,7 x 10-21,,0.24,'-,0.065 s.d. increase,[0.051-0.079],APOB,HDL cholesterol,high density lipoprotein cholesterol measurement,GCST002899,2:21003688,Cholesterol
1388,APOB,APOB,N/a,rs11902417-<b>?</b>,9 x 10-10,,NR,'-,0.7960089 unit increase,[0.54-1.05],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:20976028,Cholesterol
1389,APOB,APOB,N/a,rs4665710-<b>?</b>,3 x 10-8,,NR,'-,0.7165994 unit decrease,[0.46-0.97],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:20998163,Cholesterol
1390,APOB,APOB,N/a,rs6544366-<b>?</b>,1 x 10-11,,NR,'-,0.9127752 unit increase,[0.65-1.18],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:20981153,Cholesterol
1391,APOB,APOB,N/a,rs673548-<b>?</b>,3 x 10-9,,NR,'-,0.7666658 unit increase,[0.51-1.02],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:21014672,Cholesterol
1392,APOB,APOB,N/a,rs6754295-<b>?</b>,2 x 10-8,,NR,'-,0.701763 unit increase,[0.46-0.95],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:20983311,Cholesterol
1393,APOB,APOB,N/a,rs676210-<b>?</b>,2 x 10-12,,NR,'-,0.9516762 unit increase,[0.69-1.22],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:21008652,Cholesterol
1394,APOB,APOB,N/a,rs693-<b>?</b>,1 x 10-6,,NR,'-,0.5936694 unit decrease,[0.35-0.83],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:21009323,Cholesterol
1395,APOB,APOB,N/a,rs7557067-<b>?</b>,7 x 10-12,,NR,'-,0.9193369 unit increase,[0.66-1.18],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:20985339,Cholesterol
1396,APOB,APOB,N/a,rs676210-<b>A</b>,5 x 10-63,,0.2052,'-,0.0546 mg dl-1 increase,[0.048-0.061],APOB,HDL cholesterol,high density lipoprotein cholesterol measurement,GCST006611,2:21008652,Cholesterol
1397,APOB,APOB,N/a,rs6544366-<b>T</b>,1 x 10-7,,0.23,'-,0.78 unit increase,[0.49-1.07],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST90010361,2:20981153,Cholesterol
1398,APOB,APOB,N/a,rs1042034-<b>T</b>,1 x 10-21,(EA),0.7884,'-,0.015 unit decrease,[0.012-0.018],APOB,HDL cholesterol levels,high density lipoprotein cholesterol measurement,GCST008685,2:21002409,Cholesterol
1399,APOB,APOB,N/a,rs676210-<b>G</b>,4 x 10-140,,0.794769,'-,0.0592929 unit decrease,[0.055-0.064],APOB,HDL cholesterol levels,high density lipoprotein cholesterol measurement,GCST010242,2:21008652,Cholesterol
1400,APOB,APOB,N/a,rs2678379-<b>?</b>,5 x 10-9,,NR,'-,0.753948 unit decrease,[0.5-1.01],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:21003688,Cholesterol
1401,APOB,APOB,N/a,rs13392272-<b>?</b>,5 x 10-6,,NR,'-,0.5633115 unit decrease,[0.32-0.81],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:20994618,Cholesterol
1402,APOB,APOB,N/a,rs1041968-<b>?</b>,1 x 10-6,,NR,'-,0.596959 unit decrease,[0.36-0.84],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:21009932,Cholesterol
1403,APOB,APOB,N/a,rs1042034-<b>?</b>,2 x 10-12,,NR,'-,0.9489343 unit decrease,[0.68-1.21],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST008035,2:21002409,Cholesterol
1404,APOB,APOB,N/a,rs6754295-<b>C</b>,4 x 10-8,,0.25,'-,0.07 s.d. increase,[NR],APOB,HDL cholesterol,high density lipoprotein cholesterol measurement,GCST000288,2:20983311,Cholesterol
1405,APOB,APOB,N/a,rs11902417-<b>G</b>,4 x 10-7,,0.78,'-,0.02 unit decrease,[0.01-0.03],APOB,HDL cholesterol,high density lipoprotein cholesterol measurement,GCST000805,2:20976028,Cholesterol
1406,APOB,APOB,N/a,rs1042034-<b>C</b>,1 x 10-30,,0.22,'-,0.9 mg/dL increase,[0.72-1.08],APOB,HDL cholesterol,high density lipoprotein cholesterol measurement,GCST000755,2:21002409,Cholesterol
1407,APOB,APOB,N/a,rs673548-<b>A</b>,2 x 10-119,,NR,'-,0.071 unit increase,[0.065-0.077],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST90019510,2:21014672,Cholesterol
1408,APOB,APOB,N/a,rs533617-<b>C</b>,1 x 10-43,,NR,'-,0.0889 unit increase,[0.076-0.101],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST90019510,2:21011100,Cholesterol
1409,APOB,APOB,N/a,rs11676704-<b>G</b>,1 x 10-19,,NR,'-,0.0298 unit increase,[0.023-0.036],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST90019510,2:21021486,Cholesterol
1410,APOB,APOB,N/a,rs1042031-<b>T</b>,1 x 10-12,,NR,'-,0.0231 unit decrease,[0.017-0.029],APOB,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST90019510,2:21002881,Cholesterol
1411,APOB,APOB,N/a,rs36143286-<b>?</b>,1 x 10-20,,'-,'-,0.0721 unit decrease,[0.057-0.087],"APOB, LINC02850",High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST011348,2:20952480,Cholesterol
209,DNM3,DNM3,N/a,rs2301453-<b>?</b>,2 x 10-6,,NR,'-,'-,'-,"DNM3, PIGC",Lipid traits (pleiotropy) (HIPO component 1),"total cholesterol measurement, triglyceride measurement, low density lipoprotein cholesterol measurement, high density lipoprotein cholesterol measurement",GCST006666,1:172389027,Cholesterol
1413,DNM3,DNM3,N/a,rs7519429-<b>A</b>,6 x 10-7,,NR,'-,0.018 unit decrease,'-,"PIGC, DNM3",High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007140,1:172380106,Cholesterol
1414,DNM3,DNM3,N/a,rs1011731-<b>A</b>,3 x 10-8,,0.57,'-,0.017 unit increase,'-,"DNM3, PIGC",High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST009148,1:172377408,Cholesterol
1415,DNM3,DNM3,N/a,rs1011731-<b>A</b>,1 x 10-11,,NR,'-,0.013541268 unit increase,[0.0096-0.0175],"DNM3, PIGC",High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST009151,1:172377408,Cholesterol
231,FCGR2A,FCGR2A,N/a,rs373579-<b>A</b>,2 x 10-7,,NR,'-,0.035 unit decrease,'-,FCGR2A,Total cholesterol levels,total cholesterol measurement,GCST007143,1:161513694,Cholesterol
232,FCGR2A,FCGR2A,N/a,rs373579-<b>A</b>,2 x 10-7,(EA),0.866,'-,0.036 unit decrease,'-,FCGR2A,Total cholesterol levels,total cholesterol measurement,GCST007143,1:161513694,Cholesterol
233,FCGR2A,FCGR2A,N/a,rs373579-<b>A</b>,1 x 10-11,,NR,'-,0.033 unit decrease,'-,FCGR2A,Total cholesterol levels,total cholesterol measurement,GCST007134,1:161513694,Cholesterol
1106,FCGR2A,FCGR2A,N/a,rs373579-<b>A</b>,4 x 10-11,,NR,'-,0.031 unit decrease,'-,FCGR2A,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007131,1:161513694,Cholesterol
1107,FCGR2A,FCGR2A,N/a,rs373579-<b>A</b>,6 x 10-7,,NR,'-,0.034 unit decrease,'-,FCGR2A,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,1:161513694,Cholesterol
1108,FCGR2A,FCGR2A,N/a,rs373579-<b>A</b>,5 x 10-7,(EA),NR,'-,0.036 unit decrease,'-,FCGR2A,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST007141,1:161513694,Cholesterol
1109,GUCY1A1,GUCY1A1,N/a,rs990619-<b>C</b>,2 x 10-8,,0.47636,'-,0.0117349 unit increase,[0.0076-0.0158],GUCY1A1,LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST010245,4:155586526,Cholesterol
322,NKPD1,NKPD1,N/a,rs10417602-<b>T</b>,6 x 10-11,,NR,'-,0.0292 unit increase,[0.02-0.038],"MARK4, NKPD1",Total cholesterol levels,total cholesterol measurement,GCST90019501,19:45157381,Cholesterol
323,NKPD1,NKPD1,N/a,rs10421247-<b>T</b>,1 x 10-15,,NR,'-,0.019 unit decrease,[0.014-0.024],"NKPD1, MARK4",Total cholesterol levels,total cholesterol measurement,GCST90019501,19:45154228,Cholesterol
1223,NKPD1,NKPD1,N/a,rs10417602-<b>T</b>,4 x 10-11,,NR,'-,0.0295 unit increase,[0.021-0.038],"MARK4, NKPD1",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,19:45157381,Cholesterol
1224,NKPD1,NKPD1,N/a,rs10421247-<b>T</b>,2 x 10-25,,NR,'-,0.0247 unit decrease,[0.02-0.029],"NKPD1, MARK4",Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST90019512,19:45154228,Cholesterol
1220,PDGFD,PDGFD,N/a,rs115739682-<b>T</b>,1 x 10-9,,0.808433,'-,0.0161412 unit increase,[0.011-0.021],PDGFD,LDL cholesterol levels,low density lipoprotein cholesterol measurement,GCST010245,11:103999912,Cholesterol
1221,PDGFD,PDGFD,N/a,rs10791660-<b>?</b>,4 x 10-11,,NR,'-,0.0218 unit decrease,[0.016-0.028],PDGFD,Low density lipoprotein cholesterol levels,low density lipoprotein cholesterol measurement,GCST010204,11:104000311,Cholesterol
1222,PDGFD,PDGFD,N/a,rs10895547-<b>T</b>,3 x 10-6,,0.23,'-,0.0747 unit decrease,[0.043-0.106],PDGFD,LDL cholesterol,low density lipoprotein cholesterol measurement,GCST000975,11:103937424,Cholesterol
1412,PDGFD,PDGFD,N/a,rs12146566-<b>A</b>,1 x 10-8,,0.802646,'-,0.0136347 unit increase,[0.0089-0.0183],PDGFD,HDL cholesterol levels,high density lipoprotein cholesterol measurement,GCST010242,11:104000676,Cholesterol
321,SLC22A4,SLC22A4,N/a,rs272838-<b>T</b>,1 x 10-9,,NR,'-,0.0197 unit decrease,[0.013-0.026],SLC22A4,Total cholesterol levels,total cholesterol measurement,GCST90019501,5:132303124,Cholesterol
1264,TAF1A-AS1,TAF1A-AS1,N/a,rs3002142-<b>G</b>,7 x 10-6,,0.145640074,'-,0.050391905 unit decrease,[0.028-0.072],"MIA3, TAF1A-AS1",LDL peak particle diameter (total fat intake interaction),"LDL peak particle diameter measurement, total fat intake measurement",GCST002989,1:222614720,Cholesterol
1359,TF,TF,N/a,rs6762415-<b>T</b>,1 x 10-8,,0.464711,'-,0.010907 unit increase,[0.0072-0.0147],TF,HDL cholesterol levels,high density lipoprotein cholesterol measurement,GCST010242,3:133759713,Cholesterol
1360,TF,TF,N/a,rs6762415-<b>G</b>,1 x 10-12,,NR,'-,0.0177 unit decrease,[0.013-0.023],TF,High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST90019510,3:133759713,Cholesterol
1089,TNIP1,TNIP1,N/a,rs1862364-<b>?</b>,7 x 10-6,(African American),'-,'-,0.15747027 unit decrease,[0.089-0.226],TNIP1,LDL cholesterol levels in HIV infection,"low density lipoprotein cholesterol measurement, HIV infection",GCST011741,5:151068815,Cholesterol
1090,TNIP1,TNIP1,N/a,rs1862364-<b>?</b>,7 x 10-6,(EA),'-,'-,0.15747027 unit decrease,[0.089-0.226],TNIP1,LDL cholesterol levels in HIV infection,"low density lipoprotein cholesterol measurement, HIV infection",GCST011741,5:151068815,Cholesterol
417,PROM1,PROM1,N/a,rs2677780-<b>A</b>,2 x 10-6,,0.9356,'-,6.3471 unit decrease,[NR],PROM1,Smooth-surface caries,smooth surface dental caries,GCST001896,4:16020917,Dental
1674,PROM1,PROM1,N/a,rs2531154-<b>?</b>,9 x 10-7,(DMFS5max),NR,'-,'-,'-,PROM1,Dental caries,dental caries,GCST001713,4:16016701,Dental
843,SMURF2,SMURF2,N/a,rs111854052-<b>A</b>,9 x 10-6,(Age 20-60 years),0.99,'-,0.3228 unit decrease,[0.18-0.47],SMURF2,Periodontitis (Mean PAL),periodontitis,GCST002127,17:64604817,Dental
214,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Diabetes
217,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Diabetes
222,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Diabetes
225,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Diabetes
227,APOB,APOB,N/a,rs562338-<b>?</b>,3 x 10-25,,NR,'-,'-,'-,"APOB, TDRD15",Age-related disease endophenotypes,"total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement",GCST004046,2:21065449,Diabetes
117,DNM3,DNM3,N/a,rs7546252-<b>G</b>,2 x 10-10,,0.5727,'-,0.0262 unit decrease,[0.018-0.034],"DNM3, PIGC",Type 2 diabetes,type II diabetes mellitus,GCST010557,1:172399170,Diabetes
118,DNM3,DNM3,N/a,rs4916253-<b>G</b>,3 x 10-9,,0.4311,'-,0.0274 unit increase,[0.018-0.036],"PIGC, DNM3",Type 2 diabetes,type II diabetes mellitus,GCST010555,1:172391892,Diabetes
1514,FGF12,FGF12,N/a,rs189651013-<b>A</b>,2 x 10-7,,0.0074,'-,0.11 unit increase,[0.063-0.157],FGF12,Fasting glucose,glucose measurement,GCST90002232,3:192684261,Diabetes
1728,GIMAP1-GIMAP5,GIMAP1-GIMAP5,N/a,rs61751050-<b>?</b>,4 x 10-6,,NR,'-,0.292 unit decrease,[0.12-0.46],"GIMAP1-GIMAP5, GIMAP5",Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,"coronary artery calcification, type II diabetes mellitus",GCST005173,7:150742952,Diabetes
1672,GUCY1A1,GUCY1A1,N/a,rs10019835-<b>?</b>,5 x 10-7,"(American Indian, additive )",0.63,1.4285715,'-,'-,GUCY1A1,Diabetic kidney disease,diabetic nephropathy,GCST003098,4:155712034,Diabetes
116,LINC00382,LINC00382,N/a,rs10830963-<b>G</b> x rs1360814-<b>G</b>,3 x 10-6,,NR,'-,'-,'-,MTNR1B x LINC01038 - LINC00382,"Type 2 diabetes (SNP x SNP interaction, 2df)",type II diabetes mellitus,GCST006495,11:92975544|13:79829782,Diabetes
48,PDGFD,PDGFD,N/a,rs7103465-<b>A</b>,4 x 10-7,,0.03,'-,0.248 unit increase,[0.15-0.34],PDGFD,Urinary albumin-to-creatinine ratio,urinary albumin to creatinine ratio,GCST010736,11:103974051,Diabetes
94,PRC1,PRC1,N/a,rs8042680-<b>A</b>,2 x 10-9,,0.331,'-,0.057 unit increase,[0.039-0.075],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST004894,15:90978107,Diabetes
95,PRC1,PRC1,N/a,rs8042680-<b>A</b>,6 x 10-9,(EA),0.331,'-,0.0627 unit increase,[0.042-0.084],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST004894,15:90978107,Diabetes
96,PRC1,PRC1,N/a,rs2290203-<b>G</b>,2 x 10-31,,0.6998,'-,0.0506 unit decrease,[0.042-0.059],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST010557,15:90968837,Diabetes
97,PRC1,PRC1,N/a,rs2290203-<b>A</b>,3 x 10-10,,0.47043929,1.0533636,'-,[1.036497938-1.070503529],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST90013693,15:90968837,Diabetes
98,PRC1,PRC1,N/a,rs8026714-<b>A</b>,1 x 10-22,,0.486,1.07,'-,[1.05-1.08],"PRC1-AS1, PRC1",Type 2 diabetes,type II diabetes mellitus,GCST010118,15:90979023,Diabetes
99,PRC1,PRC1,N/a,rs2290203-<b>G</b>,2 x 10-22,,0.7977,'-,0.0557 unit decrease,[0.045-0.067],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST010555,15:90968837,Diabetes
100,PRC1,PRC1,N/a,rs2290203-<b>G</b>,2 x 10-10,,0.526,'-,0.0559 unit decrease,[0.039-0.073],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST010553,15:90968837,Diabetes
101,PRC1,PRC1,N/a,rs12910825-<b>G</b>,2 x 10-12,,0.360390809,'-,0.0517 unit increase,[0.037-0.066],"PRC1-AS1, PRC1",Type 2 diabetes,type II diabetes mellitus,GCST006867,15:90968030,Diabetes
102,PRC1,PRC1,N/a,rs12910825-<b>G</b>,2 x 10-15,,0.3612,1.05,'-,[1.04-1.07],"PRC1-AS1, PRC1",Type 2 diabetes,type II diabetes mellitus,GCST009379,15:90968030,Diabetes
103,PRC1,PRC1,N/a,rs2290203-<b>A</b>,2 x 10-10,,0.47,1.06,'-,1.04-1.08,"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST007847,15:90968837,Diabetes
104,PRC1,PRC1,N/a,rs8042680-<b>A</b>,2 x 10-10,,'-,1.07,'-,[1.05-1.09],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST000712,15:90978107,Diabetes
105,PRC1,PRC1-AS1,N/a,rs8042680-<b>A</b>,2 x 10-9,,0.331,'-,0.057 unit increase,[0.039-0.075],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST004894,15:90978107,Diabetes
106,PRC1,PRC1-AS1,N/a,rs8042680-<b>A</b>,6 x 10-9,(EA),0.331,'-,0.0627 unit increase,[0.042-0.084],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST004894,15:90978107,Diabetes
107,PRC1,PRC1-AS1,N/a,rs2290203-<b>G</b>,2 x 10-31,,0.6998,'-,0.0506 unit decrease,[0.042-0.059],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST010557,15:90968837,Diabetes
108,PRC1,PRC1-AS1,N/a,rs2290203-<b>A</b>,3 x 10-10,,0.47043929,1.0533636,'-,[1.036497938-1.070503529],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST90013693,15:90968837,Diabetes
109,PRC1,PRC1-AS1,N/a,rs8026714-<b>A</b>,1 x 10-22,,0.486,1.07,'-,[1.05-1.08],"PRC1-AS1, PRC1",Type 2 diabetes,type II diabetes mellitus,GCST010118,15:90979023,Diabetes
110,PRC1,PRC1-AS1,N/a,rs2290203-<b>G</b>,2 x 10-22,,0.7977,'-,0.0557 unit decrease,[0.045-0.067],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST010555,15:90968837,Diabetes
111,PRC1,PRC1-AS1,N/a,rs2290203-<b>G</b>,2 x 10-10,,0.526,'-,0.0559 unit decrease,[0.039-0.073],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST010553,15:90968837,Diabetes
112,PRC1,PRC1-AS1,N/a,rs12910825-<b>G</b>,2 x 10-12,,0.360390809,'-,0.0517 unit increase,[0.037-0.066],"PRC1-AS1, PRC1",Type 2 diabetes,type II diabetes mellitus,GCST006867,15:90968030,Diabetes
113,PRC1,PRC1-AS1,N/a,rs12910825-<b>G</b>,2 x 10-15,,0.3612,1.05,'-,[1.04-1.07],"PRC1-AS1, PRC1",Type 2 diabetes,type II diabetes mellitus,GCST009379,15:90968030,Diabetes
114,PRC1,PRC1-AS1,N/a,rs2290203-<b>A</b>,2 x 10-10,,0.47,1.06,'-,1.04-1.08,"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST007847,15:90968837,Diabetes
115,PRC1,PRC1-AS1,N/a,rs8042680-<b>A</b>,2 x 10-10,,'-,1.07,'-,[1.05-1.09],"PRC1, PRC1-AS1",Type 2 diabetes,type II diabetes mellitus,GCST000712,15:90978107,Diabetes
936,RN7SL824P,RN7SL824P,N/a,rs6662618-<b>?</b>,3 x 10-10,,NR,'-,'-,[1.0965-1.1754],"RN7SL824P, GFI1",Multiple sclerosis and type 2 diabetes (pleiotropy),"multiple sclerosis, type II diabetes mellitus",GCST007120,1:92469854,Diabetes
119,TCF19,TCF19,N/a,rs2073721-<b>G</b>,2 x 10-9,,0.749,1.04,'-,[1.02-1.05],TCF19,Type 2 diabetes (adjusted for BMI),type II diabetes mellitus,GCST007516,6:31161839,Diabetes
120,TCF19,TCF19,N/a,rs2073721-<b>G</b>,2 x 10-10,,0.749,1.04,'-,[1.02-1.05],TCF19,Type 2 diabetes,type II diabetes mellitus,GCST007515,6:31161839,Diabetes
121,TCF19,TCF19,N/a,rs3130931-<b>C</b>,2 x 10-32,,0.6765,'-,0.0482 unit increase,[0.04-0.056],"POU5F1, TCF19",Type 2 diabetes,type II diabetes mellitus,GCST010557,6:31167111,Diabetes
122,TCF19,TCF19,N/a,rs2073721-<b>G</b>,6 x 10-10,,0.742,1.04,'-,[1.03-1.06],TCF19,Type 2 diabetes (adjusted for BMI),type II diabetes mellitus,GCST007518,6:31161839,Diabetes
123,TCF19,TCF19,N/a,rs2073721-<b>G</b>,6 x 10-9,,0.742,1.04,'-,[1.02-1.06],TCF19,Type 2 diabetes,type II diabetes mellitus,GCST007517,6:31161839,Diabetes
730,TNIP1,TNIP1,N/a,rs2233278-<b>C</b>,5 x 10-30,,'-,1.26,'-,'-,TNIP1,Psoriasis or type 2 diabetes (trans-disease meta-analysis)(opposite effect),"psoriasis, type II diabetes mellitus",GCST011990,5:151087628,Diabetes
854,APOB,APOB,N/a,rs183117027-<b>A</b>,4 x 10-8,,0.006,2.34,'-,[1.72–3.16],APOB,Pancreatic cancer,pancreatic carcinoma,GCST009895,2:21004340,Digestive System
1523,APOB,APOB,N/a,rs11901649-<b>G</b>,1 x 10-8,,NR,1.0331372,'-,[1.0217-1.0445],APOB,Gastroesophageal reflux disease,gastroesophageal reflux disease,GCST008832,2:21027351,Digestive System
1556,APOB,APOB,N/a,rs11901649-<b>?</b>,1 x 10-7,,NR,'-,0.084 unit increase,[0.053-0.115],APOB,Barrett's esophagus  or Esophageal adenocarcinoma,"esophageal adenocarcinoma, Barrett's esophagus",GCST008831,2:21027351,Digestive System
1686,CCDC201,CCDC201,N/a,rs75764599-<b>A</b>,4 x 10-8,,0.01,3.02,'-,[2.04-4.49],"CCDC201, RNU6-326P",Poor prognosis in Crohn's disease,"Crohn's disease, disease prognosis measurement",GCST004053,7:45859651,Digestive System
1501,CHL1,CHL1,N/a,rs6442427-<b>C</b>,2 x 10-7,(Unifrac metric),0.227,'-,5.0579796 z-score increase,NR,CHL1-AS2,Gut microbiota (beta diversity),gut microbiome measurement,GCST008901,3:170062,Digestive System
1502,CHL1,CHL1-AS2,N/a,rs6442427-<b>C</b>,2 x 10-7,(Unifrac metric),0.227,'-,5.0579796 z-score increase,NR,CHL1-AS2,Gut microbiota (beta diversity),gut microbiome measurement,GCST008901,3:170062,Digestive System
1737,CHL1,CHL1,N/a,rs11129766-<b>?</b>,2 x 10-6,,NR,2.797,'-,[NR],CHL1,Colonoscopy-negative controls vs population controls,colorectal health,GCST005147,3:393460,Digestive System
81,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,2 x 10-18,,'-,'-,'-,'-,FCGR2A,Ulcerative colitis,ulcerative colitis,GCST004133,1:161509955,Digestive System
83,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,1 x 10-41,(EA),0.5,1.1863672,'-,'-,FCGR2A,Ulcerative colitis,ulcerative colitis,GCST003045,1:161509955,Digestive System
85,FCGR2A,FCGR2A,N/a,rs10800309-<b>?</b>,4 x 10-25,(EA),NR,'-,'-,'-,FCGR2A,Ulcerative colitis,ulcerative colitis,GCST003045,1:161502368,Digestive System
87,FCGR2A,FCGR2A,N/a,rs10800309-<b>A</b>,3 x 10-9,,NR,1.23,'-,[NR],FCGR2A,Ulcerative colitis,ulcerative colitis,GCST000624,1:161502368,Digestive System
89,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,2 x 10-12,,0.78,1.59,'-,[1.39-1.82],FCGR2A,Ulcerative colitis,ulcerative colitis,GCST000529,1:161509955,Digestive System
91,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,2 x 10-20,,0.51,1.21,'-,[1.16-1.26],FCGR2A,Ulcerative colitis,ulcerative colitis,GCST000964,1:161509955,Digestive System
1325,FCGR2A,FCGR2A,N/a,rs10800309-<b>?</b>,6 x 10-37,(EA),NR,'-,'-,'-,FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST003043,1:161502368,Digestive System
1327,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,9 x 10-36,(EA),0.5,1.1334659,'-,'-,FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST003043,1:161509955,Digestive System
1329,FCGR2A,FCGR2A,N/a,rs6671847-<b>G</b>,2 x 10-12,,0.49,1.13,'-,[NR],FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST011501,1:161509020,Digestive System
1331,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,9 x 10-14,,'-,'-,'-,'-,FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST004131,1:161509955,Digestive System
1333,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,2 x 10-38,,0.509,1.124,'-,[1.092-1.157],FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST001725,1:161509955,Digestive System
1688,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,9 x 10-11,(EA),0.5,1.0816648,'-,[1.06-1.11],FCGR2A,Crohn's disease,Crohn's disease,GCST003044,1:161509955,Digestive System
2125,FCGR2A,FCGR2A,N/a,rs10800314-<b>?</b>,1 x 10-32,(subset analysis),NR,'-,'-,'-,FCGR2A,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,1:161502999,Digestive System
2129,FCGR2A,FCGR2A,N/a,rs61802846-<b>?</b>,1 x 10-9,(subset analysis),NR,'-,'-,'-,FCGR2A,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,1:161504083,Digestive System
1504,FGF12,FGF12,N/a,rs11721107-<b>T</b>,2 x 10-6,,0.05,'-,0.437 unit increase,[0.26-0.62],FGF12,Gut microbiota relative abundance (Ruminococcus belonging to family Erysipelotrichaceae),gut microbiome measurement,GCST90006994,3:192179982,Digestive System
586,KHSRPP1,KHSRPP1,N/a,rs7868228-<b>?</b>,3 x 10-6,(family_Succinivibrionaceae),'-,'-,0.9584754 unit decrease,[0.58-1.34],"KHSRPP1, H3P30",Gut microbiome composition (winter),seasonal gut microbiome measurement,GCST003223,9:21667763,Digestive System
1738,LINC00382,LINC00382,N/a,rs1889642-<b>?</b>,3 x 10-6,,NR,1.361,'-,[NR],"LINC01038, LINC00382",Colonoscopy-negative controls vs population controls,colorectal health,GCST005147,13:79832085,Digestive System
968,MGST1,MGST1,N/a,rs7300446-<b>?</b>,1 x 10-6,,'-,1.56,'-,[1.30-1.87],MGST1,Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics,"metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,12:16521286,Digestive System
1550,MGST1,MGST1,N/a,rs35827298-<b>A</b>,4 x 10-8,,NR,'-,'-,'-,MGST1,Barrett's esophagus or esophageal adenocarcinoma x sex interaction (2df test),"esophageal adenocarcinoma, Barrett's esophagus, sex interaction measurement",GCST011462,12:16414631,Digestive System
1552,MGST1,MGST1,N/a,rs35827298-<b>A</b>,1 x 10-8,(male),NR,0.87,'-,[0.82-0.91],MGST1,Barrett's esophagus  or Esophageal adenocarcinoma,"esophageal adenocarcinoma, Barrett's esophagus",GCST011461,12:16414631,Digestive System
1554,MGST1,MGST1,N/a,rs35827298-<b>A</b>,5 x 10-9,,NR,0.87,'-,[0.83-0.91],MGST1,Barrett's esophagus  or Esophageal adenocarcinoma,"esophageal adenocarcinoma, Barrett's esophagus",GCST011461,12:16414631,Digestive System
1777,NONOP2,NONOP2,N/a,rs6726160-<b>?</b>,2 x 10-8,,NR,'-,0.1045 unit decrease,'-,NONOP2,Celiac disease,celiac disease,GCST008489,2:60937594,Digestive System
1503,PDGFD,PDGFD,N/a,rs117397462-<b>C</b>,4 x 10-7,(G_Sporobacter_RNT),0.051004635,'-,0.313852 unit decrease,[0.19-0.44],PDGFD,"Gut microbiota (bacterial taxa, rank normal transformation method)",gut microbiome measurement,GCST010397,11:104202897,Digestive System
1650,PSMG4,PSMG4,N/a,rs4959799-<b>?</b>,5 x 10-6,(disease-free survival),'-,3.5,'-,[2.05-5.99],"SLC22A23, PSMG4",Survival in rectal cancer,"disease free survival, rectum cancer",GCST002821,6:3294794,Digestive System
1648,RN7SL252P,RN7SL252P,N/a,rs73230688-<b>T</b>,5 x 10-7,,0.379292528,'-,0.0027841 unit decrease,[NR],"RN7SL252P, MARK2P10",Diverticular disease,diverticular disease,GCST006479,7:96880690,Digestive System
856,ROR1,ROR1,N/a,rs1747924-<b>A</b>,7 x 10-6,,0.767,1.1111112,'-,[1.06-1.16],ROR1,Pancreatic cancer,pancreatic carcinoma,GCST002991,1:64073289,Digestive System
1335,SLC22A4,SLC22A4,N/a,rs56399423-<b>?</b>,4 x 10-43,(EA),NR,'-,'-,'-,"SLC22A4, MIR3936HG",Inflammatory bowel disease,inflammatory bowel disease,GCST003043,5:132336964,Digestive System
2133,TNIP1,TNIP1,N/a,rs74817271-<b>?</b>,2 x 10-26,(subset analysis),NR,'-,'-,'-,TNIP1,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,5:151090412,Digestive System
630,APOB,APOB,N/a,rs1713222-<b>A</b>,5 x 10-8,,0.145,'-,0.013 unit decrease,[0.0091-0.0169],"TDRD15, APOB",Response to statins (LDL cholesterol change),"response to statin, LDL cholesterol change measurement",GCST010338,2:21048451,Drug Response
632,APOB,APOB,N/a,rs541041-<b>G</b>,8 x 10-6,"(LDL, sum)",0.16,'-,'-,'-,"TDRD15, APOB",Response to statin therapy,response to statin,GCST000635,2:21072103,Drug Response
1352,APOB,APOB,N/a,rs1367117-<b>A</b>,9 x 10-72,,0.337599,'-,0.10572609 unit increase,[0.094-0.117],APOB,Medication use (HMG CoA reductase inhibitors),HMG CoA reductase inhibitor use measurement,GCST007931,2:21041028,Drug Response
1354,APOB,APOB,N/a,rs73228424-<b>A</b>,1 x 10-8,,0.0164566,'-,0.12550563 unit decrease,[0.082-0.169],"LINC02850, APOB",Medication use (HMG CoA reductase inhibitors),HMG CoA reductase inhibitor use measurement,GCST007931,2:20928534,Drug Response
626,CD8B2,CD8B2,N/a,rs143354638-<b>?</b>,7 x 10-7,,NR,10,'-,[4.02-24.88],CD8B2,Sulfasalazine-induced agranulocytosis,"response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,2:106508384,Drug Response
644,CHL1,CHL1,N/a,rs6795349-<b>G</b>,2 x 10-6,"(Citalopram+Buspirone, Dizziness)",0.03,'-,'-,'-,CHL1-AS2,Response to anti-depressant treatment in major depressive disorder,"response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,3:130794,Drug Response
646,CHL1,CHL1-AS2,N/a,rs6795349-<b>G</b>,2 x 10-6,"(Citalopram+Buspirone, Dizziness)",0.03,'-,'-,'-,CHL1-AS2,Response to anti-depressant treatment in major depressive disorder,"response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,3:130794,Drug Response
1525,CHRNA1,CHRNA1,N/a,rs187076367-<b>A</b>,1 x 10-6,(AA),0.999,'-,1.863 unit increase,NR,CHRNA1,Post bronchodilator FEV1,"forced expiratory volume, response to bronchodilator",GCST003262,2:174772186,Drug Response
624,DNM3,DNM3,N/a,rs12132562-<b>?</b>,4 x 10-7,(AA),NR,'-,8.5 ms increase,[5.17-11.83],"PIGC, DNM3",QT interval (sulfonylurea treatment interaction),"response to sulfonylurea, QT interval",GCST004031,1:172384331,Drug Response
651,FGF12,FGF12,N/a,rs189326995-<b>C</b>,8 x 10-7,(AA),0.999,'-,0.443 unit increase,'-,FGF12,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,3:192657709,Drug Response
653,FGF12,FGF12,N/a,rs149667740-<b>G</b>,2 x 10-6,(AA),0.999,'-,0.362 unit increase,'-,FGF12,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,3:192299812,Drug Response
655,FGF12,FGF12,N/a,rs138641425-<b>A</b>,2 x 10-6,(AA),0.999,'-,0.389 unit increase,'-,"FGF12-AS1, FGF12",Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,3:192261578,Drug Response
657,FGF12,FGF12-AS1,N/a,rs138641425-<b>A</b>,2 x 10-6,(AA),0.999,'-,0.389 unit increase,'-,"FGF12-AS1, FGF12",Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,3:192261578,Drug Response
664,FGF12,FGF12,N/a,rs55636532-<b>C</b>,2 x 10-6,,0.019,3.495,'-,[2.077-5.883],FGF12,Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker,"response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema",GCST010247,3:192194678,Drug Response
1649,GUCY1A1,GUCY1A1,N/a,rs7688323-<b>G</b>,3 x 10-8,,0.204893,'-,0.054884225 unit decrease,[0.036-0.074],GUCY1A1,Medication use (diuretics),Diuretic use measurement,GCST007928,4:155695469,Drug Response
1785,GUCY1A1,GUCY1A1,N/a,rs72689147-<b>T</b>,2 x 10-10,,0.184352,'-,0.06605871 unit decrease,[0.046-0.086],GUCY1A1,Medication use (calcium channel blockers),Calcium channel blocker use measurement,GCST007929,4:155718736,Drug Response
2032,GUCY1A1,GUCY1A1,N/a,rs11731886-<b>C</b>,4 x 10-8,,0.236995,'-,0.0532221 unit decrease,[0.034-0.072],"GUCY1A1, GUCY1B1",Medication use (beta blocking agents),Beta blocking agent use measurement,GCST007927,4:155738667,Drug Response
2186,GUCY1A1,GUCY1A1,N/a,rs56329057-<b>T</b>,2 x 10-13,,0.183334,'-,0.05747693 unit decrease,[0.042-0.073],GUCY1A1,Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,4:155712292,Drug Response
649,KC6,KC6,N/a,rs184167040-<b>A</b>,1 x 10-6,(AA),1,'-,0.544 unit increase,'-,KC6,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,18:41458077,Drug Response
969,MGST1,MGST1,N/a,rs7300446-<b>?</b>,1 x 10-6,,'-,1.56,'-,[1.30-1.87],MGST1,Metastatic colorectal cancer survival in treatment with chemotherapy plus biologics,"metastatic colorectal cancer, survival time, response to antineoplastic agent",GCST011584,12:16521286,Drug Response
875,NDST1,NDST1,N/a,rs6891880-<b>G</b>,5 x 10-8,,0.42715,'-,0.03849182 unit decrease,[0.025-0.052],"NDST1, SYNPO","Medication use (anti-inflammatory and antirheumatic products, non-steroids)",Non-steroidal anti-inflammatory and antirheumatic product use measurement,GCST007934,5:150593232,Drug Response
876,NDST1,NDST1,N/a,rs6891880-<b>G</b>,5 x 10-8,,0.42715,'-,0.03849182 unit decrease,[0.025-0.052],"NDST1, SYNPO","Medication use (anti-inflammatory and antirheumatic products, non-steroids)",Non-steroidal anti-inflammatory and antirheumatic product use measurement,GCST007934,5:150593232,Drug Response
634,OR51B5,OR51B5,N/a,rs7482428-<b>?</b>,4 x 10-7,,NR,1.4643433,'-,NR,"OR51B5, HBG2, HBE1",Response to SSRI (symptom remission),response to selective serotonin reuptake inhibitor,GCST007060,11:5321196,Drug Response
661,OR51B5,OR51B5,N/a,rs7482428-<b>?</b>,2 x 10-7,,NR,1.440507,'-,NR,"OR51B5, HBG2, HBE1",Response to antidepressants (symptom remission),response to antidepressant,GCST007061,11:5321196,Drug Response
2194,PDGFD,PDGFD,N/a,rs591118-<b>A</b>,4 x 10-9,,NR,5.89,'-,[2.97-11.68],PDGFD,Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L),"adrenal suppression measurement, response to corticosteroid",GCST005927,11:104095993,Drug Response
2195,PDGFD,PDGFD,N/a,rs591118-<b>A</b>,4 x 10-10,,NR,4.05,'-,[2.00-8.21],PDGFD,Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L),"adrenal suppression measurement, response to corticosteroid",GCST005924,11:104095993,Drug Response
660,PMAIP1,PMAIP1,N/a,rs8093763-<b>A</b>,3 x 10-8,,0.25,'-,0.18 unit increase,[0.12-0.24],"PMAIP1, GLUD1P4",Response to bleomycin (chromatid breaks),"response to bleomycin, chromatid break measurement, response to antibiotic",GCST000882,18:59836146,Drug Response
659,ROR1,ROR1,N/a,rs192166173-<b>A</b>,4 x 10-6,(AA),0.999,'-,0.342 unit increase,'-,"ROR1, PGM1",Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,1:63696337,Drug Response
403,TCF19,TCF19,N/a,rs3130931-<b>C</b>,8 x 10-7,,0.69,1.54,'-,[1.29-1.84],"POU5F1, TCF19",Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),"Stevens-Johnson syndrome, toxic epidermal necrolysis",GCST001181,6:31167111,Drug Response
628,TUBB4BP4,TUBB4BP4,N/a,rs149020156-<b>?</b>,6 x 10-7,,NR,7.41,'-,[3.38-16.25],"LINC02756, TUBB4BP4",Sulfasalazine-induced agranulocytosis,"response to sulfasalazine, Drug-induced agranulocytosis",GCST004781,11:91940355,Drug Response
562,APOB,APOB,N/a,rs97458-<b>A</b>,2 x 10-8,(MTAG),0.6957,'-,0.008 unit increase,[0.0053-0.0107],"TDRD15, APOB",Educational attainment (MTAG),self reported educational attainment,GCST006571,2:21104763,Educational and Intelligence
563,APOB,APOB,N/a,rs312945-<b>A</b>,2 x 10-9,,0.3051,'-,0.0091 unit decrease,[0.0062-0.012],"TDRD15, APOB",Educational attainment (years of education),self reported educational attainment,GCST006442,2:21105953,Educational and Intelligence
1740,ARHGAP24,ARHGAP24,N/a,rs111882035-<b>G</b>,3 x 10-8,,0.02,'-,0.93 unit decrease,[0.6-1.26],ARHGAP24,Logical memory (delayed recall) in mild cognitive impairment,"cognitive impairment measurement, memory performance",GCST007000,4:85495401,Educational and Intelligence
557,CHL1,CHL1,N/a,rs4685448-<b>A</b>,4 x 10-8,(MTAG),0.4454,'-,0.0072 unit decrease,[0.0047-0.0097],CHL1,Educational attainment (MTAG),self reported educational attainment,GCST006571,3:210661,Educational and Intelligence
1048,CHL1,CHL1,N/a,rs6442537-<b>G</b>,2 x 10-8,,0.7939,'-,0.0156 unit decrease,[0.01-0.021],CHL1-AS2,Highest math class taken,mathematical ability,GCST006574,3:185620,Educational and Intelligence
1049,CHL1,CHL1,N/a,rs56032805-<b>A</b>,2 x 10-10,(MTAG),0.5849,'-,0.0107 unit decrease,[0.0074-0.014],CHL1-AS2,Highest math class taken (MTAG),mathematical ability,GCST006568,3:194819,Educational and Intelligence
1050,CHL1,CHL1,N/a,rs17050452-<b>T</b>,3 x 10-10,,0.3227,'-,0.0131 unit decrease,[0.009-0.0172],"LINC01986, CHL1-AS2",Self-reported math ability,mathematical ability,GCST006573,3:107496,Educational and Intelligence
1051,CHL1,CHL1,N/a,rs1016162-<b>T</b>,5 x 10-10,(MTAG),0.3194,'-,0.0119 unit decrease,[0.0082-0.0156],"LINC01986, CHL1-AS2",Self-reported math ability (MTAG),mathematical ability,GCST006569,3:102299,Educational and Intelligence
1052,CHL1,CHL1-AS2,N/a,rs6442537-<b>G</b>,2 x 10-8,,0.7939,'-,0.0156 unit decrease,[0.01-0.021],CHL1-AS2,Highest math class taken,mathematical ability,GCST006574,3:185620,Educational and Intelligence
1053,CHL1,CHL1-AS2,N/a,rs56032805-<b>A</b>,2 x 10-10,(MTAG),0.5849,'-,0.0107 unit decrease,[0.0074-0.014],CHL1-AS2,Highest math class taken (MTAG),mathematical ability,GCST006568,3:194819,Educational and Intelligence
1054,CHL1,CHL1-AS2,N/a,rs17050452-<b>T</b>,3 x 10-10,,0.3227,'-,0.0131 unit decrease,[0.009-0.0172],"LINC01986, CHL1-AS2",Self-reported math ability,mathematical ability,GCST006573,3:107496,Educational and Intelligence
1055,CHL1,CHL1-AS2,N/a,rs1016162-<b>T</b>,5 x 10-10,(MTAG),0.3194,'-,0.0119 unit decrease,[0.0082-0.0156],"LINC01986, CHL1-AS2",Self-reported math ability (MTAG),mathematical ability,GCST006569,3:102299,Educational and Intelligence
556,DNM3,DNM3,N/a,rs1066391-<b>A</b>,3 x 10-9,(conditional-joint),0.3521,'-,0.0087 unit decrease,[0.0058-0.0116],"MRPL40P1, CAND1",Educational attainment (years of education),self reported educational attainment,GCST006442,12:67322923,Educational and Intelligence
569,DNM3,DNM3,N/a,rs3817923-<b>A</b>,4 x 10-8,(MTAG),0.1133,'-,0.0114 unit decrease,[0.0073-0.0155],"EEF1AKNMT, DNM3",Educational attainment (MTAG),self reported educational attainment,GCST006571,1:171840071,Educational and Intelligence
570,DNM3,DNM3,N/a,rs3817923-<b>A</b>,4 x 10-8,,0.1133,'-,0.0121 unit decrease,[0.0078-0.0164],"EEF1AKNMT, DNM3",Educational attainment (years of education),self reported educational attainment,GCST006442,1:171840071,Educational and Intelligence
1295,FAM180B,FAM180B,N/a,rs11605348-<b>A</b>,1 x 10-8,,NR,'-,5.735 z-score decrease,'-,"NDUFS3, FAM180B",Intelligence,intelligence,GCST006250,11:47584931,Educational and Intelligence
1071,FGF12,FGF12,N/a,rs12107377-<b>A</b>,3 x 10-8,(MTAG),0.5168,'-,0.0092 unit increase,[0.0061-0.0123],FGF12,Highest math class taken (MTAG),mathematical ability,GCST006568,3:192433028,Educational and Intelligence
1750,FGF12,FGF12,N/a,rs28636751-<b>G</b>,1 x 10-6,,0.53,'-,0.21 unit increase,'-,FGF12,Age-related cognitive decline (memory) (slope of z-scores),cognitive decline measurement,GCST009441,3:192493896,Educational and Intelligence
575,FGF8,FGF8,N/a,rs2735421-<b>?</b>,4 x 10-18,,NR,'-,'-,'-,"FGF8, NPM3",Educational attainment (years of education),self reported educational attainment,GCST007037,10:101781259,Educational and Intelligence
576,FGF8,FGF8,N/a,rs78079366-<b>T</b>,2 x 10-9,(MTAG),0.7982,'-,0.0097 unit increase,[0.0066-0.0128],"FBXW4, FGF8",Educational attainment (MTAG),self reported educational attainment,GCST006571,10:101716541,Educational and Intelligence
1063,FGF8,FGF8,N/a,rs2735421-<b>T</b>,7 x 10-11,,0.2991,'-,0.0161 unit increase,[0.011-0.021],"FGF8, NPM3",Highest math class taken,mathematical ability,GCST006574,10:101781259,Educational and Intelligence
1064,FGF8,FGF8,N/a,rs749694-<b>A</b>,2 x 10-16,(MTAG),0.4702,'-,0.0147 unit increase,[0.011-0.018],"FGF8, FBXW4",Self-reported math ability (MTAG),mathematical ability,GCST006569,10:101760027,Educational and Intelligence
1065,FGF8,FGF8,N/a,rs749694-<b>A</b>,5 x 10-9,,0.4702,'-,0.0115 unit increase,[0.0076-0.0154],"FGF8, FBXW4",Self-reported math ability,mathematical ability,GCST006573,10:101760027,Educational and Intelligence
1066,FGF8,FGF8,N/a,rs749694-<b>A</b>,6 x 10-28,(MTAG),0.4705,'-,0.0181 unit increase,[0.015-0.021],"FGF8, FBXW4",Highest math class taken (MTAG),mathematical ability,GCST006568,10:101760027,Educational and Intelligence
1290,FGF8,FGF8,N/a,rs2735421-<b>T</b>,4 x 10-11,,NR,'-,0.021916008 unit increase,[0.015-0.028],"FGF8, NPM3",Intelligence (MTAG),intelligence,GCST005316,10:101781259,Educational and Intelligence
1291,FGF8,FGF8,N/a,rs7077446-<b>T</b>,1 x 10-17,,NR,'-,0.02622558 unit increase,[0.02-0.032],"FBXW4, FGF8",Intelligence (MTAG),intelligence,GCST005316,10:101742008,Educational and Intelligence
1292,FGF8,FGF8,N/a,rs2735421-<b>T</b>,2 x 10-10,,NR,'-,6.372 z-score increase,'-,"FGF8, NPM3",Intelligence,intelligence,GCST006250,10:101781259,Educational and Intelligence
1293,FGF8,FGF8,N/a,rs749694-<b>A</b>,2 x 10-13,,NR,'-,7.365 z-score increase,'-,"FGF8, FBXW4",Intelligence,intelligence,GCST006250,10:101760027,Educational and Intelligence
1294,FGF8,FGF8,N/a,rs749694-<b>A</b>,1 x 10-8,,NR,'-,5.728 z-score increase,'-,"FGF8, FBXW4",General cognitive ability,intelligence,GCST006269,10:101760027,Educational and Intelligence
1746,FGF8,FGF8,N/a,rs2735421-<b>?</b>,6 x 10-9,,NR,'-,'-,'-,"FGF8, NPM3",Cognitive traits (MTAG),cognitive function measurement,GCST90011293,10:101781259,Educational and Intelligence
1056,H2AC6,H2AC6,N/a,rs198806-<b>A</b>,6 x 10-10,(MTAG),0.4005,'-,0.0113 unit increase,[0.0078-0.0148],H2AC6,Self-reported math ability (MTAG),mathematical ability,GCST006569,6:26133388,Educational and Intelligence
1288,H2AC6,H2AC6,N/a,rs198813-<b>T</b>,2 x 10-10,,NR,'-,0.01943674 unit decrease,[0.013-0.025],H2AC6,Intelligence (MTAG),intelligence,GCST005316,6:26127998,Educational and Intelligence
1547,HS3ST1,HS3ST1,N/a,rs4916646-<b>?</b>,3 x 10-7,,NR,'-,2.125 unit decrease,[1.36-2.89],HS3ST1,Exploratory eye movement dysfunction in schizophrenia (cognitive search score),exploratory eye movement measurement,GCST003064,4:11468106,Educational and Intelligence
1298,IL20RB,IL20RB,N/a,rs13099657-<b>?</b>,3 x 10-6,,NR,'-,4.648 z-score decrease,'-,IL20RB,General cognitive ability,intelligence,GCST006269,3:137033748,Educational and Intelligence
566,KC6,KC6,N/a,rs56393977-<b>T</b>,2 x 10-11,(MTAG),0.103,'-,0.0144 unit increase,[0.01-0.019],KC6,Educational attainment (MTAG),self reported educational attainment,GCST006571,18:41685233,Educational and Intelligence
567,KC6,KC6,N/a,rs34298584-<b>A</b>,4 x 10-9,,0.1688,'-,0.0111 unit increase,[0.0074-0.0148],KC6,Educational attainment (years of education),self reported educational attainment,GCST006442,18:41446731,Educational and Intelligence
568,KC6,KC6,N/a,rs11875240-<b>A</b>,9 x 10-9,(conditional-joint),0.8295,'-,0.0107 unit decrease,[0.007-0.0144],KC6,Educational attainment (years of education),self reported educational attainment,GCST006442,18:41447079,Educational and Intelligence
1060,KC6,KC6,N/a,rs56393977-<b>T</b>,2 x 10-11,(MTAG),0.1075,'-,0.0179 unit increase,[0.013-0.023],KC6,Highest math class taken (MTAG),mathematical ability,GCST006568,18:41685233,Educational and Intelligence
1321,KC6,KC6,N/a,rs3752060-<b>?</b>,1 x 10-6,,NR,'-,0.296 unit increase,[0.18-0.41],KC6,Cognitive performance (processing speed),information processing speed,GCST008891,18:41565183,Educational and Intelligence
702,LINC00578,LINC00578,N/a,rs11705870-<b>?</b>,3 x 10-7,,NR,'-,0.0088756 unit increase,[0.0055-0.0123],LINC00578,Reaction time,reaction time measurement,GCST006268,3:177472205,Educational and Intelligence
559,MGST1,MGST1,N/a,rs10846380-<b>T</b>,5 x 10-10,(conditional-joint),0.4161,'-,0.0088 unit increase,[0.0061-0.0115],"MGST1, LMO3",Educational attainment (years of education),self reported educational attainment,GCST006442,12:16594100,Educational and Intelligence
560,MGST1,MGST1,N/a,rs2160514-<b>A</b>,3 x 10-11,,0.5548,'-,0.0094 unit decrease,[0.0067-0.0121],"MGST1, LMO3",Educational attainment (years of education),self reported educational attainment,GCST006442,12:16603574,Educational and Intelligence
561,MGST1,MGST1,N/a,rs2160514-<b>A</b>,2 x 10-13,(MTAG),0.5548,'-,0.0097 unit decrease,[0.0072-0.0122],"MGST1, LMO3",Educational attainment (MTAG),self reported educational attainment,GCST006571,12:16603574,Educational and Intelligence
1057,MGST1,MGST1,N/a,rs2160514-<b>A</b>,9 x 10-11,(MTAG),0.5601,'-,0.0108 unit decrease,[0.0075-0.0141],"MGST1, LMO3",Highest math class taken (MTAG),mathematical ability,GCST006568,12:16603574,Educational and Intelligence
1058,NANOS3,NANOS3,N/a,rs4635447-<b>A</b>,2 x 10-10,,0.7594,'-,0.0168 unit decrease,[0.012-0.022],"NANOS3, MIR23AHG",Highest math class taken,mathematical ability,GCST006574,19:13845711,Educational and Intelligence
1059,NANOS3,NANOS3,N/a,rs4271693-<b>T</b>,6 x 10-11,(MTAG),0.7467,'-,0.0124 unit decrease,[0.0087-0.0161],"NANOS3, MIR23AHG",Highest math class taken (MTAG),mathematical ability,GCST006568,19:13845849,Educational and Intelligence
558,PCDHGA2,PCDHGA2,N/a,rs1002519-<b>T</b>,4 x 10-10,,0.229622,'-,0.052421402 unit increase,[0.036-0.069],"PCDHGA11, PCDHGB5, PCDHGA1, PCDHGA6, PCDHGA3, PCDHGB4, PCDHGC5, PCDHGA5, PCDHGB2, PCDHGB3, PCDHGC3, PCDHGA9, PCDHGA8, PCDHGA2, PCDHGA4, PCDHGB7, PCDHGB1, PCDHGB6, PCDHGA7, PCDHGC4, PCDHGA10, PCDHGA12",Noncognitive aspects of educational attainment,self reported educational attainment,GCST90011874,5:141489436,Educational and Intelligence
577,PHF2,PHF2,N/a,rs2989751-<b>A</b>,3 x 10-8,,0.244,'-,0.0092 unit decrease,[0.0059-0.0125],PHF2,Educational attainment (years of education),self reported educational attainment,GCST006442,9:93604365,Educational and Intelligence
578,PHF2,PHF2,N/a,rs10761251-<b>A</b>,3 x 10-14,,0.6633,'-,0.0113 unit increase,[0.0084-0.0142],PHF2,Educational attainment (years of education),self reported educational attainment,GCST006442,9:93659264,Educational and Intelligence
579,PHF2,PHF2,N/a,rs7040340-<b>A</b>,1 x 10-11,(conditional-joint),0.3915,'-,0.0098 unit increase,[0.0071-0.0125],PHF2,Educational attainment (years of education),self reported educational attainment,GCST006442,9:93681628,Educational and Intelligence
580,PHF2,PHF2,N/a,rs10761251-<b>A</b>,2 x 10-18,(MTAG),0.6633,'-,0.0121 unit increase,[0.0094-0.0148],PHF2,Educational attainment (MTAG),self reported educational attainment,GCST006571,9:93659264,Educational and Intelligence
1067,PHF2,PHF2,N/a,rs10992806-<b>C</b>,1 x 10-12,,0.5031,'-,0.0138 unit decrease,[0.01-0.018],PHF2,Self-reported math ability,mathematical ability,GCST006573,9:93621190,Educational and Intelligence
1068,PHF2,PHF2,N/a,rs10761251-<b>T</b>,3 x 10-11,,0.3417,'-,0.0159 unit decrease,[0.011-0.021],PHF2,Highest math class taken,mathematical ability,GCST006574,9:93659264,Educational and Intelligence
1069,PHF2,PHF2,N/a,rs10761251-<b>A</b>,7 x 10-19,(MTAG),0.6583,'-,0.0154 unit increase,[0.012-0.019],PHF2,Highest math class taken (MTAG),mathematical ability,GCST006568,9:93659264,Educational and Intelligence
1070,PHF2,PHF2,N/a,rs10992806-<b>C</b>,8 x 10-16,(MTAG),0.5031,'-,0.0144 unit decrease,[0.011-0.018],PHF2,Self-reported math ability (MTAG),mathematical ability,GCST006569,9:93621190,Educational and Intelligence
1296,PHF2,PHF2,N/a,rs10992797-<b>A</b>,9 x 10-9,,NR,'-,0.01718294 unit increase,[0.011-0.023],PHF2,Intelligence (MTAG),intelligence,GCST005316,9:93599833,Educational and Intelligence
1297,PHF2,PHF2,N/a,rs10992853-<b>T</b>,2 x 10-8,,NR,'-,0.016856678 unit decrease,[0.011-0.023],PHF2,Intelligence (MTAG),intelligence,GCST005316,9:93674643,Educational and Intelligence
1286,PRC1,PRC1,N/a,rs540970650-<b>?</b>,6 x 10-6,,NR,'-,4.539 z-score decrease,'-,"PRC1-AS1, PRC1",General cognitive ability,intelligence,GCST006269,15:90973347,Educational and Intelligence
1287,PRC1,PRC1-AS1,N/a,rs540970650-<b>?</b>,6 x 10-6,,NR,'-,4.539 z-score decrease,'-,"PRC1-AS1, PRC1",General cognitive ability,intelligence,GCST006269,15:90973347,Educational and Intelligence
1741,RBM25,RBM25,N/a,rs2806048-<b>A</b>,2 x 10-10,,0.364811,'-,0.041699134 unit decrease,[0.029-0.054],RBM25,Cognitive aspects of educational attainment,"cognitive function measurement, self reported educational attainment",GCST90011875,14:73062386,Educational and Intelligence
1747,RBM25,RBM25,N/a,rs2806048-<b>A</b>,1 x 10-10,,0.6194,'-,0.019 unit decrease,[0.013-0.025],RBM25,Cognitive performance,cognitive function measurement,GCST006572,14:73062386,Educational and Intelligence
564,RCN2,RCN2,N/a,rs2469226-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,"RN7SL278P, RCN2",Educational attainment (years of education),self reported educational attainment,GCST007037,15:76954649,Educational and Intelligence
565,RCN2,RCN2,N/a,rs2469226-<b>A</b>,1 x 10-8,,0.2228,'-,0.0096 unit increase,[0.0063-0.0129],"RN7SL278P, RCN2",Educational attainment (years of education),self reported educational attainment,GCST006442,15:76954649,Educational and Intelligence
1300,ROR1,ROR1,N/a,rs147482589-<b>?</b>,7 x 10-6,,NR,'-,4.505 z-score decrease,'-,"ROR1-AS1, ROR1",General cognitive ability,intelligence,GCST006269,1:64152111,Educational and Intelligence
1301,ROR1,ROR1-AS1,N/a,rs147482589-<b>?</b>,7 x 10-6,,NR,'-,4.505 z-score decrease,'-,"ROR1-AS1, ROR1",General cognitive ability,intelligence,GCST006269,1:64152111,Educational and Intelligence
1289,TAF1A-AS1,TAF1A-AS1,N/a,rs34123076-<b>?</b>,3 x 10-6,,NR,'-,4.681 z-score increase,'-,TAF1A-AS1,General cognitive ability,intelligence,GCST006269,1:222590887,Educational and Intelligence
1739,TGM3,TGM3,N/a,rs6132559-<b>C</b>,3 x 10-6,,NR,'-,5.6118593 unit decrease,[3.3-7.93],"TGM6, TGM3",Prepulse inhibition of the startle response,cognitive inhibition measurement,GCST009313,20:2373547,Educational and Intelligence
571,TNNI3K,TNNI3K,N/a,rs1569092-<b>A</b>,6 x 10-16,(MTAG),0.152,'-,0.0148 unit increase,[0.011-0.018],"FPGT-TNNI3K, TNNI3K",Educational attainment (MTAG),self reported educational attainment,GCST006571,1:74393040,Educational and Intelligence
572,TNNI3K,TNNI3K,N/a,rs1569092-<b>A</b>,2 x 10-16,,0.152,'-,0.016 unit increase,[0.012-0.02],"FPGT-TNNI3K, TNNI3K",Educational attainment (years of education),self reported educational attainment,GCST006442,1:74393040,Educational and Intelligence
573,TNNI3K,FPGT-TNNI3K,N/a,rs1569092-<b>A</b>,6 x 10-16,(MTAG),0.152,'-,0.0148 unit increase,[0.011-0.018],"FPGT-TNNI3K, TNNI3K",Educational attainment (MTAG),self reported educational attainment,GCST006571,1:74393040,Educational and Intelligence
574,TNNI3K,FPGT-TNNI3K,N/a,rs1569092-<b>A</b>,2 x 10-16,,0.152,'-,0.016 unit increase,[0.012-0.02],"FPGT-TNNI3K, TNNI3K",Educational attainment (years of education),self reported educational attainment,GCST006442,1:74393040,Educational and Intelligence
1061,TNNI3K,TNNI3K,N/a,rs61778068-<b>A</b>,2 x 10-12,(MTAG),0.9653,'-,0.0318 unit decrease,[0.023-0.041],"TNNI3K, FPGT-TNNI3K",Highest math class taken (MTAG),mathematical ability,GCST006568,1:74518677,Educational and Intelligence
1062,TNNI3K,FPGT-TNNI3K,N/a,rs61778068-<b>A</b>,2 x 10-12,(MTAG),0.9653,'-,0.0318 unit decrease,[0.023-0.041],"TNNI3K, FPGT-TNNI3K",Highest math class taken (MTAG),mathematical ability,GCST006568,1:74518677,Educational and Intelligence
1742,TNNI3K,TNNI3K,N/a,rs61776255-<b>C</b>,1 x 10-10,(MTAG),0.9587,'-,0.037 unit decrease,[0.026-0.048],"FPGT-TNNI3K, LRRC53, TNNI3K",Cognitive performance (MTAG),cognitive function measurement,GCST006570,1:74489377,Educational and Intelligence
1743,TNNI3K,TNNI3K,N/a,rs485929-<b>A</b>,5 x 10-9,(MTAG),0.6111,'-,0.0138 unit decrease,[0.0091-0.0185],"FPGT, FPGT-TNNI3K",Cognitive performance (MTAG),cognitive function measurement,GCST006570,1:74212601,Educational and Intelligence
1744,TNNI3K,FPGT-TNNI3K,N/a,rs485929-<b>A</b>,5 x 10-9,(MTAG),0.6111,'-,0.0138 unit decrease,[0.0091-0.0185],"FPGT, FPGT-TNNI3K",Cognitive performance (MTAG),cognitive function measurement,GCST006570,1:74212601,Educational and Intelligence
1745,TNNI3K,FPGT-TNNI3K,N/a,rs61776255-<b>C</b>,1 x 10-10,(MTAG),0.9587,'-,0.037 unit decrease,[0.026-0.048],"FPGT-TNNI3K, LRRC53, TNNI3K",Cognitive performance (MTAG),cognitive function measurement,GCST006570,1:74489377,Educational and Intelligence
581,VIRMA,VIRMA,N/a,rs72674898-<b>?</b>,1 x 10-8,,NR,'-,'-,'-,"VIRMA, LINC02894",Educational attainment (years of education),self reported educational attainment,GCST007037,8:94619327,Educational and Intelligence
582,VIRMA,VIRMA,N/a,rs4735297-<b>A</b>,5 x 10-9,(MTAG),0.6741,'-,0.0083 unit decrease,[0.0056-0.011],"LINC02894, VIRMA",Educational attainment (MTAG),self reported educational attainment,GCST006571,8:94577112,Educational and Intelligence
583,VIRMA,VIRMA,N/a,rs4735297-<b>A</b>,2 x 10-8,,0.6741,'-,0.0086 unit decrease,[0.0057-0.0115],"LINC02894, VIRMA",Educational attainment (years of education),self reported educational attainment,GCST006442,8:94577112,Educational and Intelligence
584,VIRMA,VIRMA,N/a,rs9642928-<b>A</b>,5 x 10-8,(conditional-joint),0.3261,'-,0.0083 unit increase,[0.0054-0.0112],"VIRMA, LINC02894",Educational attainment (years of education),self reported educational attainment,GCST006442,8:94601698,Educational and Intelligence
1549,VIRMA,VIRMA,N/a,rs117966288-<b>A</b>,6 x 10-6,,NR,'-,0.54783386 unit decrease,[0.31-0.79],"VIRMA, LINC02894",Abstraction and mental flexibility,executive function measurement,GCST009303,8:94623105,Educational and Intelligence
1299,YWHAZP2,YWHAZP2,N/a,rs1550404-<b>?</b>,1 x 10-6,(high intelligence),NR,'-,7.05 unit increase,[4.23-9.87],"YWHAZP2, GYPC",Intelligence,intelligence,GCST001428,2:126573377,Educational and Intelligence
1500,AP3M2,AP3M2,N/a,rs113060680-<b>T</b>,2 x 10-10,,0.1172,1.078,'-,NR,"KAT6A, AP3M2",Blond vs. brown/black hair color,hair color,GCST006988,8:42130366,Facial Morphology
1491,ARHGAP24,ARHGAP24,N/a,rs1482099-<b>?</b>,6 x 10-30,,NR,'-,'-,'-,ARHGAP24,Hair color,hair colour measurement,GCST007082,4:85679939,Facial Morphology
1492,ARHGAP24,ARHGAP24,N/a,rs4693741-<b>?</b>,6 x 10-9,,NR,'-,'-,'-,ARHGAP24,Hair color,hair colour measurement,GCST007082,4:85831651,Facial Morphology
1497,ARHGAP24,ARHGAP24,N/a,rs1026872-<b>?</b>,1 x 10-13,,NR,1.0597711,'-,NR,ARHGAP24,Blond vs. brown/black hair color,hair color,GCST006988,4:85680478,Facial Morphology
1493,CHL1,CHL1,N/a,rs4685448-<b>?</b>,8 x 10-14,,NR,'-,'-,'-,CHL1,Hair color,hair colour measurement,GCST007082,3:210661,Facial Morphology
1498,CHL1,CHL1,N/a,rs9809528-<b>G</b>,5 x 10-8,,0.4383,1.043,'-,NR,CHL1,Blond vs. brown/black hair color,hair color,GCST006988,3:209075,Facial Morphology
2059,COL4A2-AS2,COL4A2-AS2,N/a,rs41275110-<b>A</b>,2 x 10-9,,0.197374,'-,0.0232512 unit decrease,[0.016-0.031],"COL4A2-AS2, COL4A2",Male-pattern baldness,balding measurement,GCST007020,13:110462207,Facial Morphology
1771,LINC00578,LINC00578,N/a,rs2133593-<b>?</b>,7 x 10-11,,NR,1.1061947,'-,[1.07-1.14],LINC00578,Chin dimples,chin morphology measurement,GCST003989,3:177584204,Facial Morphology
1494,MYO1B,MYO1B,N/a,rs12614848-<b>?</b>,2 x 10-15,,NR,'-,'-,'-,"HMGB1P27, MYO1B",Hair color,hair colour measurement,GCST007082,2:191231993,Facial Morphology
1499,MYO1B,MYO1B,N/a,rs12614848-<b>?</b>,1 x 10-8,,NR,1.0498688,'-,NR,"HMGB1P27, MYO1B",Blond vs. brown/black hair color,hair color,GCST006988,2:191231993,Facial Morphology
1543,PHF2,PHF2,N/a,rs3763605-<b>?</b>,4 x 10-8,"(Quadrant I (Philtrum), Segment 16)",NR,'-,0.031986132 unit increase,NR,PHF2,Facial morphology traits (59 NSCL/P endophenotypic segments),facial morphology measurement,GCST011429,9:93658108,Facial Morphology
1544,ROR1,ROR1,N/a,rs11208297-<b>?</b>,2 x 10-10,(≥14 yr),NR,'-,'-,'-,ROR1,Normal facial asymmetry (angle of surface orientation score),facial asymmetry measurement,GCST007448,1:63809749,Facial Morphology
1489,S100A11,S100A11,N/a,rs12130862-<b>?</b>,9 x 10-9,,'-,'-,0.016 unit decrease,[0.01-0.022],"S100A11, SPTLC1P4",Hair curvature (quantitative),hair morphology measurement,GCST011641,1:152054539,Facial Morphology
1490,S100A11,S100A11,N/a,rs3124314-<b>T</b>,4 x 10-6,,NR,'-,'-,'-,"SPTLC1P4, S100A11",Hair morphology,hair morphology,GCST000519,1:152065039,Facial Morphology
1496,TMEM45B,TMEM45B,N/a,rs10791037-<b>?</b>,4 x 10-13,,NR,'-,'-,'-,TMEM45B,Hair color,hair colour measurement,GCST007082,11:129723274,Facial Morphology
1495,TUBB4BP4,TUBB4BP4,N/a,rs12225068-<b>?</b>,8 x 10-9,,NR,'-,'-,'-,"LINC02756, TUBB4BP4",Hair color,hair colour measurement,GCST007082,11:91883525,Facial Morphology
1678,TUBB4BP4,TUBB4BP4,N/a,rs12225068-<b>A</b>,6 x 10-10,,0.917154,'-,'-,'-,"LINC02756, TUBB4BP4",Cutaneous melanoma or hair colour,"cutaneous melanoma, hair color",GCST010302,11:91883525,Facial Morphology
1755,VIRMA,VIRMA,N/a,rs957448-<b>A</b>,1 x 10-12,,0.5,1.2345679,'-,[NR],VIRMA,Nonsyndromic cleft lip with cleft palate,"Cleft palate, cleft lip",GCST004166,8:94529074,Facial Morphology
1756,VIRMA,VIRMA,N/a,rs76706433-<b>C</b>,6 x 10-6,(EA),NR,6.79,'-,[2.964-15.56],VIRMA,Cleft palate,Cleft palate,GCST005946,8:94529231,Facial Morphology
1757,VIRMA,VIRMA,N/a,rs76706433-<b>C</b>,6 x 10-6,,NR,6.79,'-,[2.96-15.56],VIRMA,Cleft palate,Cleft palate,GCST005946,8:94529231,Facial Morphology
1758,VIRMA,VIRMA,N/a,rs76706433-<b>C</b>,8 x 10-6,,NR,5.96,'-,[2.72-13.05],VIRMA,Cleft palate,Cleft palate,GCST005947,8:94529231,Facial Morphology
1545,WDR86,WDR86,N/a,rs57687654-<b>A</b>,2 x 10-6,,0.232452,'-,0.475295 unit increase,[0.28-0.67],"CRYGN, WDR86-AS1",Iris color (a* coordinate),eye colour measurement,GCST007740,7:151421400,Facial Morphology
1546,WDR86,WDR86-AS1,N/a,rs57687654-<b>A</b>,2 x 10-6,,0.232452,'-,0.475295 unit increase,[0.28-0.67],"CRYGN, WDR86-AS1",Iris color (a* coordinate),eye colour measurement,GCST007740,7:151421400,Facial Morphology
1796,ARHGAP24,ARHGAP24,N/a,rs71599425-<b>A</b>,6 x 10-6,(EA),0.0382,'-,0.0797 unit decrease,[0.045-0.114],ARHGAP24,Breast cancer,breast carcinoma,GCST004988,4:85740190,Female Reproductive System
47,DNM3,DNM3,N/a,rs17361789-<b>G</b>,5 x 10-8,,0.32,1.0638298,'-,[1.04-1.09],DNM3,Uterine fibroids,uterine fibroid,GCST008423,1:172153461,Female Reproductive System
864,DNM3,DNM3,N/a,rs484686-<b>?</b>,8 x 10-6,,'-,1.3,'-,[1.16-1.46],DNM3,Ovarian cancer,ovarian carcinoma,GCST009830,1:172183062,Female Reproductive System
866,DNM3,DNM3,N/a,rs12117623-<b>C</b>,1 x 10-6,,0.5306,1.312336,'-,[1.18-1.46],DNM3,Ovarian cancer,ovarian carcinoma,GCST007239,1:172072640,Female Reproductive System
1810,DNM3,DNM3,N/a,rs1894633-<b>G</b>,2 x 10-6,(EA),0.3337,'-,0.0312 unit decrease,[0.018-0.044],DNM3,Breast cancer,breast carcinoma,GCST004988,1:172361919,Female Reproductive System
45,GUCY1A1,GUCY1A1,N/a,rs4691052-<b>?</b>,3 x 10-6,,'-,1.04,'-,[1.02-1.05],GUCY1A1,Uterine fibroids (MTAG),uterine fibroid,GCST009833,4:155692026,Female Reproductive System
46,GUCY1A1,GUCY1A1,N/a,rs10030758-<b>?</b>,1 x 10-6,,'-,1.12,'-,[1.07-1.17],"GUCY1B1, GUCY1A1",Uterine fibroids,uterine fibroid,GCST009834,4:155747570,Female Reproductive System
1802,NANOS3,NANOS3,N/a,rs2594714-<b>G</b>,1 x 10-8,(EA),0.77,1.0309278,'-,[1.01-1.05],"MIR23AHG, NANOS3",Breast cancer,breast carcinoma,GCST004988,19:13843757,Female Reproductive System
703,PMAIP1,PMAIP1,N/a,rs7242599-<b>G</b>,9 x 10-6,,0.645120631,'-,0.16764931 unit increase,[0.094-0.242],PMAIP1,Menstruation quality of life impact (aggressiveness),"quality of life during menstruation measurement, aggressive behavior",GCST006641,18:59882031,Female Reproductive System
1798,PPM1K,PPM1K,N/a,rs10022462-<b>T</b>,2 x 10-9,(EA),0.44,1.04,'-,[1.02-1.06],PPM1K-DT,Breast cancer,breast carcinoma,GCST004988,4:88322666,Female Reproductive System
1800,PPM1K,PPM1K-DT,N/a,rs10022462-<b>T</b>,2 x 10-9,(EA),0.44,1.04,'-,[1.02-1.06],PPM1K-DT,Breast cancer,breast carcinoma,GCST004988,4:88322666,Female Reproductive System
858,PRC1,PRC1,N/a,rs8037137-<b>C</b>,1 x 10-7,,0.133619,1.1235955,'-,[1.08-1.18],"RCCD1, PRC1",Serous invasive ovarian cancer,ovarian serous carcinoma,GCST004478,15:90963407,Female Reproductive System
860,PRC1,PRC1,N/a,rs8037137-<b>C</b>,7 x 10-8,,0.133619,1.1363636,'-,[1.09-1.19],"RCCD1, PRC1",High-grade serous ovarian cancer,ovarian serous carcinoma,GCST004480,15:90963407,Female Reproductive System
862,PRC1,PRC1,N/a,rs8037137-<b>C</b>,5 x 10-7,,0.134,1.098901,'-,[1.06-1.15],"RCCD1, PRC1",Invasive epithelial ovarian cancer,ovarian carcinoma,GCST004415,15:90963407,Female Reproductive System
1786,PRC1,PRC1,N/a,rs2290203-<b>G</b>,8 x 10-10,,0.79,1.0638298,'-,[1.04-1.09],"PRC1, PRC1-AS1",Breast cancer,breast carcinoma,GCST004988,15:90968837,Female Reproductive System
1788,PRC1,PRC1,N/a,rs77554484-<b>A</b>,1 x 10-15,(EA),0.1319,'-,0.0741 unit decrease,[0.056-0.092],"RCCD1, PRC1",Breast cancer,breast carcinoma,GCST004988,15:90965985,Female Reproductive System
1790,PRC1,PRC1,N/a,rs2290203-<b>G</b>,4 x 10-8,(East Asian),0.504,1.08,'-,[1.05-1.11],"PRC1, PRC1-AS1",Breast cancer,breast carcinoma,GCST002537,15:90968837,Female Reproductive System
1792,PRC1,PRC1-AS1,N/a,rs2290203-<b>G</b>,8 x 10-10,,0.79,1.0638298,'-,[1.04-1.09],"PRC1, PRC1-AS1",Breast cancer,breast carcinoma,GCST004988,15:90968837,Female Reproductive System
1794,PRC1,PRC1-AS1,N/a,rs2290203-<b>G</b>,4 x 10-8,(East Asian),0.504,1.08,'-,[1.05-1.11],"PRC1, PRC1-AS1",Breast cancer,breast carcinoma,GCST002537,15:90968837,Female Reproductive System
1804,SLC22A4,SLC22A4,N/a,rs6860806-<b>G</b>,8 x 10-8,(EA),0.5391,'-,0.0335 unit increase,[0.021-0.046],SLC22A4,Breast cancer,breast carcinoma,GCST004988,5:132304843,Female Reproductive System
1806,SLC22A4,SLC22A4,N/a,rs6860806-<b>?</b>,3 x 10-8,,NR,'-,'-,'-,SLC22A4,Breast cancer,breast carcinoma,GCST010098,5:132304843,Female Reproductive System
2187,SLC38A10,SLC38A10,N/a,rs2725405-<b>?</b>,7 x 10-12,,NR,'-,'-,'-,SLC38A10,Menarche (age at onset),age at menarche,GCST007078,17:81246424,Female Reproductive System
1808,SSBP4,SSBP4,N/a,rs7258465-<b>C</b>,3 x 10-28,(EA),0.3436,'-,0.0725 unit decrease,[0.06-0.085],SSBP4,Breast cancer,breast carcinoma,GCST004988,19:18422832,Female Reproductive System
2188,TNNI3K,TNNI3K,N/a,rs1040070-<b>?</b>,2 x 10-12,,NR,'-,0.031 unit decrease,[0.040-0.022],"LRRC53, TNNI3K, FPGT-TNNI3K",Menarche (age at onset),age at menarche,GCST003993,1:74512186,Female Reproductive System
2189,TNNI3K,TNNI3K,N/a,rs7514705-<b>C</b>,2 x 10-16,,0.56,'-,0.04 unit increase,[0.03-0.05],"TNNI3K, FPGT-TNNI3K",Menarche (age at onset),age at menarche,GCST002541,1:74541036,Female Reproductive System
2190,TNNI3K,TNNI3K,N/a,rs7553348-<b>?</b>,6 x 10-39,,NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Menarche (age at onset),age at menarche,GCST007078,1:74539383,Female Reproductive System
2191,TNNI3K,FPGT-TNNI3K,N/a,rs1040070-<b>?</b>,2 x 10-12,,NR,'-,0.031 unit decrease,[0.040-0.022],"LRRC53, TNNI3K, FPGT-TNNI3K",Menarche (age at onset),age at menarche,GCST003993,1:74512186,Female Reproductive System
2192,TNNI3K,FPGT-TNNI3K,N/a,rs7514705-<b>C</b>,2 x 10-16,,0.56,'-,0.04 unit increase,[0.03-0.05],"TNNI3K, FPGT-TNNI3K",Menarche (age at onset),age at menarche,GCST002541,1:74541036,Female Reproductive System
2193,TNNI3K,FPGT-TNNI3K,N/a,rs7553348-<b>?</b>,6 x 10-39,,NR,'-,'-,'-,"TNNI3K, FPGT-TNNI3K",Menarche (age at onset),age at menarche,GCST007078,1:74539383,Female Reproductive System
1645,DTD1,DTD1,N/a,rs148286224-<b>?</b>,5 x 10-8,,NR,'-,'-,'-,DTD1,DNA methylation variation (age effect),DNA methylation,GCST006660,20:18659884,Genetic Regulation
1647,LINC02414,LINC02414,N/a,rs12813347-<b>?</b>,1 x 10-8,,NR,'-,'-,'-,LINC02414,DNA methylation variation (age effect),DNA methylation,GCST006660,12:131603856,Genetic Regulation
1646,LINC02502,LINC02502,N/a,rs149029090-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,LINC02502,DNA methylation variation (age effect),DNA methylation,GCST006660,4:119957380,Genetic Regulation
2141,PPM1K,PPM1K,N/a,rs7678928-<b>T</b>,6 x 10-19,,0.46,'-,0.09 unit increase,[0.065-0.115],PPM1K-DT,Branched-chain amino acid levels (Isoleucine),amino acid measurement,GCST006077,4:88301675,Genetic Regulation
2142,PPM1K,PPM1K,N/a,rs1440581-<b>C</b>,4 x 10-25,,0.53,'-,0.08 unit increase,[0.055-0.105],PPM1K-DT,Branched-chain amino acid levels (Leucine),amino acid measurement,GCST006076,4:88305270,Genetic Regulation
2143,PPM1K,PPM1K,N/a,rs1440581-<b>C</b>,4 x 10-24,,0.53,'-,0.1 unit increase,[-0.15480-0.35480],PPM1K-DT,Branched-chain amino acid levels (Valine),amino acid measurement,GCST006078,4:88305270,Genetic Regulation
2144,PPM1K,PPM1K-DT,N/a,rs7678928-<b>T</b>,6 x 10-19,,0.46,'-,0.09 unit increase,[0.065-0.115],PPM1K-DT,Branched-chain amino acid levels (Isoleucine),amino acid measurement,GCST006077,4:88301675,Genetic Regulation
2145,PPM1K,PPM1K-DT,N/a,rs1440581-<b>C</b>,4 x 10-25,,0.53,'-,0.08 unit increase,[0.055-0.105],PPM1K-DT,Branched-chain amino acid levels (Leucine),amino acid measurement,GCST006076,4:88305270,Genetic Regulation
2146,PPM1K,PPM1K-DT,N/a,rs1440581-<b>C</b>,4 x 10-24,,0.53,'-,0.1 unit increase,[-0.15480-0.35480],PPM1K-DT,Branched-chain amino acid levels (Valine),amino acid measurement,GCST006078,4:88305270,Genetic Regulation
541,SLC38A10,SLC38A10,N/a,rs7224668-<b>C</b>,3 x 10-8,(IGP31),0.524575415,'-,0.1729 unit increase,[0.11-0.23],SLC38A10,IgG glycosylation,serum IgG glycosylation measurement,GCST001848,17:81261988,Genetic Regulation
1339,ADH1A,ADH1A,N/a,rs904092-<b>G</b>,4 x 10-10,,NR,'-,0.0194 unit decrease,[0.013-0.025],"ADH1B, ADH1A",Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,4:99293007,Hormone
495,AP1S1,AP1S1,N/a,rs10755866-<b>A</b>,8 x 10-12,,NR,'-,0.0199 unit increase,[0.014-0.026],"AP1S1, VGF",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90019518,7:101162179,Hormone
1350,ARHGAP24,ARHGAP24,N/a,rs7687906-<b>C</b>,5 x 10-6,(Amylin ),0.217,'-,0.03 pM increase,[NR],ARHGAP24,Obesity-related traits,hormone measurement,GCST001762,4:85794159,Hormone
500,DCAF6,DCAF6,N/a,rs10489206-<b>C</b>,4 x 10-8,,0.779271,'-,0.00793774 unit increase,[0.005-0.0108],DCAF6,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012106,1:168071994,Hormone
501,DCAF6,DCAF6,N/a,rs10489206-<b>C</b>,4 x 10-7,,0.779271,'-,0.00856665 unit increase,[0.0052-0.0119],DCAF6,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012107,1:168071994,Hormone
502,DCAF6,DCAF6,N/a,rs5778564-<b>GA</b>,1 x 10-11,,0.418193,'-,0.00543322 unit increase,[0.0038-0.0071],DCAF6,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012110,1:168050067,Hormone
503,DCAF6,DCAF6,N/a,rs5778564-<b>GA</b>,3 x 10-10,,0.418193,'-,0.00571711 unit increase,[0.0038-0.0076],DCAF6,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012111,1:168050067,Hormone
496,DNM3,DNM3,N/a,rs12138803-<b>C</b>,1 x 10-9,,0.730533,'-,0.00856942 unit increase,[0.0059-0.0113],"DNM3, PIGC",Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012106,1:172379683,Hormone
497,DNM3,DNM3,N/a,rs12138803-<b>C</b>,4 x 10-7,,0.730533,'-,0.00832136 unit increase,[0.0052-0.0114],"DNM3, PIGC",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012107,1:172379683,Hormone
498,DNM3,DNM3,N/a,rs12138803-<b>C</b>,2 x 10-10,,0.730211,'-,0.00605624 unit increase,[0.0042-0.0079],"DNM3, PIGC",Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012110,1:172379683,Hormone
499,DNM3,DNM3,N/a,rs12138803-<b>C</b>,1 x 10-7,,0.730211,'-,0.00558389 unit increase,[0.0035-0.0076],"DNM3, PIGC",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012111,1:172379683,Hormone
1262,LINC02414,LINC02414,N/a,rs10082903-<b>?</b>,9 x 10-6,,0.41,'-,'-,'-,LINC02414,Circulating leptin levels x sex interaction in high cardiovascular risk,"leptin measurement, sex interaction measurement",GCST009533,12:131593515,Hormone
1341,PHF2,PHF2,N/a,rs72747427-<b>T</b>,4 x 10-12,,NR,'-,0.0261 unit increase,[0.019-0.034],PHF2,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,9:93651312,Hormone
1340,PSMC5,PSMC5,N/a,rs13030-<b>T</b>,7 x 10-38,,NR,'-,0.0326 unit decrease,[0.028-0.038],PSMC5,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,17:63831196,Hormone
399,ADGRG2,ADGRG2,N/a,rs192490304-<b>?</b>,1 x 10-6,,NR,'-,0.4448 unit decrease,[0.28-0.61],ADGRG2,Chronic sinus infection,susceptibility to chronic sinus infection measurement,GCST005021,X:19189260,Immune
365,ALG1L13P,ALG1L13P,N/a,rs2955587-<b>?</b>,6 x 10-10,,NR,1.11,'-,[1.06-1.17],"ALG1L13P, FAM86B3P",Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,8:8240557,Immune
615,CCDC201,CCDC201,N/a,rs6956740-<b>?</b>,5 x 10-7,(ACPA-negative RA vs controls),NR,3.49,'-,[2.08-5.85],CCDC201,Rheumatoid arthritis,rheumatoid arthritis,GCST000917,7:45864208,Immune
1685,CCDC201,CCDC201,N/a,rs75764599-<b>A</b>,4 x 10-8,,0.01,3.02,'-,[2.04-4.49],"CCDC201, RNU6-326P",Poor prognosis in Crohn's disease,"Crohn's disease, disease prognosis measurement",GCST004053,7:45859651,Immune
704,CHL1,CHL1,N/a,rs11917787-<b>?</b>,9 x 10-6,,NR,'-,'-,'-,CHL1,QT interval in Tripanosoma cruzi seropositivity,"QT interval, Trypanosoma cruzi seropositivity",GCST002278,3:212236,Immune
941,DNM3,DNM3,N/a,rs146287327-<b>G</b>,9 x 10-7,,NR,'-,1.06175 unit decrease,[0.64-1.48],"DNM3, EEF1AKNMT",Mosquito bite size,mosquito bite reaction size measurement,GCST004863,1:171825757,Immune
82,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,2 x 10-18,,'-,'-,'-,'-,FCGR2A,Ulcerative colitis,ulcerative colitis,GCST004133,1:161509955,Immune
84,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,1 x 10-41,(EA),0.5,1.1863672,'-,'-,FCGR2A,Ulcerative colitis,ulcerative colitis,GCST003045,1:161509955,Immune
86,FCGR2A,FCGR2A,N/a,rs10800309-<b>?</b>,4 x 10-25,(EA),NR,'-,'-,'-,FCGR2A,Ulcerative colitis,ulcerative colitis,GCST003045,1:161502368,Immune
88,FCGR2A,FCGR2A,N/a,rs10800309-<b>A</b>,3 x 10-9,,NR,1.23,'-,[NR],FCGR2A,Ulcerative colitis,ulcerative colitis,GCST000624,1:161502368,Immune
90,FCGR2A,FCGR2A,N/a,rs10800309-<b>A</b>,3 x 10-9,,NR,1.23,'-,[NR],FCGR2A,Ulcerative colitis,ulcerative colitis,GCST000624,1:161502368,Immune
92,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,2 x 10-20,,0.51,1.21,'-,[1.16-1.26],FCGR2A,Ulcerative colitis,ulcerative colitis,GCST000964,1:161509955,Immune
366,FCGR2A,FCGR2A,N/a,rs6671847-<b>A</b>,1 x 10-12,,'-,1.2,'-,[NR],FCGR2A,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003156,1:161509020,Immune
367,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,7 x 10-6,,NR,1.35,'-,[1.18-1.53],FCGR2A,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003599,1:161509955,Immune
368,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,2 x 10-14,,NR,1.16,'-,[1.11-1.20],FCGR2A,Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,1:161509955,Immune
369,FCGR2A,FCGR2A,N/a,rs12129787-<b>?</b>,1 x 10-9,,NR,1.22,'-,[1.14-1.29],FCGR2A,Systemic lupus erythematosus,systemic lupus erythematosus,GCST007400,1:161522797,Immune
370,FCGR2A,FCGR2A,N/a,rs1801274-<b>C</b>,1 x 10-12,,'-,1.16,'-,[1.11–1.21],FCGR2A,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003155,1:161509955,Immune
371,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,6 x 10-11,(EA),0.497,1.21,'-,[NR],FCGR2A,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003622,1:161509955,Immune
372,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,9 x 10-6,,NR,'-,'-,'-,FCGR2A,Systemic lupus erythematosus,systemic lupus erythematosus,GCST002463,1:161509955,Immune
373,FCGR2A,FCGR2A,N/a,rs111994823-<b>T</b>,3 x 10-11,,0.964,1.409,'-,[1.31-1.51],"FCGR2A, RNU6-481P",Systemic lupus erythematosus,systemic lupus erythematosus,GCST011956,1:161500484,Immune
374,FCGR2A,FCGR2A,N/a,rs12120358-<b>A</b>,3 x 10-11,,0.893,0.842,'-,[0.79-0.89],"FCGR2A, RNU6-481P",Systemic lupus erythematosus,systemic lupus erythematosus,GCST011956,1:161474579,Immune
551,FCGR2A,FCGR2A,N/a,rs114414096-<b>A</b>,8 x 10-10,,NR,'-,0.0263 unit decrease,[0.018-0.035],FCGR2A,Serum albumin level,serum albumin measurement,GCST90019493,1:161521553,Immune
599,FCGR2A,FCGR2A,N/a,rs10494360-<b>A</b>,3 x 10-7,,0.13,1.14,'-,[1.08-1.20],FCGR2A,Rheumatoid arthritis (ACPA-positive),rheumatoid arthritis,GCST006048,1:161505960,Immune
601,FCGR2A,FCGR2A,N/a,rs72717009-<b>T</b>,2 x 10-6,,NR,'-,0.119221 unit increase,[0.071-0.168],"RNU6-481P, FCGR2A",Rheumatoid arthritis,rheumatoid arthritis,GCST006959,1:161435263,Immune
603,FCGR2A,FCGR2A,N/a,rs72717009-<b>T</b>,1 x 10-6,(EA),0.12,'-,0.12237 unit increase,[0.073-0.172],"RNU6-481P, FCGR2A",Rheumatoid arthritis,rheumatoid arthritis,GCST006959,1:161435263,Immune
605,FCGR2A,FCGR2A,N/a,rs72717009-<b>T</b>,5 x 10-7,(EA),0.12,1.12,'-,[1.07-1.18],"RNU6-481P, FCGR2A",Rheumatoid arthritis,rheumatoid arthritis,GCST002318,1:161435263,Immune
607,FCGR2A,FCGR2A,N/a,rs72717009-<b>T</b>,1 x 10-7,,0.1,1.13,'-,[1.08-1.18],"RNU6-481P, FCGR2A",Rheumatoid arthritis,rheumatoid arthritis,GCST002318,1:161435263,Immune
937,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,1 x 10-7,"(East Asian, males)",0.758,1.48,'-,[1.28-1.71],FCGR2A,Kawasaki disease,mucocutaneous lymph node syndrome,GCST004859,1:161509955,Immune
938,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,7 x 10-11,,0.47,1.32,'-,[1.22-1.44],FCGR2A,Kawasaki disease,mucocutaneous lymph node syndrome,GCST001322,1:161509955,Immune
939,FCGR2A,FCGR2A,N/a,rs6671847-<b>A</b>,3 x 10-9,(EA),0.508,0.7,'-,[0.6-0.8],FCGR2A,Kawasaki disease,mucocutaneous lymph node syndrome,GCST90013537,1:161509020,Immune
1326,FCGR2A,FCGR2A,N/a,rs10800309-<b>?</b>,6 x 10-37,(EA),NR,'-,'-,'-,FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST003043,1:161502368,Immune
1328,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,9 x 10-36,(EA),0.5,1.1334659,'-,'-,FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST003043,1:161509955,Immune
1330,FCGR2A,FCGR2A,N/a,rs6671847-<b>G</b>,2 x 10-12,,0.49,1.13,'-,[NR],FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST011501,1:161509020,Immune
1332,FCGR2A,FCGR2A,N/a,rs1801274-<b>?</b>,9 x 10-14,,'-,'-,'-,'-,FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST004131,1:161509955,Immune
1334,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,2 x 10-38,,0.509,1.124,'-,[1.092-1.157],FCGR2A,Inflammatory bowel disease,inflammatory bowel disease,GCST001725,1:161509955,Immune
1687,FCGR2A,FCGR2A,N/a,rs1801274-<b>A</b>,9 x 10-11,(EA),0.5,1.0816648,'-,[1.06-1.11],FCGR2A,Crohn's disease,Crohn's disease,GCST003044,1:161509955,Immune
2121,FCGR2A,FCGR2A,N/a,rs368433-<b>C</b>,2 x 10-8,,0.84,1.37,'-,[1.23-1.54],FCGR2A,Helicobacter pylori serologic status,anti-Helicobacter pylori serum IgG measurement,GCST002014,1:161514420,Immune
2123,FCGR2A,FCGR2A,N/a,rs10800314-<b>?</b>,1 x 10-32,(subset analysis),NR,'-,'-,'-,FCGR2A,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,1:161502999,Immune
2127,FCGR2A,FCGR2A,N/a,rs61802846-<b>?</b>,1 x 10-9,(subset analysis),NR,'-,'-,'-,FCGR2A,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,1:161504083,Immune
738,GUCY1A1,GUCY1A1,N/a,rs12650590-<b>?</b>,4 x 10-8,,NR,2.41,'-,[1.78‐3.26],GUCY1A1,Psoriasis,psoriasis,GCST008096,4:155618869,Immune
1322,GUCY1A1,GUCY1A1,N/a,rs1483035-<b>?</b>,6 x 10-6,,0.5385,4.16,'-,[2.18-7.94],GUCY1A1,Influenza A (H1N1) severity,influenza A severity measurement,GCST003126,4:155588884,Immune
1076,KC6,KC6,N/a,rs16974953-<b>?</b>,6 x 10-6,(heterogeneous),'-,'-,0.257 unit decrease,[0.15-0.37],KC6,Malaria,malaria,GCST010725,18:41548233,Immune
1077,KC6,KC6,N/a,rs16974953-<b>?</b>,3 x 10-6,(additive),'-,'-,0.248 unit decrease,[0.14-0.35],KC6,Malaria,malaria,GCST010725,18:41548233,Immune
1078,KC6,KC6,N/a,rs16974953-<b>?</b>,3 x 10-6,(dominant),'-,'-,0.263 unit decrease,[NR],KC6,Malaria,malaria,GCST010725,18:41548233,Immune
1778,KDM4A-AS1,KDM4A-AS1,N/a,rs145155829-<b>C</b>,4 x 10-6,,'-,'-,0.2153 SD units increase,[0.12-0.31],"KDM4A-AS1, KDM4A",Monocyte chemoattractant protein-1 levels,CCL2 measurement,GCST004438,1:43699975,Immune
395,LINC00382,LINC00382,N/a,rs187319756-<b>?</b>,7 x 10-6,,NR,'-,0.1255 unit increase,[0.071-0.18],"LINC01038, LINC00382",Strep throat,susceptibility to strep throat measurement,GCST005007,13:79852507,Immune
376,LINC00578,LINC00578,N/a,rs12629106-<b>?</b>,4 x 10-6,(case-only),0.81,1.56,'-,[1.30-1.89],"LINC00501, LINC00578",Systemic lupus erythematosus,systemic lupus erythematosus,GCST000996,3:177377284,Immune
397,LINC02502,LINC02502,N/a,rs183838363-<b>?</b>,3 x 10-6,,NR,'-,0.5231 unit increase,[0.32-0.73],"MAD2L1, LINC02502",Tuberculosis,susceptibility to Mycobacterium tuberculosis infection measurement,GCST005006,4:120002322,Immune
1535,LINC02502,LINC02502,N/a,rs1845344-<b>T</b>,7 x 10-6,,0.27,'-,0.97 unit increase,[0.56-1.38],"LINC02502, MAD2L1",F-cell distribution in sickle cell anaemia,"fetal hemoglobin measurement, Sickle cell anemia",GCST000982,4:120041230,Immune
1694,NKPD1,NKPD1,N/a,rs10417602-<b>T</b>,2 x 10-15,,NR,'-,0.0354 unit decrease,[0.027-0.044],"MARK4, NKPD1",C-reactive protein levels,C-reactive protein measurement,GCST90019499,19:45157381,Immune
613,NONOP2,NONOP2,N/a,rs13017599-<b>A</b>,2 x 10-12,,0.34,1.21,'-,[1.15-1.28],NONOP2,Rheumatoid arthritis,rheumatoid arthritis,GCST000420,2:60937196,Immune
1776,NONOP2,NONOP2,N/a,rs6726160-<b>?</b>,2 x 10-8,,NR,'-,0.1045 unit decrease,'-,NONOP2,Celiac disease,celiac disease,GCST008489,2:60937594,Immune
2070,NONOP2,NONOP2,N/a,rs67766926-<b>?</b>,7 x 10-9,(Shared),NR,'-,'-,'-,"NONOP2, REL",Inflammatory skin disease,"atopic eczema, psoriasis",GCST002740,2:60936446,Immune
364,OR51B5,OR51B5,N/a,rs10838094-<b>A</b>,7 x 10-12,,0.4106,0.2761,'-,[-0.11649-0.66869],"HBG2, OR51B5, OR51Q1, HBE1",Systemic mastocytosis,systemic mastocytosis,GCST011382,11:5422663,Immune
1072,OR51B5,OR51B5,N/a,rs10838094-<b>A</b>,8 x 10-35,,0.4106,0.2071,'-,[-0.06848-0.48268],"HBG2, OR51B5, OR51Q1, HBE1",Mastocytosis,Mastocytosis,GCST011383,11:5422663,Immune
1075,OR51B5,OR51B5,N/a,rs372091-<b>C</b>,6 x 10-14,,0.972,2.17,'-,[NR],"HBE1, OR51B5, HBG2",Malaria,malaria,GCST001637,11:5496926,Immune
1285,PDGFD,PDGFD,N/a,rs12420286-<b>C</b>,2 x 10-6,,'-,'-,0.2376 SD units decrease,[0.14-0.34],"PDGFD, MIR4693",Interferon gamma levels,interferon gamma measurement,GCST004456,11:103907166,Immune
943,PHF2,PHF2,N/a,rs10761256-<b>G</b>,2 x 10-6,,NR,'-,0.0181507 unit decrease,[0.011-0.026],PHF2,Itch intensity from mosquito bite adjusted by bite size,"mosquito bite reaction itch intensity measurement, mosquito bite reaction size measurement",GCST004865,9:93684413,Immune
944,PHF2,PHF2,N/a,rs4287000-<b>G</b>,3 x 10-6,(women),NR,'-,0.0210734 unit decrease,[0.012-0.03],PHF2,Itch intensity from mosquito bite adjusted by bite size,"mosquito bite reaction itch intensity measurement, mosquito bite reaction size measurement",GCST004862,9:93689502,Immune
758,PSMG4,PSMG4,N/a,rs4305775-<b>?</b>,2 x 10-7,,0.714,1.25,'-,[1.14-1.35],"PSMG4, SLC22A23",Primary biliary cholangitis,primary biliary cirrhosis,GCST004302,6:3296763,Immune
1753,PSMG4,PSMG4,N/a,rs9385905-<b>?</b>,2 x 10-6,,'-,'-,'-,'-,"MCHR2, PSMG4",Clostridium difficile infection in multiple myeloma,"clostridium difficile infection, multiple myeloma",GCST005686,6:99843632,Immune
1693,RBM25,RBM25,N/a,rs8009347-<b>T</b>,5 x 10-20,,0.533507,'-,0.0190765 unit decrease,[0.015-0.023],RBM25,C-reactive protein levels,C-reactive protein measurement,GCST009777,14:73092858,Immune
394,RN7SL824P,RN7SL824P,N/a,rs6662618-<b>?</b>,1 x 10-7,,NR,1.14,'-,[1.08-1.21],"RN7SL824P, GFI1",Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,1:92469854,Immune
935,RN7SL824P,RN7SL824P,N/a,rs6662618-<b>?</b>,3 x 10-10,,NR,'-,'-,[1.0965-1.1754],"RN7SL824P, GFI1",Multiple sclerosis and type 2 diabetes (pleiotropy),"multiple sclerosis, type II diabetes mellitus",GCST007120,1:92469854,Immune
1284,ROR1,ROR1,N/a,rs200046222-<b>C</b>,9 x 10-6,,'-,'-,0.0795 SD units decrease,[0.044-0.115],ROR1,Interleukin-10 levels,interleukin 10 measurement,GCST004444,1:63792778,Immune
963,SLC16A1,SLC16A1,N/a,rs147836155-<b>T</b>,2 x 10-6,,0.0129,'-,0.1346 unit increase,NR,SLC16A1-AS1,Proportion of activated microglia (inferior temporal cortex),microglial activation measurement,GCST010916,1:112958985,Immune
965,SLC16A1,SLC16A1-AS1,N/a,rs147836155-<b>T</b>,2 x 10-6,,0.0129,'-,0.1346 unit increase,NR,SLC16A1-AS1,Proportion of activated microglia (inferior temporal cortex),microglial activation measurement,GCST010916,1:112958985,Immune
945,SLC22A4,SLC22A4,N/a,rs35260072-<b>C</b>,8 x 10-38,,NR,'-,0.0482062 unit increase,[0.041-0.056],"SLC22A4, P4HA2",Itch intensity from mosquito bite,mosquito bite reaction itch intensity measurement,GCST004861,5:132295159,Immune
1336,SLC22A4,SLC22A4,N/a,rs56399423-<b>?</b>,4 x 10-43,(EA),NR,'-,'-,'-,"SLC22A4, MIR3936HG",Inflammatory bowel disease,inflammatory bowel disease,GCST003043,5:132336964,Immune
553,SPTBN4,SPTBN4,N/a,rs6508941-<b>T</b>,8 x 10-7,(Influenza A),0.217,'-,0.26 unit increase,[NR],SPTBN4,Antibody level in response to infection,"seropositivity measurement, Influenza A seropositivity",GCST002804,19:40510058,Immune
389,SSBP4,SSBP4,N/a,rs11673604-<b>T</b>,4 x 10-12,,0.759,1.144,'-,[1.11-1.18],SSBP4,Systemic lupus erythematosus,systemic lupus erythematosus,GCST011956,19:18430178,Immune
390,SSBP4,SSBP4,N/a,rs13344313-<b>?</b>,1 x 10-8,,NR,1.1111112,'-,[1.08-1.16],"SSBP4, LRRC25",Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,19:18406957,Immune
391,SSBP4,SSBP4,N/a,rs12971295-<b>?</b>,7 x 10-7,,NR,1.1363636,'-,[1.08-1.19],"LRRC25, SSBP4",Systemic lupus erythematosus,systemic lupus erythematosus,GCST007400,19:18406521,Immune
392,SSBP4,SSBP4,N/a,rs13344313-<b>A</b>,2 x 10-6,,NR,0.862,'-,[0.8-0.92],"SSBP4, LRRC25",Systemic lupus erythematosus,systemic lupus erythematosus,GCST011097,19:18406957,Immune
393,SSBP4,SSBP4,N/a,rs13344313-<b>A</b>,1 x 10-10,,NR,0.86,'-,[0.81-0.91],"SSBP4, LRRC25",Systemic lupus erythematosus,systemic lupus erythematosus,GCST011096,19:18406957,Immune
946,SSBP4,SSBP4,N/a,rs1985157-<b>T</b>,4 x 10-7,,NR,'-,0.0193726 unit decrease,[0.012-0.027],"SSBP4, LRRC25",Itch intensity from mosquito bite,mosquito bite reaction itch intensity measurement,GCST004861,19:18402784,Immune
1692,SSBP4,SSBP4,N/a,rs1985157-<b>T</b>,1 x 10-15,,0.58735,'-,0.0166675 unit decrease,[0.013-0.021],"SSBP4, LRRC25",C-reactive protein levels,C-reactive protein measurement,GCST009777,19:18402784,Immune
1283,TAF1A-AS1,TAF1A-AS1,N/a,rs3002131-<b>G</b>,5 x 10-6,,'-,'-,0.1182 SD units decrease,[0.067-0.169],"TAF1A-AS1, MIA3",Interleukin-10 levels,interleukin 10 measurement,GCST004444,1:222602315,Immune
1418,TCF19,TCF19,N/a,rs1419881-<b>?</b>,1 x 10-18,,NR,1.37,'-,[1.23-1.52],TCF19,Chronic hepatitis B infection,hepatitis B virus infection,GCST002068,6:31162816,Immune
1770,TCF19,TCF19,N/a,rs1419881-<b>G</b>,3 x 10-7,,0.55,1.12,'-,[1.08-1.18],TCF19,Chronic hepatitis B infection,chronic hepatitis B virus infection,GCST002879,6:31162816,Immune
549,TF,TF,N/a,rs72382362-<b>T</b>,1 x 10-10,,NR,'-,0.0163 unit decrease,[0.011-0.021],TF,Serum albumin level,serum albumin measurement,GCST90019493,3:133773486,Immune
2067,TGM3,TGM3,N/a,rs1012621-<b>?</b>,5 x 10-6,(Shared),NR,'-,'-,'-,TGM3,Inflammatory skin disease,"atopic eczema, psoriasis",GCST002740,20:2325666,Immune
352,TNIP1,TNIP1,N/a,rs960709-<b>?</b>,2 x 10-8,,NR,1.212,'-,[NR],TNIP1,Systemic lupus erythematosus and Systemic sclerosis,"systemic scleroderma, systemic lupus erythematosus",GCST002069,5:151081488,Immune
354,TNIP1,TNIP1,N/a,rs4958880-<b>A</b>,1 x 10-11,,NR,1.16,'-,[1.10-1.22],TNIP1,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies),"systemic scleroderma, rheumatoid arthritis, myositis, systemic lupus erythematosus",GCST007278,5:151058916,Immune
356,TNIP1,TNIP1,N/a,rs10463312-<b>?</b>,5 x 10-6,(EA),NR,'-,'-,'-,TNIP1,Systemic sclerosis,systemic scleroderma,GCST005554,5:151031333,Immune
358,TNIP1,TNIP1,N/a,rs1422673-<b>T</b>,1 x 10-8,,0.194,1.2280027,'-,'-,TNIP1,Systemic sclerosis,systemic scleroderma,GCST009876,5:151059427,Immune
360,TNIP1,TNIP1,N/a,rs3792783-<b>G</b>,2 x 10-12,,0.16,1.2,'-,'-,TNIP1,Systemic sclerosis,systemic scleroderma,GCST009131,5:151076171,Immune
362,TNIP1,TNIP1,N/a,rs2233287-<b>A</b>,5 x 10-9,,0.1,1.31,'-,[1.15-1.43],TNIP1,Systemic sclerosis,systemic scleroderma,GCST001146,5:151060536,Immune
377,TNIP1,TNIP1,N/a,rs6889239-<b>C</b>,4 x 10-24,,'-,1.33,'-,[NR],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003156,5:151078210,Immune
378,TNIP1,TNIP1,N/a,rs10036748-<b>T</b>,1 x 10-45,,'-,1.38,'-,[1.32–1.45],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003155,5:151078585,Immune
379,TNIP1,TNIP1,N/a,rs10036748-<b>?</b>,2 x 10-34,,NR,1.27,'-,[1.22-1.33],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,5:151078585,Immune
380,TNIP1,TNIP1,N/a,rs7708392-<b>?</b>,5 x 10-9,(Hispanic),NR,1.31,'-,[1.20-1.44],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,5:151077924,Immune
381,TNIP1,TNIP1,N/a,rs10057690-<b>?</b>,3 x 10-6,(AA),NR,1.2,'-,[1.11-1.30],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,5:151065654,Immune
382,TNIP1,TNIP1,N/a,rs10036748-<b>T</b>,6 x 10-26,,0.76,1.194,'-,[1.16-1.23],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST011956,5:151078585,Immune
383,TNIP1,TNIP1,N/a,rs7708392-<b>C</b>,4 x 10-13,,0.24,1.27,'-,[1.10–1.35],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST004867,5:151077924,Immune
384,TNIP1,TNIP1,N/a,rs7708392-<b>C</b>,2 x 10-11,,0.499,1.76,'-,[1.50-2.07],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003252,5:151077924,Immune
385,TNIP1,TNIP1,N/a,rs6889239-<b>?</b>,2 x 10-18,(EA),0.251,1.32,'-,[NR],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003622,5:151078210,Immune
386,TNIP1,TNIP1,N/a,rs6889239-<b>?</b>,3 x 10-6,(Chinese),0.743,1.28,'-,[NR],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003622,5:151078210,Immune
387,TNIP1,TNIP1,N/a,rs10036748-<b>T</b>,3 x 10-6,,0.74,1.25,'-,'-,TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST001795,5:151078585,Immune
388,TNIP1,TNIP1,N/a,rs10036748-<b>A</b>,2 x 10-9,,0.76,1.23,'-,[1.15-1.33],TNIP1,Systemic lupus erythematosus,systemic lupus erythematosus,GCST000507,5:151078585,Immune
491,TNIP1,TNIP1,N/a,rs6579837-<b>T</b>,3 x 10-8,,0.09,1.43,'-,[1.20–1.71],TNIP1,Sjögren's syndrome,Sjogren syndrome,GCST004878,5:151055333,Immune
609,TNIP1,TNIP1,N/a,rs6579837-<b>A</b>,2 x 10-6,,NR,1.2062,'-,'-,TNIP1,Rheumatoid arthritis (ACPA-positive),rheumatoid arthritis,GCST005568,5:151055333,Immune
611,TNIP1,TNIP1,N/a,rs1422673-<b>T</b>,2 x 10-6,,0.198,1.0997517,'-,'-,TNIP1,Rheumatoid arthritis,rheumatoid arthritis,GCST009877,5:151059427,Immune
732,TNIP1,TNIP1,N/a,rs2233278-<b>C</b>,4 x 10-10,,0.09,1.96,'-,[1.59-2.41],TNIP1,Psoriasis vulgaris,psoriasis vulgaris,GCST006036,5:151087628,Immune
734,TNIP1,TNIP1,N/a,rs2233278-<b>C</b>,4 x 10-37,,NR,1.658,'-,NR,TNIP1,Psoriasis vulgaris,psoriasis vulgaris,GCST003268,5:151087628,Immune
740,TNIP1,TNIP1,N/a,rs2233278-<b>C</b>,2 x 10-42,,0.058,1.59,'-,'-,TNIP1,Psoriasis,psoriasis,GCST005527,5:151087628,Immune
742,TNIP1,TNIP1,N/a,rs10036748-<b>?</b>,4 x 10-9,,'-,1.1,'-,1.06-1.13,TNIP1,Psoriasis,psoriasis,GCST008479,5:151078585,Immune
744,TNIP1,TNIP1,N/a,rs2233278-<b>A</b>,1 x 10-18,,NR,1.647,'-,[1.557-1.743],TNIP1,Psoriasis,psoriasis,GCST002738,5:151087628,Immune
1338,TNIP1,TNIP1,N/a,rs4958881-<b>G</b>,3 x 10-10,,0.09,1.73,'-,[1.46-2.06],TNIP1,Myasthenia gravis,immune system disease,GCST001611,5:151070675,Immune
1690,TNIP1,TNIP1,N/a,rs12516176-<b>T</b>,3 x 10-11,,0.72613,'-,0.015154 unit decrease,[0.011-0.02],TNIP1,C-reactive protein levels,C-reactive protein measurement,GCST009777,5:151056084,Immune
1691,TNIP1,TNIP1,N/a,rs2233278-<b>G</b>,1 x 10-8,,0.945324,'-,0.0270159 unit decrease,[0.018-0.036],TNIP1,C-reactive protein levels,C-reactive protein measurement,GCST009777,5:151087628,Immune
2061,TNIP1,TNIP1,N/a,rs1422673-<b>T</b>,2 x 10-9,,NA,'-,'-,'-,TNIP1,Autoimmune traits (pleiotropy),autoimmune disease,GCST009873,5:151059427,Immune
2131,TNIP1,TNIP1,N/a,rs74817271-<b>?</b>,2 x 10-26,(subset analysis),NR,'-,'-,'-,TNIP1,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,5:151090412,Immune
942,TNNI3K,TNNI3K,N/a,rs140656307-<b>T</b>,5 x 10-7,(men),0,'-,3.19603 unit increase,[1.95-4.44],"TNNI3K, ERICH3",Itch intensity from mosquito bite adjusted by bite size,"mosquito bite reaction itch intensity measurement, mosquito bite reaction size measurement",GCST004862,1:74547740,Immune
1768,ADH1A,ADH1A,N/a,rs28364331-<b>G</b>,1 x 10-21,(gluconate),0.02,'-,0.811 unit decrease,[0.64-0.98],ADH1A,Urinary metabolite levels in chronic kidney disease,"chronic kidney disease, urinary metabolite measurement",GCST009733,4:99280138,Kidney
1520,DNAJC9,DNAJC9,N/a,rs12240572-<b>A</b>,1 x 10-11,,0.1671,'-,0.0032 unit decrease,[0.002-0.0044],"CFAP70, DNAJC9-AS1",Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,10:73256607,Kidney
1521,DNAJC9,DNAJC9-AS1,N/a,rs12240572-<b>A</b>,1 x 10-11,,0.1671,'-,0.0032 unit decrease,[0.002-0.0044],"CFAP70, DNAJC9-AS1",Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,10:73256607,Kidney
1522,DNAJC9,DNAJC9-AS1,N/a,rs12240572-<b>A</b>,1 x 10-11,,0.1671,'-,0.0032 unit decrease,[0.002-0.0044],"CFAP70, DNAJC9-AS1",Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,10:73256607,Kidney
1519,DNM3,DNM3,N/a,rs1011731-<b>A</b>,1 x 10-9,,0.5961,'-,0.0019 unit decrease,[0.0013-0.0025],"DNM3, PIGC",Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,1:172377408,Kidney
1671,GUCY1A1,GUCY1A1,N/a,rs10019835-<b>?</b>,5 x 10-7,"(American Indian, additive )",0.63,1.4285715,'-,'-,GUCY1A1,Diabetic kidney disease,diabetic nephropathy,GCST003098,4:155712034,Kidney
50,PPM1K,PPM1K,N/a,rs13120254-<b>A</b>,9 x 10-15,,0.5953,'-,0.138 unit increase,[0.1-0.17],"PPM1K, ABCG2",Serum uric acid levels,uric acid measurement,GCST010512,4:88239409,Kidney
54,PPM1K,PPM1K,N/a,rs74962708-<b>T</b>,3 x 10-12,,NR,'-,0.074 unit increase,[0.053-0.095],"PPM1K, PPM1K-DT",Urate levels,urate measurement,GCST90019524,4:88284508,Kidney
57,PPM1K,PPM1K,N/a,rs28793136-<b>C</b>,6 x 10-55,,NR,'-,0.0707 unit increase,[0.062-0.08],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88295616,Kidney
60,PPM1K,PPM1K,N/a,rs4693211-<b>C</b>,1 x 10-82,,NR,'-,0.0941 unit increase,[0.084-0.104],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88327909,Kidney
63,PPM1K,PPM1K-DT,N/a,rs28793136-<b>C</b>,6 x 10-55,,NR,'-,0.0707 unit increase,[0.062-0.08],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88295616,Kidney
66,PPM1K,PPM1K-DT,N/a,rs4693211-<b>C</b>,1 x 10-82,,NR,'-,0.0941 unit increase,[0.084-0.104],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88327909,Kidney
69,PPM1K,PPM1K-DT,N/a,rs74962708-<b>T</b>,3 x 10-12,,NR,'-,0.074 unit increase,[0.053-0.095],"PPM1K, PPM1K-DT",Urate levels,urate measurement,GCST90019524,4:88284508,Kidney
124,PROM1,PROM1,N/a,rs317865-<b>G</b>,2 x 10-6,,0.12,1.37,'-,[1.19-1.57],"PROM1, TAPT1",Kidney disease (early stage) in type 1 diabetes,"type 1 diabetes nephropathy, chronic kidney disease",GCST003865,4:16155043,Kidney
1515,PROM1,PROM1,N/a,rs894638-<b>C</b>,8 x 10-6,(EA),0.19,'-,0.1 unit decrease,[0.061-0.139],"PROM1, TAPT1",Glomerular filtration rate in chronic kidney disease,"glomerular filtration rate, chronic kidney disease",GCST003139,4:16118049,Kidney
72,RCN2,RCN2,N/a,rs932046-<b>T</b>,5 x 10-11,,NR,'-,0.056 unit increase,[0.039-0.073],"RN7SL278P, RCN2",Urate levels,urate measurement,GCST90019524,15:76955213,Kidney
506,RCN2,RCN2,N/a,rs932046-<b>T</b>,7 x 10-12,,NR,'-,0.0584 unit increase,[0.042-0.075],"RN7SL278P, RCN2",Urea levels,serum urea measurement,GCST90019525,15:76955213,Kidney
1518,RCN2,RCN2,N/a,rs932046-<b>T</b>,4 x 10-14,,NR,'-,0.0643 unit decrease,[0.048-0.081],"RN7SL278P, RCN2",Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,15:76955213,Kidney
1675,RCN2,RCN2,N/a,rs932046-<b>T</b>,5 x 10-10,,NR,'-,0.053 unit increase,[0.036-0.07],"RN7SL278P, RCN2",Cystatin C levels,cystatin C measurement,GCST90019504,15:76955213,Kidney
1689,RCN2,RCN2,N/a,rs932046-<b>T</b>,4 x 10-15,,NR,'-,0.0669 unit increase,[0.05-0.084],"RN7SL278P, RCN2",Creatinine levels,creatinine measurement,GCST90019502,15:76955213,Kidney
1516,SLC22A4,SLC22A4,N/a,rs419291-<b>T</b>,2 x 10-9,,0.3876,'-,0.0021 unit increase,[0.0013-0.0029],SLC22A4,Estimated glomerular filtration rate,glomerular filtration rate,GCST008059,5:132297662,Kidney
1517,SLC22A4,SLC22A4,N/a,rs12777-<b>C</b>,9 x 10-11,,0.9586,'-,0.005 unit increase,[0.0032-0.0068],"MIR3936HG, SLC22A4",Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,5:132335969,Kidney
749,ADH1A,ADH1A,N/a,rs17583844-<b>A</b>,6 x 10-9,(SERPINC1),0.3171,'-,0.003173 unit decrease,NR,"ADH1A, ADH6",Protein quantitative trait loci (liver),protein measurement,GCST011427,4:99265066,Liver
1235,APOB,APOB,N/a,rs62122515-<b>?</b>,8 x 10-9,,0.3534,'-,0.002857 unit decrease,'-,"APOB, TDRD15",Forns index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011734,2:21072355,Liver
2164,APOB,APOB,N/a,rs661665-<b>A</b>,3 x 10-11,,0.5,'-,6.64 z-score increase,'-,APOB,Serum alkaline phosphatase levels,alkaline phosphatase measurement,GCST90011900,2:21042269,Liver
552,CHL1,CHL1,N/a,rs892295-<b>A</b>,4 x 10-6,(ALT ),0.033,'-,0.03 U/L increase,[NR],CHL1,Obesity-related traits,serum alanine aminotransferase measurement,GCST001762,3:355870,Liver
747,CHL1,CHL1,N/a,rs17032691-<b>G</b>,3 x 10-8,(CPQ),0.01045,'-,0.0322 unit increase,NR,CHL1-AS2,Protein quantitative trait loci (liver),protein measurement,GCST011427,3:115016,Liver
748,CHL1,CHL1-AS2,N/a,rs17032691-<b>G</b>,3 x 10-8,(CPQ),0.01045,'-,0.0322 unit increase,NR,CHL1-AS2,Protein quantitative trait loci (liver),protein measurement,GCST011427,3:115016,Liver
2083,CHL1,CHL1,N/a,rs892295-<b>A</b>,1 x 10-6,(ALT/AST),0.033,'-,0.03 unit increase,[NR],CHL1,Obesity-related traits,"aspartate aminotransferase measurement, serum alanine aminotransferase measurement",GCST001762,3:355870,Liver
2165,COL4A2-AS2,COL4A2-AS2,N/a,rs9521787-<b>C</b>,2 x 10-17,,0.39,'-,8.5 z-score increase,'-,"COL4A2, COL4A2-AS2",Serum alkaline phosphatase levels,alkaline phosphatase measurement,GCST90011900,13:110463211,Liver
1236,DNM3,DNM3,N/a,rs2038479-<b>?</b>,5 x 10-9,,0.195,'-,0.003542 unit decrease,'-,DNM3,Forns index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011734,1:171970150,Liver
1237,DNM3,DNM3,N/a,rs6425521-<b>?</b>,7 x 10-9,,0.1966,'-,0.00348 unit decrease,'-,DNM3,Forns index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011734,1:171973643,Liver
1238,DNM3,DNM3,N/a,rs6425521-<b>?</b>,3 x 10-8,,0.1966,'-,0.007861 unit decrease,'-,DNM3,Fibrosis-4 index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011736,1:171973643,Liver
1239,DNM3,DNM3,N/a,rs2038479-<b>?</b>,5 x 10-8,,0.195,'-,0.007745 unit decrease,'-,DNM3,Fibrosis-4 index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011736,1:171970150,Liver
1240,DNM3,DNM3,N/a,rs6425521-<b>?</b>,8 x 10-7,,0.1966,'-,0.008611 unit decrease,'-,DNM3,Aspartate aminotransferase platelet ratio index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011735,1:171973643,Liver
1241,DNM3,DNM3,N/a,rs2038479-<b>?</b>,2 x 10-6,,0.195,'-,0.00838 unit decrease,'-,DNM3,Aspartate aminotransferase platelet ratio index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011735,1:171970150,Liver
2082,DNM3,DNM3,N/a,rs547043321-<b>AAAG</b>,3 x 10-9,,NR,'-,0.0144 unit increase,[0.0097-0.0191],"PIGC, DNM3",Aspartate aminotransferase to alanine aminotransferase ratio,aspartate aminotransferase to alanine aminotransferase ratio,GCST90019498,1:172393605,Liver
550,FCGR2A,FCGR2A,N/a,rs114414096-<b>A</b>,8 x 10-10,,NR,'-,0.0263 unit decrease,[0.018-0.035],FCGR2A,Serum albumin level,serum albumin measurement,GCST90019493,1:161521553,Liver
2085,FCGR2A,FCGR2A,N/a,rs114414096-<b>A</b>,4 x 10-13,,NR,'-,0.0298 unit decrease,[0.022-0.038],FCGR2A,Aspartate aminotransferase levels,aspartate aminotransferase measurement,GCST90019497,1:161521553,Liver
754,FGF12,FGF12,N/a,rs79765582-<b>G</b>,3 x 10-8,(PYCARD),0.01742,'-,0.02018 unit increase,NR,FGF12,Protein quantitative trait loci (liver),protein measurement,GCST011427,3:192474445,Liver
755,FGF12,FGF12,N/a,rs79765582-<b>G</b>,1 x 10-8,(ARHGDIA),0.01742,'-,0.1047 unit increase,NR,FGF12,Protein quantitative trait loci (liver),protein measurement,GCST011427,3:192474445,Liver
880,HS3ST1,HS3ST1,N/a,rs1390096-<b>A</b>,3 x 10-6,,0.372,1.44,'-,[1.24-1.68],"NAA15, HS3ST1",Nonalcoholic fatty liver disease,non-alcoholic fatty liver disease,GCST001576,4:11501980,Liver
543,MYO1B,MYO1B,N/a,rs11681777-<b>?</b>,4 x 10-17,,'-,'-,0.0347 unit increase,[0.027-0.043],MYO1B,Gamma glutamyl transferase levels,serum gamma-glutamyl transferase measurement,GCST011349,2:191256741,Liver
544,MYO1B,MYO1B,N/a,rs35530564-<b>T</b>,5 x 10-87,,0.67649,'-,0.0106301 unit decrease,[0.0096-0.0117],MYO1B,Liver enzyme levels (gamma-glutamyl transferase),serum gamma-glutamyl transferase measurement,GCST90013407,2:191247324,Liver
545,MYO1B,MYO1B,N/a,rs7579443-<b>?</b>,3 x 10-16,,NR,'-,0.03607 unit decrease,[0.027-0.045],"HMGB1P27, MYO1B",Gamma glutamyl transferase levels,serum gamma-glutamyl transferase measurement,GCST006019,2:191192680,Liver
546,MYO1B,MYO1B,N/a,rs115860688-<b>G</b>,2 x 10-9,,NR,'-,0.047 unit increase,[0.032-0.062],"MYO1B, HMGB1P27",Gamma glutamyl transferase levels,serum gamma-glutamyl transferase measurement,GCST90019507,2:191231770,Liver
547,MYO1B,MYO1B,N/a,rs13030978-<b>T</b>,1 x 10-11,,0.32,'-,3.7 % increase,[2.80-4.6],MYO1B,Liver enzyme levels (gamma-glutamyl transferase),serum gamma-glutamyl transferase measurement,GCST001277,2:191252512,Liver
2162,MYO1B,MYO1B,N/a,rs13013390-<b>A</b>,5 x 10-22,,0.670529,'-,0.0023429 unit decrease,[0.0019-0.0028],MYO1B,Liver enzyme levels (alkaline phosphatase),alkaline phosphatase measurement,GCST90013406,2:191262001,Liver
2163,MYO1B,MYO1B,N/a,rs13019004-<b>T</b>,1 x 10-15,,0.32,'-,8.02 z-score increase,'-,MYO1B,Serum alkaline phosphatase levels,alkaline phosphatase measurement,GCST90011900,2:191245493,Liver
1644,OR5H8,OR5H8,N/a,rs1497546-<b>?</b>,2 x 10-7,,0.02,6.57,'-,[NR],"OR5K4, OR5H8",Drug-induced liver injury (flucloxacillin),drug-induced liver injury,GCST000415,3:98315682,Liver
49,PPM1K,PPM1K,N/a,rs13120254-<b>A</b>,9 x 10-15,,0.5953,'-,0.138 unit increase,[0.1-0.17],"PPM1K, ABCG2",Serum uric acid levels,uric acid measurement,GCST010512,4:88239409,Liver
750,PROM1,PROM1,N/a,rs10006258-<b>A</b>,1 x 10-8,(FERMT2),0.0122,'-,0.08025 unit increase,NR,"TAPT1, PROM1",Protein quantitative trait loci (liver),protein measurement,GCST011427,4:16116520,Liver
751,PSMC5,PSMC5,N/a,rs141975038-<b>G</b>,2 x 10-8,(TTN),0.01045,'-,1.085 unit increase,NR,"FTSJ3, PSMC5",Protein quantitative trait loci (liver),protein measurement,GCST011427,17:63827384,Liver
752,PSMC5,PSMC5,N/a,rs141975038-<b>G</b>,2 x 10-8,(APOC1),0.01045,'-,0.03345 unit increase,NR,"FTSJ3, PSMC5",Protein quantitative trait loci (liver),protein measurement,GCST011427,17:63827384,Liver
2030,PSMC5,PSMC5,N/a,rs13030-<b>T</b>,2 x 10-11,,NR,'-,0.017 unit decrease,[0.012-0.022],PSMC5,Total bilirubin levels,bilirubin measurement,GCST90019521,17:63831196,Liver
759,PSMG4,PSMG4,N/a,rs4305775-<b>?</b>,2 x 10-7,,0.714,1.25,'-,[1.14-1.35],"PSMG4, SLC22A23",Primary biliary cholangitis,primary biliary cirrhosis,GCST004302,6:3296763,Liver
756,RBM25,RBM25,N/a,rs1271276057-<b>AT</b>,9 x 10-9,(MYL6),0.0122,'-,0.09668 unit increase,NR,RBM25,Protein quantitative trait loci (liver),protein measurement,GCST011427,14:73061535,Liver
753,RPS3AP5,RPS3AP5,N/a,rs77188389-<b>G</b>,1 x 10-8,(F2),0.01045,'-,0.04489 unit increase,NR,RPS3AP5,Protein quantitative trait loci (liver),protein measurement,GCST011427,10:84654691,Liver
1528,SLC22A4,SLC22A4,N/a,rs12777-<b>G</b>,9 x 10-27,,0.044,'-,0.024 unit increase,NR,"MIR3936HG, SLC22A4",Fibrinogen levels,fibrinogen measurement,GCST003194,5:132335969,Liver
1529,SLC22A4,SLC22A4,N/a,rs10479002-<b>C</b>,1 x 10-6,,0.04,'-,9.51 mg/dl increase,[NR],"MIR3936HG, SLC22A4",Fibrinogen,fibrinogen measurement,GCST000368,5:132335969,Liver
548,TF,TF,N/a,rs72382362-<b>T</b>,1 x 10-10,,NR,'-,0.0163 unit decrease,[0.011-0.021],TF,Serum albumin level,serum albumin measurement,GCST90019493,3:133773486,Liver
2166,TNIP1,TNIP1,N/a,rs3792784-<b>A</b>,1 x 10-8,,0.9,'-,5.73 z-score increase,'-,TNIP1,Serum alkaline phosphatase levels,alkaline phosphatase measurement,GCST90011900,5:151076111,Liver
2084,TUBB4BP4,TUBB4BP4,N/a,rs113034494-<b>?</b>,3 x 10-6,,NR,'-,0.0882 unit increase,[0.052-0.125],TUBB4BP4,Aspartate aminotransferase levels in low alcohol consumption,"aspartate aminotransferase measurement, alcohol consumption measurement",GCST007378,11:91952037,Liver
757,WDR86,WDR86,N/a,rs10235381-<b>C</b>,5 x 10-9,(TXNL1),0.0122,'-,0.06755 unit increase,NR,WDR86,Protein quantitative trait loci (liver),protein measurement,GCST011427,7:151402142,Liver
1227,LINC02414,LINC02414,N/a,rs7315621-<b>?</b>,1 x 10-6,(less than or equal to),NR,'-,'-,'-,LINC02414,Longevity,longevity,GCST000785,12:131600651,Longevity
1226,SLC38A10,SLC38A10,N/a,rs10445407-<b>?</b>,1 x 10-6,(less than or equal to),NR,'-,'-,'-,SLC38A10,Longevity,longevity,GCST000785,17:81288009,Longevity
851,TNNI3K,TNNI3K,N/a,rs146254978-<b>T</b>,5 x 10-8,,0.98,'-,0.0692 unit decrease,[0.045-0.094],"TNNI3K, FPGT-TNNI3K",Parental longevity (combined parental age at death),parental longevity,GCST006702,1:74402115,Longevity
852,TNNI3K,FPGT-TNNI3K,N/a,rs146254978-<b>T</b>,5 x 10-8,,0.98,'-,0.0692 unit decrease,[0.045-0.094],"TNNI3K, FPGT-TNNI3K",Parental longevity (combined parental age at death),parental longevity,GCST006702,1:74402115,Longevity
637,CHRNA1,CHRNA1,N/a,rs77530448-<b>G</b>,7 x 10-8,,0.09,'-,0.36 unit increase,[0.23-0.49],"CHRNA1, H3P6",Response to radiotherapy in prostate cancer (overall toxicity),"response to radiation, prostate carcinoma",GCST003583,2:174729547,Male reproductive system
326,DNM3,DNM3,N/a,rs12125882-<b>A</b>,4 x 10-8,,0.579284,'-,0.0168277 unit increase,[0.011-0.023],DNM3,Total testosterone levels,testosterone measurement,GCST90012113,1:172172263,Male reproductive system
327,DNM3,DNM3,N/a,rs733190-<b>T</b>,2 x 10-9,,0.525563,'-,0.00773479 unit increase,[0.0052-0.0103],DNM3,Total testosterone levels,testosterone measurement,GCST90012114,1:172126086,Male reproductive system
723,IL20RB,IL20RB,N/a,rs835648-<b>A</b>,5 x 10-10,,NR,'-,0.021898791 years increase,[0.015-0.029],IL20RB,Male puberty timing (age at voice breaking MTAG),puberty onset measurement,GCST90012088,3:136952662,Male reproductive system
635,LINC00578,LINC00578,N/a,rs6791846-<b>?</b>,5 x 10-7,,0.45,1.47,'-,[1.26-1.71],"LINC00578, LINC00501",Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event),"response to radiation, prostate carcinoma, Abnormality of the urinary system",GCST008382,3:177401529,Male reproductive system
719,TNNI3K,TNNI3K,N/a,rs1514177-<b>G</b>,2 x 10-6,,NR,'-,0.00328093 years decrease,[0.0019-0.0047],"TNNI3K, FPGT-TNNI3K",Male puberty timing (early vs. average onset voice breaking),puberty onset measurement,GCST90012086,1:74525718,Male reproductive system
720,TNNI3K,TNNI3K,N/a,rs1514177-<b>G</b>,6 x 10-11,,NR,'-,0.021518093 years increase,[0.015-0.028],"TNNI3K, FPGT-TNNI3K",Male puberty timing (age at voice breaking MTAG),puberty onset measurement,GCST90012088,1:74525718,Male reproductive system
721,TNNI3K,FPGT-TNNI3K,N/a,rs1514177-<b>G</b>,2 x 10-6,,NR,'-,0.00328093 years decrease,[0.0019-0.0047],"TNNI3K, FPGT-TNNI3K",Male puberty timing (early vs. average onset voice breaking),puberty onset measurement,GCST90012086,1:74525718,Male reproductive system
722,TNNI3K,FPGT-TNNI3K,N/a,rs1514177-<b>G</b>,6 x 10-11,,NR,'-,0.021518093 years increase,[0.015-0.028],"TNNI3K, FPGT-TNNI3K",Male puberty timing (age at voice breaking MTAG),puberty onset measurement,GCST90012088,1:74525718,Male reproductive system
77,ADH1A,ADH1A,N/a,rs543964416-<b>AA</b>,7 x 10-6,,0.258,'-,0.404 unit decrease,[0.23-0.58],"ADH1B, ADH1A",Major depression and alcohol dependence,"unipolar depression, alcohol dependence",GCST005022,4:99302636,Mental or Behavioural Disorder
1318,ADH1A,ADH1A,N/a,rs111858442-<b>G</b>,4 x 10-7,,NR,2.2727273,'-,'-,"ADH1A, RNU6-578P",Insomnia,insomnia,GCST005566,4:12350898,Mental or Behavioural Disorder
2169,ADH1A,ADH1A,N/a,rs150627184-<b>C</b>,7 x 10-21,(AA),0.809,'-,0.112 unit increase,[0.089-0.135],"ADH1A, ADH6",Alcohol use disorder (consumption score),"alcohol use disorder measurement, longitudinal alcohol consumption measurement",GCST008258,4:99242230,Mental or Behavioural Disorder
2176,ADH1A,ADH1A,N/a,rs904092-<b>?</b>,3 x 10-11,(AA),0.24,'-,0.022 unit decrease,NR,"ADH1B, ADH1A",Alcohol dependence,alcohol dependence measurement,GCST004711,4:99293007,Mental or Behavioural Disorder
2177,ADH1A,ADH1A,N/a,rs904092-<b>?</b>,9 x 10-6,,NR,'-,'-,'-,"ADH1B, ADH1A",Alcohol dependence,alcohol dependence measurement,GCST004711,4:99293007,Mental or Behavioural Disorder
2178,ADH1A,ADH1A,N/a,rs904092-<b>G</b>,5 x 10-9,(AA),0.763,1.3003901,'-,NR,"ADH1B, ADH1A",Alcohol dependence,alcohol dependence,GCST004712,4:99293007,Mental or Behavioural Disorder
2179,ADH1A,ADH1A,N/a,rs62307263-<b>T</b>,3 x 10-11,,0.1018,'-,0.0244556 unit decrease,[0.017-0.032],"ADH1A, ADH6",Alcohol consumption (drinks per week),alcohol consumption measurement,GCST007328,4:99245955,Mental or Behavioural Disorder
2180,ADH1A,ADH1A,N/a,rs12499107-<b>G</b>,4 x 10-9,"(Conditioned on chr4:100273594, chr4:99713350,chr4:101243023 ,chr4:100000136, chr4:100254520, chr4:100443853, chr4:100286085, chr4:100260679, chr4:100444363, chr4:100239319)",0.131202,'-,0.012661209 unit increase,[0.0084-0.0169],"ADH1A, BTF3P13",Alcohol consumption (drinks per week),alcohol consumption measurement,GCST007461,4:98757540,Mental or Behavioural Disorder
589,ALG1L13P,ALG1L13P,N/a,rs2945232-<b>C</b>,2 x 10-8,,NR,1.0638298,'-,[NR],"ALG1L13P, FAM86B3P",Schizophrenia,schizophrenia,GCST003048,8:8240516,Mental or Behavioural Disorder
899,ALG1L13P,ALG1L13P,N/a,rs2980439-<b>A</b>,7 x 10-28,,0.46895,'-,10.944 z score decrease,'-,"ALG1L13P, FAM86B3P",Neuroticism,neuroticism measurement,GCST005232,8:8237348,Mental or Behavioural Disorder
900,ALG1L13P,ALG1L13P,N/a,rs2945232-<b>C</b>,1 x 10-27,,0.465417481,'-,0.020243598 unit decrease,[0.017-0.024],"ALG1L13P, FAM86B3P",Neuroticism,neuroticism measurement,GCST007339,8:8240516,Mental or Behavioural Disorder
901,ALG1L13P,ALG1L13P,N/a,rs2945232-<b>T</b>,5 x 10-17,,NR,'-,0.014614 unit decrease,[0.011-0.018],"ALG1L13P, FAM86B3P",General factor of neuroticism,neuroticism measurement,GCST007709,8:8240516,Mental or Behavioural Disorder
427,AP1S1,AP1S1,N/a,rs13226049-<b>A</b>,8 x 10-10,,0.542,'-,0.00673551 unit decrease,[0.0046-0.0089],"SERPINE1, AP1S1",Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,7:101149581,Mental or Behavioural Disorder
2029,APOB,APOB,N/a,rs10198175-<b>?</b>,1 x 10-6,,NR,1.92,'-,[NR],"APOB, LINC02850",Binge eating behaviour and bipolar disorder,"binge eating, bipolar disorder",GCST002419,2:20934123,Mental or Behavioural Disorder
2148,APOB,APOB,N/a,rs2678379-<b>?</b>,1 x 10-19,,'-,'-,'-,'-,APOB,Alzheimer's disease or HDL levels (pleiotropy),"Alzheimer's disease, high density lipoprotein cholesterol measurement",GCST007827,2:21003688,Mental or Behavioural Disorder
665,ARHGAP24,ARHGAP24,N/a,rs115496994-<b>?</b>,7 x 10-6,,NR,'-,'-,'-,ARHGAP24,Initial alcohol sensitivity,response to alcohol,GCST006633,4:85432552,Mental or Behavioural Disorder
594,CHL1,CHL1,N/a,rs2063886-<b>A</b>,5 x 10-8,,0.308,'-,0.007 unit decrease,[0.0045-0.0095],CHL1-AS2,General risk tolerance (MTAG),risk-taking behaviour,GCST007325,3:181221,Mental or Behavioural Disorder
595,CHL1,CHL1,N/a,rs17328201-<b>T</b>,2 x 10-9,,0.812,'-,0.0091 unit decrease,[0.0062-0.012],CHL1-AS2,General risk tolerance (MTAG),risk-taking behaviour,GCST007325,3:174352,Mental or Behavioural Disorder
596,CHL1,CHL1-AS2,N/a,rs2063886-<b>A</b>,5 x 10-8,,0.308,'-,0.007 unit decrease,[0.0045-0.0095],CHL1-AS2,General risk tolerance (MTAG),risk-taking behaviour,GCST007325,3:181221,Mental or Behavioural Disorder
597,CHL1,CHL1-AS2,N/a,rs17328201-<b>T</b>,2 x 10-9,,0.812,'-,0.0091 unit decrease,[0.0062-0.012],CHL1-AS2,General risk tolerance (MTAG),risk-taking behaviour,GCST007325,3:174352,Mental or Behavioural Disorder
645,CHL1,CHL1,N/a,rs6795349-<b>G</b>,2 x 10-6,"(Citalopram+Buspirone, Dizziness)",0.03,'-,'-,'-,CHL1-AS2,Response to anti-depressant treatment in major depressive disorder,"response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,3:130794,Mental or Behavioural Disorder
647,CHL1,CHL1-AS2,N/a,rs6795349-<b>G</b>,2 x 10-6,"(Citalopram+Buspirone, Dizziness)",0.03,'-,'-,'-,CHL1-AS2,Response to anti-depressant treatment in major depressive disorder,"response to citalopram, antidepressant-induced dizziness, response to buspirone, response to antidepressant",GCST001308,3:130794,Mental or Behavioural Disorder
2167,CHL1,CHL1,N/a,rs991639-<b>A</b>,1 x 10-6,"(AA, initial)",0.13,'-,2.24 unit increase,[1.34-3.14],"CHL1-AS2, LINC01986",Problematic alcohol use in trauma-exposed individuals,"alcohol use disorder measurement, response to trauma exposure",GCST005236,3:47829,Mental or Behavioural Disorder
2168,CHL1,CHL1-AS2,N/a,rs991639-<b>A</b>,1 x 10-6,"(AA, initial)",0.13,'-,2.24 unit increase,[1.34-3.14],"CHL1-AS2, LINC01986",Problematic alcohol use in trauma-exposed individuals,"alcohol use disorder measurement, response to trauma exposure",GCST005236,3:47829,Mental or Behavioural Disorder
590,COQ10B,COQ10B,N/a,rs2565164-<b>?</b>,2 x 10-11,,NR,'-,'-,'-,COQ10B,Schizophrenia,schizophrenia,GCST008459,2:197472796,Mental or Behavioural Disorder
904,DNM3,DNM3,N/a,rs12127965-<b>?</b>,4 x 10-9,,NR,'-,'-,'-,DNM3,Neuroticism,neuroticism measurement,GCST007084,1:171845825,Mental or Behavioural Disorder
907,DNM3,DNM3,N/a,rs12145171-<b>C</b>,7 x 10-9,,0.4283,'-,0.01105 unit decrease,[0.0073-0.0148],DNM3,Neuroticism,neurotic disorder,GCST010017,1:171874109,Mental or Behavioural Disorder
2120,DTD1,DTD1,N/a,rs1998122-<b>A</b>,1 x 10-8,,NR,'-,0.01403 unit decrease,[0.0092-0.0188],DTD1,Worry,anxiety,GCST006478,20:18727895,Mental or Behavioural Disorder
2170,DTD1,DTD1,N/a,rs6136465-<b>A</b>,1 x 10-8,,0.3967,'-,0.012194927 unit decrease,[0.008-0.0164],"DTD1, DTD1-AS1",Problematic alcohol use (MTAG),"alcohol use disorder measurement, alcohol consumption measurement",GCST010544,20:18678750,Mental or Behavioural Disorder
2171,DTD1,DTD1-AS1,N/a,rs6136465-<b>A</b>,1 x 10-8,,0.3967,'-,0.012194927 unit decrease,[0.008-0.0164],"DTD1, DTD1-AS1",Problematic alcohol use (MTAG),"alcohol use disorder measurement, alcohol consumption measurement",GCST010544,20:18678750,Mental or Behavioural Disorder
2181,DTD1,DTD1,N/a,rs62217022-<b>G</b>,1 x 10-8,,0.396,'-,0.0148 unit decrease,[0.0097-0.0199],DTD1,Alcohol consumption (drinks per week),alcohol consumption measurement,GCST008811,20:18712436,Mental or Behavioural Disorder
2182,DTD1,DTD1,N/a,rs28429420-<b>A</b>,4 x 10-9,,0.395,'-,0.010665695 unit decrease,[0.0071-0.0142],"DTD1, DTD1-AS1",Alcohol consumption (drinks per week) (MTAG),alcohol consumption measurement,GCST010543,20:18675886,Mental or Behavioural Disorder
2183,DTD1,DTD1-AS1,N/a,rs28429420-<b>A</b>,4 x 10-9,,0.395,'-,0.010665695 unit decrease,[0.0071-0.0142],"DTD1, DTD1-AS1",Alcohol consumption (drinks per week) (MTAG),alcohol consumption measurement,GCST010543,20:18675886,Mental or Behavioural Disorder
1228,FAM180B,FAM180B,N/a,rs11605348-<b>G</b>,1 x 10-7,,0.65,'-,0.0045 unit increase,[0.0029-0.0061],"NDUFS3, FAM180B",Loneliness,loneliness measurement,GCST006923,11:47584931,Mental or Behavioural Disorder
1229,FAM180B,FAM180B,N/a,rs11605348-<b>G</b>,1 x 10-8,,0.649676,'-,0.012172433 unit increase,[0.008-0.0164],"NDUFS3, FAM180B",Loneliness (MTAG),loneliness measurement,GCST006924,11:47584931,Mental or Behavioural Disorder
1306,FAM180B,FAM180B,N/a,rs11605348-<b>G</b>,3 x 10-8,(Female),0.657,1.0438414,'-,[1.03-1.06],"NDUFS3, FAM180B",Insomnia,insomnia measurement,GCST007988,11:47584931,Mental or Behavioural Disorder
1308,FAM180B,FAM180B,N/a,rs11605348-<b>G</b>,7 x 10-13,,0.6505,1.0460252,'-,[1.03-1.06],"NDUFS3, FAM180B",Insomnia,insomnia measurement,GCST007988,11:47584931,Mental or Behavioural Disorder
73,FCGR2A,FCGR2A,N/a,rs7535475-<b>?</b>,3 x 10-6,(MCS),NR,'-,'-,'-,"FCGR2A, RNU6-481P","Functional impairment in major depressive disorder, bipolar disorder and schizophrenia","unipolar depression, schizophrenia, bipolar disorder, functional impairment measurement",GCST002188,1:161493797,Mental or Behavioural Disorder
79,FGF12,FGF12,N/a,rs4585146-<b>G</b>,6 x 10-6,(% improvement - 2 weeks),0.65,1.1643,'-,[1.11-1.22],"FGF12, RN7SKP222",Major depressive disorder,unipolar depression,GCST001850,3:192100853,Mental or Behavioural Disorder
80,FGF12,FGF12,N/a,rs4585146-<b>A</b>,3 x 10-7,(% improvement - SSRI treated - 2 weeks),0.362271,'-,0.2208 unit decrease,[0.14-0.31],"FGF12, RN7SKP222",Major depressive disorder,unipolar depression,GCST001850,3:192100853,Mental or Behavioural Disorder
2028,FGF12,FGF12,N/a,rs6788153-<b>T</b>,9 x 10-6,,0.921,1.09604,'-,[1.06-1.14],FGF12,Bipolar disorder,bipolar disorder,GCST008103,3:192499942,Mental or Behavioural Disorder
2062,FGF12,FGF12,N/a,rs79940520-<b>G</b>,9 x 10-6,,0.141,1.0893246,'-,[NR],"RN7SKP222, FGF12",Autism spectrum disorder,autism spectrum disorder,GCST007556,3:192120380,Mental or Behavioural Disorder
591,FGF8,FGF8,N/a,rs114540395-<b>T</b>,1 x 10-6,,NR,1.1,'-,[NR],"FGF8, FBXW4",Schizophrenia,schizophrenia,GCST003048,10:101719305,Mental or Behavioural Disorder
598,H2AC6,H2AC6,N/a,rs198801-<b>T</b>,4 x 10-10,,0.63,'-,0.0076 unit decrease,[0.0052-0.01],"H1-4, H2AC6",General risk tolerance (MTAG),risk-taking behaviour,GCST007325,6:26139513,Mental or Behavioural Disorder
902,H2AC6,H2AC6,N/a,rs198800-<b>T</b>,7 x 10-9,,0.479939,'-,5.8 z score increase,'-,"H2AC6, H1-4",Neurociticism,neuroticism measurement,GCST006940,6:26139705,Mental or Behavioural Disorder
1751,H2AC6,H2AC6,N/a,rs806973-<b>A</b>,3 x 10-6,,NR,'-,0.2008 unit increase,[0.12-0.29],"H2AC6, H1-4",Cocaine dependence,cocaine dependence,GCST008399,6:26148098,Mental or Behavioural Disorder
76,IL20RB,IL20RB,N/a,rs17374749-<b>?</b>,7 x 10-6,(Dichotomous),0.78,1.54,'-,[NR],IL20RB,Anxiety in major depressive disorder,"unipolar depression, anxiety",GCST002202,3:137049168,Mental or Behavioural Disorder
593,IL20RB,IL20RB,N/a,rs1682361-<b>G</b>,8 x 10-7,,NR,1.0526316,'-,[NR],IL20RB,Schizophrenia,schizophrenia,GCST003048,3:137015172,Mental or Behavioural Disorder
906,IL20RB,IL20RB,N/a,rs7651736-<b>A</b>,9 x 10-12,,0.56895,'-,6.821 z score increase,'-,IL20RB,Neuroticism,neuroticism measurement,GCST005232,3:137041756,Mental or Behavioural Disorder
428,KC6,KC6,N/a,rs67050670-<b>G</b>,2 x 10-11,,0.229,'-,0.020272274 unit decrease,[0.014-0.026],"NPM1P1, KC6",Smoking initiation (ever regular vs never regular),smoking status measurement,GCST007474,18:41717290,Mental or Behavioural Disorder
429,KC6,KC6,N/a,rs4890355-<b>G</b>,9 x 10-15,,0.221,'-,0.0100786 unit decrease,[0.0075-0.0126],"KC6, NPM1P1",Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,18:41723663,Mental or Behavioural Disorder
438,KC6,KC6,N/a,rs72903956-<b>C</b>,5 x 10-9,,0.101,'-,0.0144162 unit increase,[0.0096-0.0192],KC6,Age of smoking initiation (MTAG),smoking initiation,GCST007462,18:41564800,Mental or Behavioural Disorder
868,KC6,KC6,N/a,rs9961367-<b>?</b>,2 x 10-8,,NR,'-,0.0237 unit increase,NR,KC6,ADHD vs obsessive compulsive disorder (ordinary least squares (OLS)),"obsessive-compulsive disorder, attention deficit hyperactivity disorder",GCST90016597,18:41672373,Mental or Behavioural Disorder
903,KC6,KC6,N/a,rs4890357-<b>T</b>,2 x 10-8,,0.1868,'-,5.645 z score decrease,'-,"KC6, NPM1P1",Neuroticism,neuroticism measurement,GCST005232,18:41724212,Mental or Behavioural Disorder
2172,KC6,KC6,N/a,rs7242858-<b>A</b>,1 x 10-8,,0.1856,'-,0.015081556 unit decrease,[0.0099-0.0203],"NPM1P1, KC6",Problematic alcohol use (MTAG),"alcohol use disorder measurement, alcohol consumption measurement",GCST010544,18:41721634,Mental or Behavioural Disorder
1761,KDM4A-AS1,KDM4A-AS1,N/a,rs56319043-<b>T</b>,4 x 10-8,,0.244,'-,0.0140718 unit decrease,[0.0091-0.0191],KDM4A-AS1,Cigarettes smoked per day (MTAG),cigarettes per day measurement,GCST007463,1:43705540,Mental or Behavioural Disorder
2063,KDM4A-AS1,KDM4A-AS1,N/a,rs56319043-<b>C</b>,4 x 10-9,,NR,1.0869565,'-,[1.05-1.11],KDM4A-AS1,Attention deficit hyperactivity disorder or cannabis use,"attention deficit hyperactivity disorder, Cannabis use",GCST006983,1:43705540,Mental or Behavioural Disorder
2064,KDM4A-AS1,KDM4A-AS1,N/a,rs112984125-<b>A</b>,2 x 10-7,(males),NR,'-,0.097 unit decrease,[0.06-0.134],"KDM4A-AS1, ST3GAL3",Attention deficit hyperactivity disorder,attention deficit hyperactivity disorder,GCST005362,1:43707752,Mental or Behavioural Disorder
324,KHSRPP1,KHSRPP1,N/a,rs184042824-<b>C</b>,2 x 10-6,,'-,'-,0.23 unit decrease,[0.13-0.33],"KHSRPP1, H3P30",Time to smoke first cigarette in the morning,time to first cigarette measurement,GCST008547,9:21673860,Mental or Behavioural Disorder
78,LINC00578,LINC00578,N/a,rs644695-<b>A</b>,5 x 10-6,,0.88,1.35,'-,[NR],LINC00578,Major depressive disorder (broad),unipolar depression,GCST000551,3:177573909,Mental or Behavioural Disorder
2119,LINC00578,LINC00578,N/a,rs6799682-<b>A</b>,8 x 10-6,"(AA, case-control analysis)",'-,1.79,'-,[NR],LINC00578,Anxiety disorder,anxiety disorder,GCST002696,3:177458728,Mental or Behavioural Disorder
2175,LINC00578,LINC00578,N/a,rs1353899-<b>?</b>,4 x 10-6,,0.22,'-,0.09 unit decrease,[0.051-0.129],LINC00578,Alcohol consumption,alcohol drinking,GCST002065,3:177511191,Mental or Behavioural Disorder
2156,LINC02414,LINC02414,N/a,rs7963314-<b>?</b>,3 x 10-6,(females),NR,1.4279574,'-,'-,LINC02414,Alzheimer's disease,Alzheimer's disease,GCST007600,12:131573284,Mental or Behavioural Disorder
1,MGST1,MGST1,N/a,rs2160515-<b>A</b>,8 x 10-10,,0.429309,'-,6.15 z score decrease,'-,"LMO3, MGST1",Worry too long after an embarrassing experience,worry measurement,GCST006946,12:16601031,Mental or Behavioural Disorder
205,MGST1,MGST1,N/a,rs10846381-<b>T</b>,1 x 10-6,,0.5897,1.1308845,'-,'-,"LMO3, MGST1",Tourette syndrome,Tourette syndrome,GCST007277,12:16599165,Mental or Behavioural Disorder
425,MGST1,MGST1,N/a,rs11057005-<b>G</b>,9 x 10-10,,0.441,'-,0.015713902 unit decrease,[0.011-0.021],"MGST1, LMO3",Smoking initiation (ever regular vs never regular),smoking status measurement,GCST007474,12:16595787,Mental or Behavioural Disorder
426,MGST1,MGST1,N/a,rs9651873-<b>C</b>,7 x 10-14,,0.442,'-,0.00818572 unit decrease,[0.006-0.0103],"MGST1, LMO3",Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,12:16602438,Mental or Behavioural Disorder
437,MGST1,MGST1,N/a,rs11057005-<b>G</b>,2 x 10-8,,'-,0.981,'-,[NR],"MGST1, LMO3",Smoking initiation,smoking initiation,GCST011703,12:16595787,Mental or Behavioural Disorder
446,MGST1,MGST1,N/a,rs9651873-<b>C</b>,2 x 10-12,,0.441,'-,0.0109714 unit decrease,[0.0079-0.014],"MGST1, LMO3",Smoking cessation (MTAG),smoking cessation,GCST007464,12:16602438,Mental or Behavioural Disorder
1760,MGST1,MGST1,N/a,rs10846380-<b>T</b>,1 x 10-10,,0.41,'-,0.014287 unit decrease,[0.0099-0.0187],"MGST1, LMO3",Cigarettes smoked per day (MTAG),cigarettes per day measurement,GCST007463,12:16594100,Mental or Behavioural Disorder
2150,NKPD1,NKPD1,N/a,rs28469095-<b>C</b>,2 x 10-38,,0.09149,'-,12.963469 z-unit increase,NR,"MARK4, NKPD1",Alzheimer's disease or family history of Alzheimer's disease,"Alzheimer's disease, family history of Alzheimer’s disease",GCST007320,19:45152075,Mental or Behavioural Disorder
2152,NKPD1,NKPD1,N/a,rs10421247-<b>C</b>,7 x 10-9,,0.4994,'-,5.801472 z-unit decrease,NR,"NKPD1, MARK4",Alzheimer's disease or family history of Alzheimer's disease,"Alzheimer's disease, family history of Alzheimer’s disease",GCST007320,19:45154228,Mental or Behavioural Disorder
633,OR51B5,OR51B5,N/a,rs7482428-<b>?</b>,4 x 10-7,,NR,1.4643433,'-,NR,"OR51B5, HBG2, HBE1",Response to SSRI (symptom remission),response to selective serotonin reuptake inhibitor,GCST007060,11:5321196,Mental or Behavioural Disorder
662,OR51B5,OR51B5,N/a,rs7482428-<b>?</b>,2 x 10-7,,NR,1.440507,'-,NR,"OR51B5, HBG2, HBE1",Response to antidepressants (symptom remission),response to antidepressant,GCST007061,11:5321196,Mental or Behavioural Disorder
976,PCDHGA2,PCDHGA2,N/a,rs3806830-<b>?</b>,4 x 10-6,,NR,'-,4.5 unit increase,[2.58-6.41],"PCDHGA8, PCDHGA1, PCDHGB4, PCDHGB3, PCDHGA7, PCDHGA3, PCDHGB2, PCDHGA5, PCDHGB6, PCDHGA2, PCDHGA9, PCDHGB1, PCDHGA6, PCDHGB5, PCDHGA10, PCDHGA4",Mental composite score,mental development measurement,GCST006441,5:141416532,Mental or Behavioural Disorder
74,PHF2,PHF2,N/a,rs2895249-<b>A</b>,2 x 10-8,,NR,'-,0.0133 unit decrease,[0.0086-0.018],PHF2,Depressed affect,"unipolar depression, mood disorder",GCST006475,9:93603471,Mental or Behavioural Disorder
416,PHF2,PHF2,N/a,rs10992800-<b>G</b>,2 x 10-9,,0.603,'-,0.0064 unit increase,[-0.00614-0.01894],PHF2,Ability to confide in someone,social interaction measurement,GCST006919,9:93611536,Mental or Behavioural Disorder
592,PHF2,PHF2,N/a,rs6479495-<b>C</b>,4 x 10-9,,NR,1.06,'-,[1.04-1.08],"PHF2, FAM120A",Schizophrenia,schizophrenia,GCST011768,9:93572320,Mental or Behavioural Disorder
905,PHF2,PHF2,N/a,rs10429558-<b>A</b>,6 x 10-9,,0.14431,'-,5.817 z score increase,'-,"FAM120A, PHF2",Neuroticism,neuroticism measurement,GCST005232,9:93574508,Mental or Behavioural Disorder
1230,PHF2,PHF2,N/a,rs10992800-<b>G</b>,7 x 10-11,,0.603,'-,0.0054 unit increase,[0.0038-0.007],PHF2,Loneliness,loneliness measurement,GCST006923,9:93611536,Mental or Behavioural Disorder
1231,PHF2,PHF2,N/a,rs10992800-<b>G</b>,1 x 10-13,,0.603196,'-,0.015511454 unit increase,[0.011-0.02],PHF2,Loneliness (MTAG),loneliness measurement,GCST006924,9:93611536,Mental or Behavioural Disorder
1232,PHF2,PHF2,N/a,rs7044244-<b>A</b>,2 x 10-10,,0.378475,'-,6.37 z score decrease,'-,PHF2,Feeling lonely,loneliness measurement,GCST006942,9:93635407,Mental or Behavioural Disorder
1233,PHF2,PHF2,N/a,rs13291079-<b>?</b>,2 x 10-11,,NR,'-,0.02 unit increase,[0.014-0.026],PHF2,Loneliness,loneliness measurement,GCST009463,9:93598368,Mental or Behavioural Disorder
1310,PHF2,PHF2,N/a,rs10156602-<b>A</b>,2 x 10-8,,0.638126,1.02,'-,[1.01-1.03],PHF2,Insomnia symptoms (never/rarely vs. sometimes/usually),insomnia measurement,GCST007387,9:93583046,Mental or Behavioural Disorder
1312,PHF2,PHF2,N/a,rs10156602-<b>A</b>,7 x 10-12,,0.638126,1.02,'-,[1.01-1.03],PHF2,Insomnia symptoms (never/rarely vs. usually),insomnia measurement,GCST007388,9:93583046,Mental or Behavioural Disorder
1314,PHF2,PHF2,N/a,rs7872863-<b>C</b>,1 x 10-8,(Female),0.2845,1.048218,'-,[1.03-1.06],PHF2,Insomnia,insomnia measurement,GCST007988,9:93630533,Mental or Behavioural Disorder
1317,PHF2,PHF2,N/a,rs10761240-<b>G</b>,2 x 10-12,,0.6037,1.0438414,'-,[1.03-1.06],PHF2,Insomnia,insomnia measurement,GCST007988,9:93599640,Mental or Behavioural Disorder
1673,PHF2,PHF2,N/a,rs6479494-<b>?</b>,2 x 10-8,,'-,'-,'-,'-,"PHF2, FAM120A",Depressive symptoms (MTAG),depressive symptom measurement,GCST010642,9:93568217,Mental or Behavioural Disorder
2154,PMAIP1,PMAIP1,N/a,rs142176337-<b>T</b>,8 x 10-8,(between families),NR,'-,5.36 unit decrease,'-,"NFE2L3P1, PMAIP1",Alzheimer disease and age of onset,"Alzheimer's disease, age at onset",GCST003427,18:59914255,Mental or Behavioural Disorder
2026,PPM1K,PPM1K,N/a,rs9995093-<b>?</b>,7 x 10-6,(NSM vs. Control),NR,2.067,'-,[NR],PPM1K-DT,Bipolar disorder,bipolar disorder,GCST001647,4:88299792,Mental or Behavioural Disorder
2027,PPM1K,PPM1K-DT,N/a,rs9995093-<b>?</b>,7 x 10-6,(NSM vs. Control),NR,2.067,'-,[NR],PPM1K-DT,Bipolar disorder,bipolar disorder,GCST001647,4:88299792,Mental or Behavioural Disorder
75,PROM1,PROM1,N/a,rs17387100-<b>G</b>,8 x 10-7,,0.078,1.76,'-,[1.54-1.99],PROM1,Suicide attempts in depression or bipolar disorder,"unipolar depression, bipolar disorder, attempted suicide",GCST002503,4:15993502,Mental or Behavioural Disorder
555,RPS3AP5,RPS3AP5,N/a,rs2488647-<b>C</b>,3 x 10-6,,0,1.0638298,'-,[-0.97457-3.10223],RPS3AP5,Deliberate self-harm,Self-injurious behavior,GCST010506,10:84603883,Mental or Behavioural Disorder
881,RPS3AP5,RPS3AP5,N/a,rs2488637-<b>T</b>,3 x 10-6,,0.421,'-,0.35 unit decrease,[0.21-0.49],RPS3AP5,Nicotine withdrawal symptom count,nicotine withdrawal symptom count,GCST006303,10:84599521,Mental or Behavioural Disorder
882,RPS3AP5,RPS3AP5,N/a,rs2488637-<b>T</b>,1 x 10-7,,0.42082,'-,0.08783225 unit decrease,[0.055-0.12],RPS3AP5,Nicotine withdrawal,nicotine withdrawal measurement,GCST006869,10:84599521,Mental or Behavioural Disorder
436,SPTBN4,SPTBN4,N/a,rs843778-<b>G</b>,3 x 10-8,,0.413,'-,0.00620758 unit decrease,[0.004-0.0084],SPTBN4,Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,19:40574908,Mental or Behavioural Disorder
883,TF,TF,N/a,rs9871148-<b>C</b>,2 x 10-6,(EA),NR,'-,'-,'-,"SRPRB, TF",Nicotine dependence symptom count,nicotine dependence symptom count,GCST010105,3:133788665,Mental or Behavioural Disorder
2173,TF,TF,N/a,rs1799899-<b>A</b>,1 x 10-9,(CDT concentration),0.06,'-,0.402 unit decrease,[0.27-0.53],TF,Alcohol consumption (transferrin glycosylation),alcohol drinking,GCST001103,3:133756968,Mental or Behavioural Disorder
2174,TF,TF,N/a,rs3811647-<b>A</b>,1 x 10-35,(Total transferrin),0.32,'-,0.358 unit increase,[0.30-0.42],TF,Alcohol consumption (transferrin glycosylation),alcohol drinking,GCST001103,3:133765185,Mental or Behavioural Disorder
430,TNNI3K,TNNI3K,N/a,rs1514176-<b>A</b>,8 x 10-14,,0.58,'-,0.019300157 unit decrease,[0.014-0.024],"TNNI3K, FPGT-TNNI3K",Smoking initiation (ever regular vs never regular),smoking status measurement,GCST007474,1:74525912,Mental or Behavioural Disorder
431,TNNI3K,TNNI3K,N/a,rs7525548-<b>T</b>,5 x 10-19,,0.564,'-,0.0096699 unit decrease,[0.0075-0.0118],"TNNI3K, FPGT-TNNI3K",Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,1:74535790,Mental or Behavioural Disorder
432,TNNI3K,TNNI3K,N/a,rs1514174-<b>?</b>,9 x 10-11,,NR,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Smoking status,smoking status measurement,GCST007085,1:74527379,Mental or Behavioural Disorder
433,TNNI3K,FPGT-TNNI3K,N/a,rs1514176-<b>A</b>,8 x 10-14,,0.58,'-,0.019300157 unit decrease,[0.014-0.024],"TNNI3K, FPGT-TNNI3K",Smoking initiation (ever regular vs never regular),smoking status measurement,GCST007474,1:74525912,Mental or Behavioural Disorder
434,TNNI3K,FPGT-TNNI3K,N/a,rs7525548-<b>T</b>,5 x 10-19,,0.564,'-,0.0096699 unit decrease,[0.0075-0.0118],"TNNI3K, FPGT-TNNI3K",Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,1:74535790,Mental or Behavioural Disorder
435,TNNI3K,FPGT-TNNI3K,N/a,rs1514174-<b>?</b>,9 x 10-11,,NR,'-,'-,'-,"FPGT-TNNI3K, TNNI3K",Smoking status,smoking status measurement,GCST007085,1:74527379,Mental or Behavioural Disorder
439,TNNI3K,TNNI3K,N/a,rs1514175-<b>G</b>,5 x 10-9,,0.57,'-,0.011 unit decrease,[0.0051-0.0169],"FPGT-TNNI3K, TNNI3K",Smoking initiation,smoking initiation,GCST007603,1:74525960,Mental or Behavioural Disorder
440,TNNI3K,TNNI3K,N/a,rs7553158-<b>G</b>,5 x 10-9,,'-,1.021,'-,[NR],"TNNI3K, FPGT-TNNI3K",Smoking initiation,smoking initiation,GCST011703,1:74539554,Mental or Behavioural Disorder
441,TNNI3K,TNNI3K,N/a,rs10789396-<b>C</b>,1 x 10-10,,0.567,'-,0.00966569 unit increase,[0.0067-0.0126],"ERICH3, TNNI3K",Age of smoking initiation (MTAG),smoking initiation,GCST007462,1:74548678,Mental or Behavioural Disorder
442,TNNI3K,TNNI3K,N/a,rs1514175-<b>G</b>,2 x 10-10,,0.575,'-,0.0138 unit decrease,[0.0095-0.0181],"FPGT-TNNI3K, TNNI3K",Smoking initiation (ever regular vs never regular),smoking initiation,GCST008810,1:74525960,Mental or Behavioural Disorder
443,TNNI3K,FPGT-TNNI3K,N/a,rs1514175-<b>G</b>,5 x 10-9,,0.57,'-,0.011 unit decrease,[0.0051-0.0169],"FPGT-TNNI3K, TNNI3K",Smoking initiation,smoking initiation,GCST007603,1:74525960,Mental or Behavioural Disorder
444,TNNI3K,FPGT-TNNI3K,N/a,rs7553158-<b>G</b>,5 x 10-9,,'-,1.021,'-,[NR],"TNNI3K, FPGT-TNNI3K",Smoking initiation,smoking initiation,GCST011703,1:74539554,Mental or Behavioural Disorder
445,TNNI3K,FPGT-TNNI3K,N/a,rs1514175-<b>G</b>,2 x 10-10,,0.575,'-,0.0138 unit decrease,[0.0095-0.0181],"FPGT-TNNI3K, TNNI3K",Smoking initiation (ever regular vs never regular),smoking initiation,GCST008810,1:74525960,Mental or Behavioural Disorder
447,TNNI3K,TNNI3K,N/a,rs7553348-<b>G</b>,5 x 10-12,,0.438,'-,0.014 unit increase,[0.01-0.018],"TNNI3K, FPGT-TNNI3K",Lifetime smoking index,smoking behaviour measurement,GCST009096,1:74539383,Mental or Behavioural Disorder
448,TNNI3K,FPGT-TNNI3K,N/a,rs7553348-<b>G</b>,5 x 10-12,,0.438,'-,0.014 unit increase,[0.01-0.018],"TNNI3K, FPGT-TNNI3K",Lifetime smoking index,smoking behaviour measurement,GCST009096,1:74539383,Mental or Behavioural Disorder
468,TNNI3K,TNNI3K,N/a,rs4650277-<b>A</b>,6 x 10-12,,0.4344,'-,0.01508202 unit increase,[0.011-0.019],"TNNI3K, FPGT-TNNI3K",Smoking status (ever vs never smokers),smoking behavior,GCST007327,1:74528037,Mental or Behavioural Disorder
469,TNNI3K,FPGT-TNNI3K,N/a,rs4650277-<b>A</b>,6 x 10-12,,0.4344,'-,0.01508202 unit increase,[0.011-0.019],"TNNI3K, FPGT-TNNI3K",Smoking status (ever vs never smokers),smoking behavior,GCST007327,1:74528037,Mental or Behavioural Disorder
884,TNNI3K,TNNI3K,N/a,rs11210482-<b>G</b>,8 x 10-6,(AA),NR,'-,'-,'-,"TNNI3K, ERICH3",Nicotine dependence symptom count,nicotine dependence symptom count,GCST010105,1:74561025,Mental or Behavioural Disorder
1302,TNNI3K,TNNI3K,N/a,rs699844-<b>A</b>,4 x 10-8,,0.9195,1.062,'-,[1.04-1.08],"FPGT-TNNI3K, TNNI3K",Insomnia,insomnia measurement,GCST007988,1:74412569,Mental or Behavioural Disorder
1304,TNNI3K,FPGT-TNNI3K,N/a,rs699844-<b>A</b>,4 x 10-8,,0.9195,1.062,'-,[1.04-1.08],"FPGT-TNNI3K, TNNI3K",Insomnia,insomnia measurement,GCST007988,1:74412569,Mental or Behavioural Disorder
1480,TNNI3K,TNNI3K,N/a,rs485929-<b>A</b>,4 x 10-10,,0.61,0.97,'-,"[0.96, 0.98]","FPGT, FPGT-TNNI3K",Acceptance of an invitation to participate in a mental health questionnaire,health study participation,GCST90012792,1:74212601,Mental or Behavioural Disorder
1481,TNNI3K,TNNI3K,N/a,rs485929-<b>G</b>,4 x 10-8,,0.39,'-,0.0060822 unit increase,[0.0039-0.0082],"FPGT, FPGT-TNNI3K",Mental health study participation (completed survey),health study participation,GCST008550,1:74212601,Mental or Behavioural Disorder
1482,TNNI3K,FPGT-TNNI3K,N/a,rs485929-<b>A</b>,4 x 10-10,,0.61,0.97,'-,"[0.96, 0.98]","FPGT, FPGT-TNNI3K",Acceptance of an invitation to participate in a mental health questionnaire,health study participation,GCST90012792,1:74212601,Mental or Behavioural Disorder
1483,TNNI3K,FPGT-TNNI3K,N/a,rs485929-<b>G</b>,4 x 10-8,,0.39,'-,0.0060822 unit increase,[0.0039-0.0082],"FPGT, FPGT-TNNI3K",Mental health study participation (completed survey),health study participation,GCST008550,1:74212601,Mental or Behavioural Disorder
1539,TNNI3K,TNNI3K,N/a,rs114134414-<b>C</b>,9 x 10-7,,0.03,'-,2.15 unit increase,'-,"FPGT-TNNI3K, TNNI3K",Fear of medical pain (dental),fear of medical pain measurement,GCST004707,1:74242875,Mental or Behavioural Disorder
1540,TNNI3K,FPGT-TNNI3K,N/a,rs114134414-<b>C</b>,9 x 10-7,,0.03,'-,2.15 unit increase,'-,"FPGT-TNNI3K, TNNI3K",Fear of medical pain (dental),fear of medical pain measurement,GCST004707,1:74242875,Mental or Behavioural Disorder
449,VIRMA,VIRMA,N/a,rs72674867-<b>A</b>,4 x 10-8,,0.765,'-,0.013 unit increase,[0.0091-0.0169],"VIRMA, LINC02894",Lifetime smoking index,smoking behaviour measurement,GCST009096,8:94565973,Mental or Behavioural Disorder
465,ADGRG2,ADGRG2,N/a,rs139545172-<b>?</b>,3 x 10-7,,NR,'-,0.3328 unit decrease,[NR],ADGRG2,3-hydroxypropylmercapturic acid levels in smokers,"smoking behavior, 3-hydroxypropylmercapturic acid measurement",GCST002956,X:19186106,Metabolism
1273,ADH1A,ADH1A,N/a,rs4147531-<b>?</b>,5 x 10-6,(isoleucine),NR,'-,0.15412723 unit increase,[0.088-0.22],"ADH1A, ADH1B",Metabolite levels,isoleucine measurement,GCST009391,4:99291040,Metabolism
1769,ADH1A,ADH1A,N/a,rs28364331-<b>G</b>,1 x 10-21,(gluconate),0.02,'-,0.811 unit decrease,[0.64-0.98],ADH1A,Urinary metabolite levels in chronic kidney disease,"chronic kidney disease, urinary metabolite measurement",GCST009733,4:99280138,Metabolism
973,APOB,APOB,N/a,rs673548-<b>A</b>,2 x 10-32,,0.204049,'-,0.0977899 unit decrease,[0.082-0.114],APOB,Metabolic syndrome,metabolic syndrome,GCST009602,2:21014672,Metabolism
974,APOB,APOB,N/a,rs673548-<b>G</b>,1 x 10-10,(HDL),0.73,'-,0.11 mmol/l decrease,[NR],APOB,Metabolic syndrome,metabolic syndrome,GCST001436,2:21014672,Metabolism
975,APOB,APOB,N/a,rs6711016-<b>C</b>,4 x 10-8,(TG),0.71,'-,0.08 mmol/l increase,[NR],"APOB, LINC02850",Metabolic syndrome,metabolic syndrome,GCST001436,2:20923592,Metabolism
180,APOB,APOB,N/a,rs673548-<b>A</b>,2 x 10-8,(TG),0.27,'-,0.08 mmol/l decrease,[0.05-0.11],APOB,Metabolic traits,triglyceride measurement,GCST000292,2:21014672,Metabolism
517,APOB,APOB,N/a,rs1042034-<b>?</b>,1 x 10-9,(M_VLDL_PL),NR,'-,0.067285426 unit decrease,NR,APOB,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,2:21002409,Metabolism
518,APOB,APOB,N/a,rs1042034-<b>?</b>,5 x 10-10,(S_VLDL_L),NR,'-,0.05131833 unit decrease,NR,APOB,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,2:21002409,Metabolism
519,APOB,APOB,N/a,rs6728178-<b>?</b>,2 x 10-13,(S_VLDL_TG),NR,'-,0.06284242 unit decrease,NR,APOB,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,2:20971074,Metabolism
520,APOB,APOB,N/a,rs676210-<b>?</b>,3 x 10-7,(M_VLDL_P),NR,'-,0.0639099 unit decrease,NR,APOB,Serum metabolite levels,serum metabolite measurement,GCST009242,2:21008652,Metabolism
521,APOB,APOB,N/a,rs6728178-<b>?</b>,2 x 10-10,(S_VLDL_TG),NR,'-,0.07923133 unit decrease,NR,APOB,Serum metabolite levels,serum metabolite measurement,GCST009242,2:20971074,Metabolism
522,APOB,APOB,N/a,rs673548-<b>?</b>,6 x 10-10,(S_VLDL_P),NR,'-,0.0776248 unit decrease,NR,APOB,Serum metabolite levels,serum metabolite measurement,GCST009242,2:21014672,Metabolism
523,APOB,APOB,N/a,rs1042034-<b>?</b>,2 x 10-7,(M_VLDL_PL),NR,'-,0.065373324 unit decrease,NR,APOB,Serum metabolite levels,serum metabolite measurement,GCST009242,2:21002409,Metabolism
524,APOB,APOB,N/a,rs1042034-<b>?</b>,2 x 10-7,(S_VLDL_L),NR,'-,0.07703361 unit decrease,NR,APOB,Serum metabolite levels,serum metabolite measurement,GCST009242,2:21002409,Metabolism
525,APOB,APOB,N/a,rs1042034-<b>?</b>,3 x 10-10,(TotFA),NR,'-,0.027771853 unit decrease,NR,APOB,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,2:21002409,Metabolism
526,APOB,APOB,N/a,rs1367117-<b>?</b>,1 x 10-9,(S_LDL_P),NR,'-,0.04359237 unit increase,NR,APOB,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,2:21041028,Metabolism
527,APOB,APOB,N/a,rs673548-<b>?</b>,2 x 10-8,(S_VLDL_P),NR,'-,0.05945241 unit decrease,NR,APOB,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,2:21014672,Metabolism
528,APOB,APOB,N/a,rs676210-<b>?</b>,2 x 10-10,(M_VLDL_P),NR,'-,0.06349305 unit decrease,NR,APOB,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,2:21008652,Metabolism
529,APOB,APOB,N/a,rs673548-<b>?</b>,1 x 10-12,(XS_VLDL_TG),NR,'-,0.08938208 unit decrease,NR,APOB,Serum metabolite levels,serum metabolite measurement,GCST009242,2:21014672,Metabolism
530,APOB,APOB,N/a,rs673548-<b>?</b>,9 x 10-12,(XS_VLDL_TG),NR,'-,0.068695925 unit decrease,NR,APOB,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,2:21014672,Metabolism
1243,APOB,APOB,N/a,rs13011615-<b>?</b>,6 x 10-19,"(Free cholesterol in large LDL, conditioned)",NR,'-,0.1247424 unit decrease,[0.097-0.152],"APOB, TDRD15",Metabolite levels (lipoprotein measures),"lipoprotein measurement, blood metabolite measurement",GCST003665,2:21051295,Metabolism
1244,APOB,APOB,N/a,rs952275-<b>G</b>,2 x 10-27,(Free cholesterol in IDL),0.43,'-,0.11 unit increase,[0.09-0.13],APOB,Metabolite levels (lipoprotein measures),"lipoprotein measurement, blood metabolite measurement",GCST003665,2:20998527,Metabolism
1245,APOB,APOB,N/a,rs1367117-<b>?</b>,2 x 10-17,"(LDL-C.assay, fasting)",NR,'-,3.916 unit increase,[NR],APOB,Lipid metabolism phenotypes,lipid measurement,GCST000533,2:21041028,Metabolism
1246,APOB,APOB,N/a,rs1367117-<b>?</b>,6 x 10-25,"(LDL-C.assay, whole)",NR,'-,4.027 unit increase,[NR],APOB,Lipid metabolism phenotypes,lipid measurement,GCST000533,2:21041028,Metabolism
1247,APOB,APOB,N/a,rs676210-<b>?</b>,2 x 10-9,"(TG.assay, fasting)",NR,'-,0.047 unit decrease,[NR],APOB,Lipid metabolism phenotypes,lipid measurement,GCST000533,2:21008652,Metabolism
1248,APOB,APOB,N/a,rs673548-<b>?</b>,4 x 10-10,"(TG.assay, whole)",NR,'-,0.041 unit decrease,[NR],APOB,Lipid metabolism phenotypes,lipid measurement,GCST000533,2:21014672,Metabolism
1249,APOB,APOB,N/a,rs6754295-<b>?</b>,4 x 10-47,"(VLDL.small, fasting)",NR,'-,4.127 unit decrease,[NR],APOB,Lipid metabolism phenotypes,lipid measurement,GCST000533,2:20983311,Metabolism
1250,APOB,APOB,N/a,rs676210-<b>?</b>,4 x 10-64,"(VLDL.small, whole)",NR,'-,4.219 unit decrease,[NR],APOB,Lipid metabolism phenotypes,lipid measurement,GCST000533,2:21008652,Metabolism
1251,APOB,APOB,N/a,rs673548-<b>?</b>,5 x 10-42,"(VLDL.total, fasting)",NR,'-,6.624 unit decrease,[NR],APOB,Lipid metabolism phenotypes,lipid measurement,GCST000533,2:21014672,Metabolism
1252,APOB,APOB,N/a,rs676210-<b>?</b>,9 x 10-56,"(VLDL.total, whole)",NR,'-,6.384 unit decrease,[NR],APOB,Lipid metabolism phenotypes,lipid measurement,GCST000533,2:21008652,Metabolism
1729,APOB,APOB,N/a,rs673548-<b>?</b>,1 x 10-13,,0.27,'-,'-,'-,APOB,Metabolite levels,coronary artery calcification,GCST001639,2:21014672,Metabolism
2089,APOB,APOB,N/a,rs62122481-<b>C</b>,7 x 10-335,,0.623091,'-,0.0839859 unit decrease,[0.08-0.088],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST010243,2:20993943,Metabolism
2090,APOB,APOB,N/a,rs12720796-<b>A</b>,8 x 10-12,,0.980336,'-,0.0509845 unit decrease,[0.036-0.066],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST010243,2:21039126,Metabolism
2091,APOB,APOB,N/a,rs1801701-<b>T</b>,4 x 10-23,,NR,'-,0.0399 unit increase,[0.032-0.048],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21005955,Metabolism
2092,APOB,APOB,N/a,rs1042031-<b>T</b>,3 x 10-75,,NR,'-,0.0569 unit decrease,[0.051-0.063],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21002881,Metabolism
2093,APOB,APOB,N/a,rs550619-<b>A</b>,9 x 10-154,,NR,'-,0.1143 unit increase,[0.11-0.12],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21037729,Metabolism
2094,APOB,APOB,N/a,rs12691202-<b>T</b>,2 x 10-143,,NR,'-,0.1587 unit decrease,[0.15-0.17],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21026844,Metabolism
2095,APOB,APOB,N/a,rs1801699-<b>C</b>,9 x 10-16,,NR,'-,0.0696 unit increase,[0.053-0.087],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21011127,Metabolism
2096,APOB,APOB,N/a,rs533617-<b>C</b>,2 x 10-316,,NR,'-,0.2335 unit decrease,[0.22-0.25],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21011100,Metabolism
2097,APOB,APOB,N/a,rs79106033-<b>T</b>,1 x 10-9,,NR,'-,0.0458 unit decrease,[0.031-0.061],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:20971271,Metabolism
2098,APOB,APOB,N/a,rs12720842-<b>C</b>,5 x 10-34,,NR,'-,0.0778 unit increase,[0.065-0.09],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21035055,Metabolism
2099,APOB,APOB,N/a,rs12713559-<b>A</b>,7 x 10-28,,NR,'-,0.4012 unit increase,[0.33-0.47],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21006196,Metabolism
2100,APOB,APOB,N/a,rs673548-<b>A</b>,6 x 10-219,,NR,'-,0.0924 unit decrease,[0.087-0.098],APOB,Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21014672,Metabolism
2101,APOB,APOB,N/a,rs60403635-<b>T</b>,9 x 10-112,,0.956951,'-,0.114956 unit increase,[0.1-0.12],"TDRD15, APOB",Apolipoprotein B levels,apolipoprotein B measurement,GCST010243,2:21049906,Metabolism
2102,APOB,APOB,N/a,rs10175646-<b>C</b>,7 x 10-26,,NR,'-,0.0682 unit decrease,[0.055-0.081],"APOB, LINC02850",Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:20945905,Metabolism
2103,APOB,APOB,N/a,rs61636751-<b>A</b>,9 x 10-13,,NR,'-,0.0442 unit increase,[0.032-0.056],"APOB, LINC02850",Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:20916126,Metabolism
2104,APOB,APOB,N/a,rs74629722-<b>C</b>,8 x 10-142,,NR,'-,0.0931 unit increase,[0.086-0.1],"APOB, LINC02850",Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:20927284,Metabolism
2105,APOB,APOB,N/a,rs72902579-<b>C</b>,4 x 10-123,,NR,'-,0.1362 unit decrease,[0.12-0.15],"APOB, TDRD15",Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21053136,Metabolism
2106,APOB,APOB,N/a,rs111548358-<b>C</b>,6 x 10-102,,NR,'-,0.0974 unit increase,[0.089-0.106],"TDRD15, APOB",Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:21114434,Metabolism
2107,APOB,APOB,N/a,rs72788528-<b>C</b>,2 x 10-16,,NR,'-,0.0427 unit increase,[0.033-0.053],"APOB, LINC02850",Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,2:20916057,Metabolism
2112,APOB,APOB,N/a,rs1801699-<b>C</b>,2 x 10-15,,NR,'-,0.0717 unit decrease,[0.054-0.09],APOB,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST90019495,2:21011127,Metabolism
2113,APOB,APOB,N/a,rs11676704-<b>G</b>,6 x 10-18,,NR,'-,0.0283 unit increase,[0.022-0.035],APOB,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST90019495,2:21021486,Metabolism
2114,APOB,APOB,N/a,rs673548-<b>A</b>,3 x 10-117,,NR,'-,0.0705 unit increase,[0.064-0.077],APOB,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST90019495,2:21014672,Metabolism
2115,APOB,APOB,N/a,rs533617-<b>C</b>,2 x 10-47,,NR,'-,0.0931 unit increase,[0.081-0.106],APOB,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST90019495,2:21011100,Metabolism
2116,APOB,APOB,N/a,rs676210-<b>G</b>,9 x 10-136,,0.794905,'-,0.0601182 unit decrease,[0.055-0.065],APOB,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST010241,2:21008652,Metabolism
1670,CDKN2AIP,CDKN2AIP,N/a,rs17293543-<b>?</b>,8 x 10-6,(DAG 36:1),NR,'-,0.15033792 unit increase,[0.084-0.217],"CLDN24, CDKN2AIP",Metabolite levels,diacylglycerol 36:1 measurement,GCST009391,4:183380896,Metabolism
42,DNM3,DNM3,N/a,rs12077769-<b>A</b>,4 x 10-6,,NR,'-,4.631 Z score increase,[NR],"PIGC, DNM3",Very long-chain saturated fatty acid levels (fatty acid 22:0),very long-chain saturated fatty acid measurement,GCST002688,1:172379811,Metabolism
831,FGF12,FGF12,N/a,rs4453795-<b>?</b>,4 x 10-7,(PC),0.41,'-,'-,'-,FGF12,Metabolite levels,phospholipid measurement,GCST000274,3:192376186,Metabolism
467,GAPDHP67,GAPDHP67,N/a,rs150889544-<b>?</b>,3 x 10-6,(Latino),NR,'-,0.8548 unit decrease,[NR],"SLC9A6, GAPDHP67",3-hydroxy-1-methylpropylmercapturic acid levels in smokers,"smoking behavior, 3-hydroxy-1-methylpropylmercapturic acid measurement",GCST002957,X:136051802,Metabolism
200,MYO1B,MYO1B,N/a,rs9750499-<b>?</b>,7 x 10-6,(TAG 50:5),NR,'-,0.2725102 unit increase,[0.15-0.39],MYO1B,Metabolite levels,triacylglycerol 50:5 measurement,GCST009391,2:191476121,Metabolism
832,MYO1B,MYO1B,N/a,rs1400884-<b>?</b>,3 x 10-6,(PC 34:3),NR,'-,0.21137981 unit decrease,[0.12-0.3],MYO1B,Metabolite levels,phosphatidylcholine 34:3 measurement,GCST009391,2:191496714,Metabolism
2109,NKPD1,NKPD1,N/a,rs10417602-<b>T</b>,1 x 10-11,,NR,'-,0.0305 unit increase,[0.022-0.039],"MARK4, NKPD1",Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,19:45157381,Metabolism
2110,NKPD1,NKPD1,N/a,rs10421247-<b>T</b>,1 x 10-35,,NR,'-,0.0297 unit decrease,[0.025-0.034],"NKPD1, MARK4",Apolipoprotein B levels,apolipoprotein B measurement,GCST90019496,19:45154228,Metabolism
466,PDGFD,PDGFD,N/a,rs7930114-<b>?</b>,2 x 10-6,,NR,'-,0.4242 unit decrease,[NR],PDGFD,3-hydroxypropylmercapturic acid levels in smokers,"smoking behavior, 3-hydroxypropylmercapturic acid measurement",GCST002956,11:104170883,Metabolism
2108,PDGFD,PDGFD,N/a,rs115739682-<b>T</b>,4 x 10-8,,0.808467,'-,0.0145929 unit increase,[0.0094-0.0198],PDGFD,Apolipoprotein B levels,apolipoprotein B measurement,GCST010243,11:103999912,Metabolism
2117,PDGFD,PDGFD,N/a,rs145184406-<b>T</b>,4 x 10-9,,0.808425,'-,0.0147506 unit increase,[0.0098-0.0197],PDGFD,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST010241,11:103999913,Metabolism
2122,PDGFD,PDGFD,N/a,rs7127296-<b>?</b>,8 x 10-6,(anthranilic acid),NR,'-,0.20721538 unit decrease,[0.12-0.3],"PDGFD, MIR4693",Metabolite levels,anthranilic acid measurement,GCST009391,11:103900193,Metabolism
2184,PDGFD,PDGFD,N/a,rs11226171-<b>?</b>,2 x 10-6,(alanine),NR,'-,1.9834033 unit decrease,[1.17-2.79],PDGFD,Metabolite levels,alanine measurement,GCST009391,11:104113826,Metabolism
52,PPM1K,PPM1K,N/a,rs74962708-<b>T</b>,3 x 10-12,,NR,'-,0.074 unit increase,[0.053-0.095],"PPM1K, PPM1K-DT",Urate levels,urate measurement,GCST90019524,4:88284508,Metabolism
55,PPM1K,PPM1K,N/a,rs28793136-<b>C</b>,6 x 10-55,,NR,'-,0.0707 unit increase,[0.062-0.08],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88295616,Metabolism
58,PPM1K,PPM1K,N/a,rs4693211-<b>C</b>,1 x 10-82,,NR,'-,0.0941 unit increase,[0.084-0.104],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88327909,Metabolism
61,PPM1K,PPM1K-DT,N/a,rs28793136-<b>C</b>,6 x 10-55,,NR,'-,0.0707 unit increase,[0.062-0.08],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88295616,Metabolism
64,PPM1K,PPM1K-DT,N/a,rs4693211-<b>C</b>,1 x 10-82,,NR,'-,0.0941 unit increase,[0.084-0.104],PPM1K-DT,Urate levels,urate measurement,GCST90019524,4:88327909,Metabolism
67,PPM1K,PPM1K-DT,N/a,rs74962708-<b>T</b>,3 x 10-12,,NR,'-,0.074 unit increase,[0.053-0.095],"PPM1K, PPM1K-DT",Urate levels,urate measurement,GCST90019524,4:88284508,Metabolism
531,PPM1K,PPM1K,N/a,rs7661312-<b>?</b>,4 x 10-13,(Val),NR,'-,0.091263585 unit increase,NR,PPM1K,Serum metabolite levels,serum metabolite measurement,GCST009242,4:88279855,Metabolism
532,PPM1K,PPM1K,N/a,rs7661312-<b>?</b>,2 x 10-17,(Val),NR,'-,0.09077292 unit increase,NR,PPM1K,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,4:88279855,Metabolism
533,PPM1K,PPM1K,N/a,rs34813495-<b>?</b>,2 x 10-16,(Leu),NR,'-,0.06857474 unit increase,NR,PPM1K-DT,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,4:88291925,Metabolism
534,PPM1K,PPM1K,N/a,rs34813495-<b>?</b>,1 x 10-6,(Leu),NR,'-,0.060484387 unit increase,NR,PPM1K-DT,Serum metabolite levels,serum metabolite measurement,GCST009242,4:88291925,Metabolism
535,PPM1K,PPM1K-DT,N/a,rs34813495-<b>?</b>,2 x 10-16,(Leu),NR,'-,0.06857474 unit increase,NR,PPM1K-DT,Serum metabolite levels (CMS),serum metabolite measurement,GCST009240,4:88291925,Metabolism
536,PPM1K,PPM1K-DT,N/a,rs34813495-<b>?</b>,1 x 10-6,(Leu),NR,'-,0.060484387 unit increase,NR,PPM1K-DT,Serum metabolite levels,serum metabolite measurement,GCST009242,4:88291925,Metabolism
970,PPM1K,PPM1K,N/a,rs1440581-<b>?</b>,2 x 10-16,(Fischer's ratio),NR,'-,0.13 unit increase,[0.091-0.169],PPM1K-DT,Metabolite levels,metabolite measurement,GCST001391,4:88305270,Metabolism
971,PPM1K,PPM1K-DT,N/a,rs1440581-<b>?</b>,2 x 10-16,(Fischer's ratio),NR,'-,0.13 unit increase,[0.091-0.169],PPM1K-DT,Metabolite levels,metabolite measurement,GCST001391,4:88305270,Metabolism
1730,PPM1K,PPM1K,N/a,rs1440581-<b>?</b>,1 x 10-10,,0.47,'-,'-,'-,PPM1K-DT,Metabolite levels,coronary artery calcification,GCST001639,4:88305270,Metabolism
1731,PPM1K,PPM1K-DT,N/a,rs1440581-<b>?</b>,1 x 10-10,,0.47,'-,'-,'-,PPM1K-DT,Metabolite levels,coronary artery calcification,GCST001639,4:88305270,Metabolism
2006,PPM1K,PPM1K,N/a,rs34226052-<b>?</b>,5 x 10-12,"(Valine, conditioned)",NR,'-,0.0967459 unit decrease,[0.069-0.124],"ABCG2, PPM1K",Metabolite levels (small molecules and protein measures),"blood metabolite measurement, protein measurement, amino acid measurement",GCST003666,4:88242371,Metabolism
2007,PPM1K,PPM1K,N/a,rs9637599-<b>C</b>,2 x 10-35,(Valine),0.47,'-,0.11 unit increase,[0.09-0.13],PPM1K-DT,Metabolite levels (small molecules and protein measures),"blood metabolite measurement, protein measurement, amino acid measurement",GCST003666,4:88285078,Metabolism
2008,PPM1K,PPM1K-DT,N/a,rs9637599-<b>C</b>,2 x 10-35,(Valine),0.47,'-,0.11 unit increase,[0.09-0.13],PPM1K-DT,Metabolite levels (small molecules and protein measures),"blood metabolite measurement, protein measurement, amino acid measurement",GCST003666,4:88285078,Metabolism
2009,PPM1K,PPM1K,N/a,rs10022462-<b>T</b>,5 x 10-11,(2-aminobutyrate),0.45,'-,0.012 unit decrease,[0.0081-0.0159],PPM1K-DT,Blood metabolite levels,blood metabolite measurement,GCST002443,4:88322666,Metabolism
2010,PPM1K,PPM1K,N/a,rs1440581-<b>T</b>,1 x 10-19,(leucine),0.46,'-,0.008 unit decrease,[0.006-0.01],PPM1K-DT,Blood metabolite levels,blood metabolite measurement,GCST002443,4:88305270,Metabolism
2011,PPM1K,PPM1K,N/a,rs1440581-<b>T</b>,1 x 10-16,(3-methyl-2-oxovalerate),0.46,'-,0.014 unit decrease,[0.01-0.018],PPM1K-DT,Blood metabolite levels,blood metabolite measurement,GCST002443,4:88305270,Metabolism
2012,PPM1K,PPM1K,N/a,rs1440581-<b>T</b>,3 x 10-12,(valine),0.46,'-,0.008 unit decrease,[0.006-0.01],PPM1K-DT,Blood metabolite levels,blood metabolite measurement,GCST002443,4:88305270,Metabolism
2013,PPM1K,PPM1K-DT,N/a,rs10022462-<b>T</b>,5 x 10-11,(2-aminobutyrate),0.45,'-,0.012 unit decrease,[0.0081-0.0159],PPM1K-DT,Blood metabolite levels,blood metabolite measurement,GCST002443,4:88322666,Metabolism
2014,PPM1K,PPM1K-DT,N/a,rs1440581-<b>T</b>,1 x 10-19,(leucine),0.46,'-,0.008 unit decrease,[0.006-0.01],PPM1K-DT,Blood metabolite levels,blood metabolite measurement,GCST002443,4:88305270,Metabolism
2015,PPM1K,PPM1K-DT,N/a,rs1440581-<b>T</b>,1 x 10-16,(3-methyl-2-oxovalerate),0.46,'-,0.014 unit decrease,[0.01-0.018],PPM1K-DT,Blood metabolite levels,blood metabolite measurement,GCST002443,4:88305270,Metabolism
2016,PPM1K,PPM1K-DT,N/a,rs1440581-<b>T</b>,3 x 10-12,(valine),0.46,'-,0.008 unit decrease,[0.006-0.01],PPM1K-DT,Blood metabolite levels,blood metabolite measurement,GCST002443,4:88305270,Metabolism
93,RBM25,RBM25,N/a,rs17570658-<b>?</b>,5 x 10-6,(tyrosine),NR,'-,0.3967962 unit increase,[0.23-0.57],"RN7SL586P, RBM25",Metabolite levels,tyrosine measurement,GCST009391,14:73058413,Metabolism
70,RCN2,RCN2,N/a,rs932046-<b>T</b>,5 x 10-11,,NR,'-,0.056 unit increase,[0.039-0.073],"RN7SL278P, RCN2",Urate levels,urate measurement,GCST90019524,15:76955213,Metabolism
507,RCN2,RCN2,N/a,rs932046-<b>T</b>,7 x 10-12,,NR,'-,0.0584 unit increase,[0.042-0.075],"RN7SL278P, RCN2",Urea levels,serum urea measurement,GCST90019525,15:76955213,Metabolism
972,SLC22A4,SLC22A4,N/a,rs272889-<b>A</b>,7 x 10-16,(isovalerylcarnitine + 7 other traits),0.37,'-,0.084 unit increase,[NR],"SLC22A4, MIR3936HG",Metabolic traits,metabolite measurement,GCST001217,5:132329685,Metabolism
537,SLC22A4,SLC22A4,N/a,rs273913-<b>?</b>,2 x 10-11,(3dehydrocarnitine),NR,'-,0.0298 unit increase,[NR],"MIR3936HG, SLC22A4",Serum metabolite levels,serum metabolite measurement,GCST006249,5:132325463,Metabolism
538,SLC22A4,SLC22A4,N/a,rs272889-<b>?</b>,9 x 10-15,(isovalerylcarnitine),NR,'-,0.04099 unit increase,[NR],"SLC22A4, MIR3936HG",Serum metabolite levels,serum metabolite measurement,GCST006249,5:132329685,Metabolism
2017,SLC22A4,SLC22A4,N/a,rs272889-<b>A</b>,3 x 10-51,(valine/isovalerylcarnitine),0.37,'-,0.039 unit decrease,[0.033-0.045],"SLC22A4, MIR3936HG",Blood metabolite ratios,blood metabolite measurement,GCST002442,5:132329685,Metabolism
2018,SLC22A4,SLC22A4,N/a,rs419291-<b>T</b>,3 x 10-18,(carnitine),0.37,'-,0.008 unit increase,[0.006-0.01],SLC22A4,Blood metabolite levels,blood metabolite measurement,GCST002443,5:132297662,Metabolism
2019,SLC22A4,SLC22A4,N/a,rs11950562-<b>A</b>,2 x 10-41,(isovalerylcarnitine),0.52,'-,0.036 unit increase,[0.03-0.042],"MIR3936HG, SLC22A4",Blood metabolite levels,blood metabolite measurement,GCST002443,5:132316836,Metabolism
2020,SLC22A4,SLC22A4,N/a,rs273913-<b>T</b>,1 x 10-25,(3-dehydrocarnitine),0.38,'-,0.026 unit increase,[0.02-0.032],"MIR3936HG, SLC22A4",Blood metabolite levels,blood metabolite measurement,GCST002443,5:132325463,Metabolism
2021,SLC22A4,SLC22A4,N/a,rs272869-<b>A</b>,1 x 10-11,(hexanoylcarnitine),0.37,'-,0.022 unit increase,[0.016-0.028],"MIR3936HG, SLC22A4",Blood metabolite levels,blood metabolite measurement,GCST002443,5:132342304,Metabolism
2022,SLC22A4,SLC22A4,N/a,rs273914-<b>A</b>,3 x 10-11,(oleoylcarnitine),0.37,'-,0.023 unit increase,[0.015-0.031],"SLC22A4, MIR3936HG",Blood metabolite levels,blood metabolite measurement,GCST002443,5:132324738,Metabolism
2023,SLC22A4,SLC22A4,N/a,rs11950562-<b>A</b>,7 x 10-11,(homostachydrine),0.53,'-,0.03 unit increase,[0.020-0.040],"MIR3936HG, SLC22A4",Blood metabolite levels,blood metabolite measurement,GCST002443,5:132316836,Metabolism
2204,SLC22A4,SLC22A4,N/a,rs270602-<b>T</b>,2 x 10-15,(Acetylcarnitine),0.3826,'-,0.0505 unit increase,[0.038-0.063],"MIR3936HG, SLC22A4",Acylcarnitine levels,"acylcarnitine measurement, blood metabolite measurement",GCST002961,5:132321007,Metabolism
2205,SLC22A4,SLC22A4,N/a,rs270601-<b>T</b>,8 x 10-16,(Octadecenoylcarnitine),0.2979,'-,0.0433 unit increase,[0.033-0.054],"MIR3936HG, SLC22A4",Acylcarnitine levels,"acylcarnitine measurement, blood metabolite measurement",GCST002961,5:132321304,Metabolism
2111,TF,TF,N/a,rs6762415-<b>G</b>,1 x 10-9,,NR,'-,0.0152 unit decrease,[0.01-0.02],TF,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST90019495,3:133759713,Metabolism
1513,TGM3,TGM3,N/a,rs126635-<b>?</b>,4 x 10-6,(glycerol),NR,'-,6.0770044 unit increase,[3.49-8.66],TGM3,Metabolite levels,glycerol measurement,GCST009391,20:2333260,Metabolism
2,APOB,APOB,N/a,rs10495713-<b>?</b>,8 x 10-9,(Posterior limb of internal capsule),'-,'-,'-,'-,APOB,White matter microstructure (mode of anisotropy),white matter microstructure measurement,GCST009536,2:20977647,Nervous System
213,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Nervous System
221,APOB,APOB,N/a,rs562338-<b>?</b>,5 x 10-21,,NR,'-,'-,'-,"APOB, TDRD15","Age-related diseases, mortality and associated endophenotypes","total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, cancer, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality",GCST004045,2:21065449,Nervous System
2147,APOB,APOB,N/a,rs2678379-<b>?</b>,1 x 10-19,,'-,'-,'-,'-,APOB,Alzheimer's disease or HDL levels (pleiotropy),"Alzheimer's disease, high density lipoprotein cholesterol measurement",GCST007827,2:21003688,Nervous System
916,ARHGAP24,ARHGAP24,N/a,rs4693128-<b>T</b>,1 x 10-7,,0.17587,1.09834,'-,[1.06-1.13],ARHGAP24,Neuroblastoma or malignant cutaneous melanoma,"neuroblastoma, cutaneous melanoma",GCST010152,4:85809561,Nervous System
18,C11orf71,C11orf71,N/a,rs2847476-<b>?</b>,3 x 10-6,(ALLV),NR,'-,'-,'-,"NNMT, C11orf71",Volumetric brain MRI,volumetric brain MRI,GCST000088,11:114320294,Nervous System
2031,CDKN2AIP,CDKN2AIP,N/a,rs4241767-<b>?</b>,9 x 10-6,,'-,'-,152.1046 unit decrease,[NR],CDKN2AIP,Cerebrospinal fluid AB1-42 levels,beta-amyloid 1-42 measurement,GCST006672,4:183431985,Nervous System
847,CHL1,CHL1,N/a,rs3773384-<b>C</b>,4 x 10-6,,0.58,2.3255813,'-,[1.28-12.5],"CHL1, CHL1-AS1",Parkinsonism in frontotemporal lobe dementia,"Parkinson's disease, Frontotemporal dementia",GCST006153,3:374758,Nervous System
848,CHL1,CHL1-AS1,N/a,rs3773384-<b>C</b>,4 x 10-6,,0.58,2.3255813,'-,[1.28-12.5],"CHL1, CHL1-AS1",Parkinsonism in frontotemporal lobe dementia,"Parkinson's disease, Frontotemporal dementia",GCST006153,3:374758,Nervous System
1779,CHL1,CHL1,N/a,rs35210560-<b>C</b>,3 x 10-6,,0.283743,'-,0.68471986 unit increase,[0.42-0.95],CHL1,Caudate activity during reward,"caudate nucleus measurement, functional brain measurement, response to reward",GCST004970,3:219074,Nervous System
839,DNAJC9,DNAJC9,N/a,rs13401549-<b>?</b> x rs17738368-<b>?</b>,5 x 10-12,,NR,'-,'-,'-,"No mapped genes x FAM149B1, DNAJC9",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,10:73242769,Nervous System
911,DNM3,DNM3,N/a,rs3026627-<b>?</b> x rs9425308-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,"ZNF831 - EDN3 x DNM3, PIGC",Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,20:59280688|1:172414125,Nervous System
940,DNM3,DNM3,N/a,rs4641331-<b>G</b>,4 x 10-6,,0.9,1.4285715,'-,[NR],DNM3,Moyamoya disease,Moyamoya disease,GCST005575,1:172070315,Nervous System
1773,DPP7,DPP7,N/a,rs13631-<b>?</b>,7 x 10-14,(Dipeptidyl peptidase 2),NR,'-,'-,'-,DPP7,Cerebrospinal fluid biomarker levels,cerebrospinal fluid biomarker measurement,GCST004000,9:137111750,Nervous System
850,FCGR2A,FCGR2A,N/a,rs6658353-<b>C</b>,6 x 10-12,,0.5011,'-,0.065 unit increase,[0.047-0.083],"RNU6-481P, FCGR2A",Parkinson's disease or first degree relation to individual with Parkinson's disease,Parkinson's disease,GCST009325,1:161499264,Nervous System
1772,FCGR2A,FCGR2A,N/a,rs1801274-<b>G</b>,9 x 10-36,(Low affinity immunoglobulin gamma Fc region receptor II-a/b),NR,'-,'-,'-,FCGR2A,Cerebrospinal fluid biomarker levels,cerebrospinal fluid biomarker measurement,GCST004000,1:161509955,Nervous System
838,FGF12,FGF12,N/a,rs877333-<b>?</b> x rs1922911-<b>?</b>,9 x 10-8,,NR,'-,'-,'-,No mapped genes x FGF12,Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,3:192614237,Nervous System
914,FGF12,FGF12,N/a,rs2199398-<b>?</b> x rs4687306-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,"No mapped genes x FGF12-AS1, FGF12",Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,3:192271230,Nervous System
915,FGF12,FGF12-AS1,N/a,rs2199398-<b>?</b> x rs4687306-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,"No mapped genes x FGF12-AS1, FGF12",Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,3:192271230,Nervous System
1812,H2AC6,H2AC6,N/a,rs72834694-<b>?</b>,1 x 10-9,(right putamen),NR,'-,'-,'-,"H2AC6, H1-4",Brain region volumes,brain volume measurement,GCST009518,6:26144930,Nervous System
918,IL20RB,IL20RB,N/a,rs13361104-<b>?</b> x rs6766709-<b>?</b>,3 x 10-8,,NR,'-,'-,'-,No mapped genes x IL20RB - N/A,Neuritic plaques (SNP x SNP interaction),neuritic plaque measurement,GCST010342,3:137051421,Nervous System
411,KC6,KC6,N/a,rs16975050-<b>?</b>,5 x 10-7,,'-,'-,'-,'-,KC6,Amyotrophic lateral sclerosis (sporadic),sporadic amyotrophic lateral sclerosis,GCST002337,18:41607206,Nervous System
913,LINC00308,LINC00308,N/a,rs1472476-<b>?</b> x rs17004123-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,No mapped genes x LINC00308 - RNU4-45P,Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,21:22144457,Nervous System
3,LINC00578,LINC00578,N/a,rs6766914-<b>?</b>,5 x 10-8,(Superior longitudinal fasciculus),'-,'-,'-,'-,LINC00578,White matter microstructure (mode of anisotropy),white matter microstructure measurement,GCST009536,3:177605079,Nervous System
909,LINC00578,LINC00578,N/a,rs7141420-<b>?</b> x rs13070316-<b>?</b>,1 x 10-10,,NR,'-,'-,'-,NRXN3 x LINC00578,Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,14:79433111|3:177544755,Nervous System
910,LINC00578,LINC00578,N/a,rs2745477-<b>?</b> x rs1406545-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,No mapped genes x LINC00578,Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,3:177512861,Nervous System
1696,LINC00578,LINC00578,N/a,rs4241484-<b>?</b>,4 x 10-16,,'-,'-,'-,'-,LINC00578,Cortical surface area (MOSTest),"cortical surface area measurement, neuroimaging measurement",GCST010701,3:177598297,Nervous System
1697,LINC00578,LINC00578,N/a,rs1875102-<b>?</b>,9 x 10-9,,'-,'-,'-,'-,LINC00578,Cortical surface area (min-P),"cortical surface area measurement, neuroimaging measurement",GCST010697,3:177624680,Nervous System
1699,LINC00578,LINC00578,N/a,rs552305-<b>T</b>,4 x 10-10,(Lateral Occipital),0.3995,'-,17.187178 unit increase,[11.81-22.56],LINC00578,Cortical surface area,cortical surface area measurement,GCST010282,3:177577427,Nervous System
1814,LINC00578,LINC00578,N/a,rs35770472-<b>?</b>,2 x 10-8,(left lateral occipital),NR,'-,'-,'-,LINC00578,Brain region volumes,brain volume measurement,GCST009518,3:177581952,Nervous System
1815,LINC00578,LINC00578,N/a,rs13084960-<b>?</b>,1 x 10-11,(Superior temporal),'-,'-,'-,'-,LINC00578,Cortical volume,brain volume measurement,GCST011616,3:177578660,Nervous System
1816,LINC00578,LINC00578,N/a,rs35614773-<b>?</b>,4 x 10-15,,'-,'-,'-,'-,LINC00578,Brain morphology (MOSTest),"brain measurement, neuroimaging measurement",GCST010703,3:177593205,Nervous System
1817,LINC00578,LINC00578,N/a,rs1875102-<b>?</b>,3 x 10-8,,'-,'-,'-,'-,LINC00578,Brain morphology (min-P),"brain measurement, neuroimaging measurement",GCST010699,3:177624680,Nervous System
5,LINC02414,LINC02414,N/a,rs145070280-<b>T</b>,3 x 10-6,,0.0257,'-,0.1131 unit decrease,[0.066-0.161],"LINC02414, RAP1B",Periventricular white matter hyperintensities,white matter hyperintensity measurement,GCST010726,12:131561792,Nervous System
1263,LINC02414,LINC02414,N/a,rs10082903-<b>?</b>,9 x 10-6,,0.41,'-,'-,'-,LINC02414,Circulating leptin levels x sex interaction in high cardiovascular risk,"leptin measurement, sex interaction measurement",GCST009533,12:131593515,Nervous System
2140,LINC02414,LINC02414,N/a,rs12370900-<b>T</b>,4 x 10-6,,0.6219,'-,0.042 unit increase,[0.024-0.06],LINC02414,Central cerebrospinal fluid amyloid beta 42 to 40 ratio,amyloid-beta measurement,GCST90013674,12:131547668,Nervous System
2155,LINC02414,LINC02414,N/a,rs7963314-<b>?</b>,3 x 10-6,(females),NR,1.4279574,'-,'-,LINC02414,Alzheimer's disease,Alzheimer's disease,GCST007600,12:131573284,Nervous System
2157,LINC02502,LINC02502,N/a,rs62319710-<b>G</b>,5 x 10-6,,NR,'-,0.02878494 unit decrease,[0.016-0.041],"LINC02502, LINC01365",Alpha synuclein levels (MTAG),alpha synuclein measurement,GCST011818,4:119884972,Nervous System
2034,MGST1,MGST1,N/a,rs758858632-<b>G</b>,8 x 10-6,,0.0004,3.84356,'-,NR,MGST1,Bell's palsy,Bell's palsy,GCST011354,12:16368123,Nervous System
833,NDST1,NDST1,N/a,rs2647581-<b>?</b> x rs2545342-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,No mapped genes x NDST1,Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,5:150536114,Nervous System
2149,NKPD1,NKPD1,N/a,rs28469095-<b>C</b>,2 x 10-38,,0.09149,'-,12.963469 z-unit increase,NR,"MARK4, NKPD1",Alzheimer's disease or family history of Alzheimer's disease,"Alzheimer's disease, family history of Alzheimer’s disease",GCST007320,19:45152075,Nervous System
2151,NKPD1,NKPD1,N/a,rs10421247-<b>C</b>,7 x 10-9,,0.4994,'-,5.801472 z-unit decrease,NR,"NKPD1, MARK4",Alzheimer's disease or family history of Alzheimer's disease,"Alzheimer's disease, family history of Alzheimer’s disease",GCST007320,19:45154228,Nervous System
1337,OR51B5,OR51B5,N/a,rs2030094-<b>?</b>,4 x 10-6,,'-,'-,'-,'-,"HBG2, OR51I2, OR51B5, HBE1",Inferior parietal cortex volume,inferior parietal cortex volume measurement,GCST009184,11:5453608,Nervous System
40,PDGFD,PDGFD,N/a,rs1681464-<b>?</b>,3 x 10-10,(EA),NR,'-,0.0829 unit decrease,[0.057-0.109],PDGFD,Cortical surface area (visual PC2),visual cortical surface area measurement,GCST010225,11:104141928,Nervous System
834,PDGFD,PDGFD,N/a,rs13113026-<b>?</b> x rs12791086-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,No mapped genes x MIR4693 - PDGFD,Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,11:103870320,Nervous System
849,PDGFD,PDGFD,N/a,rs77942836-<b>A</b>,8 x 10-6,,0.02,'-,0.53 unit decrease,[0.29-0.77],PDGFD,Parkinson's disease motor subtype (tremor to postural instability/gait difficulty score ratio),Parkinson's disease symptom measurement,GCST90000015,11:104045915,Nervous System
908,PDGFD,PDGFD,N/a,rs117457382-<b>A</b>,2 x 10-7,,'-,'-,0.0020824 unit decrease,[0.0013-0.0029],PDGFD,Brain asymmetrical skew (vertical),neuroimaging measurement,GCST90017148,11:103928099,Nervous System
1695,PDGFD,PDGFD,N/a,rs2449611-<b>?</b>,4 x 10-8,,'-,'-,'-,'-,PDGFD,Cortical surface area (min-P),"cortical surface area measurement, neuroimaging measurement",GCST010697,11:104199940,Nervous System
1813,PDGFD,PDGFD,N/a,rs1681464-<b>?</b>,8 x 10-11,(Pericalcarine),'-,'-,'-,'-,PDGFD,Cortical volume,brain volume measurement,GCST011616,11:104141928,Nervous System
41,PHF2,PHF2,N/a,rs4743930-<b>T</b>,3 x 10-9,,0.2505,'-,0.017068336 unit increase,[0.011-0.023],PHF2,Predicted visceral adipose tissue,visceral adipose tissue measurement,GCST008744,9:93683312,Nervous System
414,PHF2,PHF2,N/a,rs10122014-<b>?</b>,4 x 10-6,,NR,'-,1520.4484 unit increase,NR,PHF2,Cerebrospinal fluid sTREM-2 levels,soluble triggering receptor expressed on myeloid cells 2 measurement,GCST009246,9:93591203,Nervous System
1654,PHF2,PHF2,N/a,rs10438600-<b>?</b> x rs4744272-<b>?</b>,1 x 10-7,,NR,'-,'-,'-,No mapped genes x PHF2 - N/A,Diffuse plaques (SNP x SNP interaction),diffuse plaque measurement,GCST010341,9:93706793,Nervous System
620,PMAIP1,PMAIP1,N/a,rs58127855-<b>T</b>,6 x 10-7,,0.01,3.03,'-,[2.01-4.97],"PMAIP1, NFE2L3P1",Restless legs syndrome,restless legs syndrome,GCST011995,18:59943413,Nervous System
2153,PMAIP1,PMAIP1,N/a,rs142176337-<b>T</b>,8 x 10-8,(between families),NR,'-,5.36 unit decrease,'-,"NFE2L3P1, PMAIP1",Alzheimer disease and age of onset,"Alzheimer's disease, age at onset",GCST003427,18:59914255,Nervous System
1819,PROM1,PROM1,N/a,rs116130729-<b>?</b>,2 x 10-7,(French Canadians),'-,3.2881217,'-,'-,PROM1,Intracranial aneurysm,brain aneurysm,GCST005576,4:16011163,Nervous System
1234,RN7SL252P,RN7SL252P,N/a,rs11771984-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,"MARK2P10, RN7SL252P",Lobe attachment (rater-scored or self-reported),lobe attachment,GCST005192,7:96933599,Nervous System
934,RN7SL824P,RN7SL824P,N/a,rs6662618-<b>?</b>,3 x 10-10,,NR,'-,'-,[1.0965-1.1754],"RN7SL824P, GFI1",Multiple sclerosis and type 2 diabetes (pleiotropy),"multiple sclerosis, type II diabetes mellitus",GCST007120,1:92469854,Nervous System
840,ROR1,ROR1,N/a,rs158871-<b>?</b> x rs6686041-<b>?</b>,2 x 10-10,,NR,'-,'-,'-,"No mapped genes x ROR1, ROR1-AS1",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,1:64147962,Nervous System
841,ROR1,ROR1-AS1,N/a,rs158871-<b>?</b> x rs6686041-<b>?</b>,2 x 10-10,,NR,'-,'-,'-,"No mapped genes x ROR1, ROR1-AS1",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,1:64147962,Nervous System
1698,ROR1,ROR1,N/a,rs1766362-<b>?</b>,6 x 10-9,,'-,'-,'-,'-,"PGM1, ROR1",Cortical surface area (MOSTest),"cortical surface area measurement, neuroimaging measurement",GCST010701,1:63750880,Nervous System
1700,ROR1,ROR1,N/a,rs4915928-<b>A</b>,2 x 10-9,(Superior Frontal),0.1455,'-,32.851543 unit increase,[22.15-43.56],ROR1,Cortical surface area,cortical surface area measurement,GCST010282,1:63770056,Nervous System
1818,ROR1,ROR1,N/a,rs2819184-<b>?</b>,1 x 10-8,,'-,'-,'-,'-,"ROR1, PGM1",Brain morphology (MOSTest),"brain measurement, neuroimaging measurement",GCST010703,1:63746954,Nervous System
912,RPS3AP5,RPS3AP5,N/a,rs7668760-<b>?</b> x rs2505782-<b>?</b>,2 x 10-13,,NR,'-,'-,'-,No mapped genes x RPS3AP5 - N/A,Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,10:84632635,Nervous System
964,SLC16A1,SLC16A1,N/a,rs147836155-<b>T</b>,2 x 10-6,,0.0129,'-,0.1346 unit increase,NR,SLC16A1-AS1,Proportion of activated microglia (inferior temporal cortex),microglial activation measurement,GCST010916,1:112958985,Nervous System
966,SLC16A1,SLC16A1-AS1,N/a,rs147836155-<b>T</b>,2 x 10-6,,0.0129,'-,0.1346 unit increase,NR,SLC16A1-AS1,Proportion of activated microglia (inferior temporal cortex),microglial activation measurement,GCST010916,1:112958985,Nervous System
4,SSBP4,SSBP4,N/a,rs11673604-<b>?</b>,4 x 10-9,(Anterior corona radiata),'-,'-,'-,'-,SSBP4,White matter microstructure (fractional anisotropy),white matter microstructure measurement,GCST009539,19:18430178,Nervous System
836,TNNI3K,TNNI3K,N/a,rs17057830-<b>?</b> x rs485414-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,"No mapped genes x FPGT-TNNI3K, TNNI3K",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,1:74283758,Nervous System
837,TNNI3K,FPGT-TNNI3K,N/a,rs17057830-<b>?</b> x rs485414-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,"No mapped genes x FPGT-TNNI3K, TNNI3K",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,1:74283758,Nervous System
410,TUBB4BP4,TUBB4BP4,N/a,rs10501765-<b>?</b>,8 x 10-6,,'-,'-,'-,'-,"TUBB4BP4, LINC02756",Amyotrophic lateral sclerosis (sporadic),Amyotrophic lateral sclerosis (sporadic),GCST002337,11:91924110,Nervous System
835,TUBB4BP4,TUBB4BP4,N/a,rs3013177-<b>?</b> x rs7931977-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,No mapped genes x TUBB4BP4 - N/A,Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,11:91976870,Nervous System
616,CCDC201,CCDC201,N/a,rs6956740-<b>?</b>,5 x 10-7,(ACPA-negative RA vs controls),NR,3.49,'-,[2.08-5.85],CCDC201,Rheumatoid arthritis,rheumatoid arthritis,GCST000917,7:45864208,Orthopaedic
2202,CD8B2,CD8B2,N/a,rs1117160-<b>?</b>,2 x 10-6,,NR,'-,'-,'-,"CD8B2, EEF1A1P12",Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,2:106602375,Orthopaedic
1512,CDKN2AIP,CDKN2AIP,N/a,rs17074636-<b>T</b>,7 x 10-7,,0.9862,'-,0.7091 unit decrease,[0.43-0.99],"CDKN2AIP, CLDN24",Gout,gout,GCST001790,4:183356978,Orthopaedic
587,CHL1,CHL1,N/a,rs10510181-<b>A</b>,8 x 10-7,(EA),0.33,1.37,'-,[1.20-1.58],CHL1-AS2,Adolescent idiopathic scoliosis,scoliosis,GCST000938,3:149364,Orthopaedic
588,CHL1,CHL1-AS2,N/a,rs10510181-<b>A</b>,8 x 10-7,(EA),0.33,1.37,'-,[1.20-1.58],CHL1-AS2,Adolescent idiopathic scoliosis,scoliosis,GCST000938,3:149364,Orthopaedic
2196,CHL1,CHL1,N/a,rs11129708-<b>?</b>,5 x 10-37,,NR,'-,'-,'-,"CHL1, CHL1-AS1",Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,3:381216,Orthopaedic
2197,CHL1,CHL1-AS1,N/a,rs11129708-<b>?</b>,5 x 10-37,,NR,'-,'-,'-,"CHL1, CHL1-AS1",Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,3:381216,Orthopaedic
600,FCGR2A,FCGR2A,N/a,rs10494360-<b>A</b>,3 x 10-7,,0.13,1.14,'-,[1.08-1.20],FCGR2A,Rheumatoid arthritis (ACPA-positive),rheumatoid arthritis,GCST006048,1:161505960,Orthopaedic
602,FCGR2A,FCGR2A,N/a,rs72717009-<b>T</b>,2 x 10-6,,NR,'-,0.119221 unit increase,[0.071-0.168],"RNU6-481P, FCGR2A",Rheumatoid arthritis,rheumatoid arthritis,GCST006959,1:161435263,Orthopaedic
604,FCGR2A,FCGR2A,N/a,rs72717009-<b>T</b>,1 x 10-6,(EA),0.12,'-,0.12237 unit increase,[0.073-0.172],"RNU6-481P, FCGR2A",Rheumatoid arthritis,rheumatoid arthritis,GCST006959,1:161435263,Orthopaedic
606,FCGR2A,FCGR2A,N/a,rs72717009-<b>T</b>,5 x 10-7,(EA),0.12,1.12,'-,[1.07-1.18],"RNU6-481P, FCGR2A",Rheumatoid arthritis,rheumatoid arthritis,GCST002318,1:161435263,Orthopaedic
608,FCGR2A,FCGR2A,N/a,rs72717009-<b>T</b>,1 x 10-7,,0.1,1.13,'-,[1.08-1.18],"RNU6-481P, FCGR2A",Rheumatoid arthritis,rheumatoid arthritis,GCST002318,1:161435263,Orthopaedic
2126,FCGR2A,FCGR2A,N/a,rs10800314-<b>?</b>,1 x 10-32,(subset analysis),NR,'-,'-,'-,FCGR2A,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,1:161502999,Orthopaedic
2130,FCGR2A,FCGR2A,N/a,rs61802846-<b>?</b>,1 x 10-9,(subset analysis),NR,'-,'-,'-,FCGR2A,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,1:161504083,Orthopaedic
2135,FCGR2A,FCGR2A,N/a,rs1801274-<b>T</b>,1 x 10-9,,0.476,1.11,'-,'-,FCGR2A,Ankylosing spondylitis,ankylosing spondylitis,GCST005529,1:161509955,Orthopaedic
2136,FCGR2A,FCGR2A,N/a,rs1801274-<b>T</b>,1 x 10-9,(EA),0.476,1.12,'-,'-,FCGR2A,Ankylosing spondylitis,ankylosing spondylitis,GCST005529,1:161509955,Orthopaedic
2137,HS3ST1,HS3ST1,N/a,rs10000518-<b>G</b>,6 x 10-6,,NR,2.0833335,'-,[2.08-2.08],HS3ST1,Ankylosing spondylitis,ankylosing spondylitis,GCST007844,4:11502867,Orthopaedic
2203,KC6,KC6,N/a,rs16975080-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,KC6,Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,18:41619033,Orthopaedic
1488,LINC00578,LINC00578,N/a,rs9850315-<b>C</b>,3 x 10-7,,0.02,2.43,'-,[1.73-3.41],LINC00578,Hallux valgus,Hallux valgus,GCST009849,3:177430803,Orthopaedic
2200,MGST1,MGST1,N/a,rs4149202-<b>?</b>,3 x 10-19,,NR,'-,'-,'-,MGST1,Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,12:16361675,Orthopaedic
2201,MGST1,MGST1,N/a,rs7138976-<b>?</b>,9 x 10-8,,NR,'-,'-,'-,"SLC15A5, MGST1",Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,12:16317801,Orthopaedic
1486,MYO1B,MYO1B,N/a,rs139705512-<b>A</b>,5 x 10-7,,0.02,3.05,'-,[1.97-4.70],MYO1B,Hallux valgus,Hallux valgus,GCST009849,2:191296244,Orthopaedic
1487,MYO1B,MYO1B,N/a,rs145025296-<b>C</b>,2 x 10-6,,0.02,3.333333,'-,[2.04-5.56],MYO1B,Hallux valgus,Hallux valgus,GCST009849,2:191427982,Orthopaedic
2198,MYO1B,MYO1B,N/a,rs1947457-<b>?</b>,1 x 10-37,,NR,'-,'-,'-,MYO1B,Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,2:191298970,Orthopaedic
2199,MYO1B,MYO1B,N/a,rs10432510-<b>?</b>,3 x 10-13,,NR,'-,'-,'-,MYO1B,Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,2:191522137,Orthopaedic
614,NONOP2,NONOP2,N/a,rs13017599-<b>A</b>,2 x 10-12,,0.34,1.21,'-,[1.15-1.28],NONOP2,Rheumatoid arthritis,rheumatoid arthritis,GCST000420,2:60937196,Orthopaedic
726,NONOP2,NONOP2,N/a,rs13017599-<b>G</b>,6 x 10-7,,NR,1.193,'-,NR,NONOP2,Psoriatic arthritis,psoriatic arthritis,GCST003270,2:60937196,Orthopaedic
728,NONOP2,NONOP2,N/a,rs13017599-<b>?</b>,1 x 10-8,,NR,1.27,'-,[1.18-1.35],NONOP2,Psoriatic arthritis,psoriatic arthritis,GCST001355,2:60937196,Orthopaedic
51,PPM1K,PPM1K,N/a,rs13120254-<b>A</b>,9 x 10-15,,0.5953,'-,0.138 unit increase,[0.1-0.17],"PPM1K, ABCG2",Serum uric acid levels,uric acid measurement,GCST010512,4:88239409,Orthopaedic
1272,SMURF2,SMURF2,N/a,rs6504249-<b>?</b>,9 x 10-9,,NR,'-,0.072 unit decrease,[0.097-0.048],"MICOS10P2, SMURF2",Joint mobility (Beighton score),joint hypermobility measurement,GCST003998,17:64680031,Orthopaedic
2138,TF,TF,N/a,rs2718798-<b>A</b>,7 x 10-6,,NR,1.1787,'-,'-,TF,Ankle injury,ankle injury,GCST004952,3:133773244,Orthopaedic
610,TNIP1,TNIP1,N/a,rs6579837-<b>A</b>,2 x 10-6,,NR,1.2062,'-,'-,TNIP1,Rheumatoid arthritis (ACPA-positive),rheumatoid arthritis,GCST005568,5:151055333,Orthopaedic
612,TNIP1,TNIP1,N/a,rs1422673-<b>T</b>,2 x 10-6,,0.198,1.0997517,'-,'-,TNIP1,Rheumatoid arthritis,rheumatoid arthritis,GCST009877,5:151059427,Orthopaedic
724,TNIP1,TNIP1,N/a,rs74817271-<b>?</b>,2 x 10-8,,NR,'-,5.64 z-score increase,[NR],TNIP1,Psoriatic arthritis,psoriatic arthritis,GCST007043,5:151090412,Orthopaedic
2134,TNIP1,TNIP1,N/a,rs74817271-<b>?</b>,2 x 10-26,(subset analysis),NR,'-,'-,'-,TNIP1,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,5:151090412,Orthopaedic
2139,TNIP1,TNIP1,N/a,rs10463311-<b>?</b>,4 x 10-8,(EA),0.2479,1.0869565,'-,[1.05-1.12],TNIP1,Amyotrophic lateral sclerosis,amyotrophic lateral sclerosis,GCST005647,5:151031274,Orthopaedic
640,ARHGAP24,ARHGAP24,N/a,rs16995986-<b>G</b>,1 x 10-6,,0.001,34.08,'-,[3.52-329.69],ARHGAP24,Diisocyanate-induced asthma,"response to diisocyanate, asthma",GCST002875,4:85772164,Respiratory
2079,C11orf71,C11orf71,N/a,rs4938096-<b>T</b>,1 x 10-6,(African),0.21,1.3,'-,[1.17‐1.44],"NNMT, C11orf71",Asthma,asthma,GCST005212,11:114365008,Respiratory
2081,C11orf71,C11orf71,N/a,rs11214966-<b>?</b>,6 x 10-7,,NR,'-,'-,'-,"C11orf71, NNMT",Asthma,asthma,GCST001182,11:114360533,Respiratory
1524,CHRNA1,CHRNA1,N/a,rs187076367-<b>A</b>,1 x 10-6,(AA),0.999,'-,1.863 unit increase,NR,CHRNA1,Post bronchodilator FEV1,"forced expiratory volume, response to bronchodilator",GCST003262,2:174772186,Respiratory
1577,DCAF6,DCAF6,N/a,rs11803859-<b>G</b>,7 x 10-6,(EA),0.927,'-,0.178 unit increase,[0.1-0.256],DCAF6,Emphysema annual change measurement in smokers (percent low attenuation area),"emphysema imaging measurement, smoking status measurement",GCST008476,1:168059436,Respiratory
1652,DNM3,DNM3,N/a,rs113989831-<b>G</b>,7 x 10-6,(African American),0.08,'-,0.31 unit increase,0.18-0.45,"EEF1AKNMT, DNM3",Diffusing capacity of carbon monoxide,diffusing capacity of the lung for carbon monoxide,GCST007637,1:171814725,Respiratory
1530,FCGR2A,FCGR2A,N/a,rs9427401-<b>?</b>,7 x 10-10,,NR,'-,'-,'-,FCGR2A,Lung function (FEV1/FVC),FEV/FEC ratio,GCST007080,1:161522385,Respiratory
650,FGF12,FGF12,N/a,rs189326995-<b>C</b>,8 x 10-7,(AA),0.999,'-,0.443 unit increase,'-,FGF12,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,3:192657709,Respiratory
652,FGF12,FGF12,N/a,rs149667740-<b>G</b>,2 x 10-6,(AA),0.999,'-,0.362 unit increase,'-,FGF12,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,3:192299812,Respiratory
654,FGF12,FGF12,N/a,rs138641425-<b>A</b>,2 x 10-6,(AA),0.999,'-,0.389 unit increase,'-,"FGF12-AS1, FGF12",Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,3:192261578,Respiratory
656,FGF12,FGF12-AS1,N/a,rs138641425-<b>A</b>,2 x 10-6,(AA),0.999,'-,0.389 unit increase,'-,"FGF12-AS1, FGF12",Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,3:192261578,Respiratory
407,H2AC6,H2AC6,N/a,rs36109883-<b>A</b>,6 x 10-12,,0.068507564,1.2887794,'-,[1.198871275-1.385430147],H2AC6,Squamous cell lung carcinoma,squamous cell lung carcinoma,GCST004750,6:26132842,Respiratory
421,H2AC6,H2AC6,N/a,rs36109883-<b>A</b>,2 x 10-7,,0.067018189,1.1676731,'-,[1.102051078-1.237202699],H2AC6,Lung cancer in ever smokers,"smoking status measurement, lung carcinoma",GCST004749,6:26132842,Respiratory
2075,HIF1A-AS1,HIF1A-AS1,N/a,rs2253681-<b>A</b>,6 x 10-9,,0.16,1.55,'-,[1.34-1.79],"HIF1A-AS1, LINC01303",Severe exacerbations in childhood asthma,"asthma exacerbation measurement, asthma",GCST011737,14:61613308,Respiratory
648,KC6,KC6,N/a,rs184167040-<b>A</b>,1 x 10-6,(AA),1,'-,0.544 unit increase,'-,KC6,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,18:41458077,Respiratory
409,KDM4A-AS1,KDM4A-AS1,N/a,rs113688544-<b>C</b>,4 x 10-6,,0.747240408,1.1049403,'-,[1.06-1.15],"KDM4A, KDM4A-AS1",Squamous cell lung carcinoma,squamous cell lung carcinoma,GCST004750,1:43686240,Respiratory
405,KHSRPP1,KHSRPP1,N/a,rs12686364-<b>G</b>,6 x 10-9,,0.004,8.49,'-,[4.12-17.49],"KHSRPP1, H3P30",Familial squamous cell lung carcinoma,"squamous cell lung carcinoma, family history of lung cancer",GCST006088,9:21670088,Respiratory
31,LINC00382,LINC00382,N/a,rs4885681-<b>T</b>,1 x 10-11,,0.7248,'-,0.018 unit increase,[0.013-0.023],LINC00382,Lung function (FVC),vital capacity,GCST007429,13:79893100,Respiratory
32,LINC00382,LINC00382,N/a,rs4885681-<b>?</b>,9 x 10-13,,NR,'-,'-,'-,LINC00382,Lung function (FVC),vital capacity,GCST007081,13:79893100,Respiratory
845,LINC00382,LINC00382,N/a,rs4885681-<b>T</b>,2 x 10-9,,0.7248,'-,0.0171 unit increase,[0.012-0.023],LINC00382,Peak expiratory flow,peak expiratory flow,GCST007430,13:79893100,Respiratory
1526,LINC00382,LINC00382,N/a,rs4885681-<b>T</b>,2 x 10-12,,0.7248,'-,0.0186 unit increase,[0.014-0.024],LINC00382,FEV1,forced expiratory volume,GCST007432,13:79893100,Respiratory
641,MGST1,MGST1,N/a,rs74377925-<b>G</b>,2 x 10-6,,0.013,5.34,'-,[2.48-11.51],MGST1,Diisocyanate-induced asthma,"response to diisocyanate, asthma",GCST002875,12:16546316,Respiratory
35,NDST1,NDST1,N/a,rs2545339-<b>?</b>,9 x 10-8,,NR,'-,'-,'-,NDST1,Lung function (FVC),vital capacity,GCST007081,5:150531657,Respiratory
1533,PHF2,PHF2,N/a,rs10156602-<b>?</b>,4 x 10-10,,NR,'-,'-,'-,PHF2,Lung function (FEV1/FVC),FEV/FEC ratio,GCST007080,9:93583046,Respiratory
36,PMAIP1,PMAIP1,N/a,rs75282864-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,"PMAIP1, GLUD1P4",Lung function (FVC),vital capacity,GCST007081,18:59812237,Respiratory
423,RNU5E-5P,RNU5E-5P,N/a,rs7979031-<b>C</b>,7 x 10-6,,0.455423445,1.205228,'-,[1.110720693-1.307776555],"RNA5SP367, RNU5E-5P",Lung cancer in never smokers,"smoking status measurement, lung carcinoma",GCST004747,12:101467714,Respiratory
658,ROR1,ROR1,N/a,rs192166173-<b>A</b>,4 x 10-6,(AA),0.999,'-,0.342 unit increase,'-,"ROR1, PGM1",Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,1:63696337,Respiratory
2077,S100A11,S100A11,N/a,rs115045402-<b>A</b>,2 x 10-20,,NR,1.249,'-,[1.2-1.3],"SPTLC1P4, S100A11",Asthma,asthma,GCST007798,1:152057072,Respiratory
2159,S100A11,S100A11,N/a,rs115288876-<b>?</b>,2 x 10-8,,NR,1.15,'-,[1.09-1.21],"NBPF18P, S100A11","Allergic disease (asthma, hay fever or eczema)","allergy, asthma",GCST007563,1:152027641,Respiratory
33,SMURF2,SMURF2,N/a,rs11653958-<b>A</b>,3 x 10-10,,0.7425,'-,0.0171 unit decrease,[0.012-0.022],"SMURF2, MICOS10P2",Lung function (FVC),vital capacity,GCST007429,17:64690612,Respiratory
34,SMURF2,SMURF2,N/a,rs11656678-<b>?</b>,4 x 10-16,,NR,'-,'-,'-,"SMURF2, MICOS10P2",Lung function (FVC),vital capacity,GCST007081,17:64685387,Respiratory
1531,SMURF2,SMURF2,N/a,rs11653958-<b>A</b>,9 x 10-13,,0.7425,'-,0.0197 unit increase,[0.014-0.025],"SMURF2, MICOS10P2",Lung function (FEV1/FVC),FEV/FEC ratio,GCST007431,17:64690612,Respiratory
1532,SMURF2,SMURF2,N/a,rs9900062-<b>?</b>,4 x 10-17,,NR,'-,'-,'-,"SMURF2, MICOS10P2",Lung function (FEV1/FVC),FEV/FEC ratio,GCST007080,17:64743456,Respiratory
2024,DTD1,DTD1,N/a,rs6136459-<b>T</b>,5 x 10-7,,0.5997,'-,0.0052 unit increase,[0.0032-0.0072],DTD1,Bitter alcoholic beverage consumption,bitter alcoholic beverage consumption measurement,GCST008522,20:18664994,Sensory System
1320,IL20RB,IL20RB,N/a,rs12489946-<b>A</b>,6 x 10-6,(EA),0.1506,'-,'-,'-,IL20RB,Initial pursuit acceleration,initial pursuit acceleration,GCST005023,3:137044095,Sensory System
668,KC6,KC6,N/a,rs10221329-<b>C</b>,6 x 10-9,,'-,'-,0.1 unit increase,[0.061-0.139],KC6,Spherical equivalent,refractive error measurement,GCST010378,18:41623429,Sensory System
2256,KC6,KC6,N/a,rs10163854-<b>?</b>,6 x 10-12,,'-,'-,'-,'-,KC6,Refractive error,Abnormality of refraction,GCST010002,18:41582560,Sensory System
2074,KHSRPP1,KHSRPP1,N/a,rs116945318-<b>A</b>,8 x 10-6,,0.985,'-,0.055 dioptres decrease,[0.031-0.079],"H3P30, KHSRPP1",Refractive astigmatism,Astigmatism,GCST007160,9:21638724,Sensory System
667,LINC00382,LINC00382,N/a,rs9601285-<b>T</b>,4 x 10-9,,'-,'-,0.08 unit increase,[0.06-0.1],LINC00382,Spherical equivalent,refractive error measurement,GCST010378,13:79891482,Sensory System
2255,LINC00382,LINC00382,N/a,rs4052505-<b>?</b>,8 x 10-20,,'-,'-,'-,'-,"LINC01080, LINC00382",Refractive error,Abnormality of refraction,GCST010002,13:79938352,Sensory System
37,LINC00578,LINC00578,N/a,rs12632195-<b>?</b>,3 x 10-8,,NR,'-,5.565 z score increase,NR,LINC00578,Ebbinghaus illusion (underestimation),visual perception measurement,GCST011567,3:177497439,Sensory System
1732,LINC00578,LINC00578,N/a,rs7620503-<b>T</b>,1 x 10-8,,0.39,'-,0.06 unit decrease,[0.04-0.08],LINC00578,Corneal structure,corneal topography,GCST001806,3:177586510,Sensory System
1774,LINC00578,LINC00578,N/a,rs13079175-<b>?</b>,4 x 10-16,,NA,'-,1.97 unit increase,[1.5-2.44],LINC00578,Central corneal thickness,central corneal thickness,GCST90000654,3:177591745,Sensory System
1775,LINC00578,LINC00578,N/a,rs4857714-<b>T</b>,4 x 10-9,,0.4,'-,2.342 μm decrease,[1.56-3.12],LINC00578,Central corneal thickness,central corneal thickness,GCST009414,3:177592657,Sensory System
669,LINC02502,LINC02502,N/a,rs13143759-<b>A</b>,3 x 10-12,,'-,'-,0.08 unit increase,[0.06-0.1],"LINC02502, MAD2L1",Spherical equivalent,refractive error measurement,GCST010378,4:119987548,Sensory System
2257,LINC02502,LINC02502,N/a,rs12511880-<b>?</b>,5 x 10-18,,'-,'-,'-,'-,"MAD2L1, LINC02502",Refractive error,Abnormality of refraction,GCST010002,4:119980371,Sensory System
554,OR51B5,OR51B5,N/a,rs317787-<b>T</b>,5 x 10-17,(Cinnamon naming problem),0.322,0.75,'-,[0.70-0.80],"HBG2, OR51B5, HBE1",Odorant perception,sensory perception of smell,GCST011623,11:5504313,Sensory System
666,SLC16A1,SLC16A1,N/a,rs7542229-<b>C</b>,6 x 10-12,,'-,'-,0.1 unit increase,[0.08-0.12],SLC16A1,Spherical equivalent,refractive error measurement,GCST010378,1:112921127,Sensory System
1079,SLC16A1,SLC16A1,N/a,rs55992320-<b>?</b>,5 x 10-18,,NR,'-,0.6397 unit increase,[0.48-0.8],SLC16A1,Macular thickness,macula measurement,GCST006976,1:112950793,Sensory System
2254,SLC16A1,SLC16A1,N/a,rs4839270-<b>?</b>,8 x 10-20,,'-,'-,'-,'-,SLC16A1,Refractive error,Abnormality of refraction,GCST010002,1:112934698,Sensory System
919,SLC22A4,SLC22A4,N/a,rs1050152-<b>C</b>,1 x 10-8,,0.594,1.1363636,'-,[1.09-1.19],"SLC22A4, MIR3936HG",Nasal polyps,Nasal Cavity Polyp,GCST007443,5:132340627,Sensory System
39,SPTBN4,SPTBN4,N/a,rs45572933-<b>?</b>,1 x 10-9,,NR,'-,6.08 z score increase,NR,SPTBN4,Ebbinghaus illusion (underestimation),visual perception measurement,GCST011567,19:40467455,Sensory System
38,TCF19,TCF19,N/a,rs182661945-<b>?</b>,2 x 10-9,,NR,'-,5.977 z score increase,NR,TCF19,Ebbinghaus illusion (overestimation),visual perception measurement,GCST011568,6:31163668,Sensory System
846,TNIP1,TNIP1,N/a,rs999556-<b>?</b>,1 x 10-15,,0.2722,'-,'-,[NR],"TNIP1, ANXA6",Myopia (pathological),pathological myopia,GCST001712,5:151094113,Sensory System
2258,WDR86,WDR86,N/a,rs58287690-<b>?</b>,1 x 10-20,,'-,'-,'-,'-,"CRYGN, WDR86-AS1",Refractive error,Abnormality of refraction,GCST010002,7:151425613,Sensory System
2259,WDR86,WDR86-AS1,N/a,rs58287690-<b>?</b>,1 x 10-20,,'-,'-,'-,'-,"CRYGN, WDR86-AS1",Refractive error,Abnormality of refraction,GCST010002,7:151425613,Sensory System
2124,FCGR2A,FCGR2A,N/a,rs10800314-<b>?</b>,1 x 10-32,(subset analysis),NR,'-,'-,'-,FCGR2A,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,1:161502999,Skin
2128,FCGR2A,FCGR2A,N/a,rs61802846-<b>?</b>,1 x 10-9,(subset analysis),NR,'-,'-,'-,FCGR2A,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,1:161504083,Skin
739,GUCY1A1,GUCY1A1,N/a,rs12650590-<b>?</b>,4 x 10-8,,NR,2.41,'-,[1.78‐3.26],GUCY1A1,Psoriasis,psoriasis,GCST008096,4:155618869,Skin
977,KHSRPP1,KHSRPP1,N/a,rs141111252-<b>A</b>,7 x 10-8,,NR,1.3846581,'-,NR,"RN7SL151P, KHSRPP1",Melanoma,melanoma,GCST90011809,9:21698290,Skin
490,LINC00382,LINC00382,N/a,rs9601280-<b>T</b>,1 x 10-8,,0.795173,0.9697707,'-,NR,LINC00382,Youthful appearance (self-reported),skin aging measurement,GCST011011,13:79882817,Skin
727,NONOP2,NONOP2,N/a,rs13017599-<b>G</b>,6 x 10-7,,NR,1.193,'-,NR,NONOP2,Psoriatic arthritis,psoriatic arthritis,GCST003270,2:60937196,Skin
729,NONOP2,NONOP2,N/a,rs13017599-<b>?</b>,1 x 10-8,,NR,1.27,'-,[1.18-1.35],NONOP2,Psoriatic arthritis,psoriatic arthritis,GCST001355,2:60937196,Skin
2069,NONOP2,NONOP2,N/a,rs67766926-<b>?</b>,7 x 10-9,(Shared),NR,'-,'-,'-,"NONOP2, REL",Inflammatory skin disease,"atopic eczema, psoriasis",GCST002740,2:60936446,Skin
1679,OR51B5,OR51B5,N/a,rs10838094-<b>A</b>,1 x 10-9,,0.4106,0.2393,'-,[-0.26109-0.73969],"HBG2, OR51B5, OR51Q1, HBE1",Cutaneous mastocytosis (adult),cutaneous mastocytosis,GCST011380,11:5422663,Skin
1681,OR51B5,OR51B5,N/a,rs10838094-<b>A</b>,2 x 10-25,,0.4106,0.1646,'-,[-0.22152-0.55072],"HBG2, OR51B5, OR51Q1, HBE1",Cutaneous mastocytosis,cutaneous mastocytosis,GCST011381,11:5422663,Skin
1683,OR51B5,OR51B5,N/a,rs10838094-<b>A</b>,9 x 10-18,,0.4106,0.1089,'-,[-0.50517-0.72297],"HBG2, OR51B5, OR51Q1, HBE1",Cutaneous mastocytosis (childhood),cutaneous mastocytosis,GCST011379,11:5422663,Skin
396,S100A11,S100A11,N/a,rs115288876-<b>?</b>,1 x 10-8,,NR,'-,0.1687 unit increase,[0.11-0.23],"NBPF18P, S100A11",Plantar warts,susceptibility to plantar warts measurement,GCST005005,1:152027641,Skin
1642,S100A11,S100A11,N/a,rs115288876-<b>?</b>,2 x 10-28,,NR,'-,'-,'-,"NBPF18P, S100A11",Eczema,Eczema,GCST007075,1:152027641,Skin
2073,S100A11,S100A11,N/a,rs78914480-<b>A</b>,8 x 10-11,,0.014657419,2.400272,'-,[1.843869165-3.124573471],S100A11,Atopic dermatitis,atopic eczema,GCST90013680,1:152033551,Skin
402,TCF19,TCF19,N/a,rs3130931-<b>C</b>,8 x 10-7,,0.69,1.54,'-,[1.29-1.84],"POU5F1, TCF19",Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),"Stevens-Johnson syndrome, toxic epidermal necrolysis",GCST001181,6:31167111,Skin
877,TGM3,TGM3,N/a,rs6082600-<b>T</b>,1 x 10-18,,NR,1.25,'-,[1.19-1.32],TGM3,Non-melanoma skin cancer,non-melanoma skin carcinoma,GCST005896,20:2281891,Skin
1266,TGM3,TGM3,N/a,rs214831-<b>G</b>,1 x 10-12,,0.608868,1.06,'-,[1.05-1.08],TGM3,Keratinocyte cancer (MTAG),keratinocyte carcinoma,GCST008870,20:2340717,Skin
1268,TGM3,TGM3,N/a,rs214803-<b>C</b>,6 x 10-66,,0.179072,1.2,'-,[1.17-1.22],TGM3,Keratinocyte cancer (MTAG),keratinocyte carcinoma,GCST008870,20:2309687,Skin
1270,TGM3,TGM3,N/a,rs6137442-<b>T</b>,7 x 10-18,,0.361945,1.08,'-,[1.06-1.10],"STK35, TGM3",Keratinocyte cancer (MTAG),keratinocyte carcinoma,GCST008870,20:2249690,Skin
2042,TGM3,TGM3,N/a,rs214803-<b>C</b>,3 x 10-81,,0.1836,1.2195122,'-,[1.19-1.25],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST008871,20:2309687,Skin
2044,TGM3,TGM3,N/a,rs214785-<b>C</b>,8 x 10-33,,0.18,1.19,'-,[NR],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST003726,20:2302811,Skin
2046,TGM3,TGM3,N/a,rs214803-<b>C</b>,1 x 10-59,,0.179593,'-,0.21616812 unit increase,[0.19-0.24],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST90013410,20:2309687,Skin
2048,TGM3,TGM3,N/a,rs214830-<b>G</b>,1 x 10-11,,0.371612,'-,0.077058256 unit decrease,[0.055-0.099],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST90013410,20:2340459,Skin
2050,TGM3,TGM3,N/a,rs6113392-<b>A</b>,5 x 10-20,,0.439823,'-,0.1027148 unit decrease,[0.081-0.125],"STK35, TGM3",Basal cell carcinoma,basal cell carcinoma,GCST90013410,20:2254824,Skin
2052,TGM3,TGM3,N/a,rs214782-<b>G</b>,6 x 10-17,,0.17,1.29,'-,[1.22-1.37],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST002331,20:2301324,Skin
2054,TGM3,TGM3,N/a,rs214782-<b>G</b>,2 x 10-13,,0.171,1.28,'-,[NR],TGM3,Basal cell carcinoma,basal cell carcinoma,GCST002842,20:2301324,Skin
2056,TGM3,TGM3,N/a,rs59586681-<b>T</b>,3 x 10-9,,0.61,1.16,'-,[1.11-1.22],"TGM3, STK35",Basal cell carcinoma,basal cell carcinoma,GCST002331,20:2239664,Skin
2066,TGM3,TGM3,N/a,rs1012621-<b>?</b>,5 x 10-6,(Shared),NR,'-,'-,'-,TGM3,Inflammatory skin disease,"atopic eczema, psoriasis",GCST002740,20:2325666,Skin
353,TNIP1,TNIP1,N/a,rs960709-<b>?</b>,2 x 10-8,,NR,1.212,'-,[NR],TNIP1,Systemic lupus erythematosus and Systemic sclerosis,"systemic scleroderma, systemic lupus erythematosus",GCST002069,5:151081488,Skin
355,TNIP1,TNIP1,N/a,rs4958880-<b>A</b>,1 x 10-11,,NR,1.16,'-,[1.10-1.22],TNIP1,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies),"systemic scleroderma, rheumatoid arthritis, myositis, systemic lupus erythematosus",GCST007278,5:151058916,Skin
357,TNIP1,TNIP1,N/a,rs10463312-<b>?</b>,5 x 10-6,(EA),NR,'-,'-,'-,TNIP1,Systemic sclerosis,systemic scleroderma,GCST005554,5:151031333,Skin
359,TNIP1,TNIP1,N/a,rs1422673-<b>T</b>,1 x 10-8,,0.194,1.2280027,'-,'-,TNIP1,Systemic sclerosis,systemic scleroderma,GCST009876,5:151059427,Skin
361,TNIP1,TNIP1,N/a,rs3792783-<b>G</b>,2 x 10-12,,0.16,1.2,'-,'-,TNIP1,Systemic sclerosis,systemic scleroderma,GCST009131,5:151076171,Skin
363,TNIP1,TNIP1,N/a,rs2233287-<b>A</b>,5 x 10-9,,0.1,1.31,'-,[1.15-1.43],TNIP1,Systemic sclerosis,systemic scleroderma,GCST001146,5:151060536,Skin
725,TNIP1,TNIP1,N/a,rs74817271-<b>?</b>,2 x 10-8,,NR,'-,5.64 z-score increase,[NR],TNIP1,Psoriatic arthritis,psoriatic arthritis,GCST007043,5:151090412,Skin
731,TNIP1,TNIP1,N/a,rs2233278-<b>C</b>,5 x 10-30,,'-,1.26,'-,'-,TNIP1,Psoriasis or type 2 diabetes (trans-disease meta-analysis)(opposite effect),"psoriasis, type II diabetes mellitus",GCST011990,5:151087628,Skin
733,TNIP1,TNIP1,N/a,rs2233278-<b>C</b>,4 x 10-10,,0.09,1.96,'-,[1.59-2.41],TNIP1,Psoriasis vulgaris,psoriasis vulgaris,GCST006036,5:151087628,Skin
735,TNIP1,TNIP1,N/a,rs2233278-<b>C</b>,4 x 10-37,,NR,1.658,'-,NR,TNIP1,Psoriasis vulgaris,psoriasis vulgaris,GCST003268,5:151087628,Skin
741,TNIP1,TNIP1,N/a,rs2233278-<b>C</b>,2 x 10-42,,0.058,1.59,'-,'-,TNIP1,Psoriasis,psoriasis,GCST005527,5:151087628,Skin
743,TNIP1,TNIP1,N/a,rs10036748-<b>?</b>,4 x 10-9,,'-,1.1,'-,1.06-1.13,TNIP1,Psoriasis,psoriasis,GCST008479,5:151078585,Skin
745,TNIP1,TNIP1,N/a,rs2233278-<b>A</b>,1 x 10-18,,NR,1.647,'-,[1.557-1.743],TNIP1,Psoriasis,psoriasis,GCST002738,5:151087628,Skin
2132,TNIP1,TNIP1,N/a,rs74817271-<b>?</b>,2 x 10-26,(subset analysis),NR,'-,'-,'-,TNIP1,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,5:151090412,Skin
1677,TUBB4BP4,TUBB4BP4,N/a,rs12225068-<b>A</b>,6 x 10-10,,0.917154,'-,'-,'-,"LINC02756, TUBB4BP4",Cutaneous melanoma or hair colour,"cutaneous melanoma, hair color",GCST010302,11:91883525,Skin
1319,ADH1A,ADH1A,N/a,rs111858442-<b>G</b>,4 x 10-7,,NR,2.2727273,'-,'-,"ADH1A, RNU6-578P",Insomnia,insomnia,GCST005566,4:12350898,Sleep
473,APOB,APOB,N/a,rs4296389-<b>?</b>,7 x 10-25,,NR,'-,0.02271 unit decrease,[0.018-0.027],"LINC02850, APOB",Triglyceride levels x long total sleep time interaction (2df test),"sleep duration, triglyceride measurement",GCST009364,2:20943234,Sleep
475,APOB,APOB,N/a,rs4296389-<b>?</b>,3 x 10-29,,NR,'-,0.02383 unit decrease,[0.019-0.028],"LINC02850, APOB",Triglyceride levels x short total sleep time interaction (2df test),"sleep duration, triglyceride measurement",GCST009363,2:20943234,Sleep
1762,ARHGAP24,ARHGAP24,N/a,rs7683928-<b>G</b>,8 x 10-6,,NR,1.19645,'-,[1.10589-1.29442],ARHGAP24,Evening vs. morning chronotype (sMEQ score),chronotype measurement,GCST010575,4:85577344,Sleep
1759,COQ10B,COQ10B,N/a,rs3731570-<b>?</b>,4 x 10-10,,NR,'-,'-,'-,"RNU6-1029P, COQ10B",Morning vs. evening chronotype,circadian rhythm,GCST003429,2:197453059,Sleep
1763,COQ10B,COQ10B,N/a,rs3731570-<b>T</b>,3 x 10-23,,0.4737,1.0373,'-,'-,"RNU6-1029P, COQ10B",Morning person,chronotype measurement,GCST007565,2:197453059,Sleep
470,DTD1,DTD1,N/a,rs150097070-<b>G</b>,5 x 10-6,(sleep onset irregularity),NR,'-,0.1333 unit increase,[0.076-0.19],"DTD1, DTD1-AS1",Night sleep phenotypes,sleep quality,GCST003542,20:18680023,Sleep
471,DTD1,DTD1-AS1,N/a,rs150097070-<b>G</b>,5 x 10-6,(sleep onset irregularity),NR,'-,0.1333 unit increase,[0.076-0.19],"DTD1, DTD1-AS1",Night sleep phenotypes,sleep quality,GCST003542,20:18680023,Sleep
1307,FAM180B,FAM180B,N/a,rs11605348-<b>G</b>,3 x 10-8,(Female),0.657,1.0438414,'-,[1.03-1.06],"NDUFS3, FAM180B",Insomnia,insomnia measurement,GCST007988,11:47584931,Sleep
1309,FAM180B,FAM180B,N/a,rs11605348-<b>G</b>,7 x 10-13,,0.6505,1.0460252,'-,[1.03-1.06],"NDUFS3, FAM180B",Insomnia,insomnia measurement,GCST007988,11:47584931,Sleep
472,FGF12,FGF12,N/a,rs9836672-<b>T</b>,5 x 10-6,,0.05,'-,0.27 unit increase,[0.15-0.39],FGF12,Sleep quality,sleep quality,GCST002049,3:192195081,Sleep
920,H2AC6,H2AC6,N/a,rs198811-<b>A</b>,1 x 10-8,,0.81,1.69,'-,[1.41-2.03],H2AC6,Narcolepsy with cataplexy,narcolepsy with cataplexy,GCST002912,6:26128218,Sleep
489,LINC00382,LINC00382,N/a,rs9531006-<b>?</b>,4 x 10-7,(EA),NR,'-,2.43 unit increase,[1.49-3.37],"LINC00382, LINC01080",Sleep duration,sleep duration,GCST002711,13:79977428,Sleep
1311,PHF2,PHF2,N/a,rs10156602-<b>A</b>,2 x 10-8,,0.638126,1.02,'-,[1.01-1.03],PHF2,Insomnia symptoms (never/rarely vs. sometimes/usually),insomnia measurement,GCST007387,9:93583046,Sleep
1313,PHF2,PHF2,N/a,rs10156602-<b>A</b>,7 x 10-12,,0.638126,1.02,'-,[1.01-1.03],PHF2,Insomnia symptoms (never/rarely vs. usually),insomnia measurement,GCST007388,9:93583046,Sleep
1315,PHF2,PHF2,N/a,rs7872863-<b>C</b>,1 x 10-8,(Female),0.2845,1.048218,'-,[1.03-1.06],PHF2,Insomnia,insomnia measurement,GCST007988,9:93630533,Sleep
1316,PHF2,PHF2,N/a,rs10761240-<b>G</b>,2 x 10-12,,0.6037,1.0438414,'-,[1.03-1.06],PHF2,Insomnia,insomnia measurement,GCST007988,9:93599640,Sleep
619,PMAIP1,PMAIP1,N/a,rs58127855-<b>T</b>,6 x 10-7,,0.01,3.03,'-,[2.01-4.97],"PMAIP1, NFE2L3P1",Restless legs syndrome,restless legs syndrome,GCST011995,18:59943413,Sleep
488,PRC1,PRC1,N/a,rs35006130-<b>GTT</b>,3 x 10-8,,0.893,'-,0.045 SD units increase,[0.029-0.061],"RCCD1, PRC1",Sleep duration,sleep duration,GCST006914,15:90963779,Sleep
1303,TNNI3K,TNNI3K,N/a,rs699844-<b>A</b>,4 x 10-8,,0.9195,1.062,'-,[1.04-1.08],"FPGT-TNNI3K, TNNI3K",Insomnia,insomnia measurement,GCST007988,1:74412569,Sleep
1305,TNNI3K,FPGT-TNNI3K,N/a,rs699844-<b>A</b>,4 x 10-8,,0.9195,1.062,'-,[1.04-1.08],"FPGT-TNNI3K, TNNI3K",Insomnia,insomnia measurement,GCST007988,1:74412569,Sleep
23,ADH1A,ADH1A,N/a,rs28364331-<b>G</b>,1 x 10-17,,0.018845,'-,0.061386 unit increase,[0.047-0.075],ADH1A,Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST010144,4:99280138,Vitamin
24,ADH1A,ADH1A,N/a,rs28364331-<b>A</b>,2 x 10-20,,0.981914,'-,0.068 unit increase,[0.054-0.082],ADH1A,Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000616,4:99280138,Vitamin
25,ADH1A,ADH1A,N/a,rs28364331-<b>?</b>,8 x 10-17,,NR,'-,0.0644114 unit increase,[0.049-0.08],ADH1A,Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000618,4:99280138,Vitamin
26,APOB,APOB,N/a,rs7604788-<b>C</b>,2 x 10-10,,0.966567,'-,0.035 unit increase,[0.023-0.047],APOB,Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000616,2:20967152,Vitamin
27,APOB,APOB,N/a,rs1042034-<b>?</b>,1 x 10-9,,NR,'-,0.0151254 unit increase,[0.01-0.02],APOB,Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000618,2:21002409,Vitamin
28,APOB,APOB,N/a,rs952275-<b>G</b>,5 x 10-9,,NR,'-,0.0143 unit decrease,[0.0096-0.019],APOB,Vitamin D levels,vitamin D measurement,GCST90019526,2:20998527,Vitamin
29,APOB,APOB,N/a,rs541041-<b>G</b>,1 x 10-10,,0.180761,'-,0.016 unit increase,[0.01-0.022],"TDRD15, APOB",Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000616,2:21072103,Vitamin
30,APOB,APOB,N/a,rs562338-<b>?</b>,1 x 10-9,,NR,'-,0.015996 unit increase,[0.011-0.021],"APOB, TDRD15",Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000618,2:21065449,Vitamin
1527,PHF2,PHF2,N/a,rs7049001-<b>?</b>,5 x 10-6,,NR,'-,'-,'-,"PHF2, MIR4291",Serum folate levels,folic acid measurement,GCST006137,9:93731688,Vitamin
19,S100A11,S100A11,N/a,rs115288876-<b>?</b>,2 x 10-56,,NR,'-,0.0788065 unit increase,[0.069-0.089],"NBPF18P, S100A11",Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000618,1:152027641,Vitamin
20,S100A11,S100A11,N/a,rs115288876-<b>A</b>,3 x 10-41,,NR,'-,0.0829 unit increase,[0.071-0.095],"NBPF18P, S100A11",Vitamin D levels,vitamin D measurement,GCST90019526,1:152027641,Vitamin
21,S100A11,S100A11,N/a,rs115045402-<b>A</b>,3 x 10-55,,0.026334,'-,0.10713 unit increase,[0.094-0.121],"SPTLC1P4, S100A11",Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST010144,1:152057072,Vitamin
22,SLC38A10,SLC38A10,N/a,rs61698755-<b>?</b>,2 x 10-8,,NR,'-,0.011465 unit increase,[0.0074-0.0155],SLC38A10,Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000618,17:81284080,Vitamin
947,ARHGAP24,ARHGAP24,N/a,rs111260369-<b>T</b>,6 x 10-6,,NR,'-,0.2837 SD units decrease,[0.16-0.41],ARHGAP24,Monokine induced by gamma interferon levels,monokine induced by gamma interferon measurement,GCST004435,4:85456915,
1349,FGF8,FGF8,N/a,rs7077446-<b>G</b>,2 x 10-14,,0.4728,'-,0.015484313 unit decrease,[0.012-0.019],"FBXW4, FGF8",Household income (MTAG),household income,GCST009524,10:101742008,
1485,KDM4A-AS1,KDM4A-AS1,N/a,rs34550543-<b>T</b>,1 x 10-10,,0.4063,1.02047,'-,[NR],"KDM4A-AS1, ST3GAL3",Left-handedness,handedness,GCST90013421,1:43706787,
1348,MGST1,MGST1,N/a,rs2160514-<b>C</b>,6 x 10-9,,0.4373,'-,0.011857998 unit increase,[0.0079-0.0159],"MGST1, LMO3",Household income (MTAG),household income,GCST009524,12:16603574,
1643,MGST1,MGST1,N/a,rs10772939-<b>T</b>,5 x 10-6,(Economic policy),NR,'-,0.112 unit decrease,[0.065-0.159],MGST1,Economic and political preferences,economic and social preference,GCST001519,12:16456104,
933,PRC1,PRC1,N/a,rs2386584-<b>T</b>,3 x 10-11,,0.3835,'-,0.0166 unit decrease,[0.012-0.021],"PRC1, VPS33B",Multisite chronic pain,multisite chronic pain,GCST008512,15:90996342,
585,PROM1,PROM1,N/a,rs17478107-<b>C</b>,9 x 10-6,,0.28,'-,0.02 unit decrease,[NR],PROM1,Self-rated health,self rated health,GCST000747,4:16000665,
2185,RPS3AP5,RPS3AP5,N/a,rs113544501-<b>T</b>,3 x 10-6,,0.15,1.37,'-,'-,RPS3AP5,Disease progression in age-related macular degeneration (adjusted for baseline),"age-related macular degeneration, disease progression measurement",GCST009144,10:84651798,
400,SSBP4,SSBP4,N/a,rs8106096-<b>C</b>,2 x 10-6,,0.67,'-,0.84 g/day increase,[0.49-1.19],SSBP4,Intake of total sugars,sugar consumption measurement,GCST008759,19:18425606,
